{"f42489d63c91d2df34c4575847ed49db48f005fb": [["IntroductionThe ongoing global emergency linked to the Covid-19 pandemic [1] teaches us that viral diseases can be dramatic all over the world in the present period of climate, political, social and globalization change.", [["viral diseases", "DISEASE", 93, 107], ["the Covid", "TEST", 51, 60], ["viral diseases", "PROBLEM", 93, 107], ["viral diseases", "OBSERVATION", 93, 107]]], ["Scientific solutions were not available and society was unprepared, claiming that research activities for the discovery of compounds for the prevention and treatment of severe and acute viral infections are nowadays a priority.IntroductionOxidative stress-a loss in the balance between the production of free radicals including reactive oxygen species (ROS) and antioxidant cell signaling pathways [2] -can be a key factor of the pathogenesis in many acute or chronical human diseases [3] .", [["cell", "ANATOMY", 374, 378], ["acute viral infections", "DISEASE", 180, 202], ["oxygen", "CHEMICAL", 337, 343], ["ROS", "CHEMICAL", 353, 356], ["oxygen", "CHEMICAL", 337, 343], ["free radicals", "SIMPLE_CHEMICAL", 304, 317], ["reactive oxygen species", "SIMPLE_CHEMICAL", 328, 351], ["ROS", "SIMPLE_CHEMICAL", 353, 356], ["antioxidant cell", "CELL", 362, 378], ["human", "ORGANISM", 470, 475], ["human", "SPECIES", 470, 475], ["human", "SPECIES", 470, 475], ["Scientific solutions", "TREATMENT", 0, 20], ["the prevention", "TREATMENT", 137, 151], ["treatment", "TREATMENT", 156, 165], ["severe and acute viral infections", "PROBLEM", 169, 202], ["IntroductionOxidative stress", "PROBLEM", 227, 255], ["a loss in the balance", "PROBLEM", 256, 277], ["free radicals", "PROBLEM", 304, 317], ["reactive oxygen species", "PROBLEM", 328, 351], ["antioxidant cell signaling pathways", "PROBLEM", 362, 397], ["chronical human diseases", "PROBLEM", 460, 484], ["severe", "OBSERVATION_MODIFIER", 169, 175], ["acute", "OBSERVATION_MODIFIER", 180, 185], ["viral", "OBSERVATION_MODIFIER", 186, 191], ["infections", "OBSERVATION", 192, 202], ["reactive", "OBSERVATION_MODIFIER", 328, 336], ["oxygen species", "OBSERVATION", 337, 351], ["acute", "OBSERVATION_MODIFIER", 451, 456]]], ["Dietary intake of exogenous antioxidants in humans has a well-known role in preventing and protecting cellular oxidative stress.", [["cellular", "ANATOMY", 102, 110], ["humans", "ORGANISM", 44, 50], ["cellular", "CELL", 102, 110], ["humans", "SPECIES", 44, 50], ["humans", "SPECIES", 44, 50], ["exogenous antioxidants", "TREATMENT", 18, 40], ["cellular oxidative stress", "PROBLEM", 102, 127], ["exogenous antioxidants", "OBSERVATION", 18, 40], ["oxidative stress", "OBSERVATION", 111, 127]]], ["As a result, modern medicine tends to use them in the prevention and treatment of various oxidative-stress-associated diseases [4] .", [["modern medicine", "TREATMENT", 13, 28], ["treatment", "TREATMENT", 69, 78], ["various oxidative-stress-associated diseases", "PROBLEM", 82, 126]]], ["Viral infections are promoted by oxidative processes, the latter acting on replication in infected cells, cell proliferation inhibition and cell apoptosis induction [5] .", [["cells", "ANATOMY", 99, 104], ["cell", "ANATOMY", 106, 110], ["cell", "ANATOMY", 140, 144], ["Viral infections", "DISEASE", 0, 16], ["cells", "CELL", 99, 104], ["cell", "CELL", 106, 110], ["cell", "CELL", 140, 144], ["infected cells", "CELL_TYPE", 90, 104], ["Viral infections", "PROBLEM", 0, 16], ["infected cells", "PROBLEM", 90, 104], ["cell proliferation inhibition", "TREATMENT", 106, 135], ["cell apoptosis induction", "TREATMENT", 140, 164], ["infections", "OBSERVATION", 6, 16], ["oxidative processes", "OBSERVATION", 33, 52], ["infected cells", "OBSERVATION", 90, 104], ["cell proliferation", "OBSERVATION", 106, 124], ["cell apoptosis", "OBSERVATION", 140, 154]]], ["In patients affected by herpes simplex [6] , it was observed that an increase of the ROS-induced membrane phospholipids peroxidation caused dysfunction of vital cellular processes such as membrane transport and mitochondrial respiration [7] .", [["membrane", "ANATOMY", 97, 105], ["cellular", "ANATOMY", 161, 169], ["membrane", "ANATOMY", 188, 196], ["mitochondrial", "ANATOMY", 211, 224], ["herpes simplex", "DISEASE", 24, 38], ["ROS", "CHEMICAL", 85, 88], ["patients", "ORGANISM", 3, 11], ["herpes simplex", "ORGANISM", 24, 38], ["ROS", "SIMPLE_CHEMICAL", 85, 88], ["membrane", "CELLULAR_COMPONENT", 97, 105], ["cellular", "CELL", 161, 169], ["membrane", "CELLULAR_COMPONENT", 188, 196], ["mitochondrial", "CELLULAR_COMPONENT", 211, 224], ["patients", "SPECIES", 3, 11], ["herpes simplex", "PROBLEM", 24, 38], ["the ROS", "PROBLEM", 81, 88], ["membrane phospholipids peroxidation", "PROBLEM", 97, 132], ["dysfunction of vital cellular processes", "PROBLEM", 140, 179], ["mitochondrial respiration", "TEST", 211, 236], ["increase", "OBSERVATION_MODIFIER", 69, 77], ["vital cellular processes", "OBSERVATION", 155, 179]]], ["Epstein-Barr Virus (EBV) infections cause an increase in DNA damage and significant ROS accumulation, and, interestingly, treatment with ROS scavengers was able to lower DNA damage in both mitogen-stimulated and EBV-infected cells [8] .IntroductionIn this framework, discovery and screening of antioxidant compounds with antiviral properties is promising since the treatment of viral diseases requires the suppression of viral replication and cell survival promotion.", [["cells", "ANATOMY", 225, 230], ["cell", "ANATOMY", 443, 447], ["Epstein-Barr Virus (EBV) infections", "DISEASE", 0, 35], ["ROS", "CHEMICAL", 84, 87], ["ROS", "CHEMICAL", 137, 140], ["viral diseases", "DISEASE", 378, 392], ["Epstein-Barr Virus", "ORGANISM", 0, 18], ["EBV", "ORGANISM", 20, 23], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["ROS", "SIMPLE_CHEMICAL", 84, 87], ["ROS", "SIMPLE_CHEMICAL", 137, 140], ["DNA", "CELLULAR_COMPONENT", 170, 173], ["EBV", "ORGANISM", 212, 215], ["cells", "CELL", 225, 230], ["cell", "CELL", 443, 447], ["mitogen-stimulated and EBV-infected cells", "CELL_LINE", 189, 230], ["Epstein-Barr Virus", "SPECIES", 0, 18], ["EBV", "SPECIES", 20, 23], ["Barr Virus (EBV) infections", "PROBLEM", 8, 35], ["DNA damage", "PROBLEM", 57, 67], ["significant ROS accumulation", "PROBLEM", 72, 100], ["ROS scavengers", "TREATMENT", 137, 151], ["lower DNA damage", "PROBLEM", 164, 180], ["mitogen", "TEST", 189, 196], ["infected cells", "PROBLEM", 216, 230], ["antioxidant compounds", "TREATMENT", 294, 315], ["antiviral properties", "TREATMENT", 321, 341], ["viral diseases", "PROBLEM", 378, 392], ["viral replication", "TREATMENT", 421, 438], ["cell survival promotion", "TREATMENT", 443, 466], ["Barr Virus", "OBSERVATION", 8, 18], ["increase", "OBSERVATION_MODIFIER", 45, 53], ["DNA damage", "OBSERVATION", 57, 67], ["significant", "OBSERVATION_MODIFIER", 72, 83], ["ROS accumulation", "OBSERVATION", 84, 100], ["infected cells", "OBSERVATION", 216, 230], ["viral diseases", "OBSERVATION", 378, 392], ["viral replication", "OBSERVATION", 421, 438]]], ["The most known ROS scavenger compounds belong to different chemical families, such as polyphenols (phenolic acids, flavonoids, anthocyanins, lignans and stilbenes), carotenoids (xanthophylls and carotenes), sterols, or vitamins (vitamins B, D, E, and C) [9] .IntroductionFor instance, there is a lot of evidence of the capability of natural antioxidants such as vitamins C and E (ascorbic acid and tocopherol, respectively) or polyphenols (e.g., curcumin) scavenging ROS levels in infected cells, inhibiting proapoptotic factors and thus reestablishing the intracellular equilibrium between the stress-related proteins (such as c-Jun N-terminal kinases-JNK) and promitotic (MAPK) and transcription factors (NF-kB) [10] [11] [12] [13] .IntroductionThe most effective antioxidants are mainly synthetized by photosynthetic organisms, sharing these precious compounds with herbivorous animals through diet, and bioaccumulating along the trophic web [14] , as occurs in marine systems [15] .", [["cells", "ANATOMY", 490, 495], ["intracellular", "ANATOMY", 557, 570], ["ROS", "CHEMICAL", 15, 18], ["phenolic acids, flavonoids, anthocyanins, lignans and stilbenes", "CHEMICAL", 99, 162], ["carotenoids", "CHEMICAL", 165, 176], ["xanthophylls", "CHEMICAL", 178, 190], ["carotenes", "CHEMICAL", 195, 204], ["sterols", "CHEMICAL", 207, 214], ["vitamins B", "CHEMICAL", 229, 239], ["vitamins C", "CHEMICAL", 362, 372], ["ascorbic acid", "CHEMICAL", 380, 393], ["tocopherol", "CHEMICAL", 398, 408], ["curcumin", "CHEMICAL", 446, 454], ["ROS", "CHEMICAL", 467, 470], ["polyphenols", "CHEMICAL", 86, 97], ["phenolic acids", "CHEMICAL", 99, 113], ["flavonoids", "CHEMICAL", 115, 125], ["anthocyanins", "CHEMICAL", 127, 139], ["lignans", "CHEMICAL", 141, 148], ["stilbenes", "CHEMICAL", 153, 162], ["xanthophylls", "CHEMICAL", 178, 190], ["carotenes", "CHEMICAL", 195, 204], ["sterols", "CHEMICAL", 207, 214], ["vitamins", "CHEMICAL", 219, 227], ["vitamins B, D, E, and C", "CHEMICAL", 229, 252], ["vitamins C and E", "CHEMICAL", 362, 378], ["ascorbic acid", "CHEMICAL", 380, 393], ["tocopherol", "CHEMICAL", 398, 408], ["polyphenols", "CHEMICAL", 427, 438], ["curcumin", "CHEMICAL", 446, 454], ["N", "CHEMICAL", 634, 635], ["ROS", "SIMPLE_CHEMICAL", 15, 18], ["polyphenols", "SIMPLE_CHEMICAL", 86, 97], ["phenolic acids", "SIMPLE_CHEMICAL", 99, 113], ["flavonoids", "SIMPLE_CHEMICAL", 115, 125], ["anthocyanins", "SIMPLE_CHEMICAL", 127, 139], ["lignans", "SIMPLE_CHEMICAL", 141, 148], ["stilbenes", "SIMPLE_CHEMICAL", 153, 162], ["carotenoids", "SIMPLE_CHEMICAL", 165, 176], ["xanthophylls", "SIMPLE_CHEMICAL", 178, 190], ["carotenes", "SIMPLE_CHEMICAL", 195, 204], ["sterols", "SIMPLE_CHEMICAL", 207, 214], ["vitamins", "SIMPLE_CHEMICAL", 219, 227], ["vitamins B", "SIMPLE_CHEMICAL", 229, 239], ["D", "SIMPLE_CHEMICAL", 241, 242], ["E", "SIMPLE_CHEMICAL", 244, 245], ["C", "SIMPLE_CHEMICAL", 251, 252], ["vitamins C", "SIMPLE_CHEMICAL", 362, 372], ["E", "SIMPLE_CHEMICAL", 377, 378], ["ascorbic acid", "SIMPLE_CHEMICAL", 380, 393], ["tocopherol", "SIMPLE_CHEMICAL", 398, 408], ["polyphenols", "SIMPLE_CHEMICAL", 427, 438], ["curcumin", "SIMPLE_CHEMICAL", 446, 454], ["ROS", "SIMPLE_CHEMICAL", 467, 470], ["cells", "CELL", 490, 495], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 557, 570], ["c-Jun N-terminal kinases-JNK", "GENE_OR_GENE_PRODUCT", 628, 656], ["promitotic", "GENE_OR_GENE_PRODUCT", 662, 672], ["MAPK", "GENE_OR_GENE_PRODUCT", 674, 678], ["NF-kB", "GENE_OR_GENE_PRODUCT", 707, 712], ["[10] [11] [12] [13]", "SIMPLE_CHEMICAL", 714, 733], ["infected cells", "CELL_TYPE", 481, 495], ["proapoptotic factors", "PROTEIN", 508, 528], ["c-Jun N-terminal kinases", "PROTEIN", 628, 652], ["JNK", "PROTEIN", 653, 656], ["promitotic", "PROTEIN", 662, 672], ["MAPK", "PROTEIN", 674, 678], ["transcription factors", "PROTEIN", 684, 705], ["NF-kB", "PROTEIN", 707, 712], ["polyphenols (phenolic acids", "TREATMENT", 86, 113], ["flavonoids", "TREATMENT", 115, 125], ["anthocyanins", "TREATMENT", 127, 139], ["lignans and stilbenes", "TREATMENT", 141, 162], ["carotenoids (xanthophylls", "TREATMENT", 165, 190], ["carotenes", "TREATMENT", 195, 204], ["sterols", "TREATMENT", 207, 214], ["vitamins (vitamins B, D, E, and C)", "TREATMENT", 219, 253], ["natural antioxidants", "TREATMENT", 333, 353], ["vitamins C and E (ascorbic acid", "TREATMENT", 362, 393], ["tocopherol", "TREATMENT", 398, 408], ["polyphenols", "TREATMENT", 427, 438], ["scavenging ROS levels", "TEST", 456, 477], ["infected cells", "PROBLEM", 481, 495], ["inhibiting proapoptotic factors", "PROBLEM", 497, 528], ["the intracellular equilibrium", "PROBLEM", 553, 582], ["the stress-related proteins", "PROBLEM", 591, 618], ["c", "TEST", 628, 629], ["promitotic (MAPK) and transcription factors", "PROBLEM", 662, 705], ["The most effective antioxidants", "TREATMENT", 747, 778], ["ROS scavenger", "OBSERVATION", 15, 28], ["infected cells", "OBSERVATION", 481, 495]]], ["Indeed, marine organisms represent a rich source of antioxidants, in terms of quantity and/or diversity.", [["marine organisms", "PROBLEM", 8, 24]]], ["Vitamins B 12 , C, D, E, peptides, amino acids, chitooligosaccharide derivatives, carotenoids, sulphated polysaccharides, sterols, phlorotannins, phenolic compounds and flavones are examples of marine antioxidant richness [16] .IntroductionIt is not surprising, therefore, that marine pharmacology is increasingly growing.", [["Vitamins B 12 , C, D, E, peptides, amino acids", "CHEMICAL", 0, 46], ["chitooligosaccharide", "CHEMICAL", 48, 68], ["carotenoids", "CHEMICAL", 82, 93], ["sterols", "CHEMICAL", 122, 129], ["phlorotannins", "CHEMICAL", 131, 144], ["Vitamins B 12 , C, D, E", "CHEMICAL", 0, 23], ["amino acids", "CHEMICAL", 35, 46], ["chitooligosaccharide", "CHEMICAL", 48, 68], ["sterols", "CHEMICAL", 122, 129], ["phlorotannins", "CHEMICAL", 131, 144], ["flavones", "CHEMICAL", 169, 177], ["Vitamins B 12", "SIMPLE_CHEMICAL", 0, 13], ["C", "SIMPLE_CHEMICAL", 16, 17], ["D, E", "SIMPLE_CHEMICAL", 19, 23], ["amino acids", "SIMPLE_CHEMICAL", 35, 46], ["chitooligosaccharide derivatives", "SIMPLE_CHEMICAL", 48, 80], ["carotenoids", "SIMPLE_CHEMICAL", 82, 93], ["sulphated polysaccharides", "SIMPLE_CHEMICAL", 95, 120], ["sterols", "SIMPLE_CHEMICAL", 122, 129], ["phlorotannins", "SIMPLE_CHEMICAL", 131, 144], ["phenolic compounds", "SIMPLE_CHEMICAL", 146, 164], ["flavones", "SIMPLE_CHEMICAL", 169, 177], ["Vitamins B", "TEST", 0, 10], ["C, D, E, peptides", "TREATMENT", 16, 33], ["amino acids", "TREATMENT", 35, 46], ["chitooligosaccharide derivatives", "TREATMENT", 48, 80], ["carotenoids", "TREATMENT", 82, 93], ["sulphated polysaccharides", "TREATMENT", 95, 120], ["sterols", "TREATMENT", 122, 129], ["phlorotannins", "TREATMENT", 131, 144], ["phenolic compounds", "TREATMENT", 146, 164], ["flavones", "TREATMENT", 169, 177], ["marine antioxidant richness", "TREATMENT", 194, 221], ["not surprising", "UNCERTAINTY", 246, 260]]], ["Recently, Mayer et al. [17] reported that 21 studies were published in 2014/2015, focusing on marine antiviral drugs acting against human enterovirus 71, human cytomegalovirus, human immunodeficiency virus type-1 (HIV-1), human herpes simplex virus (HSV), influenza virus, hepatitis B virus, murine norovirus, respiratory syncytial virus (RSV) or sindbis virus.", [["human cytomegalovirus", "DISEASE", 154, 175], ["human immunodeficiency virus", "DISEASE", 177, 205], ["herpes simplex virus (HSV), influenza virus", "DISEASE", 228, 271], ["hepatitis B", "DISEASE", 273, 284], ["murine norovirus", "DISEASE", 292, 308], ["respiratory syncytial virus (RSV) or sindbis virus", "DISEASE", 310, 360], ["human", "ORGANISM", 132, 137], ["enterovirus 71", "ORGANISM", 138, 152], ["human cytomegalovirus", "ORGANISM", 154, 175], ["human immunodeficiency virus type-1", "ORGANISM", 177, 212], ["HIV-1", "ORGANISM", 214, 219], ["human", "ORGANISM", 222, 227], ["herpes simplex virus (HSV),", "ORGANISM", 228, 255], ["influenza virus", "ORGANISM", 256, 271], ["hepatitis B virus", "ORGANISM", 273, 290], ["murine norovirus", "ORGANISM", 292, 308], ["respiratory syncytial virus", "ORGANISM", 310, 337], ["RSV", "ORGANISM", 339, 342], ["sindbis virus", "ORGANISM", 347, 360], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 154, 159], ["human immunodeficiency virus type-1", "SPECIES", 177, 212], ["HIV-1", "SPECIES", 214, 219], ["human", "SPECIES", 222, 227], ["herpes simplex virus", "SPECIES", 228, 248], ["(HSV", "SPECIES", 249, 253], ["influenza virus", "SPECIES", 256, 271], ["hepatitis B virus", "SPECIES", 273, 290], ["murine", "SPECIES", 292, 298], ["norovirus", "SPECIES", 299, 308], ["respiratory syncytial virus", "SPECIES", 310, 337], ["RSV", "SPECIES", 339, 342], ["human enterovirus 71", "SPECIES", 132, 152], ["human cytomegalovirus", "SPECIES", 154, 175], ["human immunodeficiency virus type-1", "SPECIES", 177, 212], ["HIV-1", "SPECIES", 214, 219], ["human herpes simplex virus", "SPECIES", 222, 248], ["HSV", "SPECIES", 250, 253], ["influenza virus", "SPECIES", 256, 271], ["hepatitis B virus", "SPECIES", 273, 290], ["murine norovirus", "SPECIES", 292, 308], ["respiratory syncytial virus", "SPECIES", 310, 337], ["RSV", "SPECIES", 339, 342], ["sindbis virus", "SPECIES", 347, 360], ["marine antiviral drugs", "TREATMENT", 94, 116], ["human enterovirus", "TEST", 132, 149], ["human cytomegalovirus", "TEST", 154, 175], ["human immunodeficiency virus type", "TEST", 177, 210], ["HIV", "TEST", 214, 217], ["human herpes simplex virus", "PROBLEM", 222, 248], ["HSV", "PROBLEM", 250, 253], ["influenza virus", "PROBLEM", 256, 271], ["hepatitis B virus", "PROBLEM", 273, 290], ["murine norovirus", "PROBLEM", 292, 308], ["respiratory syncytial virus (RSV)", "PROBLEM", 310, 343], ["sindbis virus", "PROBLEM", 347, 360], ["respiratory", "ANATOMY", 310, 321], ["syncytial virus", "OBSERVATION", 322, 337], ["sindbis virus", "OBSERVATION", 347, 360]]], ["The mechanism of action of these compounds is known for five of them, although for the others it is still undetermined [17] .IntroductionThe aim of the present study is to show the state of the art, exploring the potential antiviral activity of known marine antioxidant compounds.", [["the present study", "TEST", 148, 165], ["antiviral activity", "OBSERVATION", 223, 241], ["marine", "OBSERVATION_MODIFIER", 251, 257], ["antioxidant compounds", "OBSERVATION", 258, 279]]], ["For that, we explore the relationship between oxidative stress and viral infections, looking for solutions through the deciphering of cell signaling pathways that can inhibit virus replication and infections, and the mechanisms of action of potential antiviral molecules.Viral Infections and Oxidative StressThe global public health emergency of international concern by 30 January 2020 regards the novel coronavirus [18] , which is the direct cause of the severe pneumonia (COVID-19), with a high rate of transmission and infectivity.", [["cell", "ANATOMY", 134, 138], ["viral infections", "DISEASE", 67, 83], ["infections", "DISEASE", 197, 207], ["Viral Infections", "DISEASE", 271, 287], ["pneumonia", "DISEASE", 464, 473], ["cell", "CELL", 134, 138], ["coronavirus", "ORGANISM", 405, 416], ["antiviral molecules", "PROTEIN", 251, 270], ["oxidative stress", "PROBLEM", 46, 62], ["viral infections", "PROBLEM", 67, 83], ["solutions", "TREATMENT", 97, 106], ["cell signaling pathways", "TREATMENT", 134, 157], ["virus replication", "PROBLEM", 175, 192], ["infections", "PROBLEM", 197, 207], ["potential antiviral molecules", "PROBLEM", 241, 270], ["Viral Infections", "PROBLEM", 271, 287], ["Oxidative Stress", "PROBLEM", 292, 308], ["the novel coronavirus", "PROBLEM", 395, 416], ["the severe pneumonia", "PROBLEM", 453, 473], ["COVID", "TEST", 475, 480], ["infectivity", "PROBLEM", 523, 534], ["viral infections", "OBSERVATION", 67, 83], ["antiviral molecules", "OBSERVATION", 251, 270], ["Infections", "OBSERVATION", 277, 287], ["Oxidative Stress", "OBSERVATION", 292, 308], ["global", "OBSERVATION_MODIFIER", 312, 318], ["severe", "OBSERVATION_MODIFIER", 457, 463], ["pneumonia", "OBSERVATION", 464, 473]]], ["The 85% of critically ill patients with COVID-19 showed leukocytosis, high levels of monocytes and neutrophils, and lymphopenia [19] , which is a lack of lymphocytes, with patients dying with comorbidity and high levels of plasma cytokines [20] .", [["monocytes", "ANATOMY", 85, 94], ["neutrophils", "ANATOMY", 99, 110], ["lymphocytes", "ANATOMY", 154, 165], ["plasma", "ANATOMY", 223, 229], ["critically ill", "DISEASE", 11, 25], ["leukocytosis", "DISEASE", 56, 68], ["lymphopenia", "DISEASE", 116, 127], ["patients", "ORGANISM", 26, 34], ["monocytes", "CELL", 85, 94], ["neutrophils", "CELL", 99, 110], ["lymphocytes", "CELL", 154, 165], ["patients", "ORGANISM", 172, 180], ["plasma", "ORGANISM_SUBSTANCE", 223, 229], ["monocytes", "CELL_TYPE", 85, 94], ["neutrophils", "CELL_TYPE", 99, 110], ["lymphocytes", "CELL_TYPE", 154, 165], ["plasma cytokines", "PROTEIN", 223, 239], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 172, 180], ["COVID", "TEST", 40, 45], ["leukocytosis", "PROBLEM", 56, 68], ["high levels of monocytes", "PROBLEM", 70, 94], ["neutrophils", "TEST", 99, 110], ["lymphopenia", "PROBLEM", 116, 127], ["a lack of lymphocytes", "PROBLEM", 144, 165], ["comorbidity", "PROBLEM", 192, 203], ["plasma cytokines", "TEST", 223, 239], ["leukocytosis", "OBSERVATION", 56, 68], ["high levels", "OBSERVATION_MODIFIER", 70, 81], ["neutrophils", "ANATOMY", 99, 110], ["lymphopenia", "OBSERVATION", 116, 127]]], ["Lymphopenia and hypercytokinemia are directly correlated with increased severity, mortality and a dysregulated immunological response [21] .", [["Lymphopenia", "DISEASE", 0, 11], ["hypercytokinemia", "DISEASE", 16, 32], ["Lymphopenia", "PROBLEM", 0, 11], ["hypercytokinemia", "PROBLEM", 16, 32], ["increased severity", "PROBLEM", 62, 80], ["a dysregulated immunological response", "PROBLEM", 96, 133], ["increased", "OBSERVATION_MODIFIER", 62, 71], ["severity", "OBSERVATION_MODIFIER", 72, 80]]], ["First epidemiological indications reveal that the COVID-19 patients requiring intensive care are older and are more likely to have hypertension, diabetes, cardiovascular or cerebrovascular pathologies [22] .", [["cardiovascular", "ANATOMY", 155, 169], ["cerebrovascular", "ANATOMY", 173, 188], ["hypertension", "DISEASE", 131, 143], ["diabetes", "DISEASE", 145, 153], ["cardiovascular or cerebrovascular pathologies", "DISEASE", 155, 200], ["patients", "ORGANISM", 59, 67], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 173, 188], ["patients", "SPECIES", 59, 67], ["the COVID", "TEST", 46, 55], ["intensive care", "TREATMENT", 78, 92], ["hypertension", "PROBLEM", 131, 143], ["diabetes", "PROBLEM", 145, 153], ["cardiovascular or cerebrovascular pathologies", "PROBLEM", 155, 200], ["hypertension", "OBSERVATION", 131, 143], ["diabetes", "OBSERVATION", 145, 153], ["cerebrovascular", "ANATOMY", 173, 188]]], ["Aging and chronic diseases induce chronic endothelial dysfunction that provokes disassembly of intercellular junctions, endothelial cell death and blood-tissue barrier disruption, along with enhanced leukocyte adhesion and extravasation, which could contribute to explaining the lymphopenia observed in severe COVID-19 patients [23] .", [["endothelial", "ANATOMY", 42, 53], ["intercellular junctions", "ANATOMY", 95, 118], ["endothelial cell", "ANATOMY", 120, 136], ["blood", "ANATOMY", 147, 152], ["tissue barrier", "ANATOMY", 153, 167], ["leukocyte", "ANATOMY", 200, 209], ["chronic diseases", "DISEASE", 10, 26], ["lymphopenia", "DISEASE", 279, 290], ["COVID", "DISEASE", 310, 315], ["endothelial", "CELL", 42, 53], ["intercellular junctions", "CELLULAR_COMPONENT", 95, 118], ["endothelial cell", "CELL", 120, 136], ["blood-tissue barrier", "TISSUE", 147, 167], ["leukocyte", "CELL", 200, 209], ["patients", "ORGANISM", 319, 327], ["patients", "SPECIES", 319, 327], ["chronic diseases", "PROBLEM", 10, 26], ["chronic endothelial dysfunction", "PROBLEM", 34, 65], ["endothelial cell death", "PROBLEM", 120, 142], ["blood-tissue barrier disruption", "PROBLEM", 147, 178], ["enhanced leukocyte adhesion", "PROBLEM", 191, 218], ["extravasation", "PROBLEM", 223, 236], ["the lymphopenia", "PROBLEM", 275, 290], ["severe COVID", "PROBLEM", 303, 315], ["chronic", "OBSERVATION_MODIFIER", 10, 17], ["diseases", "OBSERVATION", 18, 26], ["chronic", "OBSERVATION_MODIFIER", 34, 41], ["endothelial dysfunction", "OBSERVATION", 42, 65], ["intercellular junctions", "OBSERVATION", 95, 118], ["endothelial cell death", "OBSERVATION", 120, 142], ["blood", "OBSERVATION_MODIFIER", 147, 152], ["-tissue", "OBSERVATION_MODIFIER", 152, 159], ["barrier disruption", "OBSERVATION", 160, 178], ["enhanced", "OBSERVATION_MODIFIER", 191, 199], ["leukocyte adhesion", "OBSERVATION", 200, 218], ["extravasation", "OBSERVATION", 223, 236], ["lymphopenia", "OBSERVATION", 279, 290], ["severe", "OBSERVATION_MODIFIER", 303, 309]]], ["Endothelial dysfunction increases oxidative stress and systemic inflammation, glycocalyx degradation and inducing a procoagulant and antifibrinolytic state [24] .", [["Endothelial", "ANATOMY", 0, 11], ["Endothelial dysfunction", "DISEASE", 0, 23], ["inflammation", "DISEASE", 64, 76], ["Endothelial", "CELL", 0, 11], ["glycocalyx", "CELLULAR_COMPONENT", 78, 88], ["Endothelial dysfunction", "PROBLEM", 0, 23], ["oxidative stress", "PROBLEM", 34, 50], ["systemic inflammation", "PROBLEM", 55, 76], ["glycocalyx degradation", "PROBLEM", 78, 100], ["a procoagulant and antifibrinolytic state", "PROBLEM", 114, 155], ["dysfunction", "OBSERVATION", 12, 23], ["oxidative stress", "OBSERVATION", 34, 50], ["systemic", "OBSERVATION_MODIFIER", 55, 63], ["inflammation", "OBSERVATION", 64, 76], ["glycocalyx degradation", "OBSERVATION", 78, 100]]], ["In some, especially old patients, with COVID19 infection together with other persistent comorbidity chronic states, these pathways could induce severe respiratory failure [25] .Viral Infections and Oxidative StressCOVID-19 infection enters into the elective targets for viral diseases, which are, more generally, epithelial tissues, lung (influenza virus, coronavirus [26] ), liver (HCV and HCV [27] ) and cervix (HPV [28] ), all of which are strongly sensitive to oxidative stress and damages [29] .Viral Infections and Oxidative StressROS play a fundamental role in the normal functioning of the immune system and in the induction of proliferation of T cells and immunological defense [30] .", [["respiratory", "ANATOMY", 151, 162], ["epithelial tissues", "ANATOMY", 313, 331], ["lung", "ANATOMY", 333, 337], ["liver", "ANATOMY", 376, 381], ["cervix", "ANATOMY", 406, 412], ["immune system", "ANATOMY", 598, 611], ["T cells", "ANATOMY", 653, 660], ["infection", "DISEASE", 47, 56], ["respiratory failure", "DISEASE", 151, 170], ["Viral Infections", "DISEASE", 177, 193], ["infection", "DISEASE", 223, 232], ["viral diseases", "DISEASE", 270, 284], ["influenza virus, coronavirus [26] ), liver (HCV and HCV [27] ) and cervix", "DISEASE", 339, 412], ["Viral Infections", "DISEASE", 500, 516], ["patients", "ORGANISM", 24, 32], ["COVID19", "GENE_OR_GENE_PRODUCT", 39, 46], ["epithelial tissues", "TISSUE", 313, 331], ["lung", "ORGAN", 333, 337], ["influenza virus", "ORGANISM", 339, 354], ["coronavirus", "ORGANISM", 356, 367], ["liver", "ORGAN", 376, 381], ["cervix", "ORGAN", 406, 412], ["immune system", "ANATOMICAL_SYSTEM", 598, 611], ["T cells", "CELL", 653, 660], ["T cells", "CELL_TYPE", 653, 660], ["patients", "SPECIES", 24, 32], ["influenza virus", "SPECIES", 339, 354], ["StressCOVID-19", "SPECIES", 208, 222], ["HCV", "SPECIES", 383, 386], ["HCV", "SPECIES", 391, 394], ["COVID19 infection", "PROBLEM", 39, 56], ["other persistent comorbidity chronic states", "PROBLEM", 71, 114], ["severe respiratory failure", "PROBLEM", 144, 170], ["Viral Infections", "PROBLEM", 177, 193], ["Oxidative StressCOVID-19 infection", "PROBLEM", 198, 232], ["the elective targets", "TREATMENT", 245, 265], ["viral diseases", "PROBLEM", 270, 284], ["lung (influenza virus", "PROBLEM", 333, 354], ["coronavirus", "PROBLEM", 356, 367], ["liver (HCV and HCV", "PROBLEM", 376, 394], ["cervix (HPV", "PROBLEM", 406, 417], ["Viral Infections", "PROBLEM", 500, 516], ["Oxidative StressROS play", "PROBLEM", 521, 545], ["T cells", "PROBLEM", 653, 660], ["infection", "OBSERVATION", 47, 56], ["persistent", "OBSERVATION_MODIFIER", 77, 87], ["comorbidity", "OBSERVATION", 88, 99], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["respiratory failure", "OBSERVATION", 151, 170], ["Infections", "OBSERVATION", 183, 193], ["infection", "OBSERVATION", 223, 232], ["viral diseases", "OBSERVATION", 270, 284], ["epithelial tissues", "ANATOMY", 313, 331], ["lung", "ANATOMY", 333, 337], ["influenza virus", "OBSERVATION", 339, 354], ["liver", "ANATOMY", 376, 381], ["HCV", "OBSERVATION", 383, 386], ["cervix", "ANATOMY", 406, 412], ["Infections", "OBSERVATION", 506, 516], ["Oxidative StressROS", "OBSERVATION", 521, 540]]], ["Oxidative stress represents a key factor in inflammation cell signaling for the regulation of cytokines and growth factors, as well as for immunomodulation and apoptosis [31] .", [["cell", "ANATOMY", 57, 61], ["inflammation", "DISEASE", 44, 56], ["inflammation cell", "CELL", 44, 61], ["cytokines", "PROTEIN", 94, 103], ["growth factors", "PROTEIN", 108, 122], ["Oxidative stress", "PROBLEM", 0, 16], ["inflammation cell signaling", "PROBLEM", 44, 71], ["cytokines and growth factors", "PROBLEM", 94, 122], ["immunomodulation", "PROBLEM", 139, 155], ["apoptosis", "PROBLEM", 160, 169], ["inflammation cell", "OBSERVATION", 44, 61]]], ["Recent observations have drawn attention to the possibility that interactions between ROS and the human immunodeficiency virus (HIV) may also play a role in the pathogenesis of many other viruses as well [32] .", [["ROS", "CHEMICAL", 86, 89], ["human immunodeficiency virus (HIV)", "DISEASE", 98, 132], ["ROS", "SIMPLE_CHEMICAL", 86, 89], ["human immunodeficiency virus", "ORGANISM", 98, 126], ["HIV", "ORGANISM", 128, 131], ["human immunodeficiency virus (HIV", "SPECIES", 98, 131], ["human immunodeficiency virus", "SPECIES", 98, 126], ["HIV", "SPECIES", 128, 131], ["Recent observations", "TEST", 0, 19], ["interactions between ROS", "PROBLEM", 65, 89], ["the human immunodeficiency virus", "PROBLEM", 94, 126], ["many other viruses", "PROBLEM", 177, 195]]], ["Indeed, the role of oxidative stress has been demonstrated in a number of viral infection diseases [33] , where cell pro-oxidative signaling co-occurred with viral infections [34] .Viral Infections and Oxidative StressViral infection is generally divided into three stages:Viral Infections and Oxidative Stress\u2022 Stage I, which consists of virus adhesion, adsorption, entry and invasion of cells; \u2022 Stage II, or eclipse phase, during which the cell is forced to replicate multiple copies of virus genome; \u2022 Stage III, or maturity and release of virus particles (virions).Viral Infections and Oxidative StressViruses enter the cell through specific receptors and coreceptors using the phagocytosis mechanism.", [["cell", "ANATOMY", 112, 116], ["cells", "ANATOMY", 389, 394], ["cell", "ANATOMY", 443, 447], ["cell", "ANATOMY", 625, 629], ["viral infection diseases", "DISEASE", 74, 98], ["viral infections", "DISEASE", 158, 174], ["Viral Infections", "DISEASE", 181, 197], ["StressViral infection", "DISEASE", 212, 233], ["Viral Infections", "DISEASE", 273, 289], ["Viral Infections", "DISEASE", 570, 586], ["cell", "CELL", 112, 116], ["cells", "CELL", 389, 394], ["cell", "CELL", 443, 447], ["Stage III", "GENE_OR_GENE_PRODUCT", 506, 515], ["cell", "CELL", 625, 629], ["virus genome", "DNA", 490, 502], ["coreceptors", "PROTEIN", 661, 672], ["oxidative stress", "PROBLEM", 20, 36], ["viral infection diseases", "PROBLEM", 74, 98], ["cell pro-oxidative signaling", "PROBLEM", 112, 140], ["viral infections", "PROBLEM", 158, 174], ["Viral Infections", "PROBLEM", 181, 197], ["Oxidative StressViral infection", "PROBLEM", 202, 233], ["Viral Infections", "PROBLEM", 273, 289], ["Oxidative Stress\u2022 Stage I", "PROBLEM", 294, 319], ["virus adhesion", "PROBLEM", 339, 353], ["invasion of cells", "PROBLEM", 377, 394], ["Stage II, or eclipse phase", "PROBLEM", 398, 424], ["virus genome", "PROBLEM", 490, 502], ["Stage III", "PROBLEM", 506, 515], ["virus particles", "PROBLEM", 544, 559], ["Viral Infections", "PROBLEM", 570, 586], ["Oxidative StressViruses", "PROBLEM", 591, 614], ["the phagocytosis mechanism", "TREATMENT", 679, 705], ["viral", "OBSERVATION_MODIFIER", 74, 79], ["infection", "OBSERVATION", 80, 89], ["viral infections", "OBSERVATION", 158, 174], ["Infections", "OBSERVATION", 187, 197], ["Oxidative StressViral infection", "OBSERVATION", 202, 233], ["Viral Infections", "OBSERVATION", 273, 289], ["virus adhesion", "OBSERVATION", 339, 353], ["eclipse phase", "OBSERVATION_MODIFIER", 411, 424], ["virus genome", "OBSERVATION", 490, 502], ["Stage III", "OBSERVATION_MODIFIER", 506, 515], ["Infections", "OBSERVATION", 576, 586], ["Oxidative StressViruses", "OBSERVATION", 591, 614]]], ["The virus must then break out of the vesicle by which it was taken up in order to gain access to the cytoplasm [35] .", [["vesicle", "ANATOMY", 37, 44], ["cytoplasm", "ANATOMY", 101, 110], ["vesicle", "CELLULAR_COMPONENT", 37, 44], ["cytoplasm", "ORGANISM_SUBSTANCE", 101, 110], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["vesicle", "ANATOMY", 37, 44]]], ["The activation of phagocytes induces the release of pro-oxidant cytokines, such as tumor necrosis factor alpha (TNFa), or interleukin-1 and 6, paralleled with a significant iron uptake by the reticuloendothelial system [36] .", [["phagocytes", "ANATOMY", 18, 28], ["reticuloendothelial system", "ANATOMY", 192, 218], ["tumor necrosis", "DISEASE", 83, 97], ["iron", "CHEMICAL", 173, 177], ["iron", "CHEMICAL", 173, 177], ["phagocytes", "CELL", 18, 28], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 83, 110], ["TNFa", "GENE_OR_GENE_PRODUCT", 112, 116], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 122, 135], ["iron", "SIMPLE_CHEMICAL", 173, 177], ["phagocytes", "CELL_TYPE", 18, 28], ["pro-oxidant cytokines", "PROTEIN", 52, 73], ["tumor necrosis factor alpha", "PROTEIN", 83, 110], ["TNFa", "PROTEIN", 112, 116], ["interleukin-1 and 6", "PROTEIN", 122, 141], ["pro-oxidant cytokines", "PROBLEM", 52, 73], ["tumor necrosis factor alpha (TNFa)", "PROBLEM", 83, 117], ["interleukin", "TEST", 122, 133], ["a significant iron uptake", "PROBLEM", 159, 184], ["tumor", "OBSERVATION_MODIFIER", 83, 88], ["necrosis", "OBSERVATION", 89, 97], ["significant", "OBSERVATION_MODIFIER", 161, 172], ["iron uptake", "OBSERVATION", 173, 184], ["reticuloendothelial system", "ANATOMY", 192, 218]]], ["In turn, the release of TNFa from activated phagocytes induces different intracellular responses.", [["phagocytes", "ANATOMY", 44, 54], ["intracellular", "ANATOMY", 73, 86], ["TNFa", "GENE_OR_GENE_PRODUCT", 24, 28], ["phagocytes", "CELL", 44, 54], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 73, 86], ["TNFa", "PROTEIN", 24, 28], ["activated phagocytes", "CELL_TYPE", 34, 54], ["the release of TNFa", "TREATMENT", 9, 28], ["activated phagocytes", "PROBLEM", 34, 54], ["intracellular responses", "OBSERVATION", 73, 96]]], ["First, it acts on cell mitochondria inducing a pro-oxidant effect through the inhibition of the site of superoxide production (Site II).", [["cell mitochondria", "ANATOMY", 18, 35], ["superoxide", "CHEMICAL", 104, 114], ["superoxide", "CHEMICAL", 104, 114], ["cell", "CELL", 18, 22], ["mitochondria", "CELLULAR_COMPONENT", 23, 35], ["superoxide", "SIMPLE_CHEMICAL", 104, 114], ["Site II", "PROTEIN", 127, 134], ["cell mitochondria", "TREATMENT", 18, 35], ["a pro-oxidant effect", "PROBLEM", 45, 65], ["superoxide production", "TREATMENT", 104, 125]]], ["Second, TNFa induces the release of nuclear transcription factor kappa B(NF-K-B) from the cytoplasmic inhibitor protein IkB, activating at a genomic level the transcription of cellular and/or viral genes.Viral Infections and Oxidative StressMany viruses induce host cell death, by apoptosis or pyroptosis among others [37] , probably to enhance replication and expansion into the entire organism [38] .", [["cytoplasmic", "ANATOMY", 90, 101], ["cellular", "ANATOMY", 176, 184], ["cell", "ANATOMY", 266, 270], ["TNFa", "CHEMICAL", 8, 12], ["Viral Infections", "DISEASE", 204, 220], ["death", "DISEASE", 271, 276], ["pyroptosis", "DISEASE", 294, 304], ["TNFa", "GENE_OR_GENE_PRODUCT", 8, 12], ["nuclear transcription factor kappa B", "GENE_OR_GENE_PRODUCT", 36, 72], ["NF-K-B", "GENE_OR_GENE_PRODUCT", 73, 79], ["cytoplasmic", "ORGANISM_SUBSTANCE", 90, 101], ["IkB", "GENE_OR_GENE_PRODUCT", 120, 123], ["cellular", "CELL", 176, 184], ["host cell", "CELL", 261, 270], ["TNFa", "PROTEIN", 8, 12], ["nuclear transcription factor kappa B", "PROTEIN", 36, 72], ["NF-K-B", "PROTEIN", 73, 79], ["cytoplasmic inhibitor protein", "PROTEIN", 90, 119], ["IkB", "PROTEIN", 120, 123], ["cellular and/or viral genes", "DNA", 176, 203], ["nuclear transcription", "TEST", 36, 57], ["kappa B", "TEST", 65, 72], ["NF", "TEST", 73, 75], ["the cytoplasmic inhibitor protein IkB", "TEST", 86, 123], ["viral genes", "PROBLEM", 192, 203], ["Viral Infections", "PROBLEM", 204, 220], ["Oxidative StressMany viruses", "PROBLEM", 225, 253], ["host cell death", "PROBLEM", 261, 276], ["apoptosis", "PROBLEM", 281, 290], ["pyroptosis", "PROBLEM", 294, 304], ["viral genes", "OBSERVATION", 192, 203], ["Infections", "OBSERVATION", 210, 220], ["Oxidative StressMany viruses", "OBSERVATION", 225, 253], ["host cell death", "OBSERVATION", 261, 276], ["pyroptosis", "OBSERVATION_MODIFIER", 294, 304]]], ["For example, HIV-1 activates pathways causing CD4 T-cell death in infected hosts due to caspase-1-mediated pyroptosis triggered by abortive viral infection.", [["CD4 T-cell", "ANATOMY", 46, 56], ["pyroptosis", "DISEASE", 107, 117], ["viral infection", "DISEASE", 140, 155], ["HIV-1", "ORGANISM", 13, 18], ["CD4", "GENE_OR_GENE_PRODUCT", 46, 49], ["caspase-1", "GENE_OR_GENE_PRODUCT", 88, 97], ["CD4", "PROTEIN", 46, 49], ["caspase-1", "PROTEIN", 88, 97], ["HIV-1", "SPECIES", 13, 18], ["HIV-1", "SPECIES", 13, 18], ["HIV", "TEST", 13, 16], ["CD4 T-cell death", "PROBLEM", 46, 62], ["infected hosts", "PROBLEM", 66, 80], ["caspase", "PROBLEM", 88, 95], ["mediated pyroptosis", "PROBLEM", 98, 117], ["abortive viral infection", "PROBLEM", 131, 155], ["pyroptosis", "OBSERVATION", 107, 117], ["abortive", "OBSERVATION_MODIFIER", 131, 139], ["viral infection", "OBSERVATION", 140, 155]]], ["Pyroptosis corresponds to an intensely inflammatory form of programmed cell death in which cytoplasmic contents and proinflammatory cytokines, including IL-1\u03b2, are released.", [["cell", "ANATOMY", 71, 75], ["cytoplasmic", "ANATOMY", 91, 102], ["Pyroptosis", "DISEASE", 0, 10], ["cell", "CELL", 71, 75], ["cytoplasmic", "ORGANISM_SUBSTANCE", 91, 102], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 153, 158], ["proinflammatory cytokines", "PROTEIN", 116, 141], ["IL-1\u03b2", "PROTEIN", 153, 158], ["Pyroptosis", "PROBLEM", 0, 10], ["programmed cell death", "PROBLEM", 60, 81], ["cytoplasmic contents", "PROBLEM", 91, 111], ["proinflammatory cytokines", "TEST", 116, 141], ["intensely", "OBSERVATION_MODIFIER", 29, 38], ["inflammatory", "OBSERVATION_MODIFIER", 39, 51], ["programmed cell death", "OBSERVATION", 60, 81], ["cytoplasmic contents", "OBSERVATION", 91, 111], ["proinflammatory cytokines", "OBSERVATION", 116, 141]]], ["This death pathway relies on the two signature events in HIV infection-CD4 T-cell depletion and chronic inflammation-and creates a pathogenic vicious cycle in which dying CD4 T cells release inflammatory signals inducing enlarged cell death [39] .Viral Infections and Oxidative StressConsidering this evidence, antioxidant compounds are able to inhibit immune system cells (lymphocytes) through apoptosis and then release proinflammatory cytokines (IL-1, IL-6 and TNFa) that are likely to prevent lymphopenia, hypoferremia and, thus lower the viral replication in patients suffering severe viral diseases [40] .", [["CD4 T-cell", "ANATOMY", 71, 81], ["CD4 T cells", "ANATOMY", 171, 182], ["cell", "ANATOMY", 230, 234], ["immune system cells", "ANATOMY", 353, 372], ["lymphocytes", "ANATOMY", 374, 385], ["death", "DISEASE", 5, 10], ["HIV infection", "DISEASE", 57, 70], ["inflammation", "DISEASE", 104, 116], ["death", "DISEASE", 235, 240], ["Viral Infections", "DISEASE", 247, 263], ["lymphopenia", "DISEASE", 497, 508], ["hypoferremia", "DISEASE", 510, 522], ["viral diseases", "DISEASE", 590, 604], ["HIV", "ORGANISM", 57, 60], ["CD4 T cells", "CELL", 171, 182], ["cell", "CELL", 230, 234], ["immune system cells", "CELL", 353, 372], ["lymphocytes", "CELL", 374, 385], ["IL-1", "GENE_OR_GENE_PRODUCT", 449, 453], ["IL-6", "GENE_OR_GENE_PRODUCT", 455, 459], ["TNFa", "GENE_OR_GENE_PRODUCT", 464, 468], ["patients", "ORGANISM", 564, 572], ["CD4", "PROTEIN", 71, 74], ["CD4 T cells", "CELL_TYPE", 171, 182], ["immune system cells", "CELL_TYPE", 353, 372], ["lymphocytes", "CELL_TYPE", 374, 385], ["proinflammatory cytokines", "PROTEIN", 422, 447], ["IL-1, IL-6", "PROTEIN", 449, 459], ["TNFa", "PROTEIN", 464, 468], ["patients", "SPECIES", 564, 572], ["HIV", "SPECIES", 57, 60], ["This death pathway", "PROBLEM", 0, 18], ["the two signature events", "PROBLEM", 29, 53], ["HIV infection", "PROBLEM", 57, 70], ["CD4 T-cell depletion", "PROBLEM", 71, 91], ["chronic inflammation", "PROBLEM", 96, 116], ["a pathogenic vicious cycle", "PROBLEM", 129, 155], ["inflammatory signals", "PROBLEM", 191, 211], ["enlarged cell death", "PROBLEM", 221, 240], ["Viral Infections", "PROBLEM", 247, 263], ["Oxidative StressConsidering", "PROBLEM", 268, 295], ["antioxidant compounds", "PROBLEM", 311, 332], ["apoptosis", "PROBLEM", 395, 404], ["proinflammatory cytokines", "TEST", 422, 447], ["IL", "TEST", 449, 451], ["IL", "TEST", 455, 457], ["TNFa", "TREATMENT", 464, 468], ["lymphopenia", "PROBLEM", 497, 508], ["hypoferremia", "PROBLEM", 510, 522], ["the viral replication", "TREATMENT", 539, 560], ["severe viral diseases", "PROBLEM", 583, 604], ["cell depletion", "OBSERVATION", 77, 91], ["chronic", "OBSERVATION_MODIFIER", 96, 103], ["inflammation", "OBSERVATION", 104, 116], ["enlarged", "OBSERVATION_MODIFIER", 221, 229], ["cell death", "OBSERVATION", 230, 240], ["Infections", "OBSERVATION", 253, 263], ["Oxidative StressConsidering", "OBSERVATION", 268, 295], ["likely to prevent", "UNCERTAINTY", 479, 496], ["lymphopenia", "OBSERVATION", 497, 508], ["viral replication", "OBSERVATION", 543, 560]]], ["Antioxidants such as vitamin E [41] are able to prevent the inhibition of the site of superoxide production (Site II), while the NF-kB-induced gene transcription can be inhibited by thiol groups [42] belonging to molecules that strongly interact with the antioxidant system [43, 44] .", [["vitamin E", "CHEMICAL", 21, 30], ["superoxide", "CHEMICAL", 86, 96], ["thiol", "CHEMICAL", 182, 187], ["vitamin E", "CHEMICAL", 21, 30], ["superoxide", "CHEMICAL", 86, 96], ["thiol", "CHEMICAL", 182, 187], ["vitamin E [41]", "SIMPLE_CHEMICAL", 21, 35], ["superoxide", "SIMPLE_CHEMICAL", 86, 96], ["NF-kB", "GENE_OR_GENE_PRODUCT", 129, 134], ["thiol groups [42]", "SIMPLE_CHEMICAL", 182, 199], ["NF-kB", "PROTEIN", 129, 134], ["Antioxidants", "TREATMENT", 0, 12], ["vitamin E", "TREATMENT", 21, 30], ["gene transcription", "TREATMENT", 143, 161]]], ["Antioxidant therapy might further be related to the inhibition of virally induced cell death by antioxidants that scavenge peroxides, such as N-acetylcysteine and glutathione peroxidase [45] .", [["cell", "ANATOMY", 82, 86], ["death", "DISEASE", 87, 92], ["N-acetylcysteine", "CHEMICAL", 142, 158], ["glutathione", "CHEMICAL", 163, 174], ["peroxides", "CHEMICAL", 123, 132], ["N-acetylcysteine", "CHEMICAL", 142, 158], ["glutathione", "CHEMICAL", 163, 174], ["cell", "CELL", 82, 86], ["peroxides", "SIMPLE_CHEMICAL", 123, 132], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 142, 158], ["glutathione peroxidase", "GENE_OR_GENE_PRODUCT", 163, 185], ["glutathione peroxidase", "PROTEIN", 163, 185], ["Antioxidant therapy", "TREATMENT", 0, 19], ["virally induced cell death", "TREATMENT", 66, 92], ["antioxidants", "TREATMENT", 96, 108], ["scavenge peroxides", "TREATMENT", 114, 132], ["N-acetylcysteine and glutathione peroxidase", "TREATMENT", 142, 185]]], ["It was observed that the antioxidant N-acetylcysteine blocks viral production in monocyte cell lines, which are the major reservoir for HIV in infected patients [46] .", [["monocyte cell lines", "ANATOMY", 81, 100], ["N-acetylcysteine", "CHEMICAL", 37, 53], ["HIV in infected", "DISEASE", 136, 151], ["N-acetylcysteine", "CHEMICAL", 37, 53], ["antioxidant N-acetylcysteine", "SIMPLE_CHEMICAL", 25, 53], ["monocyte cell lines", "CELL", 81, 100], ["HIV", "ORGANISM", 136, 139], ["patients", "ORGANISM", 152, 160], ["monocyte cell lines", "CELL_LINE", 81, 100], ["HIV", "SPECIES", 136, 139], ["patients", "SPECIES", 152, 160], ["HIV", "SPECIES", 136, 139], ["the antioxidant N-acetylcysteine blocks", "TREATMENT", 21, 60], ["viral production in monocyte cell lines", "TREATMENT", 61, 100], ["HIV", "PROBLEM", 136, 139], ["monocyte cell lines", "OBSERVATION", 81, 100]]], ["The epigallocatechin-3-gallate from green tea blocks HIV entry [47] due to its antioxidant properties.Marine Antioxidants and Antiviral ActivityTherapeutic treatments to inhibit or reduce virus replication in human cells are unfortunately restricted.", [["cells", "ANATOMY", 215, 220], ["epigallocatechin-3-gallate", "CHEMICAL", 4, 30], ["green tea", "CHEMICAL", 36, 45], ["epigallocatechin-3-gallate", "CHEMICAL", 4, 30], ["epigallocatechin-3-gallate", "SIMPLE_CHEMICAL", 4, 30], ["green tea", "SIMPLE_CHEMICAL", 36, 45], ["HIV", "ORGANISM", 53, 56], ["human", "ORGANISM", 209, 214], ["cells", "CELL", 215, 220], ["human cells", "CELL_TYPE", 209, 220], ["human", "SPECIES", 209, 214], ["HIV", "SPECIES", 53, 56], ["human", "SPECIES", 209, 214], ["The epigallocatechin", "TEST", 0, 20], ["its antioxidant properties", "TREATMENT", 75, 101], ["Marine Antioxidants", "TREATMENT", 102, 121], ["Antiviral ActivityTherapeutic treatments", "TREATMENT", 126, 166], ["virus replication in human cells", "TREATMENT", 188, 220]]], ["Known examples are mostly anti-HIV drugs, such as ritonavir, sequinavir, or antiflu, such as lopinavir, abif\u00ecgavan, or anti-Ebola reagents.", [["ritonavir", "CHEMICAL", 50, 59], ["sequinavir", "CHEMICAL", 61, 71], ["antiflu", "CHEMICAL", 76, 83], ["lopinavir", "CHEMICAL", 93, 102], ["abif\u00ecgavan", "CHEMICAL", 104, 114], ["ritonavir", "CHEMICAL", 50, 59], ["sequinavir", "CHEMICAL", 61, 71], ["antiflu", "CHEMICAL", 76, 83], ["lopinavir", "CHEMICAL", 93, 102], ["abif\u00ecgavan", "CHEMICAL", 104, 114], ["ritonavir", "SIMPLE_CHEMICAL", 50, 59], ["sequinavir", "SIMPLE_CHEMICAL", 61, 71], ["antiflu", "SIMPLE_CHEMICAL", 76, 83], ["lopinavir", "SIMPLE_CHEMICAL", 93, 102], ["abif\u00ecgavan", "SIMPLE_CHEMICAL", 104, 114], ["anti-Ebola reagents", "SIMPLE_CHEMICAL", 119, 138], ["anti-HIV drugs", "TREATMENT", 26, 40], ["ritonavir", "TREATMENT", 50, 59], ["sequinavir", "TREATMENT", 61, 71], ["antiflu", "TREATMENT", 76, 83], ["lopinavir", "TREATMENT", 93, 102], ["abif\u00ecgavan", "TREATMENT", 104, 114], ["anti-Ebola reagents", "TREATMENT", 119, 138], ["mostly", "OBSERVATION_MODIFIER", 19, 25], ["anti-HIV drugs", "OBSERVATION", 26, 40]]], ["Many antiviral drugs are synthetic organic chemicals or natural derived products, for example, from secondary metabolites of plants [50] .", [["Many antiviral drugs", "TREATMENT", 0, 20], ["synthetic organic chemicals", "TREATMENT", 25, 52], ["natural derived products", "TREATMENT", 56, 80], ["antiviral drugs", "OBSERVATION", 5, 20]]], ["In the emergent \"blue\" technology era, there is a growing interest in marine-derived antiviral compounds.", [["antiviral compounds", "TREATMENT", 85, 104], ["antiviral compounds", "OBSERVATION", 85, 104]]], ["Marine organisms represent a rich source of many antioxidants that are promising for the development of drugs for the prevention and treatment of various chronic and acute human diseases [51] .", [["human", "ORGANISM", 172, 177], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 172, 177], ["Marine organisms", "PROBLEM", 0, 16], ["many antioxidants", "TREATMENT", 44, 61], ["drugs", "TREATMENT", 104, 109], ["the prevention", "TREATMENT", 114, 128], ["treatment", "TREATMENT", 133, 142], ["various chronic and acute human diseases", "PROBLEM", 146, 186], ["chronic", "OBSERVATION_MODIFIER", 154, 161], ["acute", "OBSERVATION_MODIFIER", 166, 171], ["human diseases", "OBSERVATION", 172, 186]]], ["Thus, thousands of compounds from various marine organisms such as algae, bacteria, fungi, marine invertebrates or sponges have been screened and 21 of them have demonstrated antiviral activities [17] .", [["marine invertebrates", "ORGANISM", 91, 111], ["various marine organisms", "PROBLEM", 34, 58], ["algae", "PROBLEM", 67, 72], ["bacteria", "PROBLEM", 74, 82], ["fungi", "PROBLEM", 84, 89], ["sponges", "TREATMENT", 115, 122]]], ["In 2018, Fedoreyev et al. [2] reported that an antioxidant \"soup\", containing echinochrome A (pigment of sea urchins), ascorbic acid (vitamin C) and \u03b1-Tocopherol (vitamin E) possess in vitro antiviral activity against RNA-containing tick-borne encephalitis virus and DNA-containing herpes simplex virus type 1 [2] .", [["echinochrome A", "CHEMICAL", 78, 92], ["ascorbic acid", "CHEMICAL", 119, 132], ["vitamin C", "CHEMICAL", 134, 143], ["\u03b1-Tocopherol", "CHEMICAL", 149, 161], ["vitamin E", "CHEMICAL", 163, 172], ["encephalitis", "DISEASE", 244, 256], ["herpes simplex virus", "DISEASE", 282, 302], ["echinochrome A", "CHEMICAL", 78, 92], ["ascorbic acid", "CHEMICAL", 119, 132], ["vitamin C", "CHEMICAL", 134, 143], ["\u03b1-Tocopherol", "CHEMICAL", 149, 161], ["vitamin E", "CHEMICAL", 163, 172], ["echinochrome A", "SIMPLE_CHEMICAL", 78, 92], ["sea urchins", "ORGANISM", 105, 116], ["ascorbic acid", "SIMPLE_CHEMICAL", 119, 132], ["vitamin C", "SIMPLE_CHEMICAL", 134, 143], ["\u03b1-Tocopherol", "SIMPLE_CHEMICAL", 149, 161], ["vitamin E", "SIMPLE_CHEMICAL", 163, 172], ["tick-borne encephalitis virus", "ORGANISM", 233, 262], ["DNA", "CELLULAR_COMPONENT", 267, 270], ["herpes simplex virus type 1", "ORGANISM", 282, 309], ["tick-borne encephalitis virus", "SPECIES", 233, 262], ["herpes simplex virus", "SPECIES", 282, 302], ["tick-borne encephalitis virus", "SPECIES", 233, 262], ["herpes simplex virus type 1", "SPECIES", 282, 309], ["A (pigment of sea urchins", "TREATMENT", 91, 116], ["ascorbic acid (vitamin C)", "TREATMENT", 119, 144], ["\u03b1-Tocopherol (vitamin E)", "TREATMENT", 149, 173], ["vitro antiviral activity", "TREATMENT", 185, 209], ["RNA", "TEST", 218, 221], ["tick-borne encephalitis virus", "PROBLEM", 233, 262], ["DNA", "PROBLEM", 267, 270], ["herpes simplex virus type", "PROBLEM", 282, 307]]], ["This study also demonstrated that a synergistic effect of antioxidant molecules can be effective against virus infections.Marine Antioxidants and Antiviral ActivityWhile the research and development of antiviral compounds are mainly focused on macroalgae [52] , the interest in microalgae and cyanobacteria has increased since they are known to produce many antioxidant molecules, which also possess antimicrobial, anticancer and antiviral activities [53] .", [["anticancer", "ANATOMY", 415, 425], ["infections", "DISEASE", 111, 121], ["anticancer", "CANCER", 415, 425], ["This study", "TEST", 0, 10], ["a synergistic effect of antioxidant molecules", "TREATMENT", 34, 79], ["virus infections", "PROBLEM", 105, 121], ["Marine Antioxidants", "TREATMENT", 122, 141], ["Antiviral Activity", "TREATMENT", 146, 164], ["antiviral compounds", "TREATMENT", 202, 221], ["cyanobacteria", "PROBLEM", 293, 306], ["many antioxidant molecules", "PROBLEM", 353, 379], ["antimicrobial, anticancer", "TREATMENT", 400, 425], ["antiviral activities", "TREATMENT", 430, 450], ["Antiviral Activity", "OBSERVATION", 146, 164], ["antiviral compounds", "OBSERVATION", 202, 221], ["antioxidant molecules", "OBSERVATION", 358, 379], ["antimicrobial", "OBSERVATION_MODIFIER", 400, 413]]], ["Moreover, cyanobacteria and microalgae in general are promising since the relatively low-compared to higher plants-requirements for growth make them good candidates for the production of antiviral agents at an industrial scale [54] .", [["cyanobacteria", "PROBLEM", 10, 23], ["microalgae", "PROBLEM", 28, 38], ["antiviral agents", "TREATMENT", 187, 203], ["cyanobacteria", "OBSERVATION", 10, 23], ["microalgae", "OBSERVATION_MODIFIER", 28, 38]]], ["The compounds mainly capable of antiviral activities comprise sulfated polysaccharides, phenolic compounds, and organic acids [55] .Marine Antioxidants and Antiviral ActivityIn recent years, it has been shown that marine sulfated polysaccharides possess a wide range of bioactivities, such as anticoagulant, antioxidant, anti-inflammatory, antiviral, antibacterial, antiproliferative, antitumor, anticomplementary and antiadhesive activities [56] .", [["antitumor", "ANATOMY", 385, 394], ["organic acids", "CHEMICAL", 112, 125], ["sulfated polysaccharides", "SIMPLE_CHEMICAL", 62, 86], ["phenolic compounds", "SIMPLE_CHEMICAL", 88, 106], ["organic acids", "SIMPLE_CHEMICAL", 112, 125], ["marine sulfated polysaccharides", "SIMPLE_CHEMICAL", 214, 245], ["antitumor", "CANCER", 385, 394], ["antiviral activities", "TREATMENT", 32, 52], ["sulfated polysaccharides", "TREATMENT", 62, 86], ["phenolic compounds", "TREATMENT", 88, 106], ["Marine Antioxidants", "TREATMENT", 132, 151], ["Antiviral Activity", "TREATMENT", 156, 174], ["marine sulfated polysaccharides", "TREATMENT", 214, 245], ["anticoagulant", "TREATMENT", 293, 306], ["antioxidant", "TREATMENT", 308, 319], ["anti-inflammatory", "TREATMENT", 321, 338], ["antiviral", "TREATMENT", 340, 349], ["antibacterial", "TREATMENT", 351, 364], ["antiproliferative", "TREATMENT", 366, 383], ["antitumor", "TREATMENT", 385, 394], ["anticomplementary and antiadhesive activities", "TREATMENT", 396, 441], ["Antiviral Activity", "OBSERVATION", 156, 174]]], ["Interestingly, the antiviral activity exhibited by these compounds is often related to their immunomodulation and anticancer activities [57] .", [["anticancer", "ANATOMY", 114, 124], ["anticancer", "CANCER", 114, 124], ["the antiviral activity", "PROBLEM", 15, 37], ["antiviral activity", "OBSERVATION", 19, 37]]], ["The double effect, anticancer and antiviral, of these natural compounds is mainly related to their capability to inhibit cell proliferation and to activate IFN signaling pathways that inhibit kidney and liver cancer progression [58] .Marine Antioxidants and Antiviral ActivityIn general, antiviral compounds extracted from (micro)algae are mainly polysaccharides that have been screened against pathogenic human viruses ( Table 1 ).", [["anticancer", "ANATOMY", 19, 29], ["cell", "ANATOMY", 121, 125], ["kidney", "ANATOMY", 192, 198], ["liver cancer", "ANATOMY", 203, 215], ["liver cancer", "DISEASE", 203, 215], ["anticancer", "CANCER", 19, 29], ["cell", "CELL", 121, 125], ["IFN", "GENE_OR_GENE_PRODUCT", 156, 159], ["kidney", "ORGAN", 192, 198], ["liver cancer", "CANCER", 203, 215], ["(micro)algae", "SIMPLE_CHEMICAL", 323, 335], ["human", "ORGANISM", 406, 411], ["IFN", "PROTEIN", 156, 159], ["human", "SPECIES", 406, 411], ["human viruses", "SPECIES", 406, 419], ["The double effect", "PROBLEM", 0, 17], ["anticancer", "TREATMENT", 19, 29], ["antiviral", "TREATMENT", 34, 43], ["cell proliferation", "PROBLEM", 121, 139], ["IFN signaling pathways", "PROBLEM", 156, 178], ["kidney", "PROBLEM", 192, 198], ["liver cancer progression", "PROBLEM", 203, 227], ["Marine Antioxidants", "TREATMENT", 234, 253], ["Antiviral Activity", "TREATMENT", 258, 276], ["antiviral compounds", "TREATMENT", 288, 307], ["mainly polysaccharides", "PROBLEM", 340, 362], ["pathogenic human viruses", "PROBLEM", 395, 419], ["double effect", "OBSERVATION_MODIFIER", 4, 17], ["anticancer", "OBSERVATION_MODIFIER", 19, 29], ["cell proliferation", "OBSERVATION", 121, 139], ["kidney", "ANATOMY", 192, 198], ["liver", "ANATOMY", 203, 208], ["cancer", "OBSERVATION", 209, 215], ["Antiviral Activity", "OBSERVATION", 258, 276]]], ["The mechanisms of action of these compounds against viruses are not fully clarified, but the activity seems to be related to their antioxidant power inhibiting the different stages of the viral infection, and interfering with its adhesion, penetration or replication [59] .", [["viral infection", "DISEASE", 188, 203], ["viruses", "PROBLEM", 52, 59], ["the viral infection", "PROBLEM", 184, 203], ["viral", "OBSERVATION_MODIFIER", 188, 193], ["infection", "OBSERVATION", 194, 203]]], ["For example, the sulfated polysaccharide isolated from the cyanobacteria Spirulina platensis, named Spirulan, has exhibited potent antiviral activity against both the herpes simplex virus type 1 (HSV-1) and the human immunodeficiency virus type 1 (HIV-1) [87] .Marine Antioxidants and Antiviral ActivityThe sulfated polysaccharides (SPs) carrageenans from red algae (Rhodophyta) display antiviral effects on several viral agents [60] , and are significantly active against HPV [61] .", [["Spirulan", "CHEMICAL", 100, 108], ["herpes simplex virus", "DISEASE", 167, 187], ["human immunodeficiency virus", "DISEASE", 211, 239], ["carrageenans", "CHEMICAL", 338, 350], ["cyanobacteria", "ORGANISM", 59, 72], ["Spirulina platensis", "ORGANISM", 73, 92], ["Spirulan", "SIMPLE_CHEMICAL", 100, 108], ["herpes simplex virus type 1", "ORGANISM", 167, 194], ["HSV-1", "ORGANISM", 196, 201], ["human immunodeficiency virus type 1", "ORGANISM", 211, 246], ["HIV-1", "ORGANISM", 248, 253], ["sulfated polysaccharides", "SIMPLE_CHEMICAL", 307, 331], ["carrageenans", "SIMPLE_CHEMICAL", 338, 350], ["red algae", "ORGANISM", 356, 365], ["Rhodophyta)", "ORGANISM", 367, 378], ["HPV", "ORGANISM", 473, 476], ["Spirulina platensis", "SPECIES", 73, 92], ["herpes simplex virus type 1", "SPECIES", 167, 194], ["HSV-1", "SPECIES", 196, 201], ["human immunodeficiency virus type 1", "SPECIES", 211, 246], ["HIV-1", "SPECIES", 248, 253], ["Spirulina platensis", "SPECIES", 73, 92], ["herpes simplex virus type 1", "SPECIES", 167, 194], ["HSV-1", "SPECIES", 196, 201], ["human immunodeficiency virus type 1", "SPECIES", 211, 246], ["HIV-1", "SPECIES", 248, 253], ["red algae", "SPECIES", 356, 365], ["HPV", "SPECIES", 473, 476], ["the sulfated polysaccharide", "PROBLEM", 13, 40], ["the cyanobacteria Spirulina platensis", "PROBLEM", 55, 92], ["the herpes simplex virus type", "TEST", 163, 192], ["HSV", "TEST", 196, 199], ["the human immunodeficiency virus type", "TEST", 207, 244], ["HIV", "TEST", 248, 251], ["Marine Antioxidants", "TREATMENT", 261, 280], ["Antiviral ActivityThe sulfated polysaccharides (SPs) carrageenans", "TREATMENT", 285, 350], ["red algae (Rhodophyta", "TREATMENT", 356, 377], ["antiviral effects", "TREATMENT", 387, 404], ["several viral agents", "TREATMENT", 408, 428], ["cyanobacteria Spirulina platensis", "OBSERVATION", 59, 92], ["potent", "OBSERVATION_MODIFIER", 124, 130], ["antiviral activity", "OBSERVATION", 131, 149], ["herpes simplex", "OBSERVATION", 167, 181]]], ["They predominantly act by inhibiting the binding or the internalization of virus into the host cells [62] .", [["cells", "ANATOMY", 95, 100], ["cells", "CELL", 95, 100], ["host cells", "CELL_TYPE", 90, 100], ["the binding", "PROBLEM", 37, 48]]], ["The carrageenan isolated from Gigartina skottsbergii exert promising antiviral activities towards diverse strains of HSV-1 and HSV-2 during virus attachment stage [63] and against human rhinovirus (HRV) proliferation by preventing the primary phases of virus replication [64] .", [["carrageenan", "CHEMICAL", 4, 15], ["carrageenan", "SIMPLE_CHEMICAL", 4, 15], ["Gigartina skottsbergii", "ORGANISM", 30, 52], ["HSV-1", "ORGANISM", 117, 122], ["HSV-2", "ORGANISM", 127, 132], ["human", "ORGANISM", 180, 185], ["rhinovirus", "ORGANISM", 186, 196], ["Gigartina skottsbergii", "SPECIES", 30, 52], ["HSV-1", "SPECIES", 117, 122], ["HSV-2", "SPECIES", 127, 132], ["human", "SPECIES", 180, 185], ["rhinovirus", "SPECIES", 186, 196], ["Gigartina skottsbergii", "SPECIES", 30, 52], ["HSV-1", "SPECIES", 117, 122], ["HSV-2", "SPECIES", 127, 132], ["human rhinovirus", "SPECIES", 180, 196], ["HRV", "SPECIES", 198, 201], ["The carrageenan", "TREATMENT", 0, 15], ["Gigartina skottsbergii", "PROBLEM", 30, 52], ["HSV", "TEST", 117, 120], ["HSV", "PROBLEM", 127, 130], ["human rhinovirus (HRV) proliferation", "PROBLEM", 180, 216], ["virus replication", "TREATMENT", 253, 270]]], ["A recent in vivo study in mice indicated that low molecular weight carrageenans (3, 5, and 10 kDa), as well as acetylated and sulfated derivatives, were active against influenza virus and reduced the HIV activity by depolymerization and sulfation processes [65] .Marine Antioxidants and Antiviral ActivityAnother class of sulfated polysaccharides is represented by galactans, present in the external membranes of red algae [66] .", [["external membranes", "ANATOMY", 391, 409], ["carrageenans", "CHEMICAL", 67, 79], ["influenza virus", "DISEASE", 168, 183], ["Antioxidants", "CHEMICAL", 270, 282], ["carrageenans", "CHEMICAL", 67, 79], ["mice", "ORGANISM", 26, 30], ["sulfated derivatives", "SIMPLE_CHEMICAL", 126, 146], ["influenza virus", "ORGANISM", 168, 183], ["HIV", "ORGANISM", 200, 203], ["sulfated polysaccharides", "SIMPLE_CHEMICAL", 322, 346], ["galactans", "SIMPLE_CHEMICAL", 365, 374], ["membranes", "CELLULAR_COMPONENT", 400, 409], ["mice", "SPECIES", 26, 30], ["influenza virus", "SPECIES", 168, 183], ["mice", "SPECIES", 26, 30], ["influenza virus", "SPECIES", 168, 183], ["HIV", "SPECIES", 200, 203], ["A recent in vivo study", "TEST", 0, 22], ["low molecular weight carrageenans", "PROBLEM", 46, 79], ["acetylated and sulfated derivatives", "TREATMENT", 111, 146], ["influenza virus", "PROBLEM", 168, 183], ["Marine Antioxidants", "TREATMENT", 263, 282], ["Antiviral Activity", "TREATMENT", 287, 305], ["sulfated polysaccharides", "TREATMENT", 322, 346], ["HIV activity", "OBSERVATION", 200, 212], ["Antiviral Activity", "OBSERVATION", 287, 305], ["external membranes", "ANATOMY", 391, 409]]], ["The various structural types of this class of polysaccharides display relevant antiviral activity against several enveloped viruses, such as HSV-1 and HSV-2, DENV, HIV-1 and HIV-2, and hepatitis A virus [67] .", [["hepatitis A", "DISEASE", 185, 196], ["HSV-1", "ORGANISM", 141, 146], ["HSV-2", "ORGANISM", 151, 156], ["DENV", "ORGANISM", 158, 162], ["HIV-1", "ORGANISM", 164, 169], ["HIV-2", "ORGANISM", 174, 179], ["hepatitis A virus", "ORGANISM", 185, 202], ["HSV-1", "SPECIES", 141, 146], ["HSV-2", "SPECIES", 151, 156], ["HIV-1", "SPECIES", 164, 169], ["HIV-2", "SPECIES", 174, 179], ["hepatitis A virus", "SPECIES", 185, 202], ["HSV-1", "SPECIES", 141, 146], ["HSV-2", "SPECIES", 151, 156], ["DENV", "SPECIES", 158, 162], ["HIV-1", "SPECIES", 164, 169], ["HIV-2", "SPECIES", 174, 179], ["hepatitis A virus", "SPECIES", 185, 202], ["polysaccharides", "TREATMENT", 46, 61], ["several enveloped viruses", "PROBLEM", 106, 131], ["HSV", "TEST", 141, 144], ["HSV", "TEST", 151, 154], ["DENV", "PROBLEM", 158, 162], ["HIV", "TEST", 164, 167], ["HIV", "TEST", 174, 177], ["hepatitis A virus", "PROBLEM", 185, 202], ["antiviral activity", "OBSERVATION", 79, 97], ["enveloped", "OBSERVATION_MODIFIER", 114, 123], ["viruses", "OBSERVATION", 124, 131]]], ["The galactan sulfate (GS), isolated from the red alga Agardhiella tenera, displays an effective control against HIV-1 and HIV-2, blocking the virus adhesion to the cell as well as the attachment of gp120 on CD4+ T cell receptor to HIV-1 gp120 [68] .", [["cell", "ANATOMY", 164, 168], ["CD4+ T cell", "ANATOMY", 207, 218], ["galactan sulfate", "CHEMICAL", 4, 20], ["GS", "CHEMICAL", 22, 24], ["galactan sulfate", "CHEMICAL", 4, 20], ["galactan sulfate", "SIMPLE_CHEMICAL", 4, 20], ["GS", "SIMPLE_CHEMICAL", 22, 24], ["red alga", "ORGANISM", 45, 53], ["Agardhiella tenera", "ORGANISM", 54, 72], ["HIV-1", "ORGANISM", 112, 117], ["HIV-2", "ORGANISM", 122, 127], ["cell", "CELL", 164, 168], ["gp120", "GENE_OR_GENE_PRODUCT", 198, 203], ["CD4+ T cell receptor", "GENE_OR_GENE_PRODUCT", 207, 227], ["HIV-1", "ORGANISM", 231, 236], ["gp120", "PROTEIN", 198, 203], ["CD4", "PROTEIN", 207, 210], ["T cell receptor", "PROTEIN", 212, 227], ["gp120", "PROTEIN", 237, 242], ["Agardhiella tenera", "SPECIES", 54, 72], ["HIV-1", "SPECIES", 112, 117], ["HIV-2", "SPECIES", 122, 127], ["HIV-1", "SPECIES", 231, 236], ["red alga Agardhiella tenera", "SPECIES", 45, 72], ["HIV-1", "SPECIES", 112, 117], ["HIV-2", "SPECIES", 122, 127], ["HIV-1", "SPECIES", 231, 236], ["The galactan sulfate (GS)", "TREATMENT", 0, 25], ["the red alga Agardhiella tenera", "TREATMENT", 41, 72], ["HIV", "TEST", 112, 115], ["HIV", "PROBLEM", 122, 125], ["blocking the virus adhesion", "PROBLEM", 129, 156], ["CD4", "TEST", 207, 210], ["HIV", "TEST", 231, 234]]], ["Another sulfated galactan isolated from the red seaweed, Schizymenia binderi, presented highly selective antiviral effects against HSV types 1 and 2 by the inhibition of the attachment of virus to host cells [69] .", [["cells", "ANATOMY", 202, 207], ["galactan", "CHEMICAL", 17, 25], ["Schizymenia binderi", "CHEMICAL", 57, 76], ["sulfated galactan", "CHEMICAL", 8, 25], ["sulfated galactan", "SIMPLE_CHEMICAL", 8, 25], ["red seaweed", "ORGANISM", 44, 55], ["Schizymenia binderi", "ORGANISM", 57, 76], ["HSV", "ORGANISM", 131, 134], ["host cells", "CELL", 197, 207], ["host cells", "CELL_TYPE", 197, 207], ["Schizymenia binderi", "SPECIES", 57, 76], ["red seaweed", "SPECIES", 44, 55], ["Schizymenia binderi", "SPECIES", 57, 76], ["HSV", "SPECIES", 131, 134], ["Another sulfated galactan", "TREATMENT", 0, 25], ["the red seaweed", "TREATMENT", 40, 55], ["Schizymenia binderi", "PROBLEM", 57, 76], ["HSV types 1", "PROBLEM", 131, 142], ["galactan isolated", "OBSERVATION", 17, 34], ["selective", "OBSERVATION_MODIFIER", 95, 104], ["antiviral", "OBSERVATION", 105, 114]]], ["The D,L-galactan hybrid C2S-3, extracted from the marine red alga Cryptonemia crenulata, blocks the multiplication of DENV-2 in Vero cell line [70] .Marine Antioxidants and Antiviral ActivityAlginates are polysaccharides widely distributed in brown algae (Phaeophyceae), which have also been particularly attractive for their antiviral activities [71] .", [["Vero cell line", "ANATOMY", 128, 142], ["C2S-3", "CHEMICAL", 24, 29], ["Alginates", "CHEMICAL", 191, 200], ["C2S-3", "CHEMICAL", 24, 29], ["D", "SIMPLE_CHEMICAL", 4, 5], ["L-galactan", "SIMPLE_CHEMICAL", 6, 16], ["C2S-3", "SIMPLE_CHEMICAL", 24, 29], ["red alga", "ORGANISM", 57, 65], ["Cryptonemia crenulata", "ORGANISM", 66, 87], ["DENV-2", "GENE_OR_GENE_PRODUCT", 118, 124], ["Vero cell line [70", "CELL", 128, 146], ["Alginates", "SIMPLE_CHEMICAL", 191, 200], ["brown algae", "ORGANISM", 243, 254], ["Phaeophyceae", "SIMPLE_CHEMICAL", 256, 268], ["Vero cell line", "CELL_LINE", 128, 142], ["Cryptonemia crenulata", "SPECIES", 66, 87], ["Cryptonemia crenulata", "SPECIES", 66, 87], ["L-galactan hybrid C2S", "TREATMENT", 6, 27], ["red alga Cryptonemia crenulata", "PROBLEM", 57, 87], ["DENV", "PROBLEM", 118, 122], ["Vero cell line", "TREATMENT", 128, 142], ["Marine Antioxidants", "TREATMENT", 149, 168], ["Antiviral ActivityAlginates", "TREATMENT", 173, 200], ["polysaccharides", "TREATMENT", 205, 220], ["alga Cryptonemia", "OBSERVATION", 61, 77], ["DENV", "OBSERVATION", 118, 122], ["Vero cell line", "OBSERVATION", 128, 142], ["Antiviral Activity", "OBSERVATION", 173, 191], ["brown algae", "OBSERVATION_MODIFIER", 243, 254]]], ["In particular, an alginate named 911 exhibited promising activity against HIV-1 decrementing the activity of reverse transcriptase (RTase), discontinuing the virus adsorption, and immunostimulating the host cells [72] .", [["cells", "ANATOMY", 207, 212], ["alginate", "CHEMICAL", 18, 26], ["HIV-1", "ORGANISM", 74, 79], ["RTase", "GENE_OR_GENE_PRODUCT", 132, 137], ["host cells", "CELL", 202, 212], ["reverse transcriptase", "PROTEIN", 109, 130], ["RTase", "PROTEIN", 132, 137], ["host cells", "CELL_TYPE", 202, 212], ["HIV-1", "SPECIES", 74, 79], ["HIV-1", "SPECIES", 74, 79], ["HIV", "TEST", 74, 77], ["reverse transcriptase (RTase", "TREATMENT", 109, 137], ["the virus adsorption", "TREATMENT", 154, 174], ["host cells", "OBSERVATION", 202, 212]]], ["Alternative inhibitory results were also reported against the hepatitis B virus (HBV), where 911 alginate could inhibit the virus replication by suppressing the activity of DNA polymerase [73] .", [["hepatitis B", "DISEASE", 62, 73], ["alginate", "CHEMICAL", 97, 105], ["hepatitis B virus", "ORGANISM", 62, 79], ["HBV", "ORGANISM", 81, 84], ["DNA", "CELLULAR_COMPONENT", 173, 176], ["DNA polymerase", "PROTEIN", 173, 187], ["hepatitis B virus", "SPECIES", 62, 79], ["hepatitis B virus", "SPECIES", 62, 79], ["HBV", "SPECIES", 81, 84], ["the hepatitis B virus", "PROBLEM", 58, 79], ["the virus replication", "TREATMENT", 120, 141], ["DNA polymerase", "TEST", 173, 187]]], ["Furthermore, the sulfated polymannuroguluronate (SPMG) is a promising anti-AIDS drug candidate, inhibiting the robust attachment of HIV-1 gp120 protein with CD4 molecules on the surface of T cells [74] .Marine Antioxidants and Antiviral ActivityFucans are high-molecular-weight sulfated polysaccharides, present in the intercellular tissues or mucilaginous matrix of brown algae [75] .", [["surface", "ANATOMY", 178, 185], ["T cells", "ANATOMY", 189, 196], ["intercellular tissues", "ANATOMY", 319, 340], ["mucilaginous matrix", "ANATOMY", 344, 363], ["polymannuroguluronate", "CHEMICAL", 26, 47], ["SPMG", "CHEMICAL", 49, 53], ["ActivityFucans", "CHEMICAL", 237, 251], ["polymannuroguluronate", "CHEMICAL", 26, 47], ["SPMG", "CHEMICAL", 49, 53], ["sulfated polymannuroguluronate", "SIMPLE_CHEMICAL", 17, 47], ["SPMG", "SIMPLE_CHEMICAL", 49, 53], ["anti-AIDS", "SIMPLE_CHEMICAL", 70, 79], ["HIV-1", "ORGANISM", 132, 137], ["gp120", "ORGANISM", 138, 143], ["CD4", "GENE_OR_GENE_PRODUCT", 157, 160], ["surface", "CELLULAR_COMPONENT", 178, 185], ["T cells", "CELL", 189, 196], ["ActivityFucans", "SIMPLE_CHEMICAL", 237, 251], ["high-molecular-weight sulfated polysaccharides", "SIMPLE_CHEMICAL", 256, 302], ["intercellular tissues", "TISSUE", 319, 340], ["mucilaginous matrix", "CELLULAR_COMPONENT", 344, 363], ["HIV-1 gp120 protein", "PROTEIN", 132, 151], ["CD4 molecules", "PROTEIN", 157, 170], ["T cells", "CELL_TYPE", 189, 196], ["HIV-1", "SPECIES", 132, 137], ["HIV-1", "SPECIES", 132, 137], ["the sulfated polymannuroguluronate (SPMG)", "TREATMENT", 13, 54], ["HIV", "TEST", 132, 135], ["CD4 molecules", "PROBLEM", 157, 170], ["Marine Antioxidants", "TREATMENT", 203, 222], ["Antiviral ActivityFucans", "TREATMENT", 227, 251], ["weight sulfated polysaccharides", "PROBLEM", 271, 302], ["brown algae", "PROBLEM", 367, 378], ["intercellular tissues", "ANATOMY", 319, 340]]], ["Beside many bioactivities, such as antiproliferative, antiadhesive properties can protect the cells from viral infections [76] .", [["cells", "ANATOMY", 94, 99], ["viral infections", "DISEASE", 105, 121], ["cells", "CELL", 94, 99], ["antiproliferative, antiadhesive properties", "TREATMENT", 35, 77], ["viral infections", "PROBLEM", 105, 121]]], ["For instance, the sulfated fucans from the brown seaweeds, Dictyota mertensii, Lobophora variegata, Fucus vesiculosus, and Spatoglossum schroederi, could prevent HIV infection via the blocking effect of the activity of reverse transcriptase [77] .", [["brown seaweeds", "ANATOMY", 43, 57], ["fucans", "CHEMICAL", 27, 33], ["HIV infection", "DISEASE", 162, 175], ["fucans", "CHEMICAL", 27, 33], ["sulfated fucans", "SIMPLE_CHEMICAL", 18, 33], ["brown seaweeds", "ORGANISM", 43, 57], ["Dictyota mertensii", "ORGANISM", 59, 77], ["Lobophora variegata", "ORGANISM", 79, 98], ["Fucus vesiculosus", "ORGANISM", 100, 117], ["Spatoglossum schroederi", "ORGANISM", 123, 146], ["HIV", "ORGANISM", 162, 165], ["reverse transcriptase", "PROTEIN", 219, 240], ["Dictyota mertensii", "SPECIES", 59, 77], ["Lobophora variegata", "SPECIES", 79, 98], ["Fucus vesiculosus", "SPECIES", 100, 117], ["Spatoglossum schroederi", "SPECIES", 123, 146], ["HIV", "SPECIES", 162, 165], ["Dictyota mertensii", "SPECIES", 59, 77], ["Lobophora variegata", "SPECIES", 79, 98], ["Fucus vesiculosus", "SPECIES", 100, 117], ["Spatoglossum schroederi", "SPECIES", 123, 146], ["HIV", "SPECIES", 162, 165], ["the sulfated fucans", "PROBLEM", 14, 33], ["the brown seaweeds", "PROBLEM", 39, 57], ["Dictyota mertensii", "PROBLEM", 59, 77], ["Lobophora variegata", "PROBLEM", 79, 98], ["Fucus vesiculosus", "PROBLEM", 100, 117], ["Spatoglossum schroederi", "TREATMENT", 123, 146], ["HIV infection", "PROBLEM", 162, 175], ["reverse transcriptase", "TREATMENT", 219, 240], ["brown seaweeds", "OBSERVATION", 43, 57], ["Fucus vesiculosus", "OBSERVATION", 100, 117], ["HIV", "OBSERVATION_MODIFIER", 162, 165], ["infection", "OBSERVATION", 166, 175]]], ["This study highlighted the necessity of sulfate and carboxyl groups in the inhibitory viral activity of the polysaccharides.", [["sulfate", "CHEMICAL", 40, 47], ["sulfate", "CHEMICAL", 40, 47], ["carboxyl", "CHEMICAL", 52, 60], ["sulfate", "SIMPLE_CHEMICAL", 40, 47], ["This study", "TEST", 0, 10], ["sulfate and carboxyl groups", "TREATMENT", 40, 67]]], ["The compound named MC26, a new type of fucose polysaccharide isolated from the marine brown alga, Sargassum piluliferum exhibited a strong anti-influenza virus activity [78] .", [["brown alga", "ANATOMY", 86, 96], ["MC26", "CHEMICAL", 19, 23], ["fucose polysaccharide", "CHEMICAL", 39, 60], ["MC26", "CHEMICAL", 19, 23], ["fucose", "CHEMICAL", 39, 45], ["MC26", "SIMPLE_CHEMICAL", 19, 23], ["fucose polysaccharide", "SIMPLE_CHEMICAL", 39, 60], ["brown alga", "ORGANISM", 86, 96], ["Sargassum piluliferum", "ORGANISM", 98, 119], ["Sargassum piluliferum", "SPECIES", 98, 119], ["brown alga", "SPECIES", 86, 96], ["Sargassum piluliferum", "SPECIES", 98, 119], ["anti-influenza virus", "SPECIES", 139, 159], ["fucose polysaccharide", "PROBLEM", 39, 60], ["Sargassum piluliferum", "PROBLEM", 98, 119], ["a strong anti-influenza virus activity", "PROBLEM", 130, 168], ["new", "OBSERVATION_MODIFIER", 27, 30], ["anti-influenza virus", "OBSERVATION", 139, 159]]], ["Furthermore, the sulfated fucans extracted from the brown seaweed Cystoseira indica showed a promising activity against HSV-1 and HSV-2 [79] .Marine Antioxidants and Antiviral ActivityIt was suggested that these compounds might act against viral infection through the inhibition of virus adsorption [80] .", [["fucans", "CHEMICAL", 26, 32], ["viral infection", "DISEASE", 240, 255], ["sulfated fucans", "CHEMICAL", 17, 32], ["sulfated fucans", "SIMPLE_CHEMICAL", 17, 32], ["brown seaweed", "ORGANISM", 52, 65], ["Cystoseira indica", "ORGANISM", 66, 83], ["HSV-1", "ORGANISM", 120, 125], ["HSV-2", "ORGANISM", 130, 135], ["Cystoseira indica", "SPECIES", 66, 83], ["HSV-1", "SPECIES", 120, 125], ["brown seaweed", "SPECIES", 52, 65], ["Cystoseira indica", "SPECIES", 66, 83], ["HSV-1", "SPECIES", 120, 125], ["HSV-2", "SPECIES", 130, 135], ["the sulfated fucans", "TEST", 13, 32], ["HSV", "TEST", 120, 123], ["HSV", "TEST", 130, 133], ["Marine Antioxidants", "TREATMENT", 142, 161], ["Antiviral Activity", "TREATMENT", 166, 184], ["these compounds", "PROBLEM", 206, 221], ["viral infection", "PROBLEM", 240, 255], ["virus adsorption", "TREATMENT", 282, 298], ["Antiviral Activity", "OBSERVATION", 166, 184]]], ["The polysaccharides fucoidan, based on the sulfated L-fucose, possesses various biological activities, among them activities against many RNA and DNA viruses such as HIV, HSV1-2, dengue virus, and cytomegalovirus [81] .", [["fucoidan", "CHEMICAL", 20, 28], ["-fucose", "CHEMICAL", 53, 60], ["dengue virus", "DISEASE", 179, 191], ["sulfated L-fucose", "CHEMICAL", 43, 60], ["polysaccharides fucoidan", "SIMPLE_CHEMICAL", 4, 28], ["sulfated L-fucose", "SIMPLE_CHEMICAL", 43, 60], ["DNA", "CELLULAR_COMPONENT", 146, 149], ["HIV", "ORGANISM", 166, 169], ["HSV1-2", "ORGANISM", 171, 177], ["dengue virus", "ORGANISM", 179, 191], ["cytomegalovirus", "ORGANISM", 197, 212], ["HIV", "SPECIES", 166, 169], ["dengue virus", "SPECIES", 179, 191], ["HIV", "SPECIES", 166, 169], ["HSV1-2", "SPECIES", 171, 177], ["dengue virus", "SPECIES", 179, 191], ["The polysaccharides fucoidan", "TREATMENT", 0, 28], ["the sulfated L-fucose", "TREATMENT", 39, 60], ["many RNA and DNA viruses", "PROBLEM", 133, 157], ["HIV", "PROBLEM", 166, 169], ["HSV1", "TEST", 171, 175], ["dengue virus", "PROBLEM", 179, 191], ["cytomegalovirus", "PROBLEM", 197, 212], ["polysaccharides", "OBSERVATION_MODIFIER", 4, 19], ["fucoidan", "OBSERVATION", 20, 28]]], ["Fucoidans exert their antiviral activities by blocking the interaction of viruses with the cells, thus inhibiting viral-induced syncytium formation [82] .", [["cells", "ANATOMY", 91, 96], ["syncytium", "ANATOMY", 128, 137], ["Fucoidans", "CHEMICAL", 0, 9], ["Fucoidans", "CHEMICAL", 0, 9], ["Fucoidans", "SIMPLE_CHEMICAL", 0, 9], ["cells", "CELL", 91, 96], ["syncytium", "CELL", 128, 137], ["the cells", "PROBLEM", 87, 96], ["inhibiting viral-induced syncytium formation", "PROBLEM", 103, 147]]], ["This property led to attachment of fucoidan to the F0 protein resulting in a great antiviral potency of fucoidan, e.g., higher than the antiviral drug ribavirin [83] .", [["fucoidan", "CHEMICAL", 35, 43], ["fucoidan", "CHEMICAL", 104, 112], ["ribavirin", "CHEMICAL", 151, 160], ["ribavirin", "CHEMICAL", 151, 160], ["fucoidan", "SIMPLE_CHEMICAL", 35, 43], ["fucoidan", "SIMPLE_CHEMICAL", 104, 112], ["ribavirin", "SIMPLE_CHEMICAL", 151, 160], ["F0 protein", "PROTEIN", 51, 61], ["fucoidan", "TREATMENT", 35, 43], ["the F0 protein", "TEST", 47, 61], ["the antiviral drug ribavirin", "TREATMENT", 132, 160], ["great", "OBSERVATION_MODIFIER", 77, 82], ["antiviral potency", "OBSERVATION", 83, 100]]], ["Last but not least, fucoidans also display bioactivity on the immune system at cellular and humoral level by increasing macrophage phagocytosis [84] .", [["immune system", "ANATOMY", 62, 75], ["cellular", "ANATOMY", 79, 87], ["macrophage", "ANATOMY", 120, 130], ["fucoidans", "CHEMICAL", 20, 29], ["fucoidans", "SIMPLE_CHEMICAL", 20, 29], ["immune system", "ANATOMICAL_SYSTEM", 62, 75], ["cellular", "CELL", 79, 87], ["macrophage", "CELL", 120, 130], ["increasing macrophage phagocytosis", "PROBLEM", 109, 143], ["bioactivity", "OBSERVATION", 43, 54], ["humoral", "ANATOMY", 92, 99], ["increasing", "OBSERVATION_MODIFIER", 109, 119], ["macrophage phagocytosis", "OBSERVATION", 120, 143]]], ["The glucan laminaran, one of the most common polysaccharides in brown algae, exhibits a great antiviral activity and low toxicity in vivo [78] .", [["brown algae", "ANATOMY", 64, 75], ["glucan laminaran", "CHEMICAL", 4, 20], ["toxicity", "DISEASE", 121, 129], ["glucan laminaran", "SIMPLE_CHEMICAL", 4, 20], ["brown algae", "ORGANISM", 64, 75], ["The glucan laminaran", "TREATMENT", 0, 20], ["brown algae", "PROBLEM", 64, 75], ["low toxicity in vivo", "PROBLEM", 117, 137], ["most common", "OBSERVATION_MODIFIER", 33, 44], ["brown algae", "OBSERVATION", 64, 75], ["great", "OBSERVATION_MODIFIER", 88, 93], ["antiviral activity", "OBSERVATION", 94, 112], ["low toxicity", "OBSERVATION_MODIFIER", 117, 129]]], ["Laminaran polysaccharides extracted from brown algae are proficient to prevent the activity of HIV by preventing its adsorption on human-derived lymphocytes and by blocking the ability of HIV reverse transcriptase, thus the virus' proliferation [72] .Marine Antioxidants and Antiviral ActivityThree polysaccharides extracted from marine microalgae, naviculan from the diatom Navicula directa, and two others (named A1 and A2) from the dinoflagellate Cochlodinium polykrikoides also displayed antiviral activities against several enveloped viruses, such as HIV-1, HSV-1 or influenza virus type A (IFV-A) [71] .", [["brown algae", "ANATOMY", 41, 52], ["lymphocytes", "ANATOMY", 145, 156], ["Laminaran polysaccharides", "SIMPLE_CHEMICAL", 0, 25], ["brown algae", "ORGANISM", 41, 52], ["HIV", "ORGANISM", 95, 98], ["human", "ORGANISM", 131, 136], ["lymphocytes", "CELL", 145, 156], ["HIV", "ORGANISM", 188, 191], ["naviculan", "SIMPLE_CHEMICAL", 349, 358], ["Navicula directa", "ORGANISM", 375, 391], ["A2", "GENE_OR_GENE_PRODUCT", 422, 424], ["Cochlodinium polykrikoides", "ORGANISM", 450, 476], ["HIV-1", "ORGANISM", 556, 561], ["HSV-1", "ORGANISM", 563, 568], ["influenza virus type A", "ORGANISM", 572, 594], ["IFV-A", "ORGANISM", 596, 601], ["human-derived lymphocytes", "CELL_TYPE", 131, 156], ["HIV reverse transcriptase", "PROTEIN", 188, 213], ["A2", "PROTEIN", 422, 424], ["HIV", "SPECIES", 95, 98], ["human", "SPECIES", 131, 136], ["Navicula directa", "SPECIES", 375, 391], ["Cochlodinium polykrikoides", "SPECIES", 450, 476], ["HIV-1", "SPECIES", 556, 561], ["HSV-1", "SPECIES", 563, 568], ["influenza virus", "SPECIES", 572, 587], ["HIV", "SPECIES", 95, 98], ["human", "SPECIES", 131, 136], ["HIV", "SPECIES", 188, 191], ["Navicula directa", "SPECIES", 375, 391], ["Cochlodinium polykrikoides", "SPECIES", 450, 476], ["HIV-1", "SPECIES", 556, 561], ["HSV-1", "SPECIES", 563, 568], ["influenza virus type A (IFV-A)", "SPECIES", 572, 602], ["Laminaran polysaccharides", "TREATMENT", 0, 25], ["brown algae", "PROBLEM", 41, 52], ["HIV", "PROBLEM", 95, 98], ["HIV reverse transcriptase", "TREATMENT", 188, 213], ["the virus' proliferation", "PROBLEM", 220, 244], ["Marine Antioxidants", "TREATMENT", 251, 270], ["Antiviral ActivityThree polysaccharides", "TREATMENT", 275, 314], ["the dinoflagellate Cochlodinium polykrikoides", "TREATMENT", 431, 476], ["antiviral activities", "TREATMENT", 492, 512], ["several enveloped viruses", "PROBLEM", 521, 546], ["HIV", "TEST", 556, 559], ["HSV", "TEST", 563, 566], ["influenza virus type A", "PROBLEM", 572, 594], ["brown algae", "OBSERVATION_MODIFIER", 41, 52], ["viruses", "OBSERVATION", 539, 546]]], ["The sulfated polysaccharide p-KG03 extracted from another dinoflagellate Gyrodinium impudicum has been also reported active against the encephalomyocarditis RNAvirus (EMCV) [85] , and against several strains of influenza viruses, with efficiency comparable to some existing drugs [86] .Marine Antioxidants and Antiviral ActivityThe common characteristic between the above-described examples of antiviral activity from algal polysaccharide is the presence of sulfated groups in their chemical structure [96] .", [["sulfated polysaccharide p-KG03", "CHEMICAL", 4, 34], ["impudicum", "CHEMICAL", 84, 93], ["influenza viruses", "DISEASE", 211, 228], ["sulfated polysaccharide p-KG03", "SIMPLE_CHEMICAL", 4, 34], ["Gyrodinium impudicum", "ORGANISM", 73, 93], ["encephalomyocarditis RNAvirus", "ORGANISM", 136, 165], ["EMCV", "ORGANISM", 167, 171], ["influenza viruses", "ORGANISM", 211, 228], ["algal polysaccharide", "SIMPLE_CHEMICAL", 418, 438], ["Gyrodinium impudicum", "SPECIES", 73, 93], ["Gyrodinium impudicum", "SPECIES", 73, 93], ["EMCV", "SPECIES", 167, 171], ["The sulfated polysaccharide p-KG03", "TREATMENT", 0, 34], ["the encephalomyocarditis RNAvirus", "PROBLEM", 132, 165], ["influenza viruses", "PROBLEM", 211, 228], ["Marine Antioxidants", "TREATMENT", 286, 305], ["Antiviral Activity", "TREATMENT", 310, 328], ["antiviral activity", "PROBLEM", 394, 412], ["algal polysaccharide", "PROBLEM", 418, 438], ["encephalomyocarditis", "OBSERVATION", 136, 156], ["influenza viruses", "OBSERVATION", 211, 228], ["Antiviral Activity", "OBSERVATION", 310, 328], ["common", "OBSERVATION_MODIFIER", 332, 338], ["antiviral activity", "OBSERVATION", 394, 412], ["algal", "OBSERVATION_MODIFIER", 418, 423], ["polysaccharide", "OBSERVATION_MODIFIER", 424, 438], ["sulfated groups", "OBSERVATION_MODIFIER", 458, 473]]], ["Although these compounds might act on Stage III of viral infection, selectively inhibiting reverse transcriptase in the case of HIV, thus hampering production of new viral particles after infection [97] , the inhibitory effect generally might refer to Stage I of viral infection.", [["viral infection", "DISEASE", 51, 66], ["infection", "DISEASE", 188, 197], ["viral infection", "DISEASE", 263, 278], ["HIV", "ORGANISM", 128, 131], ["reverse transcriptase", "PROTEIN", 91, 112], ["HIV", "SPECIES", 128, 131], ["viral infection", "PROBLEM", 51, 66], ["reverse transcriptase", "TREATMENT", 91, 112], ["HIV", "PROBLEM", 128, 131], ["new viral particles", "PROBLEM", 162, 181], ["infection", "PROBLEM", 188, 197], ["the inhibitory effect", "PROBLEM", 205, 226], ["viral infection", "PROBLEM", 263, 278], ["viral", "OBSERVATION_MODIFIER", 51, 56], ["infection", "OBSERVATION", 57, 66], ["viral", "OBSERVATION_MODIFIER", 263, 268], ["infection", "OBSERVATION", 269, 278]]], ["This is a crucial aspect to investigate since the antiviral property starts with the interaction between the molecule and the positive charges of the virus or on the cell surface, preventing penetration of the former into the host cells [98] .", [["cell surface", "ANATOMY", 166, 178], ["cells", "ANATOMY", 231, 236], ["cell surface", "CELLULAR_COMPONENT", 166, 178], ["cells", "CELL", 231, 236], ["host cells", "CELL_TYPE", 226, 236], ["the antiviral property", "TREATMENT", 46, 68], ["the virus", "PROBLEM", 146, 155], ["the cell surface", "TREATMENT", 162, 178], ["positive charges", "OBSERVATION", 126, 142], ["virus", "OBSERVATION", 150, 155]]], ["Indeed, sulfated exopolysaccharides from some marine microalgae have been hypothesized to interfere with Stage I of viral infection [99] .Marine Antioxidants and Antiviral ActivityTherefore, small molecules, such as sulfated polysaccharides, represent a good challenge in antiviral drug discovery studies, since the actual antiviral pharmaceutics are proteins and act at the Stage II of the infection.", [["viral infection", "DISEASE", 116, 131], ["infection", "DISEASE", 391, 400], ["sulfated exopolysaccharides", "SIMPLE_CHEMICAL", 8, 35], ["sulfated exopolysaccharides", "TREATMENT", 8, 35], ["viral infection", "PROBLEM", 116, 131], ["Marine Antioxidants", "TREATMENT", 138, 157], ["Antiviral Activity", "TREATMENT", 162, 180], ["small molecules", "PROBLEM", 191, 206], ["sulfated polysaccharides", "TREATMENT", 216, 240], ["the actual antiviral pharmaceutics", "TREATMENT", 312, 346], ["the infection", "PROBLEM", 387, 400], ["viral", "OBSERVATION_MODIFIER", 116, 121], ["infection", "OBSERVATION", 122, 131], ["Antiviral Activity", "OBSERVATION", 162, 180], ["small molecules", "OBSERVATION_MODIFIER", 191, 206], ["Stage II", "OBSERVATION_MODIFIER", 375, 383], ["infection", "OBSERVATION", 391, 400]]], ["Considering the COVID19 disease [100] , this virus is very infective due to the high adhesion capacity on the oral cell surface [101] and for the easy entrance ability through the ACE2 receptor on the lung cell surface (Stage I of the viral infection) [102] .Marine Antioxidants and Antiviral ActivityLess investigated, but with a high antioxidant activity, and therefore as potential antiviral, are the polyphenolic compounds: antioxidants produced by marine algae, such as flavonoids, cinnamic acid, benzoic acid, gallic acid, quercetin [91] and phlorotannins, the latter being found in brown macroalgae [92] , or diatoms [93] .", [["oral cell surface", "ANATOMY", 110, 127], ["lung cell surface", "ANATOMY", 201, 218], ["viral infection", "DISEASE", 235, 250], ["cinnamic acid, benzoic acid, gallic acid", "CHEMICAL", 487, 527], ["quercetin [91] and phlorotannins", "CHEMICAL", 529, 561], ["polyphenolic", "CHEMICAL", 404, 416], ["flavonoids", "CHEMICAL", 475, 485], ["cinnamic acid", "CHEMICAL", 487, 500], ["benzoic acid", "CHEMICAL", 502, 514], ["gallic acid", "CHEMICAL", 516, 527], ["quercetin", "CHEMICAL", 529, 538], ["phlorotannins", "CHEMICAL", 548, 561], ["COVID19", "GENE_OR_GENE_PRODUCT", 16, 23], ["oral cell", "CELL", 110, 119], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 180, 193], ["lung cell", "CELL", 201, 210], ["flavonoids", "SIMPLE_CHEMICAL", 475, 485], ["cinnamic acid", "SIMPLE_CHEMICAL", 487, 500], ["benzoic acid", "SIMPLE_CHEMICAL", 502, 514], ["gallic acid", "SIMPLE_CHEMICAL", 516, 527], ["quercetin [91]", "SIMPLE_CHEMICAL", 529, 543], ["phlorotannins", "SIMPLE_CHEMICAL", 548, 561], ["ACE2 receptor", "PROTEIN", 180, 193], ["the COVID19 disease", "PROBLEM", 12, 31], ["this virus", "PROBLEM", 40, 50], ["very infective", "PROBLEM", 54, 68], ["the high adhesion capacity", "PROBLEM", 76, 102], ["the ACE2 receptor", "TREATMENT", 176, 193], ["the viral infection", "PROBLEM", 231, 250], ["Marine Antioxidants", "TREATMENT", 259, 278], ["Antiviral ActivityLess", "TREATMENT", 283, 305], ["a high antioxidant activity", "PROBLEM", 329, 356], ["antioxidants", "TREATMENT", 428, 440], ["flavonoids", "TREATMENT", 475, 485], ["cinnamic acid", "TREATMENT", 487, 500], ["benzoic acid", "TREATMENT", 502, 514], ["gallic acid", "TREATMENT", 516, 527], ["quercetin", "TREATMENT", 529, 538], ["phlorotannins", "TREATMENT", 548, 561], ["infective", "OBSERVATION", 59, 68], ["high adhesion", "OBSERVATION_MODIFIER", 80, 93], ["capacity", "OBSERVATION_MODIFIER", 94, 102], ["lung", "ANATOMY", 201, 205], ["cell", "OBSERVATION", 206, 210], ["surface", "OBSERVATION_MODIFIER", 211, 218], ["viral", "OBSERVATION_MODIFIER", 235, 240], ["infection", "OBSERVATION", 241, 250], ["polyphenolic compounds", "OBSERVATION", 404, 426]]], ["Phlorotannins are tannin derivatives exhibiting numerous bioactivities, such as antioxidant, anti-inflammatory [94] antibacterial, and antimatrix metallopeptidases (MMP) activities [95] .", [["Phlorotannins", "CHEMICAL", 0, 13], ["tannin", "CHEMICAL", 18, 24], ["Phlorotannins", "CHEMICAL", 0, 13], ["tannin", "CHEMICAL", 18, 24], ["Phlorotannins", "SIMPLE_CHEMICAL", 0, 13], ["tannin derivatives", "SIMPLE_CHEMICAL", 18, 36], ["[94] antibacterial", "SIMPLE_CHEMICAL", 111, 129], ["antimatrix metallopeptidases", "SIMPLE_CHEMICAL", 135, 163], ["MMP", "GENE_OR_GENE_PRODUCT", 165, 168], ["MMP", "PROTEIN", 165, 168], ["Phlorotannins", "TREATMENT", 0, 13], ["tannin derivatives", "TREATMENT", 18, 36], ["anti-inflammatory", "TREATMENT", 93, 110], ["antibacterial", "TREATMENT", 116, 129], ["antimatrix metallopeptidases (MMP) activities", "TREATMENT", 135, 180]]], ["Ahn et al. [93] reported that phloroglucinol derivative 8,8 -bieckol inhibited the activity of recombinant RT and protease of HIV-1 in vitro.", [["phloroglucinol", "CHEMICAL", 30, 44], ["8,8 -bieckol", "CHEMICAL", 56, 68], ["phloroglucinol", "CHEMICAL", 30, 44], ["8,8 -bieckol", "CHEMICAL", 56, 68], ["phloroglucinol derivative 8,8 -bieckol", "SIMPLE_CHEMICAL", 30, 68], ["HIV-1", "ORGANISM", 126, 131], ["recombinant RT", "PROTEIN", 95, 109], ["protease", "PROTEIN", 114, 122], ["HIV-1", "SPECIES", 126, 131], ["HIV-1", "SPECIES", 126, 131], ["phloroglucinol derivative", "TREATMENT", 30, 55], ["bieckol", "TREATMENT", 61, 68], ["recombinant RT", "TREATMENT", 95, 109], ["HIV", "TREATMENT", 126, 129]]], ["Another peculiar polyphenol discovered in some diatoms, (Haslea sp.) marennine, presented relevant bioactivity and antiviral properties [95] .ConclusionsViral infections are often promoted by oxidative processes, favoring replication in infected cells, induction and inhibition of cell proliferation.", [["cells", "ANATOMY", 246, 251], ["cell", "ANATOMY", 281, 285], ["marennine", "CHEMICAL", 69, 78], ["Viral infections", "DISEASE", 153, 169], ["polyphenol", "CHEMICAL", 17, 27], ["polyphenol", "SIMPLE_CHEMICAL", 17, 27], ["Haslea sp.", "ORGANISM", 57, 67], ["marennine", "SIMPLE_CHEMICAL", 69, 78], ["Viral", "ORGANISM", 153, 158], ["cells", "CELL", 246, 251], ["cell", "CELL", 281, 285], ["infected cells", "CELL_TYPE", 237, 251], ["Haslea sp.", "SPECIES", 57, 67], ["Another peculiar polyphenol", "PROBLEM", 0, 27], ["some diatoms", "PROBLEM", 42, 54], ["antiviral properties", "TREATMENT", 115, 135], ["Viral infections", "PROBLEM", 153, 169], ["replication in infected cells", "PROBLEM", 222, 251], ["cell proliferation", "PROBLEM", 281, 299], ["some diatoms", "OBSERVATION_MODIFIER", 42, 54], ["Viral", "OBSERVATION_MODIFIER", 153, 158], ["infections", "OBSERVATION", 159, 169], ["oxidative processes", "OBSERVATION", 192, 211], ["infected cells", "OBSERVATION", 237, 251], ["cell proliferation", "OBSERVATION", 281, 299]]], ["Antiviral activities of antioxidants acting in the antiviral infection task can be exploited as the sea is a fruitful reservoir of such compounds.", [["infection", "DISEASE", 61, 70], ["Antiviral activities of antioxidants", "TREATMENT", 0, 36], ["the antiviral infection task", "TREATMENT", 47, 75]]], ["Many algal sulfated polysaccharides-several of them being exclusively marine-present strong antiviral activities.", [["algal sulfated polysaccharides", "SIMPLE_CHEMICAL", 5, 35], ["Many algal sulfated polysaccharides", "TREATMENT", 0, 35], ["sulfated polysaccharides", "OBSERVATION_MODIFIER", 11, 35], ["strong", "OBSERVATION_MODIFIER", 85, 91], ["antiviral activities", "OBSERVATION", 92, 112]]], ["Furthermore, tannins, e.g., phlorotannin-exclusive in brown algae-as well as some phycobiliproteins-exclusive in marine algae-exert antiviral activities.", [["tannins", "CHEMICAL", 13, 20], ["phlorotannin", "CHEMICAL", 28, 40], ["tannins", "CHEMICAL", 13, 20], ["phlorotannin", "CHEMICAL", 28, 40], ["tannins", "SIMPLE_CHEMICAL", 13, 20], ["phlorotannin", "SIMPLE_CHEMICAL", 28, 40], ["brown algae", "ORGANISM", 54, 65], ["algae", "SIMPLE_CHEMICAL", 120, 125], ["tannins", "TREATMENT", 13, 20], ["phlorotannin", "TREATMENT", 28, 40], ["brown algae", "PROBLEM", 54, 65], ["some phycobiliproteins", "PROBLEM", 77, 99], ["antiviral activities", "TREATMENT", 132, 152], ["phycobiliproteins", "OBSERVATION", 82, 99], ["antiviral activities", "OBSERVATION", 132, 152]]], ["To implement natural antiviral tools, there is a priority of: (i) investigating the antiviral activities and mechanisms of action, and (ii) focusing on microalgae, as fast dividing and easily exploitable organisms.", [["the antiviral activities", "TREATMENT", 80, 104], ["easily exploitable organisms", "PROBLEM", 185, 213]]], ["The antiviral activity of various microalgae has been demonstrated, although there is a lack of information on many classes.", [["antiviral activity", "OBSERVATION", 4, 22]]], ["Since microalgae are known to be rich in bioactive molecules-the so-called biofactory cells-and present a high diversity and complementarity of antioxidant compounds, they are the ideal reservoir of a sea-derived antiviral pharmacy.", [["biofactory cells", "ANATOMY", 75, 91], ["biofactory cells", "CELL", 75, 91], ["biofactory cells", "CELL_TYPE", 75, 91], ["known to be", "UNCERTAINTY", 21, 32], ["bioactive molecules", "OBSERVATION", 41, 60], ["high diversity", "OBSERVATION_MODIFIER", 106, 120], ["antioxidant compounds", "OBSERVATION", 144, 165]]], ["This is a fundamental aspect since synergy between molecules, and combinations of diverse backbones, can be further effective against virus infections, as demonstrated in the development and success of the HAART combination therapy for HIV.", [["infections", "DISEASE", 140, 150], ["HIV", "ORGANISM", 236, 239], ["HIV", "SPECIES", 236, 239], ["HIV", "SPECIES", 236, 239], ["synergy between molecules", "PROBLEM", 35, 60], ["diverse backbones", "PROBLEM", 82, 99], ["virus infections", "PROBLEM", 134, 150], ["the HAART combination therapy", "TREATMENT", 202, 231], ["HIV", "PROBLEM", 236, 239], ["diverse backbones", "OBSERVATION", 82, 99]]], ["The promising results reviewed in this communication suggest and urge for investment and advanced research into the development of knowledge on marine antiviral drugs and to develop a pipeline reaching into the biodiversity and chemodiversity of (micro)algae screening to screen them with an antiviral focus.ConclusionsAuthor Contributions: All authors have equally contributed for the realization of this paper.", [["marine antiviral drugs", "TREATMENT", 144, 166], ["algae screening", "TEST", 253, 268], ["an antiviral focus", "TREATMENT", 289, 307], ["antiviral", "OBSERVATION", 292, 301]]], ["All authors have read and agreed to the published version of the manuscript.ConclusionsFunding: This research received no external funding.", [["external funding", "TREATMENT", 122, 138], ["funding", "OBSERVATION", 131, 138]]]], "PMC7185610": [["IntroductionAntigen-presenting dendritic cells (DCs) are essential for initiating immune responses because of their unique ability to stimulate naive T lymphocytes (1).", [["dendritic cells", "ANATOMY", 31, 46], ["DCs", "ANATOMY", 48, 51], ["T lymphocytes", "ANATOMY", 150, 163], ["dendritic cells", "CELL", 31, 46], ["DCs", "CELL", 48, 51], ["T lymphocytes", "CELL", 150, 163], ["IntroductionAntigen-presenting dendritic cells", "CELL_TYPE", 0, 46], ["DCs", "CELL_TYPE", 48, 51], ["naive T lymphocytes", "CELL_TYPE", 144, 163], ["immune responses", "PROBLEM", 82, 98], ["dendritic cells", "OBSERVATION", 31, 46]]], ["However, DCs are heterogeneous in both their ontogeny and function (2).", [["DCs", "ANATOMY", 9, 12], ["DCs", "CELL", 9, 12], ["DCs", "CELL_TYPE", 9, 12], ["DCs", "OBSERVATION", 9, 12], ["heterogeneous", "OBSERVATION_MODIFIER", 17, 30], ["both", "ANATOMY_MODIFIER", 34, 38], ["ontogeny", "OBSERVATION_MODIFIER", 45, 53]]], ["In mouse spleen, there exist three major populations of conventional dendritic cells (cDCs): CD4+CD8\u2212 (CD4+ DC), CD4\u2212CD8\u2212 (double negative [DN] DC) and CD4\u2212CD8+ DC (CD8+ DC) (3).", [["spleen", "ANATOMY", 9, 15], ["dendritic cells", "ANATOMY", 69, 84], ["cDCs", "ANATOMY", 86, 90], ["CD4+CD8\u2212 (CD4+ DC", "ANATOMY", 93, 110], ["CD4\u2212CD8\u2212 (double negative [DN] DC", "ANATOMY", 113, 146], ["CD4\u2212CD8+ DC", "ANATOMY", 152, 163], ["CD8+ DC", "ANATOMY", 165, 172], ["mouse", "ORGANISM", 3, 8], ["spleen", "ORGAN", 9, 15], ["conventional dendritic cells", "CELL", 56, 84], ["cDCs", "CELL", 86, 90], ["CD4", "GENE_OR_GENE_PRODUCT", 93, 96], ["CD8", "GENE_OR_GENE_PRODUCT", 97, 100], ["CD4", "GENE_OR_GENE_PRODUCT", 103, 106], ["CD4", "GENE_OR_GENE_PRODUCT", 113, 116], ["CD8", "GENE_OR_GENE_PRODUCT", 117, 120], ["CD4", "GENE_OR_GENE_PRODUCT", 152, 155], ["CD8", "GENE_OR_GENE_PRODUCT", 156, 159], ["conventional dendritic cells", "CELL_TYPE", 56, 84], ["cDCs", "CELL_TYPE", 86, 90], ["CD4", "PROTEIN", 93, 96], ["CD8", "PROTEIN", 97, 100], ["CD4", "PROTEIN", 103, 106], ["DC", "CELL_TYPE", 108, 110], ["CD4", "PROTEIN", 113, 116], ["CD8\u2212 (double negative [DN] DC", "CELL_TYPE", 117, 146], ["CD4", "PROTEIN", 152, 155], ["CD8", "PROTEIN", 156, 159], ["DC", "CELL_TYPE", 161, 163], ["CD8", "PROTEIN", 165, 168], ["DC", "CELL_TYPE", 170, 172], ["mouse", "SPECIES", 3, 8], ["mouse", "SPECIES", 3, 8], ["conventional dendritic cells", "TEST", 56, 84], ["cDCs", "TEST", 86, 90], ["CD4", "TEST", 93, 96], ["CD4", "TEST", 103, 106], ["DC", "TEST", 108, 110], ["CD4", "TEST", 113, 116], ["CD8", "TEST", 117, 120], ["double", "TEST", 123, 129], ["DN", "TEST", 140, 142], ["DC", "TEST", 144, 146], ["CD4", "TEST", 152, 155], ["CD8", "TEST", 156, 159], ["DC", "TEST", 161, 163], ["CD8", "TEST", 165, 168], ["spleen", "ANATOMY", 9, 15], ["dendritic cells", "OBSERVATION", 69, 84]]], ["While there is debate over the haematological origins of these populations (4\u20136), they are functionally distinct.", [["haematological origins", "OBSERVATION_MODIFIER", 31, 53], ["populations", "OBSERVATION_MODIFIER", 63, 74], ["functionally", "OBSERVATION_MODIFIER", 91, 103], ["distinct", "OBSERVATION_MODIFIER", 104, 112]]], ["For example, CD8+ DCs are relatively poor stimulators of T cells (7, 8), and were originally proposed to have a regulatory function (9).", [["CD8+ DCs", "ANATOMY", 13, 21], ["T cells", "ANATOMY", 57, 64], ["CD8", "GENE_OR_GENE_PRODUCT", 13, 16], ["T cells", "CELL", 57, 64], ["CD8", "PROTEIN", 13, 16], ["DCs", "CELL_TYPE", 18, 21], ["T cells", "CELL_TYPE", 57, 64], ["CD8", "TEST", 13, 16], ["DCs", "PROBLEM", 18, 21]]], ["However, if activated, CD8+ and CD8\u2212 DCs can both induce immune responses (10, 11), though they preferentially induce Th1 and Th2 type responses, respectively (12, 13).", [["DCs", "ANATOMY", 37, 40], ["CD8", "GENE_OR_GENE_PRODUCT", 23, 26], ["CD8", "GENE_OR_GENE_PRODUCT", 32, 35], ["DCs", "CELL", 37, 40], ["Th1", "CELL", 118, 121], ["CD8", "PROTEIN", 23, 26], ["CD8", "PROTEIN", 32, 35], ["DCs", "CELL_TYPE", 37, 40], ["CD8", "TEST", 23, 26]]], ["This is in part due to CD8+ DCs being more potent producers of IL-12 (14, 15).", [["CD8+ DCs", "ANATOMY", 23, 31], ["CD8", "GENE_OR_GENE_PRODUCT", 23, 26], ["IL-12", "GENE_OR_GENE_PRODUCT", 63, 68], ["CD8", "PROTEIN", 23, 26], ["DCs", "CELL_TYPE", 28, 31], ["IL", "PROTEIN", 63, 65], ["DCs", "PROBLEM", 28, 31], ["IL", "TEST", 63, 65]]], ["CD8+ DCs have a unique ability to take-up dying cells (16), and are especially adept at cross-presenting exogenous antigen on class I MHC (17, 18).", [["CD8+ DCs", "ANATOMY", 0, 8], ["cells", "ANATOMY", 48, 53], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["cells", "CELL", 48, 53], ["CD8", "PROTEIN", 0, 3], ["DCs", "CELL_TYPE", 5, 8], ["dying cells", "CELL_TYPE", 42, 53], ["exogenous antigen", "PROTEIN", 105, 122], ["class I MHC", "PROTEIN", 126, 137], ["DCs", "PROBLEM", 5, 8]]], ["Lymph node CD8+ DCs are the most efficient at presenting viral antigen and initiating T cell responses (19).", [["Lymph node CD8+ DCs", "ANATOMY", 0, 19], ["T cell", "ANATOMY", 86, 92], ["CD8", "GENE_OR_GENE_PRODUCT", 11, 14], ["T cell", "CELL", 86, 92], ["CD8", "PROTEIN", 11, 14], ["DCs", "CELL_TYPE", 16, 19], ["viral antigen", "PROTEIN", 57, 70], ["Lymph node CD8", "TEST", 0, 14], ["DCs", "PROBLEM", 16, 19], ["viral antigen", "TEST", 57, 70], ["T cell responses", "TEST", 86, 102], ["node CD8", "OBSERVATION", 6, 14]]], ["Finally, DC populations occupy different micro-environments in lymphoid organs (15, 20), CD8+ DCs tend to concentrate in T cell areas, whereas CD8\u2212 DCs are found in marginal zones but migrate to T cell areas upon stimulation (21).IntroductionMolecules whose expression differs among these DC populations are of particular interest as they may underpin their functional differences.", [["DC populations", "ANATOMY", 9, 23], ["lymphoid organs", "ANATOMY", 63, 78], ["CD8+ DCs", "ANATOMY", 89, 97], ["T cell areas", "ANATOMY", 121, 133], ["DCs", "ANATOMY", 148, 151], ["marginal zones", "ANATOMY", 165, 179], ["T cell areas", "ANATOMY", 195, 207], ["DC", "ANATOMY", 289, 291], ["DC populations", "CELL", 9, 23], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 63, 78], ["CD8", "GENE_OR_GENE_PRODUCT", 89, 92], ["DCs", "CELL", 94, 97], ["T cell", "CELL", 121, 127], ["CD8", "GENE_OR_GENE_PRODUCT", 143, 146], ["DCs", "CELL", 148, 151], ["marginal zones", "TISSUE", 165, 179], ["T cell", "CELL", 195, 201], ["DC populations", "CELL", 289, 303], ["DC populations", "CELL_TYPE", 9, 23], ["CD8", "PROTEIN", 89, 92], ["DCs", "CELL_TYPE", 94, 97], ["CD8", "PROTEIN", 143, 146], ["DCs", "CELL_TYPE", 148, 151], ["DC populations", "CELL_TYPE", 289, 303], ["CD8", "TEST", 89, 92], ["DCs", "PROBLEM", 94, 97], ["marginal zones", "PROBLEM", 165, 179], ["lymphoid organs", "ANATOMY", 63, 78], ["T cell", "OBSERVATION_MODIFIER", 121, 127], ["marginal", "OBSERVATION_MODIFIER", 165, 173], ["zones", "OBSERVATION_MODIFIER", 174, 179], ["T cell", "OBSERVATION_MODIFIER", 195, 201]]], ["Using both genetic (22, 23) and immunophenotyping approaches (3, 24, 25), several such molecules have been identified and recently we cloned the cell-surface protein CIRE, which is expressed by DN DCs and CD4+ DCs, but not by CD8+ DCs (26).IntroductionCIRE is a type II membrane protein with a C-type lectin domain (CTLD) at the cell surface.", [["cell", "ANATOMY", 145, 149], ["surface", "ANATOMY", 150, 157], ["DN DCs", "ANATOMY", 194, 200], ["CD4+ DCs", "ANATOMY", 205, 213], ["CD8+ DCs", "ANATOMY", 226, 234], ["cell surface", "ANATOMY", 329, 341], ["cell", "CELL", 145, 149], ["CIRE", "GENE_OR_GENE_PRODUCT", 166, 170], ["DN DCs", "CELL", 194, 200], ["CD4", "GENE_OR_GENE_PRODUCT", 205, 208], ["CD8", "GENE_OR_GENE_PRODUCT", 226, 229], ["type II", "GENE_OR_GENE_PRODUCT", 262, 269], ["membrane", "CELLULAR_COMPONENT", 270, 278], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 294, 307], ["CTLD", "GENE_OR_GENE_PRODUCT", 316, 320], ["cell surface", "CELLULAR_COMPONENT", 329, 341], ["cell-surface protein", "PROTEIN", 145, 165], ["CIRE", "PROTEIN", 166, 170], ["DN DCs", "CELL_TYPE", 194, 200], ["CD4", "PROTEIN", 205, 208], ["DCs", "CELL_TYPE", 210, 213], ["CD8", "PROTEIN", 226, 229], ["DCs", "CELL_TYPE", 231, 234], ["type II membrane protein", "PROTEIN", 262, 286], ["C-type lectin domain", "PROTEIN", 294, 314], ["CTLD", "PROTEIN", 316, 320], ["immunophenotyping approaches", "TEST", 32, 60], ["CD4", "TEST", 205, 208], ["a C-type lectin domain", "PROBLEM", 292, 314], ["cell surface", "OBSERVATION", 329, 341]]], ["The CIRE protein sequence shows a 57% identity with the human molecule DC-specific intercellular adhesion molecule (ICAM)-grabbing non-integrin (hDC-SIGN) (26, 27).", [["human", "ORGANISM", 56, 61], ["DC-specific intercellular adhesion molecule (ICAM)-grabbing non-integrin", "GENE_OR_GENE_PRODUCT", 71, 143], ["hDC-SIGN", "GENE_OR_GENE_PRODUCT", 145, 153], ["CIRE protein sequence", "DNA", 4, 25], ["human molecule DC-specific intercellular adhesion molecule (ICAM)-grabbing non-integrin", "PROTEIN", 56, 143], ["hDC", "PROTEIN", 145, 148], ["SIGN", "PROTEIN", 149, 153], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["The CIRE protein sequence", "TEST", 0, 25], ["the human molecule DC", "TEST", 52, 73], ["ICAM", "TEST", 116, 120], ["intercellular", "OBSERVATION_MODIFIER", 83, 96], ["adhesion molecule", "OBSERVATION", 97, 114]]], ["Human DC-SIGN facilitates interactions with T cells by binding ICAM-3, and with endothelial cells by binding ICAM-2 (28, 29).", [["DC-SIGN", "ANATOMY", 6, 13], ["T cells", "ANATOMY", 44, 51], ["endothelial cells", "ANATOMY", 80, 97], ["Human", "ORGANISM", 0, 5], ["DC-SIGN", "CELL", 6, 13], ["T cells", "CELL", 44, 51], ["ICAM-3", "GENE_OR_GENE_PRODUCT", 63, 69], ["endothelial cells", "CELL", 80, 97], ["ICAM-2", "GENE_OR_GENE_PRODUCT", 109, 115], ["Human DC", "CELL_TYPE", 0, 8], ["SIGN", "PROTEIN", 9, 13], ["T cells", "CELL_TYPE", 44, 51], ["ICAM-3", "PROTEIN", 63, 69], ["endothelial cells", "CELL_TYPE", 80, 97], ["ICAM", "PROTEIN", 109, 113], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["binding ICAM", "TEST", 55, 67], ["binding ICAM", "TEST", 101, 113], ["endothelial cells", "ANATOMY", 80, 97]]], ["It also plays a role in the capture, internalisation and presentation of foreign antigen (30).", [["foreign antigen", "GENE_OR_GENE_PRODUCT", 73, 88], ["foreign antigen", "PROTEIN", 73, 88], ["foreign antigen", "PROBLEM", 73, 88]]], ["Notably, several pathogens interact with hDC-SIGN, including viruses such as HIV, human cytomegalovirus (HCMV) and Ebolavirus (EBOV), bacteria such as Mycobacterium and parasites such as Leishmania and the eggs of Schistosoma mansoni (31).IntroductionThe sequence similarity, together with the cellular expression and genomic localisation data, suggest that CIRE is mouse DC-SIGN (26, 27) and therefore will be referred to as CIRE/mDC-SIGN.", [["cellular", "ANATOMY", 294, 302], ["DC", "ANATOMY", 372, 374], ["HIV, human cytomegalovirus (HCMV) and Ebolavirus (EBOV)", "DISEASE", 77, 132], ["Schistosoma mansoni", "DISEASE", 214, 233], ["hDC-SIGN", "GENE_OR_GENE_PRODUCT", 41, 49], ["HIV", "ORGANISM", 77, 80], ["human cytomegalovirus", "ORGANISM", 82, 103], ["HCMV", "ORGANISM", 105, 109], ["Ebolavirus (EBOV", "ORGANISM", 115, 131], ["Leishmania", "ORGANISM", 187, 197], ["Schistosoma mansoni", "ORGANISM", 214, 233], ["cellular", "CELL", 294, 302], ["mouse", "ORGANISM", 366, 371], ["CIRE", "GENE_OR_GENE_PRODUCT", 426, 430], ["mDC-SIGN", "GENE_OR_GENE_PRODUCT", 431, 439], ["SIGN", "PROTEIN", 45, 49], ["CIRE", "DNA", 358, 362], ["CIRE", "PROTEIN", 426, 430], ["mDC", "CELL_TYPE", 431, 434], ["SIGN", "DNA", 435, 439], ["HIV", "SPECIES", 77, 80], ["human", "SPECIES", 82, 87], ["cytomegalovirus", "SPECIES", 88, 103], ["Schistosoma mansoni", "SPECIES", 214, 233], ["mouse", "SPECIES", 366, 371], ["HIV", "SPECIES", 77, 80], ["human cytomegalovirus", "SPECIES", 82, 103], ["HCMV", "SPECIES", 105, 109], ["EBOV", "SPECIES", 127, 131], ["Schistosoma mansoni", "SPECIES", 214, 233], ["mouse", "SPECIES", 366, 371], ["several pathogens", "PROBLEM", 9, 26], ["hDC", "TEST", 41, 44], ["viruses", "PROBLEM", 61, 68], ["HIV", "PROBLEM", 77, 80], ["human cytomegalovirus (HCMV)", "PROBLEM", 82, 110], ["Ebolavirus (EBOV)", "PROBLEM", 115, 132], ["bacteria", "PROBLEM", 134, 142], ["Mycobacterium", "PROBLEM", 151, 164], ["parasites", "PROBLEM", 169, 178], ["Leishmania", "PROBLEM", 187, 197], ["Schistosoma mansoni", "PROBLEM", 214, 233], ["The sequence similarity", "TEST", 251, 274], ["genomic localisation data", "TEST", 318, 343], ["several", "OBSERVATION_MODIFIER", 9, 16], ["pathogens", "OBSERVATION", 17, 26], ["cytomegalovirus", "OBSERVATION", 88, 103], ["Mycobacterium", "OBSERVATION", 151, 164], ["Leishmania", "OBSERVATION", 187, 197], ["Schistosoma mansoni", "OBSERVATION", 214, 233]]], ["However, whether CIRE/mDC-SIGN and hDC-SIGN are indeed functional orthologues is open to question.", [["CIRE", "GENE_OR_GENE_PRODUCT", 17, 21], ["mDC-SIGN", "GENE_OR_GENE_PRODUCT", 22, 30], ["hDC-SIGN", "GENE_OR_GENE_PRODUCT", 35, 43], ["CIRE", "PROTEIN", 17, 21], ["mDC", "PROTEIN", 22, 25], ["SIGN", "PROTEIN", 26, 30], ["hDC", "PROTEIN", 35, 38], ["SIGN", "DNA", 39, 43]]], ["The issue is clouded by gene duplication events in both the mouse and human genomes.", [["mouse", "ORGANISM", 60, 65], ["human", "ORGANISM", 70, 75], ["mouse and human genomes", "DNA", 60, 83], ["mouse", "SPECIES", 60, 65], ["human", "SPECIES", 70, 75], ["mouse", "SPECIES", 60, 65], ["human", "SPECIES", 70, 75], ["gene duplication events", "PROBLEM", 24, 47], ["gene duplication", "OBSERVATION", 24, 40], ["human genomes", "OBSERVATION", 70, 83]]], ["In humans, there is a DC-SIGN homologue (DC-SIGNR or L-SIGN), which is just as similar to CIRE/mDC-SIGN as is hDC-SIGN (32).", [["DC", "ANATOMY", 22, 24], ["DC", "ANATOMY", 41, 43], ["humans", "ORGANISM", 3, 9], ["SIGN", "GENE_OR_GENE_PRODUCT", 25, 29], ["DC-SIGNR", "GENE_OR_GENE_PRODUCT", 41, 49], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 53, 59], ["CIRE", "GENE_OR_GENE_PRODUCT", 90, 94], ["mDC-SIGN", "GENE_OR_GENE_PRODUCT", 95, 103], ["hDC-SIGN", "GENE_OR_GENE_PRODUCT", 110, 118], ["DC", "CELL_TYPE", 22, 24], ["SIGN homologue", "PROTEIN", 25, 39], ["DC", "PROTEIN", 41, 43], ["SIGNR", "PROTEIN", 44, 49], ["L", "PROTEIN", 53, 54], ["SIGN", "PROTEIN", 55, 59], ["CIRE", "PROTEIN", 90, 94], ["mDC", "CELL_TYPE", 95, 98], ["SIGN", "DNA", 99, 103], ["hDC", "PROTEIN", 110, 113], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9]]], ["In mice, there are four CIRE/mDC-SIGN homologues whose CTLDs display a level of identity to hDC-SIGN as close as CIRE/mDC-SIGN itself (26, 27).IntroductionWe have now generated a mAb to CIRE/mDC-SIGN, enabling us to characterise this molecule at the protein level.", [["mice", "ORGANISM", 3, 7], ["CIRE", "GENE_OR_GENE_PRODUCT", 24, 28], ["mDC", "GENE_OR_GENE_PRODUCT", 29, 32], ["SIGN", "GENE_OR_GENE_PRODUCT", 33, 37], ["CTLDs", "GENE_OR_GENE_PRODUCT", 55, 60], ["hDC-SIGN", "GENE_OR_GENE_PRODUCT", 92, 100], ["CIRE", "PROTEIN", 24, 28], ["mDC", "PROTEIN", 29, 32], ["SIGN homologues", "PROTEIN", 33, 48], ["CTLDs", "PROTEIN", 55, 60], ["hDC", "DNA", 92, 95], ["SIGN", "DNA", 96, 100], ["CIRE", "DNA", 113, 117], ["mDC", "CELL_TYPE", 118, 121], ["SIGN", "DNA", 122, 126], ["mAb", "PROTEIN", 179, 182], ["CIRE", "PROTEIN", 186, 190], ["mDC", "CELL_TYPE", 191, 194], ["SIGN", "PROTEIN", 195, 199], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["hDC", "TEST", 92, 95]]], ["We confirm the differential expression of CIRE/mDC-SIGN in DC subsets and demonstrate that CIRE/mDC-SIGN is indeed a lectin able to bind mannosylated ligands in a calcium-dependent manner.", [["DC", "ANATOMY", 59, 61], ["calcium", "CHEMICAL", 163, 170], ["calcium", "CHEMICAL", 163, 170], ["CIRE", "GENE_OR_GENE_PRODUCT", 42, 46], ["mDC-SIGN", "GENE_OR_GENE_PRODUCT", 47, 55], ["DC", "CELL", 59, 61], ["CIRE", "GENE_OR_GENE_PRODUCT", 91, 95], ["mDC-SIGN", "GENE_OR_GENE_PRODUCT", 96, 104], ["calcium", "SIMPLE_CHEMICAL", 163, 170], ["CIRE", "PROTEIN", 42, 46], ["mDC", "PROTEIN", 47, 50], ["SIGN", "PROTEIN", 51, 55], ["DC subsets", "CELL_TYPE", 59, 69], ["CIRE", "PROTEIN", 91, 95], ["mDC", "CELL_TYPE", 96, 99], ["SIGN", "PROTEIN", 100, 104], ["lectin", "PROTEIN", 117, 123], ["a lectin", "PROBLEM", 115, 123]]], ["However, CIRE/mDC-SIGN does not bind to any of the hDC-SIGN ligands tested, indicating that significant differences exist in the ligand-binding specificity of the two molecules.", [["CIRE", "CHEMICAL", 9, 13], ["CIRE", "PROTEIN", 9, 13], ["mDC", "CELL_TYPE", 14, 17], ["SIGN", "PROTEIN", 18, 22], ["hDC-SIGN ligands", "PROTEIN", 51, 67], ["the hDC", "TEST", 47, 54], ["SIGN ligands", "TEST", 55, 67], ["significant", "OBSERVATION_MODIFIER", 92, 103]]], ["The function of CIRE/mDC-SIGN might therefore differ from that of hDC-SIGN.Mice ::: MethodsC57BL/6J wehi, CBA/CaH mice and Wistar rats were bred under specific pathogen-free (SPF) conditions at the Walter and Eliza Hall Institute (WEHI).", [["CIRE", "GENE_OR_GENE_PRODUCT", 16, 20], ["mDC-SIGN", "GENE_OR_GENE_PRODUCT", 21, 29], ["hDC-SIGN", "GENE_OR_GENE_PRODUCT", 66, 74], ["Mice", "ORGANISM", 75, 79], ["MethodsC57BL/6J wehi", "ORGANISM", 84, 104], ["CBA/CaH mice", "ORGANISM", 106, 118], ["Wistar rats", "ORGANISM", 123, 134], ["CIRE", "PROTEIN", 16, 20], ["mDC", "CELL_TYPE", 21, 24], ["SIGN", "PROTEIN", 25, 29], ["hDC", "PROTEIN", 66, 69], ["SIGN", "PROTEIN", 70, 74], ["Mice", "SPECIES", 75, 79], ["mice", "SPECIES", 114, 118], ["rats", "SPECIES", 130, 134], ["mice", "SPECIES", 114, 118], ["MethodsC57BL/6J wehi", "TREATMENT", 84, 104], ["CBA/CaH mice", "TREATMENT", 106, 118], ["Wistar rats", "TREATMENT", 123, 134]]], ["Germ-free C57BL/6J mice were bred at the WEHI facility and sacrificed within 12 h of arrival into our SPF holding facility.Generating an anti-CIRE/mDC-SIGN mAb ::: MethodsA synthetic peptide was synthesised (H-MSKESTWYWVDGSPLTLSFMKYWSKC-NH2) and conjugated to keyhole limpet haemocyanin (KLH) (Mimotopes, Victoria, Australia).", [["H-MSKESTWYWVDGSPLTLSFMKYWSKC-NH2", "CHEMICAL", 208, 240], ["NH2", "CHEMICAL", 237, 240], ["Germ-free C57BL/6J mice", "ORGANISM", 0, 23], ["anti-CIRE", "GENE_OR_GENE_PRODUCT", 137, 146], ["mDC", "CELL", 147, 150], ["H-MSKESTWYWVDGSPLTLSFMKYWSKC-NH2", "SIMPLE_CHEMICAL", 208, 240], ["keyhole limpet haemocyanin", "SIMPLE_CHEMICAL", 260, 286], ["anti-CIRE", "PROTEIN", 137, 146], ["mDC", "CELL_TYPE", 147, 150], ["SIGN mAb", "PROTEIN", 151, 159], ["NH2", "PROTEIN", 237, 240], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 19, 23], ["Germ", "TEST", 0, 4], ["MethodsA synthetic peptide", "TREATMENT", 164, 190], ["H-MSKESTWYWVDGSPLTLSFMKYWSKC-NH2)", "TREATMENT", 208, 241], ["conjugated to keyhole limpet haemocyanin", "TREATMENT", 246, 286], ["free", "OBSERVATION_MODIFIER", 5, 9]]], ["To generate mAbs, Wistar rats were immunised intra-peritoneally (i.p.) with 75 \u03bcg of KLH-conjugated peptide in CFA, boosted 5 weeks later with 50 \u03bcg of KLH-conjugated peptide in incomplete Freunds adjuvant and again 4 days prior to fusion intravenously and i.p. with 10 \u03bcg of KLH-conjugated peptide in aqueous solution.", [["intravenously", "ANATOMY", 239, 252], ["Wistar rats", "ORGANISM", 18, 29], ["KLH-conjugated peptide", "SIMPLE_CHEMICAL", 85, 107], ["CFA", "SIMPLE_CHEMICAL", 111, 114], ["KLH-conjugated peptide", "SIMPLE_CHEMICAL", 152, 174], ["Freunds", "SIMPLE_CHEMICAL", 189, 196], ["KLH-conjugated peptide", "SIMPLE_CHEMICAL", 276, 298], ["mAbs", "PROTEIN", 12, 16], ["rats", "SPECIES", 25, 29], ["KLH-conjugated peptide in CFA", "TREATMENT", 85, 114], ["KLH-conjugated peptide", "TREATMENT", 152, 174], ["incomplete Freunds adjuvant", "TREATMENT", 178, 205], ["fusion intravenously", "TREATMENT", 232, 252], ["KLH-conjugated peptide in aqueous solution", "TREATMENT", 276, 318], ["CFA", "ANATOMY", 111, 114]]], ["Hybridomas secreting specific mAbs were identified by flow cytometric analysis of supernatants using FLAG-CIRE/mDC-SIGN-CHO and Neo-CHO (26).", [["supernatants", "ANATOMY", 82, 94], ["Neo-CHO", "CHEMICAL", 128, 135], ["Hybridomas", "SIMPLE_CHEMICAL", 0, 10], ["mAbs", "GENE_OR_GENE_PRODUCT", 30, 34], ["FLAG", "GENE_OR_GENE_PRODUCT", 101, 105], ["SIGN-CHO", "SIMPLE_CHEMICAL", 115, 123], ["Neo-CHO", "SIMPLE_CHEMICAL", 128, 135], ["mAbs", "PROTEIN", 30, 34], ["FLAG", "PROTEIN", 101, 105], ["CIRE", "PROTEIN", 106, 110], ["mDC", "CELL_TYPE", 111, 114], ["Hybridomas secreting specific mAbs", "PROBLEM", 0, 34], ["flow cytometric analysis", "TEST", 54, 78], ["FLAG", "TEST", 101, 105]]], ["Four clones, from several thousand screened, produced anti-CIRE/mDC-SIGN mAb, but only one clone, 5H10, remained stable in culture and continued to produce mAb.Antibodies ::: MethodsThe following fluorochrome-conjugated mAbs were used: anti-CD11c (N418)\u2013allophycocyanin, \u2013Cy5 or \u2013FITC; anti-CIRE/mDC-SIGN (5H10)\u2013biotin; anti-CD4 (GK1.5)\u2013Alexa 594, anti-CD8 (53-6.7 or YTS 169.4)\u2013FITC; anti-CD45RA (14.8)\u2013FITC; isotype control IgG2a\u2013biotin (PharMingen, San Diego, CA, USA); goat anti-rat\u2013FITC antibody (Caltag, Burlingame, CA, USA); streptavidin\u2013PE (PharMingen).", [["clones", "ANATOMY", 5, 11], ["Alexa 594", "CHEMICAL", 337, 346], ["streptavidin\u2013PE", "CHEMICAL", 532, 547], ["Alexa 594", "CHEMICAL", 337, 346], ["FITC", "CHEMICAL", 379, 383], ["anti-CD45RA (14.8)\u2013", "CHEMICAL", 385, 404], ["FITC", "CHEMICAL", 404, 408], ["FITC", "CHEMICAL", 487, 491], ["anti-CIRE", "GENE_OR_GENE_PRODUCT", 54, 63], ["mDC-SIGN mAb", "GENE_OR_GENE_PRODUCT", 64, 76], ["clone", "CELL", 91, 96], ["mAb", "GENE_OR_GENE_PRODUCT", 156, 159], ["fluorochrome", "SIMPLE_CHEMICAL", 196, 208], ["anti-CD11c", "SIMPLE_CHEMICAL", 236, 246], ["N418", "SIMPLE_CHEMICAL", 248, 252], ["\u2013allophycocyanin", "SIMPLE_CHEMICAL", 253, 269], ["\u2013Cy5", "SIMPLE_CHEMICAL", 271, 275], ["\u2013FITC", "SIMPLE_CHEMICAL", 279, 284], ["anti-CIRE", "SIMPLE_CHEMICAL", 286, 295], ["mDC-SIGN", "SIMPLE_CHEMICAL", 296, 304], ["5H10)\u2013biotin", "SIMPLE_CHEMICAL", 306, 318], ["anti-CD4", "SIMPLE_CHEMICAL", 320, 328], ["GK1.5", "SIMPLE_CHEMICAL", 330, 335], ["Alexa 594", "SIMPLE_CHEMICAL", 337, 346], ["anti-CD8", "GENE_OR_GENE_PRODUCT", 348, 356], ["FITC", "GENE_OR_GENE_PRODUCT", 379, 383], ["anti-CD45RA", "GENE_OR_GENE_PRODUCT", 385, 396], ["FITC", "SIMPLE_CHEMICAL", 404, 408], ["IgG2a\u2013biotin", "SIMPLE_CHEMICAL", 426, 438], ["goat", "ORGANISM", 473, 477], ["anti-rat\u2013FITC antibody", "GENE_OR_GENE_PRODUCT", 478, 500], ["streptavidin\u2013PE", "SIMPLE_CHEMICAL", 532, 547], ["anti-CIRE", "PROTEIN", 54, 63], ["mDC", "PROTEIN", 64, 67], ["SIGN mAb", "PROTEIN", 68, 76], ["5H10", "CELL_LINE", 98, 102], ["mAb", "PROTEIN", 156, 159], ["fluorochrome-conjugated mAbs", "PROTEIN", 196, 224], ["anti-CD11c", "PROTEIN", 236, 246], ["N418", "PROTEIN", 248, 252], ["\u2013allophycocyanin", "PROTEIN", 253, 269], ["\u2013Cy5", "PROTEIN", 271, 275], ["\u2013FITC", "PROTEIN", 279, 284], ["CIRE", "PROTEIN", 291, 295], ["mDC", "PROTEIN", 296, 299], ["SIGN (5H10)\u2013biotin", "PROTEIN", 300, 318], ["anti-CD4", "PROTEIN", 320, 328], ["GK1.5", "PROTEIN", 330, 335], ["Alexa 594", "PROTEIN", 337, 346], ["isotype control IgG2a\u2013biotin", "PROTEIN", 410, 438], ["PharMingen, San Diego, CA, USA); goat anti-rat\u2013FITC antibody", "PROTEIN", 440, 500], ["Caltag", "PROTEIN", 502, 508], ["streptavidin\u2013PE", "PROTEIN", 532, 547], ["PharMingen", "PROTEIN", 549, 559], ["goat", "SPECIES", 473, 477], ["goat", "SPECIES", 473, 477], ["culture", "TEST", 123, 130], ["The following fluorochrome-conjugated mAbs", "TREATMENT", 182, 224], ["anti-CD11c", "TREATMENT", 236, 246], ["\u2013allophycocyanin", "TREATMENT", 253, 269], ["\u2013Cy5", "TREATMENT", 271, 275], ["\u2013FITC", "TREATMENT", 279, 284], ["anti-CIRE", "TREATMENT", 286, 295], ["\u2013biotin", "TREATMENT", 311, 318], ["anti-CD4", "TREATMENT", 320, 328], ["Alexa", "TEST", 337, 342], ["anti-CD8", "TEST", 348, 356], ["anti-CD45RA", "TEST", 385, 396], ["FITC", "TEST", 404, 408], ["isotype control IgG2a\u2013biotin", "TREATMENT", 410, 438], ["goat anti-rat\u2013FITC antibody", "TEST", 473, 500], ["Caltag", "TEST", 502, 508], ["Burlingame", "TEST", 510, 520], ["streptavidin\u2013PE (PharMingen", "TREATMENT", 532, 559], ["stable", "OBSERVATION", 113, 119]]], ["To better visualise CIRE/mDC-SIGN on the DC surface, the amplification system Flow-Amp (Flow-Amp Systems, Cleveland, OH, USA) was used according to the manufacturer's guidelines.", [["DC surface", "ANATOMY", 41, 51], ["CIRE", "GENE_OR_GENE_PRODUCT", 20, 24], ["mDC", "CELL", 25, 28], ["CIRE", "PROTEIN", 20, 24], ["mDC", "CELL_TYPE", 25, 28], ["SIGN", "PROTEIN", 29, 33], ["DC", "CELL_TYPE", 41, 43], ["Amp (Flow-Amp Systems", "TREATMENT", 83, 104]]], ["CIRE/mDC-SIGN staining was always after pre-incubation with rat Ig and 2.4G2 (10 min 4\u00b0C), and anti-CIRE/mDC-SIGN or isotype control mAb was then added into the pre-blocking mix.", [["mDC-SIGN", "GENE_OR_GENE_PRODUCT", 5, 13], ["rat", "ORGANISM", 60, 63], ["Ig", "GENE_OR_GENE_PRODUCT", 64, 66], ["anti-CIRE", "GENE_OR_GENE_PRODUCT", 95, 104], ["mDC-SIGN", "SIMPLE_CHEMICAL", 105, 113], ["rat Ig", "PROTEIN", 60, 66], ["2.4G2", "PROTEIN", 71, 76], ["anti-CIRE", "PROTEIN", 95, 104], ["mDC", "PROTEIN", 105, 108], ["SIGN", "PROTEIN", 109, 113], ["isotype control mAb", "PROTEIN", 117, 136], ["rat", "SPECIES", 60, 63], ["rat", "SPECIES", 60, 63], ["rat Ig", "TREATMENT", 60, 66], ["anti-CIRE/mDC", "TREATMENT", 95, 108], ["isotype control mAb", "TREATMENT", 117, 136]]], ["The anti-hDC-SIGN (AZN-1) supernatant was kindly donated by D. Hart (Mater Institute, Queensland, Australia).Isolation of DCs, macrophages and peripheral blood monocytes ::: MethodsThe isolation of DC sub-populations has been described (3, 33).", [["supernatant", "ANATOMY", 26, 37], ["DCs", "ANATOMY", 122, 125], ["macrophages", "ANATOMY", 127, 138], ["peripheral blood monocytes", "ANATOMY", 143, 169], ["DC", "ANATOMY", 198, 200], ["anti-hDC-SIGN", "CHEMICAL", 4, 17], ["anti-hDC-SIGN", "SIMPLE_CHEMICAL", 4, 17], ["AZN-1", "CELL", 19, 24], ["DCs", "CELL", 122, 125], ["macrophages", "CELL", 127, 138], ["peripheral blood monocytes", "CELL", 143, 169], ["anti-hDC", "PROTEIN", 4, 12], ["DCs", "CELL_TYPE", 122, 125], ["macrophages", "CELL_TYPE", 127, 138], ["peripheral blood monocytes", "CELL_TYPE", 143, 169], ["DC", "CELL_TYPE", 198, 200], ["peripheral blood monocytes", "TEST", 143, 169], ["Methods", "TREATMENT", 174, 181], ["DC sub-populations", "TREATMENT", 198, 216], ["peripheral", "ANATOMY_MODIFIER", 143, 153], ["blood monocytes", "OBSERVATION", 154, 169], ["isolation", "OBSERVATION_MODIFIER", 185, 194], ["DC sub", "OBSERVATION_MODIFIER", 198, 204]]], ["Briefly, tissues were chopped, digested with collagenase and DNAase at room temperature and treated with EDTA.", [["tissues", "ANATOMY", 9, 16], ["EDTA", "CHEMICAL", 105, 109], ["tissues", "TISSUE", 9, 16], ["collagenase", "GENE_OR_GENE_PRODUCT", 45, 56], ["DNAase", "GENE_OR_GENE_PRODUCT", 61, 67], ["EDTA", "SIMPLE_CHEMICAL", 105, 109], ["collagenase", "PROTEIN", 45, 56], ["DNAase", "PROTEIN", 61, 67], ["collagenase", "TREATMENT", 45, 56], ["DNAase", "TREATMENT", 61, 67], ["EDTA", "TREATMENT", 105, 109]]], ["Low-density cells were enriched by density centrifugation.", [["Low-density cells", "ANATOMY", 0, 17], ["cells", "CELL", 12, 17], ["Low-density cells", "PROBLEM", 0, 17], ["-", "OBSERVATION_MODIFIER", 3, 4], ["density cells", "OBSERVATION", 4, 17], ["density centrifugation", "OBSERVATION", 35, 57]]], ["Non-DC-lineage cells were coated with mAb (KT3-1.1, T24/31.7, TER119, RB6-8C5, ID3) and then removed using immunomagnetic beads.", [["Non-DC-lineage cells", "ANATOMY", 0, 20], ["T24", "ANATOMY", 52, 55], ["Non-DC-lineage cells", "CELL", 0, 20], ["TER119", "CELL", 62, 68], ["RB6-8C5", "CELL", 70, 77], ["ID3", "GENE_OR_GENE_PRODUCT", 79, 82], ["Non-DC-lineage cells", "CELL_LINE", 0, 20], ["mAb", "PROTEIN", 38, 41], ["KT3", "PROTEIN", 43, 46], ["T24", "PROTEIN", 52, 55], ["TER119", "PROTEIN", 62, 68], ["RB6", "PROTEIN", 70, 73], ["8C5", "PROTEIN", 74, 77], ["ID3", "PROTEIN", 79, 82], ["mAb", "TEST", 38, 41], ["KT3", "TEST", 43, 46], ["T24", "TEST", 52, 55], ["TER119", "TEST", 62, 68], ["RB6", "TEST", 70, 73], ["immunomagnetic beads", "TREATMENT", 107, 127], ["lineage cells", "OBSERVATION", 7, 20], ["immunomagnetic beads", "OBSERVATION", 107, 127]]], ["Coating with RB6-8C5 mAb (anti-Gr-1) did not result in the depletion of plasmacytoid pre-dendritic cells (pDCs) (33).", [["plasmacytoid pre-dendritic cells", "ANATOMY", 72, 104], ["pDCs", "ANATOMY", 106, 110], ["RB6-8C5", "CHEMICAL", 13, 20], ["RB6-8C5 mAb", "SIMPLE_CHEMICAL", 13, 24], ["anti-Gr-1", "GENE_OR_GENE_PRODUCT", 26, 35], ["plasmacytoid pre-dendritic cells", "CELL", 72, 104], ["pDCs", "CELL", 106, 110], ["RB6", "PROTEIN", 13, 16], ["8C5 mAb", "PROTEIN", 17, 24], ["anti-Gr-1", "PROTEIN", 26, 35], ["plasmacytoid pre-dendritic cells", "CELL_TYPE", 72, 104], ["pDCs", "CELL_TYPE", 106, 110], ["Coating", "TEST", 0, 7], ["RB6", "TEST", 13, 16], ["plasmacytoid pre-dendritic cells", "PROBLEM", 72, 104], ["plasmacytoid pre-dendritic cells", "OBSERVATION", 72, 104]]], ["The remaining cells were stained with various combinations of fluorochrome-conjugated mAb and populations enriched for CD11c+CIRE/mDC-SIGN+ and CD11c+CIRE/mDC-SIGN\u2212 cells, or purified as CD11c+CD8+CD4\u2212, CD11c+CD8\u2212CD4+ and CD11c+CD8\u2212 CD4\u2212 or as CD11cint CD45RA+ and CD11chi and CD45RA\u2212, all by sorting on a MoFlo Instrument (Cytomation Inc.).", [["cells", "ANATOMY", 14, 19], ["CD11c+CIRE/mDC-SIGN+", "ANATOMY", 119, 139], ["CD11c+CIRE/mDC-SIGN\u2212 cells", "ANATOMY", 144, 170], ["CD11c+CD8+CD4\u2212, CD11c+CD8\u2212CD4+ and CD11c+CD8\u2212 CD4\u2212", "ANATOMY", 187, 237], ["CD11cint CD45RA+", "ANATOMY", 244, 260], ["CD11chi", "ANATOMY", 265, 272], ["cells", "CELL", 14, 19], ["fluorochrome", "SIMPLE_CHEMICAL", 62, 74], ["CD11c", "GENE_OR_GENE_PRODUCT", 119, 124], ["CIRE", "GENE_OR_GENE_PRODUCT", 125, 129], ["SIGN", "GENE_OR_GENE_PRODUCT", 134, 138], ["CD11c", "GENE_OR_GENE_PRODUCT", 144, 149], ["CD11c", "GENE_OR_GENE_PRODUCT", 187, 192], ["CD8", "GENE_OR_GENE_PRODUCT", 193, 196], ["CD4", "GENE_OR_GENE_PRODUCT", 197, 200], ["CD11c", "GENE_OR_GENE_PRODUCT", 203, 208], ["CD8", "GENE_OR_GENE_PRODUCT", 209, 212], ["CD4", "GENE_OR_GENE_PRODUCT", 213, 216], ["CD11c", "GENE_OR_GENE_PRODUCT", 222, 227], ["CD8", "GENE_OR_GENE_PRODUCT", 228, 231], ["CD4", "GENE_OR_GENE_PRODUCT", 233, 236], ["CD45RA", "GENE_OR_GENE_PRODUCT", 253, 259], ["CD11chi", "GENE_OR_GENE_PRODUCT", 265, 272], ["CD45RA", "GENE_OR_GENE_PRODUCT", 277, 283], ["fluorochrome-conjugated mAb", "PROTEIN", 62, 89], ["CD11c", "PROTEIN", 119, 124], ["CIRE", "PROTEIN", 125, 129], ["mDC", "CELL_TYPE", 130, 133], ["SIGN", "PROTEIN", 134, 138], ["CD11c", "PROTEIN", 144, 149], ["CIRE", "PROTEIN", 150, 154], ["mDC", "CELL_TYPE", 155, 158], ["SIGN\u2212 cells", "CELL_LINE", 159, 170], ["CD11c", "PROTEIN", 187, 192], ["CD8", "PROTEIN", 193, 196], ["CD4", "PROTEIN", 197, 200], ["CD11c", "PROTEIN", 203, 208], ["CD8", "PROTEIN", 209, 212], ["CD4", "PROTEIN", 213, 216], ["CD11c", "PROTEIN", 222, 227], ["CD8", "PROTEIN", 228, 231], ["CD4", "PROTEIN", 233, 236], ["CD11cint CD45RA", "PROTEIN", 244, 259], ["CD11chi", "PROTEIN", 265, 272], ["CD45RA", "PROTEIN", 277, 283], ["The remaining cells", "PROBLEM", 0, 19], ["fluorochrome-conjugated mAb", "TREATMENT", 62, 89], ["CD11c", "TEST", 119, 124], ["CIRE", "TEST", 125, 129], ["mDC", "TEST", 130, 133], ["SIGN", "TEST", 134, 138], ["CD11c", "TEST", 144, 149], ["CIRE", "TEST", 150, 154], ["mDC", "TEST", 155, 158], ["CD11c", "TEST", 187, 192], ["CD8", "TEST", 193, 196], ["CD4", "TEST", 197, 200], ["CD11c", "TEST", 203, 208], ["CD8", "TEST", 209, 212], ["CD4", "TEST", 213, 216], ["CD11c", "TEST", 222, 227], ["CD8", "TEST", 228, 231], ["CD4", "TEST", 233, 236], ["CD11cint", "TEST", 244, 252], ["CD45RA", "TEST", 253, 259], ["CD11chi", "TEST", 265, 272], ["CD45RA", "TEST", 277, 283], ["a MoFlo Instrument", "TREATMENT", 304, 322]]], ["Due to the low level and frequency of CIRE/mDC-SIGN expression on DCs, the CD11c+CIRE/mDC-SIGN\u2212 DC purity was above 98%, but the CD11c+CIRE/mDC-SIGN+ DC purity was only 50\u201375%, the main contaminants being CD11c+CIRE/mDC-SIGN\u2212 DCs.", [["DCs", "ANATOMY", 66, 69], ["mDC", "ANATOMY", 86, 89], ["DC", "ANATOMY", 96, 98], ["mDC", "ANATOMY", 140, 143], ["DC", "ANATOMY", 150, 152], ["CD11c+CIRE/mDC-SIGN\u2212 DCs", "ANATOMY", 205, 229], ["CIRE", "GENE_OR_GENE_PRODUCT", 38, 42], ["mDC-SIGN", "GENE_OR_GENE_PRODUCT", 43, 51], ["DCs", "CELL", 66, 69], ["CD11c", "GENE_OR_GENE_PRODUCT", 75, 80], ["CIRE", "GENE_OR_GENE_PRODUCT", 81, 85], ["CD11c", "GENE_OR_GENE_PRODUCT", 129, 134], ["CIRE", "GENE_OR_GENE_PRODUCT", 135, 139], ["CD11c", "GENE_OR_GENE_PRODUCT", 205, 210], ["CIRE", "GENE_OR_GENE_PRODUCT", 211, 215], ["CIRE", "PROTEIN", 38, 42], ["mDC", "CELL_TYPE", 43, 46], ["SIGN", "PROTEIN", 47, 51], ["DCs", "CELL_TYPE", 66, 69], ["CD11c", "PROTEIN", 75, 80], ["CIRE", "PROTEIN", 81, 85], ["mDC", "CELL_TYPE", 86, 89], ["DC", "CELL_TYPE", 96, 98], ["CD11c", "PROTEIN", 129, 134], ["CIRE", "PROTEIN", 135, 139], ["mDC", "CELL_TYPE", 140, 143], ["SIGN", "PROTEIN", 144, 148], ["DC", "CELL_TYPE", 150, 152], ["CD11c", "PROTEIN", 205, 210], ["CIRE", "PROTEIN", 211, 215], ["mDC", "CELL_TYPE", 216, 219], ["SIGN", "PROTEIN", 220, 224], ["DCs", "CELL_TYPE", 226, 229], ["the low level", "PROBLEM", 7, 20], ["CIRE/mDC", "TREATMENT", 38, 46], ["the CD11c", "TEST", 71, 80], ["CIRE", "TEST", 81, 85], ["mDC", "TEST", 86, 89], ["the CD11c", "TEST", 125, 134], ["CIRE", "TEST", 135, 139], ["mDC", "TEST", 140, 143], ["DC purity", "TEST", 150, 159], ["CIRE", "TEST", 211, 215]]], ["To obtain blood mononuclear cells, mice were bled by cardiac puncture into tubes containing heparinized buffered saline solution.", [["blood mononuclear cells", "ANATOMY", 10, 33], ["cardiac", "ANATOMY", 53, 60], ["blood mononuclear cells", "CELL", 10, 33], ["mice", "ORGANISM", 35, 39], ["cardiac puncture", "MULTI-TISSUE_STRUCTURE", 53, 69], ["saline", "SIMPLE_CHEMICAL", 113, 119], ["blood mononuclear cells", "CELL_TYPE", 10, 33], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["blood mononuclear cells", "TEST", 10, 33], ["cardiac puncture into tubes", "TREATMENT", 53, 80], ["heparinized buffered saline solution", "TREATMENT", 92, 128], ["mononuclear cells", "OBSERVATION", 16, 33], ["cardiac", "ANATOMY", 53, 60], ["puncture", "OBSERVATION", 61, 69]]], ["Mononuclear cells were isolated by density centrifugation using Histopaque 1.083 (Sigma, Castle Hill, Australia) and cells bearing CD3, Thy-1, Gr-1 and the erythrocyte marker TER119 removed by immunomagnetic bead depletion.", [["Mononuclear cells", "ANATOMY", 0, 17], ["cells", "ANATOMY", 117, 122], ["erythrocyte", "ANATOMY", 156, 167], ["Mononuclear cells", "CELL", 0, 17], ["cells", "CELL", 117, 122], ["CD3", "GENE_OR_GENE_PRODUCT", 131, 134], ["Thy-1", "GENE_OR_GENE_PRODUCT", 136, 141], ["Gr-1", "GENE_OR_GENE_PRODUCT", 143, 147], ["erythrocyte", "CELL", 156, 167], ["TER119", "GENE_OR_GENE_PRODUCT", 175, 181], ["Mononuclear cells", "CELL_TYPE", 0, 17], ["CD3", "PROTEIN", 131, 134], ["Thy", "PROTEIN", 136, 139], ["Gr-1", "PROTEIN", 143, 147], ["erythrocyte marker TER119", "PROTEIN", 156, 181], ["Mononuclear cells", "TEST", 0, 17], ["Histopaque", "TEST", 64, 74], ["cells bearing CD3", "TEST", 117, 134], ["Thy", "TEST", 136, 139], ["Gr", "TEST", 143, 145], ["the erythrocyte marker", "TEST", 152, 174], ["immunomagnetic bead depletion", "TREATMENT", 193, 222], ["density centrifugation", "OBSERVATION", 35, 57], ["erythrocyte", "ANATOMY", 156, 167], ["immunomagnetic bead depletion", "OBSERVATION", 193, 222]]], ["Cells from the peritoneal cavity or the bone marrow were obtained by flushing with medium, and then removing erythrocytes with lysis buffer (0.099 mM EDTA disodium, 0.145 M NH4Cl, 0.012 M NaHCO3).DC activation ::: MethodsIsolated DCs (2 \u00d7 106 cells ml\u22121) were cultured in 24-well plates for 18\u201320 h in modified RPMI-1640 medium containing 10% FCS, antibiotics, 10\u22124 M 2-mercaptoethanol, granulocyte macrophage colony-stimulating factor (GM-CSF) (50 U ml\u22121) and CpG-1668 (0.5 \u03bcM) (GeneWorks, Adelaide, Australia) or in 96-well flat-bottom plates with murine recombinant IL-4 (Immunex) and IL-13 (R&D Systems, Minneapolis, MN, USA).Mixed leucocyte reaction ::: MethodsCD4 or CD8 T cells were isolated from lymph node cell suspensions by coating irrelevant cells with mAb (anti-erythrocytes, TER119; anti-B220, RA3-6B2; anti-Gr-1, RB6-6CS; Mac-1, M1/70 and anti-CD8, 53.6-7 or anti-CD4, GK1.5), and removing coated cells using IgG-coupled magnetic beads (Dynabeads, Dynal) at a 1:10 cell-to-bead ratio; purity was >95%.", [["Cells", "ANATOMY", 0, 5], ["peritoneal cavity", "ANATOMY", 15, 32], ["bone marrow", "ANATOMY", 40, 51], ["erythrocytes", "ANATOMY", 109, 121], ["DC", "ANATOMY", 196, 198], ["DCs", "ANATOMY", 230, 233], ["cells", "ANATOMY", 243, 248], ["leucocyte", "ANATOMY", 636, 645], ["CD8 T cells", "ANATOMY", 673, 684], ["lymph node cell suspensions", "ANATOMY", 704, 731], ["cells", "ANATOMY", 754, 759], ["erythrocytes", "ANATOMY", 775, 787], ["cells", "ANATOMY", 912, 917], ["cell", "ANATOMY", 980, 984], ["EDTA disodium", "CHEMICAL", 150, 163], ["NH4Cl", "CHEMICAL", 173, 178], ["10\u22124 M 2-mercaptoethanol", "CHEMICAL", 361, 385], ["GM", "CHEMICAL", 437, 439], ["CpG-1668", "CHEMICAL", 461, 469], ["EDTA disodium", "CHEMICAL", 150, 163], ["NH4Cl", "CHEMICAL", 173, 178], ["NaHCO3", "CHEMICAL", 188, 194], ["2-mercaptoethanol", "CHEMICAL", 368, 385], ["CpG-1668", "CHEMICAL", 461, 469], ["Cells", "CELL", 0, 5], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 15, 32], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 40, 51], ["erythrocytes", "CELL", 109, 121], ["EDTA disodium", "SIMPLE_CHEMICAL", 150, 163], ["DCs", "CELL", 230, 233], ["cells", "CELL", 243, 248], ["2-mercaptoethanol", "SIMPLE_CHEMICAL", 368, 385], ["granulocyte macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 387, 435], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 437, 443], ["CpG-1668", "SIMPLE_CHEMICAL", 461, 469], ["murine", "ORGANISM", 550, 556], ["IL-4", "GENE_OR_GENE_PRODUCT", 569, 573], ["Immunex", "SIMPLE_CHEMICAL", 575, 582], ["IL-13", "SIMPLE_CHEMICAL", 588, 593], ["leucocyte", "CELL", 636, 645], ["MethodsCD4", "GENE_OR_GENE_PRODUCT", 659, 669], ["CD8", "GENE_OR_GENE_PRODUCT", 673, 676], ["lymph node cell suspensions", "CELL", 704, 731], ["cells", "CELL", 754, 759], ["mAb", "GENE_OR_GENE_PRODUCT", 765, 768], ["erythrocytes", "CELL", 775, 787], ["anti-B220", "GENE_OR_GENE_PRODUCT", 797, 806], ["RA3-6B2", "GENE_OR_GENE_PRODUCT", 808, 815], ["-Gr-1", "GENE_OR_GENE_PRODUCT", 821, 826], ["RB6-6CS", "SIMPLE_CHEMICAL", 828, 835], ["Mac-1", "GENE_OR_GENE_PRODUCT", 837, 842], ["M1/70", "ORGANISM", 844, 849], ["anti-CD8", "GENE_OR_GENE_PRODUCT", 854, 862], ["anti-CD4", "SIMPLE_CHEMICAL", 874, 882], ["GK1.5", "SIMPLE_CHEMICAL", 884, 889], ["cells", "CELL", 912, 917], ["IgG", "SIMPLE_CHEMICAL", 924, 927], ["cell", "CELL", 980, 984], ["erythrocytes", "CELL_TYPE", 109, 121], ["DC", "CELL_TYPE", 196, 198], ["MethodsIsolated DCs", "CELL_LINE", 214, 233], ["granulocyte macrophage colony-stimulating factor", "PROTEIN", 387, 435], ["GM", "PROTEIN", 437, 439], ["CSF", "PROTEIN", 440, 443], ["murine recombinant IL-4", "PROTEIN", 550, 573], ["Immunex", "PROTEIN", 575, 582], ["IL", "PROTEIN", 588, 590], ["MethodsCD4", "PROTEIN", 659, 669], ["CD8 T cells", "CELL_TYPE", 673, 684], ["mAb", "PROTEIN", 765, 768], ["TER119", "PROTEIN", 789, 795], ["anti", "PROTEIN", 797, 801], ["B220", "PROTEIN", 802, 806], ["RA3", "PROTEIN", 808, 811], ["6B2", "PROTEIN", 812, 815], ["anti-Gr", "PROTEIN", 817, 824], ["RB6", "PROTEIN", 828, 831], ["6CS", "PROTEIN", 832, 835], ["Mac", "PROTEIN", 837, 840], ["M1", "PROTEIN", 844, 846], ["70", "PROTEIN", 847, 849], ["anti-CD8, 53.6-7", "PROTEIN", 854, 870], ["anti-CD4", "PROTEIN", 874, 882], ["GK1.5", "PROTEIN", 884, 889], ["coated cells", "CELL_LINE", 905, 917], ["IgG", "PROTEIN", 924, 927], ["Dynabeads, Dynal", "PROTEIN", 952, 968], ["murine", "SPECIES", 550, 556], ["Cells from the peritoneal cavity", "TEST", 0, 32], ["erythrocytes", "TREATMENT", 109, 121], ["lysis buffer", "TREATMENT", 127, 139], ["mM EDTA disodium", "TREATMENT", 147, 163], ["NH4Cl", "TREATMENT", 173, 178], ["NaHCO3", "TREATMENT", 188, 194], ["MethodsIsolated DCs", "TREATMENT", 214, 233], ["antibiotics", "TREATMENT", 348, 359], ["mercaptoethanol", "TREATMENT", 370, 385], ["granulocyte macrophage colony", "TEST", 387, 416], ["stimulating factor", "TEST", 417, 435], ["CpG", "TEST", 461, 464], ["murine recombinant IL", "TREATMENT", 550, 571], ["IL", "TEST", 588, 590], ["Mixed leucocyte reaction", "PROBLEM", 630, 654], ["MethodsCD4", "TEST", 659, 669], ["CD8 T cells", "TREATMENT", 673, 684], ["lymph node cell suspensions", "TREATMENT", 704, 731], ["coating irrelevant cells", "TEST", 735, 759], ["mAb", "TEST", 765, 768], ["anti-erythrocytes", "TEST", 770, 787], ["TER119", "TEST", 789, 795], ["anti", "TEST", 797, 801], ["RA3", "TEST", 808, 811], ["anti-Gr", "TEST", 817, 824], ["RB6", "TEST", 828, 831], ["6CS", "TEST", 832, 835], ["Mac", "TEST", 837, 840], ["M1", "TEST", 844, 846], ["anti-CD8", "TEST", 854, 862], ["anti-CD4", "TEST", 874, 882], ["IgG", "TEST", 924, 927], ["bead ratio", "TEST", 988, 998], ["purity", "TEST", 1000, 1006], ["peritoneal", "ANATOMY", 15, 25], ["cavity", "ANATOMY_MODIFIER", 26, 32], ["bone marrow", "ANATOMY", 40, 51], ["leucocyte reaction", "OBSERVATION", 636, 654], ["lymph node cell suspensions", "OBSERVATION", 704, 731]]], ["DCs were isolated and sorted as CD11c+CIRE/mDC-SIGN+ and CD11c+CIRE/mDC-SIGN\u2212 cells.", [["DCs", "ANATOMY", 0, 3], ["CD11c+CIRE/mDC-SIGN+", "ANATOMY", 32, 52], ["CD11c+CIRE/mDC-SIGN\u2212 cells", "ANATOMY", 57, 83], ["DCs", "CELL", 0, 3], ["CD11c", "GENE_OR_GENE_PRODUCT", 32, 37], ["CIRE", "GENE_OR_GENE_PRODUCT", 38, 42], ["SIGN", "GENE_OR_GENE_PRODUCT", 47, 51], ["CD11c", "GENE_OR_GENE_PRODUCT", 57, 62], ["DCs", "CELL_TYPE", 0, 3], ["CD11c", "PROTEIN", 32, 37], ["CIRE", "PROTEIN", 38, 42], ["mDC", "CELL_TYPE", 43, 46], ["SIGN", "PROTEIN", 47, 51], ["CD11c", "PROTEIN", 57, 62], ["mDC", "CELL_TYPE", 68, 71], ["SIGN\u2212 cells", "CELL_LINE", 72, 83], ["CD11c", "TEST", 32, 37], ["CIRE", "TEST", 38, 42], ["mDC", "TEST", 43, 46], ["SIGN", "TEST", 47, 51], ["CD11c", "TEST", 57, 62], ["CIRE", "TEST", 63, 67], ["mDC", "TEST", 68, 71], ["SIGN\u2212 cells", "PROBLEM", 72, 83], ["\u2212 cells", "OBSERVATION", 76, 83]]], ["Varying numbers of DCs were incubated for 3\u20134 days with 20 000 CD4 or CD8 T cells in V-bottom 96-well plates in modified RPMI-1640 medium containing 10% FCS, antibiotics and 10\u22124 M 2-mercaptoethanol.", [["DCs", "ANATOMY", 19, 22], ["CD4", "ANATOMY", 63, 66], ["CD8 T cells", "ANATOMY", 70, 81], ["RPMI-1640", "CHEMICAL", 121, 130], ["10\u22124 M 2-mercaptoethanol", "CHEMICAL", 174, 198], ["2-mercaptoethanol", "CHEMICAL", 181, 198], ["DCs", "CELL", 19, 22], ["CD8", "GENE_OR_GENE_PRODUCT", 70, 73], ["FCS", "SIMPLE_CHEMICAL", 153, 156], ["10\u22124 M 2-mercaptoethanol", "SIMPLE_CHEMICAL", 174, 198], ["DCs", "CELL_TYPE", 19, 22], ["CD4", "PROTEIN", 63, 66], ["CD8 T cells", "CELL_TYPE", 70, 81], ["CD8 T cells", "TEST", 70, 81], ["V", "TEST", 85, 86], ["modified RPMI", "TREATMENT", 112, 125], ["antibiotics", "TREATMENT", 158, 169], ["mercaptoethanol", "TREATMENT", 183, 198]]], ["Cultures were pulsed at the end of the incubation period with 1 \u03bcCi per well of [3H]thymidine for 6 h, harvested onto glass-fibre filters and thymidine incorporation was counted by liquid scintillation.", [["[3H]thymidine", "CHEMICAL", 80, 93], ["thymidine", "CHEMICAL", 142, 151], ["[3H]thymidine", "CHEMICAL", 80, 93], ["thymidine", "CHEMICAL", 142, 151], ["[3H]thymidine", "SIMPLE_CHEMICAL", 80, 93], ["thymidine", "SIMPLE_CHEMICAL", 142, 151], ["Cultures", "TEST", 0, 8], ["thymidine", "TREATMENT", 84, 93], ["glass-fibre filters", "TREATMENT", 118, 137], ["thymidine incorporation", "TREATMENT", 142, 165], ["fibre filters", "OBSERVATION", 124, 137]]], ["Five replicates of all cultures were done.Generating constructs ::: MethodsCIRE/mDC-SIGN and hDC-SIGN cDNAs were cloned into the EcoRV restriction site of the pIRES-Neo plasmid (Clonetech, Heidelberg, Germany).", [["MethodsCIRE", "GENE_OR_GENE_PRODUCT", 68, 79], ["mDC-SIGN", "GENE_OR_GENE_PRODUCT", 80, 88], ["hDC-SIGN", "GENE_OR_GENE_PRODUCT", 93, 101], ["EcoRV", "GENE_OR_GENE_PRODUCT", 129, 134], ["MethodsCIRE/mDC-SIGN and hDC-SIGN cDNAs", "DNA", 68, 107], ["EcoRV restriction site", "DNA", 129, 151], ["pIRES", "DNA", 159, 164], ["Neo plasmid", "DNA", 165, 176], ["all cultures", "TEST", 19, 31], ["MethodsCIRE", "TEST", 68, 79], ["hDC", "TEST", 93, 96], ["SIGN cDNAs", "PROBLEM", 97, 107], ["Neo plasmid", "TREATMENT", 165, 176]]], ["Briefly, CIRE/mDC-SIGN cDNA was amplified from previously isolated clones (26) using the PCR and Pwo polymerase (Roche, Mannheim, Germany) under standard amplification conditions: 25 cycles: 94\u00b0, 30 s; 55\u00b0, 30 s; 72\u00b0, 1 min.", [["clones", "ANATOMY", 67, 73], ["CIRE", "GENE_OR_GENE_PRODUCT", 9, 13], ["SIGN", "GENE_OR_GENE_PRODUCT", 18, 22], ["CIRE/mDC-SIGN cDNA", "DNA", 9, 27], ["Pwo polymerase", "PROTEIN", 97, 111], ["previously isolated clones", "PROBLEM", 47, 73], ["the PCR", "TEST", 85, 92]]], ["The primers used in this reaction were: CIRE/mDC-SIGN-For primer 5\u2032-TAG TAG ATA TCG GCG CGC CTC ACT TGC TAG GGC AGG A and -Rev primer 5\u2032-TAG TAG ATA TCG GCG CGC CTG AAA CAT GAG TGA TTC TAA G. Similarly, hDC-SIGN was amplified from cDNA derived from human DCs, using primers designed from published sequences (34): hDC-SIGN-For primer 5\u2032-TAG TAG ATA TCT GGG GTG ACA TGA GTG AC and DC-SIGN-Rev primer 5\u2032-TAG TAG ATA TCT ACG CAG GAG GGG GGT TT.", [["DCs", "ANATOMY", 255, 258], ["5\u2032-TAG TAG", "CHEMICAL", 134, 144], ["5\u2032-TAG TAG", "CHEMICAL", 399, 409], ["hDC-SIGN", "GENE_OR_GENE_PRODUCT", 203, 211], ["human", "ORGANISM", 249, 254], ["DCs", "CELL", 255, 258], ["CIRE/mDC-SIGN-For primer 5", "DNA", 40, 66], ["Rev primer 5\u2032-TAG TAG ATA TCG GCG CGC CTG AAA CAT GAG TGA TTC TAA G.", "DNA", 123, 191], ["hDC", "DNA", 203, 206], ["SIGN", "DNA", 207, 211], ["cDNA", "DNA", 231, 235], ["human DCs", "CELL_TYPE", 249, 258], ["hDC", "DNA", 314, 317], ["SIGN", "DNA", 318, 322], ["SIGN", "DNA", 383, 387], ["Rev primer 5\u2032-TAG TAG ATA TCT ACG CAG GAG GGG GGT TT", "DNA", 388, 440], ["human", "SPECIES", 249, 254], ["human", "SPECIES", 249, 254], ["The primers", "TREATMENT", 0, 11], ["CIRE", "TEST", 40, 44], ["primer", "TEST", 58, 64], ["TAG TAG", "TEST", 68, 75], ["ATA", "TEST", 76, 79], ["TCG", "TEST", 80, 83], ["GCG", "TEST", 84, 87], ["CGC", "TEST", 88, 91], ["CTC", "TEST", 92, 95], ["ACT", "TEST", 96, 99], ["TGC", "TEST", 100, 103], ["TAG", "TEST", 104, 107], ["GGC", "TEST", 108, 111], ["AGG", "TEST", 112, 115], ["A", "TEST", 116, 117], ["Rev primer", "TEST", 123, 133], ["TAG TAG", "TEST", 137, 144], ["ATA", "TEST", 145, 148], ["TCG", "TEST", 149, 152], ["GCG", "TEST", 153, 156], ["CGC", "TEST", 157, 160], ["CTG", "TEST", 161, 164], ["AAA", "TEST", 165, 168], ["CAT", "TEST", 169, 172], ["published sequences", "TEST", 288, 307], ["hDC", "TEST", 314, 317], ["SIGN", "TEST", 318, 322], ["primer", "TEST", 327, 333], ["TAG TAG", "TEST", 337, 344], ["ATA", "TEST", 345, 348], ["TCT", "TEST", 349, 352], ["GGG", "TEST", 353, 356], ["GTG", "TEST", 357, 360], ["ACA TGA", "TEST", 361, 368], ["AC", "TEST", 373, 375], ["Rev primer", "TEST", 388, 398], ["TAG TAG", "TEST", 402, 409], ["TCT", "TEST", 414, 417], ["ACG", "TEST", 418, 421]]], ["The CIRE/mDC-SIGN/hDC-SIGN hybrid molecules were generated using an overlapping PCR strategy.", [["CIRE", "GENE_OR_GENE_PRODUCT", 4, 8], ["mDC", "CELL", 9, 12], ["SIGN", "GENE_OR_GENE_PRODUCT", 13, 17], ["hDC", "GENE_OR_GENE_PRODUCT", 18, 21], ["CIRE/mDC-SIGN/hDC-SIGN hybrid molecules", "DNA", 4, 43], ["The CIRE/mDC", "TEST", 0, 12], ["SIGN/hDC", "TEST", 13, 21], ["SIGN hybrid molecules", "PROBLEM", 22, 43], ["an overlapping PCR strategy", "TREATMENT", 65, 92]]], ["To generate CIRE/mDC-SIGN/h-CTLD, cDNA encoding the cytoplasmic domains, transmembrane domain and hinge region of CIRE/mDC-SIGN was amplified by PCR using the CIRE/mDC-SIGN-For primer, plus the CIRE/mDC-SIGN/hCTLD-Rev primer 5\u2032-TGT CCA TTC CCA GGG ACA GGA GCG GCA CAG TCG AT.", [["cytoplasmic", "ANATOMY", 52, 63], ["transmembrane", "ANATOMY", 73, 86], ["CIRE", "GENE_OR_GENE_PRODUCT", 12, 16], ["mDC", "CELL", 17, 20], ["cytoplasmic", "ORGANISM_SUBSTANCE", 52, 63], ["transmembrane", "CELLULAR_COMPONENT", 73, 86], ["CIRE", "GENE_OR_GENE_PRODUCT", 114, 118], ["mDC-SIGN", "GENE_OR_GENE_PRODUCT", 119, 127], ["CIRE", "DNA", 12, 16], ["mDC", "CELL_TYPE", 17, 20], ["SIGN", "DNA", 21, 25], ["CTLD", "DNA", 28, 32], ["cDNA", "DNA", 34, 38], ["cytoplasmic domains", "PROTEIN", 52, 71], ["transmembrane domain", "PROTEIN", 73, 93], ["hinge region", "PROTEIN", 98, 110], ["CIRE", "PROTEIN", 114, 118], ["mDC", "PROTEIN", 119, 122], ["SIGN", "PROTEIN", 123, 127], ["CIRE/mDC-SIGN-For primer", "DNA", 159, 183], ["CIRE/mDC-SIGN/hCTLD-Rev primer 5\u2032-TGT CCA TTC CCA GGG ACA GGA GCG GCA CAG TCG AT", "DNA", 194, 274], ["CTLD", "PROBLEM", 28, 32], ["transmembrane domain and hinge region of CIRE/mDC", "TREATMENT", 73, 122], ["the CIRE", "TEST", 190, 198], ["Rev primer", "TEST", 214, 224], ["TGT", "TEST", 228, 231], ["TTC", "TEST", 236, 239], ["GGG", "TEST", 244, 247], ["ACA", "TEST", 248, 251]]], ["The first 17 nt of this primer correspond to sequence encoding the C-terminus of the CIRE/mDC-SIGN hinge region, whereas the last 17 nt encode the N-terminus of the hDC-SIGN CTLD.", [["N", "CHEMICAL", 147, 148], ["C-terminus", "GENE_OR_GENE_PRODUCT", 67, 77], ["CIRE", "GENE_OR_GENE_PRODUCT", 85, 89], ["C-terminus", "PROTEIN", 67, 77], ["CIRE", "PROTEIN", 85, 89], ["mDC", "PROTEIN", 90, 93], ["SIGN hinge region", "PROTEIN", 94, 111], ["N-terminus", "PROTEIN", 147, 157], ["hDC", "PROTEIN", 165, 168], ["SIGN CTLD", "PROTEIN", 169, 178]]], ["Similarly, cDNA corresponding to the hDC-SIGN CTLD was amplified with the hDC-SIGN-Rev primer and the CIRE/mDC-SIGN/hCTLD-For primer ATC GAC TGT GCC GCT CCT GTC CCT GGG AAT GGA CA, whose sequence is the reverse and complement of the CIRE/mDC-SIGN/hCTLD-Rev primer.", [["cDNA", "CELLULAR_COMPONENT", 11, 15], ["hDC-SIGN", "GENE_OR_GENE_PRODUCT", 37, 45], ["AAT GGA CA", "GENE_OR_GENE_PRODUCT", 169, 179], ["CIRE", "GENE_OR_GENE_PRODUCT", 233, 237], ["mDC", "GENE_OR_GENE_PRODUCT", 238, 241], ["SIGN", "GENE_OR_GENE_PRODUCT", 242, 246], ["hCTLD", "GENE_OR_GENE_PRODUCT", 247, 252], ["cDNA", "DNA", 11, 15], ["hDC", "DNA", 37, 40], ["SIGN CTLD", "DNA", 41, 50], ["hDC", "DNA", 74, 77], ["SIGN", "DNA", 78, 82], ["Rev primer", "DNA", 83, 93], ["CIRE/mDC-SIGN/hCTLD-For primer ATC GAC TGT GCC GCT CCT GTC CCT GGG AAT GGA CA", "DNA", 102, 179], ["CIRE/mDC-SIGN/hCTLD-Rev primer", "DNA", 233, 263], ["the hDC", "TEST", 33, 40], ["the hDC", "TEST", 70, 77], ["the CIRE", "TEST", 98, 106], ["hCTLD", "TEST", 116, 121], ["primer ATC GAC", "TEST", 126, 140], ["TGT", "TEST", 141, 144], ["GCC", "TEST", 145, 148], ["GCT", "TEST", 149, 152], ["CCT", "TEST", 153, 156], ["GTC", "TEST", 157, 160], ["CCT", "TEST", 161, 164], ["GGG AAT GGA CA", "PROBLEM", 165, 179], ["the CIRE", "TEST", 229, 237]]], ["The cDNAs encoding the CIRE/mDC-SIGN cytoplasmic, transmembrane and hinge regions and the DC-SIGN CTLD were purified by conventional methods, and joined by PCR using the CIRE/mDC-SIGN-For and hDC-SIGN-Rev primers.", [["cytoplasmic", "ANATOMY", 37, 48], ["transmembrane", "ANATOMY", 50, 63], ["DC", "ANATOMY", 90, 92], ["CIRE", "GENE_OR_GENE_PRODUCT", 23, 27], ["mDC-SIGN", "GENE_OR_GENE_PRODUCT", 28, 36], ["cytoplasmic", "ORGANISM_SUBSTANCE", 37, 48], ["transmembrane", "CELLULAR_COMPONENT", 50, 63], ["cDNAs", "DNA", 4, 9], ["CIRE", "PROTEIN", 23, 27], ["mDC", "PROTEIN", 28, 31], ["SIGN cytoplasmic, transmembrane and hinge regions", "PROTEIN", 32, 81], ["DC", "CELL_TYPE", 90, 92], ["SIGN CTLD", "PROTEIN", 93, 102], ["CIRE/mDC-SIGN-For and hDC-SIGN-Rev primers", "DNA", 170, 212], ["The cDNAs", "TEST", 0, 9], ["the CIRE", "TEST", 19, 27], ["hDC", "TEST", 192, 195], ["Rev primers", "OBSERVATION", 201, 212]]], ["The resulting cDNA was then cloned into the EcoRV site of pIRES-Neo.", [["EcoRV", "GENE_OR_GENE_PRODUCT", 44, 49], ["cDNA", "DNA", 14, 18], ["EcoRV site", "DNA", 44, 54], ["pIRES", "DNA", 58, 63], ["Neo", "DNA", 64, 67], ["The resulting cDNA", "PROBLEM", 0, 18], ["Neo", "TREATMENT", 64, 67]]], ["A parallel strategy was used to generate the hDC-SIGN/mCTLD hybrid.", [["hDC", "GENE_OR_GENE_PRODUCT", 45, 48], ["hDC", "PROTEIN", 45, 48], ["SIGN", "PROTEIN", 49, 53], ["mCTLD hybrid", "CELL_LINE", 54, 66], ["A parallel strategy", "TREATMENT", 0, 19], ["the hDC", "TEST", 41, 48], ["SIGN/mCTLD hybrid", "TREATMENT", 49, 66]]], ["Here cDNA encoding the hDC-SIGN cytoplasmic, transmembrane and hinge regions was amplified using the hDC-SIGN-For primer and the DC-SIGN/mCTLD-Rev primer 5\u2032-CGT CCA GTC CCA GGG GCA GGG GTG GCA CAG GCG TT.", [["cytoplasmic", "ANATOMY", 32, 43], ["transmembrane", "ANATOMY", 45, 58], ["DC", "ANATOMY", 129, 131], ["hDC-SIGN", "GENE_OR_GENE_PRODUCT", 23, 31], ["cytoplasmic", "ORGANISM_SUBSTANCE", 32, 43], ["transmembrane", "CELLULAR_COMPONENT", 45, 58], ["mCTLD", "GENE_OR_GENE_PRODUCT", 137, 142], ["cDNA", "DNA", 5, 9], ["hDC-SIGN cytoplasmic, transmembrane and hinge regions", "DNA", 23, 76], ["hDC-SIGN-For primer", "DNA", 101, 120], ["DC-SIGN/mCTLD-Rev primer 5", "DNA", 129, 155], ["the hDC", "TEST", 19, 26], ["transmembrane and hinge regions", "PROBLEM", 45, 76], ["the hDC", "TEST", 97, 104], ["primer", "TEST", 114, 120], ["the DC", "TEST", 125, 131], ["mCTLD", "TEST", 137, 142], ["Rev primer", "TEST", 143, 153], ["CGT", "TEST", 157, 160], ["CCA", "TEST", 161, 164], ["CCA", "TEST", 169, 172]]], ["Similarly, cDNA encoding the mouse CIRE/mDC-SIGN CTLD was amplified using the CIRE/mDC-SIGN-Rev primer and primer whose sequence was the reverse and complement of DC-SIGN/mCTLD-Rev, namely DC-SIGN/mCTLD-For primer 5\u2032-AAC GCC TGT GCC ACC CCT GCC CCT GGG ACT GGA CG.", [["DC", "ANATOMY", 163, 165], ["cDNA", "CELLULAR_COMPONENT", 11, 15], ["mouse", "ORGANISM", 29, 34], ["CIRE", "GENE_OR_GENE_PRODUCT", 35, 39], ["mDC", "GENE_OR_GENE_PRODUCT", 40, 43], ["SIGN", "GENE_OR_GENE_PRODUCT", 44, 48], ["cDNA", "DNA", 11, 15], ["mouse CIRE/mDC-SIGN CTLD", "DNA", 29, 53], ["CIRE/mDC-SIGN-Rev primer", "DNA", 78, 102], ["DC", "CELL_TYPE", 163, 165], ["SIGN", "DNA", 166, 170], ["mCTLD", "DNA", 171, 176], ["Rev", "DNA", 177, 180], ["DC", "CELL_TYPE", 189, 191], ["SIGN", "DNA", 192, 196], ["mCTLD", "DNA", 197, 202], ["mouse", "SPECIES", 29, 34], ["mouse", "SPECIES", 29, 34], ["DC", "TEST", 163, 165], ["mCTLD", "TEST", 171, 176], ["mCTLD", "TEST", 197, 202], ["primer", "TEST", 207, 213], ["AAC GCC", "TEST", 217, 224], ["TGT", "TEST", 225, 228], ["GCC", "TEST", 229, 232], ["ACC", "TEST", 233, 236], ["CCT", "TEST", 237, 240], ["GCC", "TEST", 241, 244], ["CCT", "TEST", 245, 248], ["CG", "TEST", 261, 263]]], ["Again, the two resulting cDNA fragments were joined in an overlapping PCR using the hDC-SIGN-For and CIRE/mDC-SIGN-Rev primers.", [["cDNA fragments", "DNA", 25, 39], ["hDC-SIGN-For and CIRE/mDC-SIGN-Rev primers", "DNA", 84, 126], ["the two resulting cDNA fragments", "PROBLEM", 7, 39], ["an overlapping PCR", "TEST", 55, 73], ["the hDC", "TEST", 80, 87], ["CIRE", "TEST", 101, 105], ["cDNA fragments", "OBSERVATION", 25, 39], ["Rev primers", "OBSERVATION", 115, 126]]], ["Mouse SIGNR1 was sub-cloned into the expression plasmid pcDNA3.1Zeo (Invitrogen, CA, USA) and has the AU1 tag fused to the carboxy terminal (35).Transfection ::: MethodsCHO-KI (CHO) cells were transfected with the pIRES-Neo plasmid containing the neomycin phosphotransferase gene plus inserted gene or with the control pCI-neo plasmid (Promega, Annandale, NSW, Australia) only, using the FuGENE 6 Transfection Reagent (Roche, Indianapolis, IN, USA) according to the manufacturer's guidelines.", [["plasmid", "ANATOMY", 48, 55], ["MethodsCHO-KI (CHO) cells", "ANATOMY", 162, 187], ["1Zeo", "CHEMICAL", 63, 67], ["neomycin", "CHEMICAL", 247, 255], ["carboxy", "CHEMICAL", 123, 130], ["neomycin", "CHEMICAL", 247, 255], ["Mouse", "ORGANISM", 0, 5], ["SIGNR1", "GENE_OR_GENE_PRODUCT", 6, 12], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 56, 62], ["Invitrogen, CA, USA", "GENE_OR_GENE_PRODUCT", 69, 88], ["MethodsCHO-KI (CHO) cells", "CELL", 162, 187], ["neomycin phosphotransferase", "GENE_OR_GENE_PRODUCT", 247, 274], ["Mouse SIGNR1", "DNA", 0, 12], ["expression plasmid pcDNA3", "DNA", 37, 62], ["AU1 tag", "PROTEIN", 102, 109], ["carboxy terminal (35)", "PROTEIN", 123, 144], ["MethodsCHO-KI (CHO) cells", "CELL_LINE", 162, 187], ["pIRES", "DNA", 214, 219], ["Neo plasmid", "DNA", 220, 231], ["neomycin phosphotransferase gene", "DNA", 247, 279], ["pCI", "DNA", 319, 322], ["neo plasmid", "DNA", 323, 334], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["the expression plasmid pcDNA3", "TREATMENT", 33, 62], ["the AU1 tag", "TREATMENT", 98, 109], ["MethodsCHO-KI (CHO) cells", "TREATMENT", 162, 187], ["the pIRES", "TREATMENT", 210, 219], ["Neo plasmid", "TREATMENT", 220, 231], ["the neomycin phosphotransferase gene", "TREATMENT", 243, 279], ["the control pCI", "TREATMENT", 307, 322], ["neo plasmid", "TREATMENT", 323, 334]]], ["Transfectants were allowed to recover for 24 h before selection with 750 \u03bcg ml\u22121 G418 (Geneticin, GIBCO).", [["G418", "CHEMICAL", 81, 85], ["Geneticin", "CHEMICAL", 87, 96], ["G418", "CHEMICAL", 81, 85], ["Geneticin", "CHEMICAL", 87, 96], ["Geneticin", "SIMPLE_CHEMICAL", 87, 96]]], ["Mouse SIGNR1 transfectants were selected with Zeocin (250 \u03bcg ml\u22121) (Invitrogen).", [["SIGNR1 transfectants", "ANATOMY", 6, 26], ["Zeocin", "CHEMICAL", 46, 52], ["Zeocin", "CHEMICAL", 46, 52], ["Mouse", "ORGANISM", 0, 5], ["SIGNR1 transfectants", "CELL", 6, 26], ["Zeocin", "SIMPLE_CHEMICAL", 46, 52], ["Mouse SIGNR1 transfectants", "CELL_LINE", 0, 26], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse SIGNR1 transfectants", "TREATMENT", 0, 26], ["Zeocin", "TREATMENT", 46, 52]]], ["All tranfectants were stained with specific antibodies [anti-human DC-SIGN (120507; R&D Systems); anti-CIRE (5H10) and biotinylated AU1 mAb (AU1; Covance, CA, USA], visualised with the appropriate secondary reagent and sorted on a MoFlo Instrument (Cytomation Inc.)Binding affinity of CIRE/mDC-SIGN ::: MethodsAdherent CHO-K1 cells expressing FLAG-CIRE/mDC-SIGN, CIRE/mDC-SIGN, mouse SIGNR1 or the neomycin resistance gene only were made into single-cell suspension by a brief incubation with 0.01 M EDTA/PBS and then washed twice with 5% FCS\u2013RPMI-1640.", [["DC", "ANATOMY", 67, 69], ["CHO-K1 cells", "ANATOMY", 319, 331], ["cell", "ANATOMY", 450, 454], ["neomycin", "CHEMICAL", 398, 406], ["FCS\u2013RPMI-1640", "CHEMICAL", 539, 552], ["neomycin", "CHEMICAL", 398, 406], ["EDTA", "CHEMICAL", 500, 504], ["anti-CIRE", "SIMPLE_CHEMICAL", 98, 107], ["MethodsAdherent CHO-K1 cells", "CELL", 303, 331], ["FLAG", "GENE_OR_GENE_PRODUCT", 343, 347], ["mDC-SIGN", "GENE_OR_GENE_PRODUCT", 353, 361], ["mDC-SIGN", "GENE_OR_GENE_PRODUCT", 368, 376], ["mouse", "ORGANISM", 378, 383], ["SIGNR1", "GENE_OR_GENE_PRODUCT", 384, 390], ["neomycin", "SIMPLE_CHEMICAL", 398, 406], ["EDTA", "SIMPLE_CHEMICAL", 500, 504], ["specific antibodies", "PROTEIN", 35, 54], ["anti-human DC", "PROTEIN", 56, 69], ["anti-CIRE", "PROTEIN", 98, 107], ["5H10", "PROTEIN", 109, 113], ["biotinylated AU1 mAb", "PROTEIN", 119, 139], ["AU1", "PROTEIN", 141, 144], ["CA", "PROTEIN", 155, 157], ["CIRE", "PROTEIN", 285, 289], ["mDC", "CELL_TYPE", 290, 293], ["SIGN", "PROTEIN", 294, 298], ["MethodsAdherent CHO-K1 cells", "CELL_LINE", 303, 331], ["FLAG", "PROTEIN", 343, 347], ["CIRE", "PROTEIN", 348, 352], ["mDC", "PROTEIN", 353, 356], ["SIGN, CIRE/mDC-SIGN, mouse SIGNR1 or the neomycin resistance gene", "DNA", 357, 422], ["mouse", "SPECIES", 378, 383], ["mouse", "SPECIES", 378, 383], ["specific antibodies", "TEST", 35, 54], ["anti-human DC", "TEST", 56, 69], ["anti-CIRE", "TEST", 98, 107], ["biotinylated AU1 mAb", "TREATMENT", 119, 139], ["a MoFlo Instrument", "TREATMENT", 229, 247], ["MethodsAdherent CHO", "TEST", 303, 322], ["FLAG", "TEST", 343, 347], ["CIRE", "TEST", 363, 367], ["mouse SIGNR1", "TREATMENT", 378, 390], ["the neomycin resistance gene", "TREATMENT", 394, 422], ["0.01 M EDTA/PBS", "TREATMENT", 493, 508]]], ["Cells (105) were re-suspended in various dilutions of mannan (Sigma, Castle Hill, NSW, Australia) in an ice-cold buffered balanced salt solution containing 2% FCS, Ca2+ and Mg2+, or alternatively, in a similar solution where 5 mM EDTA substituted for Ca2+ and Mg2+, then incubated with mannosylated FITC-conjugated BSA (10 \u03bcg ml\u22121) (Sigma) for 20 min at 37\u00b0C. Binding was visualised by flow cytometry.Parasites and parasite-binding assays ::: Methods", [["Cells", "ANATOMY", 0, 5], ["Ca2", "CHEMICAL", 164, 167], ["Mg2", "CHEMICAL", 173, 176], ["EDTA", "CHEMICAL", 230, 234], ["Ca2", "CHEMICAL", 251, 254], ["Mg2", "CHEMICAL", 260, 263], ["BSA", "CHEMICAL", 315, 318], ["Ca2+", "CHEMICAL", 164, 168], ["Mg2+", "CHEMICAL", 173, 177], ["EDTA", "CHEMICAL", 230, 234], ["Ca2+", "CHEMICAL", 251, 255], ["Mg2+", "CHEMICAL", 260, 264], ["FITC", "CHEMICAL", 299, 303], ["Cells", "CELL", 0, 5], ["mannan", "SIMPLE_CHEMICAL", 54, 60], ["Sigma", "SIMPLE_CHEMICAL", 62, 67], ["FCS", "SIMPLE_CHEMICAL", 159, 162], ["Ca2+", "SIMPLE_CHEMICAL", 164, 168], ["Mg2+", "SIMPLE_CHEMICAL", 173, 177], ["EDTA", "SIMPLE_CHEMICAL", 230, 234], ["Ca2+", "SIMPLE_CHEMICAL", 251, 255], ["Mg2+", "SIMPLE_CHEMICAL", 260, 264], ["FITC-conjugated BSA", "SIMPLE_CHEMICAL", 299, 318], ["Parasites", "CELL", 401, 410], ["parasite", "CELL", 415, 423], ["Ca2", "PROTEIN", 251, 254], ["Cells", "TEST", 0, 5], ["an ice-cold buffered balanced salt solution", "TREATMENT", 101, 144], ["Ca2", "TEST", 164, 167], ["Ca2", "TEST", 251, 254], ["Mg2", "TEST", 260, 263], ["mannosylated FITC-conjugated BSA", "TREATMENT", 286, 318], ["flow cytometry", "TEST", 386, 400], ["Methods", "TREATMENT", 443, 450], ["flow cytometry", "OBSERVATION", 386, 400]]]], "PMC3307712": [["IntroductionAlcohol abuse is a risk factor for pulmonary infections.", [["pulmonary", "ANATOMY", 47, 56], ["IntroductionAlcohol abuse", "DISEASE", 0, 25], ["pulmonary infections", "DISEASE", 47, 67], ["pulmonary", "ORGAN", 47, 56], ["pulmonary infections", "PROBLEM", 47, 67], ["pulmonary", "ANATOMY", 47, 56], ["infections", "OBSERVATION", 57, 67]]], ["It is not fully understood how alcohol exposure compromises the lung host defense.", [["lung", "ANATOMY", 64, 68], ["alcohol", "CHEMICAL", 31, 38], ["alcohol", "CHEMICAL", 31, 38], ["alcohol", "SIMPLE_CHEMICAL", 31, 38], ["lung", "ORGAN", 64, 68], ["lung", "ANATOMY", 64, 68], ["host defense", "OBSERVATION", 69, 81]]], ["Previous studies suggest that multiple pathophysiological mechanisms may be involved [1], [2], [3].", [["[2]", "SIMPLE_CHEMICAL", 90, 93], ["[3]", "SIMPLE_CHEMICAL", 95, 98], ["Previous studies", "TEST", 0, 16], ["multiple pathophysiological mechanisms", "PROBLEM", 30, 68], ["multiple", "OBSERVATION_MODIFIER", 30, 38]]], ["Airway mucosal immunity and mucociliary clearance are the two primary host defense mechanisms, which take place in a thin layer of liquid on the top of airway epithelia, known as airway surface liquid (ASL).", [["Airway mucosal", "ANATOMY", 0, 14], ["mucociliary", "ANATOMY", 28, 39], ["airway epithelia", "ANATOMY", 152, 168], ["airway surface", "ANATOMY", 179, 193], ["Airway mucosal", "MULTI-TISSUE_STRUCTURE", 0, 14], ["mucociliary", "ORGAN", 28, 39], ["airway epithelia", "TISSUE", 152, 168], ["Airway mucosal immunity", "TREATMENT", 0, 23], ["mucociliary clearance", "TREATMENT", 28, 49], ["a thin layer of liquid", "TREATMENT", 115, 137], ["airway epithelia", "PROBLEM", 152, 168], ["mucosal", "ANATOMY", 7, 14], ["airway", "ANATOMY", 152, 158], ["epithelia", "OBSERVATION", 159, 168], ["airway", "ANATOMY", 179, 185]]], ["ASL, composed of a gel-like mucus layer and a sol-like periciliary liquid layer [4], [5], [6], is the \u201cbattlefield\u201d for pulmonary infection and immunity.", [["mucus layer", "ANATOMY", 28, 39], ["pulmonary", "ANATOMY", 120, 129], ["pulmonary infection", "DISEASE", 120, 139], ["[5]", "SIMPLE_CHEMICAL", 85, 88], ["[6]", "SIMPLE_CHEMICAL", 90, 93], ["pulmonary", "ORGAN", 120, 129], ["a gel-like mucus layer", "PROBLEM", 17, 39], ["a sol-like periciliary liquid layer", "TREATMENT", 44, 79], ["pulmonary infection", "PROBLEM", 120, 139], ["pulmonary", "ANATOMY", 120, 129], ["infection", "OBSERVATION", 130, 139]]], ["The viscous mucous blanket traps inhaled microorganisms and particles to restrict their spreading in the lung.", [["mucous", "ANATOMY", 12, 18], ["lung", "ANATOMY", 105, 109], ["lung", "ORGAN", 105, 109], ["The viscous mucous blanket traps inhaled microorganisms", "TREATMENT", 0, 55], ["viscous", "OBSERVATION_MODIFIER", 4, 11], ["mucous", "ANATOMY", 12, 18], ["spreading", "OBSERVATION_MODIFIER", 88, 97], ["lung", "ANATOMY", 105, 109]]], ["In contrast, the watery periciliary liquid (PCL) underneath pools antimicrobial substances, antibodies, cytokines, chemokines and other immune modulators [7], [8], [9].", [["[8]", "SIMPLE_CHEMICAL", 159, 162], ["antibodies", "PROTEIN", 92, 102], ["cytokines", "PROTEIN", 104, 113], ["chemokines", "PROTEIN", 115, 125], ["the watery periciliary liquid (PCL) underneath pools antimicrobial substances", "TREATMENT", 13, 90], ["cytokines", "TREATMENT", 104, 113], ["chemokines", "TEST", 115, 125], ["other immune modulators", "TEST", 130, 153], ["antimicrobial substances", "OBSERVATION", 66, 90]]], ["More importantly, PCL provides the milieu for innate and adaptive immune cells including neutrophils and macrophages to home and function.", [["immune cells", "ANATOMY", 66, 78], ["neutrophils", "ANATOMY", 89, 100], ["macrophages", "ANATOMY", 105, 116], ["PCL", "CHEMICAL", 18, 21], ["immune cells", "CELL", 66, 78], ["neutrophils", "CELL", 89, 100], ["macrophages", "CELL", 105, 116], ["innate and adaptive immune cells", "CELL_TYPE", 46, 78], ["neutrophils", "CELL_TYPE", 89, 100], ["macrophages", "CELL_TYPE", 105, 116], ["PCL", "TREATMENT", 18, 21], ["innate and adaptive immune cells", "TREATMENT", 46, 78], ["neutrophils", "TEST", 89, 100], ["macrophages", "TREATMENT", 105, 116]]], ["Moreover, PCL prevents cilia from being entrapped in viscous mucus and bathes them for mechanical movement for mucociliary clearance [5], [10].IntroductionASL composition and volume are collectively regulated by epithelial chloride secretion, sodium absorption and secondarily water secretion and absorption [6], [11].", [["cilia", "ANATOMY", 23, 28], ["mucus", "ANATOMY", 61, 66], ["mucociliary", "ANATOMY", 111, 122], ["epithelial", "ANATOMY", 212, 222], ["PCL", "CHEMICAL", 10, 13], ["sodium", "CHEMICAL", 243, 249], ["PCL", "CHEMICAL", 10, 13], ["chloride", "CHEMICAL", 223, 231], ["sodium", "CHEMICAL", 243, 249], ["PCL", "SIMPLE_CHEMICAL", 10, 13], ["cilia", "CELLULAR_COMPONENT", 23, 28], ["mucus", "ORGANISM_SUBSTANCE", 61, 66], ["mucociliary", "MULTI-TISSUE_STRUCTURE", 111, 122], ["epithelial", "TISSUE", 212, 222], ["chloride", "SIMPLE_CHEMICAL", 223, 231], ["sodium", "SIMPLE_CHEMICAL", 243, 249], ["PCL", "TREATMENT", 10, 13], ["cilia", "PROBLEM", 23, 28], ["viscous mucus", "PROBLEM", 53, 66], ["mucociliary clearance", "TREATMENT", 111, 132], ["IntroductionASL composition and volume", "TREATMENT", 143, 181], ["epithelial chloride secretion", "TEST", 212, 241], ["sodium absorption", "TEST", 243, 260], ["secondarily water secretion", "PROBLEM", 265, 292]]], ["Mounting evidence indicates that paracrine/autocrine purinergic signaling is critical to airway epithelial ion transport and ASL hydration [12]#.", [["airway epithelial", "ANATOMY", 89, 106], ["airway epithelial", "TISSUE", 89, 106], ["paracrine/autocrine purinergic signaling", "TREATMENT", 33, 73], ["airway epithelial ion transport", "TREATMENT", 89, 120], ["ASL hydration", "TREATMENT", 125, 138]]], ["Adenosine has been shown to be a potent regulator in the process, which can be directly released by local epithelial cells and immune cells [13] or from extracellular metabolism of ATP [12]#.", [["epithelial cells", "ANATOMY", 106, 122], ["immune cells", "ANATOMY", 127, 139], ["extracellular", "ANATOMY", 153, 166], ["Adenosine", "CHEMICAL", 0, 9], ["ATP", "CHEMICAL", 181, 184], ["Adenosine", "CHEMICAL", 0, 9], ["ATP", "CHEMICAL", 181, 184], ["Adenosine", "SIMPLE_CHEMICAL", 0, 9], ["epithelial cells", "CELL", 106, 122], ["immune cells", "CELL", 127, 139], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 153, 166], ["ATP", "SIMPLE_CHEMICAL", 181, 184], ["local epithelial cells", "CELL_TYPE", 100, 122], ["immune cells", "CELL_TYPE", 127, 139], ["Adenosine", "TREATMENT", 0, 9], ["local epithelial cells", "TEST", 100, 122], ["immune cells", "PROBLEM", 127, 139], ["ATP", "TEST", 181, 184], ["epithelial cells", "OBSERVATION", 106, 122]]], ["It is known that ATP is constitutively released by epithelia due to various stimuli including mechanical stretch and shear stress due to respiration [14].", [["epithelia", "ANATOMY", 51, 60], ["ATP", "CHEMICAL", 17, 20], ["ATP", "CHEMICAL", 17, 20], ["ATP", "SIMPLE_CHEMICAL", 17, 20], ["epithelia", "TISSUE", 51, 60], ["ATP", "PROBLEM", 17, 20], ["various stimuli", "PROBLEM", 68, 83], ["mechanical stretch", "TREATMENT", 94, 112], ["shear stress", "PROBLEM", 117, 129]]], ["The released ATP is then converted to adenosine by extracellular ectonucleotidases [15].", [["extracellular", "ANATOMY", 51, 64], ["ATP", "CHEMICAL", 13, 16], ["adenosine", "CHEMICAL", 38, 47], ["ATP", "CHEMICAL", 13, 16], ["adenosine", "CHEMICAL", 38, 47], ["ATP", "SIMPLE_CHEMICAL", 13, 16], ["adenosine", "SIMPLE_CHEMICAL", 38, 47], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 51, 64], ["adenosine", "TREATMENT", 38, 47]]], ["Thus, ASL has relatively high levels of adenosine.", [["adenosine", "CHEMICAL", 40, 49], ["adenosine", "CHEMICAL", 40, 49], ["adenosine", "SIMPLE_CHEMICAL", 40, 49], ["adenosine", "TREATMENT", 40, 49]]], ["Further studies demonstrate that adenosine largely regulates epithelial CFTR channel function by acting on A2BAR [16], [17], [18].", [["epithelial", "ANATOMY", 61, 71], ["adenosine", "CHEMICAL", 33, 42], ["adenosine", "CHEMICAL", 33, 42], ["adenosine", "SIMPLE_CHEMICAL", 33, 42], ["epithelial", "TISSUE", 61, 71], ["CFTR", "GENE_OR_GENE_PRODUCT", 72, 76], ["CFTR", "PROTEIN", 72, 76], ["Further studies", "TEST", 0, 15], ["adenosine", "TREATMENT", 33, 42], ["epithelial CFTR", "OBSERVATION", 61, 76]]], ["Thus, the adenosine-A2BAR signaling pathway is a crucial element in lung host defense [19], [20].IntroductionPrevious alcohol studies have documented that ethanol exposure decreases cAMP signaling and protein kinase A (PKA) activation [3], [21].", [["lung", "ANATOMY", 68, 72], ["adenosine", "CHEMICAL", 10, 19], ["alcohol", "CHEMICAL", 118, 125], ["ethanol", "CHEMICAL", 155, 162], ["cAMP", "CHEMICAL", 182, 186], ["adenosine", "CHEMICAL", 10, 19], ["alcohol", "CHEMICAL", 118, 125], ["ethanol", "CHEMICAL", 155, 162], ["cAMP", "CHEMICAL", 182, 186], ["adenosine", "SIMPLE_CHEMICAL", 10, 19], ["A2BAR", "GENE_OR_GENE_PRODUCT", 20, 25], ["lung", "ORGAN", 68, 72], ["ethanol", "SIMPLE_CHEMICAL", 155, 162], ["cAMP", "SIMPLE_CHEMICAL", 182, 186], ["protein kinase A", "GENE_OR_GENE_PRODUCT", 201, 217], ["PKA", "GENE_OR_GENE_PRODUCT", 219, 222], ["[21]", "SIMPLE_CHEMICAL", 240, 244], ["A2BAR", "PROTEIN", 20, 25], ["protein kinase A", "PROTEIN", 201, 217], ["PKA", "PROTEIN", 219, 222], ["the adenosine", "TREATMENT", 6, 19], ["a crucial element in lung host defense", "PROBLEM", 47, 85], ["alcohol studies", "TEST", 118, 133], ["ethanol exposure", "PROBLEM", 155, 171], ["cAMP signaling", "TEST", 182, 196], ["protein kinase", "TEST", 201, 215], ["crucial element", "OBSERVATION", 49, 64], ["lung", "ANATOMY", 68, 72]]], ["Ethanol also up-regulates phosphodiesterase 4 (PDE4), which increases cAMP degradation [22]#.", [["Ethanol", "CHEMICAL", 0, 7], ["cAMP", "CHEMICAL", 70, 74], ["Ethanol", "CHEMICAL", 0, 7], ["cAMP", "CHEMICAL", 70, 74], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["phosphodiesterase 4", "GENE_OR_GENE_PRODUCT", 26, 45], ["PDE4", "GENE_OR_GENE_PRODUCT", 47, 51], ["cAMP", "SIMPLE_CHEMICAL", 70, 74], ["phosphodiesterase 4", "PROTEIN", 26, 45], ["PDE4", "PROTEIN", 47, 51], ["Ethanol", "TREATMENT", 0, 7], ["regulates phosphodiesterase", "TREATMENT", 16, 43]]], ["In spite of the clear link between alcohol exposure and alteration of adenosine signaling, no published data are currently available concerning alcohol effects on airway ion transport through this signaling pathway.", [["airway", "ANATOMY", 163, 169], ["alcohol", "CHEMICAL", 35, 42], ["adenosine", "CHEMICAL", 70, 79], ["alcohol", "CHEMICAL", 144, 151], ["alcohol", "CHEMICAL", 35, 42], ["adenosine", "CHEMICAL", 70, 79], ["alcohol", "CHEMICAL", 144, 151], ["alcohol", "SIMPLE_CHEMICAL", 35, 42], ["adenosine", "SIMPLE_CHEMICAL", 70, 79], ["alcohol", "SIMPLE_CHEMICAL", 144, 151], ["airway ion", "MULTI-TISSUE_STRUCTURE", 163, 173], ["adenosine signaling", "TREATMENT", 70, 89], ["this signaling pathway", "TREATMENT", 192, 214], ["clear", "OBSERVATION", 16, 21]]], ["The current report directly measured the adenosine-induced chloride secretion of airway epithelia under the exposure of physiologically relevant concentrations of alcohol and found that ethanol attenuates epithelial CFTR-mediated chloride transport by modulating cellular cAMP levels.Ethics statement ::: Materials and MethodsNo human subjects or animals were used in this study.Cell culture ::: Materials and MethodsCalu-3 cells, a human airway epithelial cell line (ATCC, Manassas, VA), were seeded on collagen-coated Millicell\u00ae-PCF membrane inserts (Millipore, Billerica, MA) at a density of 1\u00d7106 cells per insert of 0.6 cm2 surface area.", [["airway epithelia", "ANATOMY", 81, 97], ["epithelial", "ANATOMY", 205, 215], ["cellular", "ANATOMY", 263, 271], ["Cell", "ANATOMY", 379, 383], ["Calu-3 cells", "ANATOMY", 417, 429], ["airway epithelial cell line", "ANATOMY", 439, 466], ["ATCC", "ANATOMY", 468, 472], ["Manassas", "ANATOMY", 474, 482], ["VA", "ANATOMY", 484, 486], ["membrane", "ANATOMY", 535, 543], ["cells", "ANATOMY", 601, 606], ["surface area", "ANATOMY", 629, 641], ["adenosine", "CHEMICAL", 41, 50], ["chloride", "CHEMICAL", 59, 67], ["alcohol", "CHEMICAL", 163, 170], ["ethanol", "CHEMICAL", 186, 193], ["chloride", "CHEMICAL", 230, 238], ["cAMP", "CHEMICAL", 272, 276], ["adenosine", "CHEMICAL", 41, 50], ["chloride", "CHEMICAL", 59, 67], ["alcohol", "CHEMICAL", 163, 170], ["ethanol", "CHEMICAL", 186, 193], ["chloride", "CHEMICAL", 230, 238], ["cAMP", "CHEMICAL", 272, 276], ["adenosine", "SIMPLE_CHEMICAL", 41, 50], ["chloride", "SIMPLE_CHEMICAL", 59, 67], ["airway epithelia", "TISSUE", 81, 97], ["alcohol", "SIMPLE_CHEMICAL", 163, 170], ["ethanol", "SIMPLE_CHEMICAL", 186, 193], ["epithelial", "TISSUE", 205, 215], ["CFTR", "GENE_OR_GENE_PRODUCT", 216, 220], ["chloride", "SIMPLE_CHEMICAL", 230, 238], ["cellular", "CELL", 263, 271], ["cAMP", "SIMPLE_CHEMICAL", 272, 276], ["human", "ORGANISM", 329, 334], ["Cell", "CELL", 379, 383], ["Calu-3 cells", "CELL", 417, 429], ["human", "ORGANISM", 433, 438], ["airway epithelial cell line", "CELL", 439, 466], ["ATCC", "CELL", 468, 472], ["Manassas", "CELL", 474, 482], ["VA", "CELL", 484, 486], ["collagen", "GENE_OR_GENE_PRODUCT", 504, 512], ["cells", "CELL", 601, 606], ["CFTR", "PROTEIN", 216, 220], ["Calu-3 cells", "CELL_LINE", 417, 429], ["human airway epithelial cell line", "CELL_LINE", 433, 466], ["ATCC", "CELL_LINE", 468, 472], ["VA", "CELL_LINE", 484, 486], ["collagen", "PROTEIN", 504, 512], ["human", "SPECIES", 329, 334], ["human", "SPECIES", 433, 438], ["human", "SPECIES", 329, 334], ["human", "SPECIES", 433, 438], ["ATCC", "SPECIES", 468, 472], ["the adenosine", "TREATMENT", 37, 50], ["airway epithelia", "PROBLEM", 81, 97], ["mediated chloride transport", "TREATMENT", 221, 248], ["cellular cAMP levels", "TEST", 263, 283], ["this study", "TEST", 368, 378], ["Cell culture", "TEST", 379, 391], ["Materials", "TEST", 396, 405], ["MethodsCalu", "TEST", 410, 421], ["a human airway epithelial cell line", "TREATMENT", 431, 466], ["collagen-coated Millicell\u00ae-PCF membrane inserts (Millipore, Billerica, MA", "TREATMENT", 504, 577], ["a density of 1\u00d7106 cells", "TREATMENT", 582, 606], ["airway epithelia", "OBSERVATION", 81, 97], ["epithelial CFTR", "OBSERVATION", 205, 220], ["cAMP levels", "OBSERVATION", 272, 283], ["airway", "ANATOMY", 439, 445], ["epithelial cell line", "OBSERVATION", 446, 466], ["PCF membrane", "OBSERVATION", 531, 543]]], ["Two days after the initial submerged culture, the apical media were aspirated off and the cells cultured at an air-liquid interface according to previously published protocol [23].", [["cells", "ANATOMY", 90, 95], ["cells", "CELL", 90, 95], ["the initial submerged culture", "TEST", 15, 44], ["the apical media", "TREATMENT", 46, 62], ["the cells", "TREATMENT", 86, 95], ["apical", "ANATOMY_MODIFIER", 50, 56], ["media", "ANATOMY", 57, 62]]], ["Regardless of submerged culture or air-liquid interface culture, the media used were the same, consisting of Advanced-MEM (Gibco, Carlsbad, CA) containing 10% fetal bovine serum, 1% L-glutamine, 100 U/ml penicillin, 100 \u00b5g/ml streptomycin and 0.25 \u00b5g/ml amphotericin B. After 2 weeks at 37\u00b0C in presence of 5% CO2, the epithelia established a dry apical surface and had a transepithelial electrical resistance greater than 1000 \u03a9/cm2.", [["fetal bovine serum", "ANATOMY", 159, 177], ["epithelia", "ANATOMY", 319, 328], ["apical surface", "ANATOMY", 347, 361], ["L-glutamine", "CHEMICAL", 182, 193], ["penicillin", "CHEMICAL", 204, 214], ["streptomycin", "CHEMICAL", 226, 238], ["amphotericin", "CHEMICAL", 254, 266], ["CO2", "CHEMICAL", 310, 313], ["L-glutamine", "CHEMICAL", 182, 193], ["penicillin", "CHEMICAL", 204, 214], ["streptomycin", "CHEMICAL", 226, 238], ["amphotericin", "CHEMICAL", 254, 266], ["CO2", "CHEMICAL", 310, 313], ["bovine", "ORGANISM", 165, 171], ["serum", "ORGANISM_SUBSTANCE", 172, 177], ["L-glutamine", "SIMPLE_CHEMICAL", 182, 193], ["penicillin", "SIMPLE_CHEMICAL", 204, 214], ["streptomycin", "SIMPLE_CHEMICAL", 226, 238], ["CO2", "SIMPLE_CHEMICAL", 310, 313], ["epithelia", "TISSUE", 319, 328], ["bovine", "SPECIES", 165, 171], ["bovine", "SPECIES", 165, 171], ["submerged culture", "TEST", 14, 31], ["air-liquid interface culture", "TEST", 35, 63], ["Gibco", "TEST", 123, 128], ["fetal bovine serum", "TEST", 159, 177], ["L-glutamine", "TREATMENT", 182, 193], ["penicillin", "TREATMENT", 204, 214], ["streptomycin", "TREATMENT", 226, 238], ["amphotericin", "TREATMENT", 254, 266], ["a dry apical surface", "PROBLEM", 341, 361], ["a transepithelial electrical resistance", "TEST", 370, 409], ["dry", "OBSERVATION", 343, 346], ["apical", "ANATOMY_MODIFIER", 347, 353], ["surface", "OBSERVATION_MODIFIER", 354, 361], ["transepithelial electrical resistance", "OBSERVATION", 372, 409]]], ["The cystic fibrosis (CF) airway epithelial cells CFBE41o- [24] were similarly cultured.", [["cystic fibrosis (CF) airway epithelial cells", "ANATOMY", 4, 48], ["fibrosis", "DISEASE", 11, 19], ["airway epithelial cells", "CELL", 25, 48], ["airway epithelial cells", "CELL_TYPE", 25, 48], ["The cystic fibrosis", "PROBLEM", 0, 19], ["airway epithelial cells", "TEST", 25, 48], ["CFBE41o", "TEST", 49, 56], ["cystic", "OBSERVATION_MODIFIER", 4, 10], ["fibrosis", "OBSERVATION", 11, 19], ["airway", "ANATOMY", 25, 31], ["epithelial cells", "OBSERVATION", 32, 48]]], ["The fully differentiated CF epithelia after 2 weeks exhibited a transepithelial resistance greater than 700 \u03a9/cm2.Ethanol exposure ::: Materials and MethodsAir-liquid interface cultures were basolaterally exposed to different concentrations of ethanol (200 Proof; AAPER Alcohol and Chemical Co., Shelbyville, KY), as indicated in individual experiments.", [["CF epithelia", "ANATOMY", 25, 37], ["transepithelial", "ANATOMY", 64, 79], ["Ethanol", "CHEMICAL", 114, 121], ["ethanol", "CHEMICAL", 244, 251], ["Ethanol", "CHEMICAL", 114, 121], ["ethanol", "CHEMICAL", 244, 251], ["CF epithelia", "TISSUE", 25, 37], ["Ethanol", "SIMPLE_CHEMICAL", 114, 121], ["ethanol", "SIMPLE_CHEMICAL", 244, 251], ["MethodsAir-liquid interface cultures", "CELL_LINE", 149, 185], ["a transepithelial resistance", "TEST", 62, 90], ["Materials", "TEST", 135, 144], ["MethodsAir-liquid interface cultures", "TEST", 149, 185], ["ethanol", "TREATMENT", 244, 251], ["differentiated", "OBSERVATION_MODIFIER", 10, 24], ["CF epithelia", "OBSERVATION", 25, 37], ["transepithelial resistance", "OBSERVATION", 64, 90]]], ["All the cultures were kept at 37\u00b0C, 5% CO2 in incubators that had been pre-saturated with specified concentrations of ethanol.Transepithelial electrical resistance (TEER) measurement ::: Materials and MethodsThe TEER of the airway epithelial cell cultures was measured by using a \u201cchop stick\u201d epithelial ohmmeter (World Precision Instruments, Sarasota, FL), as described previously [25], [26].Airway Epithelial Electrophysiology ::: Materials and MethodsCalu-3 cells, cultured at the air-liquid interface for 2 weeks, were exposed to different concentrations of ethanol for 24 hours and mounted on an Ussing chamber apparatus (World Precision Instruments, Sarasota, FL).", [["cultures", "ANATOMY", 8, 16], ["airway epithelial cell cultures", "ANATOMY", 224, 255], ["epithelial", "ANATOMY", 293, 303], ["Airway Epithelial", "ANATOMY", 393, 410], ["MethodsCalu-3 cells", "ANATOMY", 447, 466], ["CO2", "CHEMICAL", 39, 42], ["ethanol", "CHEMICAL", 118, 125], ["ethanol", "CHEMICAL", 562, 569], ["CO2", "CHEMICAL", 39, 42], ["ethanol", "CHEMICAL", 118, 125], ["ethanol", "CHEMICAL", 562, 569], ["CO2", "SIMPLE_CHEMICAL", 39, 42], ["ethanol", "SIMPLE_CHEMICAL", 118, 125], ["airway epithelial cell cultures", "CELL", 224, 255], ["epithelial", "TISSUE", 293, 303], ["MethodsCalu-3 cells", "CELL", 447, 466], ["ethanol", "SIMPLE_CHEMICAL", 562, 569], ["airway epithelial cell cultures", "CELL_LINE", 224, 255], ["MethodsCalu-3 cells", "CELL_LINE", 447, 466], ["All the cultures", "TEST", 0, 16], ["Transepithelial electrical resistance", "TEST", 126, 163], ["The TEER of the airway epithelial cell cultures", "TEST", 208, 255], ["a \u201cchop stick", "TREATMENT", 278, 291], ["Materials", "TEST", 433, 442], ["MethodsCalu-3 cells", "TREATMENT", 447, 466], ["ethanol", "TREATMENT", 562, 569], ["an Ussing chamber apparatus", "TREATMENT", 598, 625], ["electrical resistance", "OBSERVATION", 142, 163], ["airway", "ANATOMY", 224, 230], ["epithelial cell", "OBSERVATION", 231, 246], ["Epithelial", "ANATOMY_MODIFIER", 400, 410]]], ["The cells were bathed with an apical low chloride buffer (135 mM sodium gluconate, 5.0 mM HEPES, 1.2 mM MgCl2, 0.6 mM KH2PO4, 4 mM CaCl2, 2.4 mM K2HPO4 \u02d93H2O, and 10 mM Dextrose, pH 7.4) and with a basal high chloride buffer (135 mM NaCl, 5.0 mM HEPES, 1.2 mM MgCl2, 0.6 mM KH2PO4, 1.2 mM CaCl2, 2.4 mM, K2HPO4 \u02d93H2O, and 10 mM Dextrose, pH 7.4).", [["cells", "ANATOMY", 4, 9], ["sodium gluconate", "CHEMICAL", 65, 81], ["MgCl2", "CHEMICAL", 104, 109], ["CaCl2", "CHEMICAL", 131, 136], ["K2HPO4 \u02d93H2O", "CHEMICAL", 145, 157], ["Dextrose", "CHEMICAL", 169, 177], ["NaCl", "CHEMICAL", 233, 237], ["CaCl2", "CHEMICAL", 289, 294], ["K2HPO4 \u02d93H2O", "CHEMICAL", 304, 316], ["chloride", "CHEMICAL", 41, 49], ["sodium gluconate", "CHEMICAL", 65, 81], ["HEPES", "CHEMICAL", 90, 95], ["MgCl2", "CHEMICAL", 104, 109], ["KH2PO4", "CHEMICAL", 118, 124], ["CaCl2", "CHEMICAL", 131, 136], ["K2HPO4 \u02d93H2O", "CHEMICAL", 145, 157], ["Dextrose", "CHEMICAL", 169, 177], ["chloride", "CHEMICAL", 209, 217], ["NaCl", "CHEMICAL", 233, 237], ["HEPES", "CHEMICAL", 246, 251], ["MgCl2", "CHEMICAL", 260, 265], ["KH2PO4", "CHEMICAL", 274, 280], ["CaCl2", "CHEMICAL", 289, 294], ["K2HPO4 \u02d93H2O", "CHEMICAL", 304, 316], ["Dextrose", "CHEMICAL", 328, 336], ["cells", "CELL", 4, 9], ["sodium gluconate", "SIMPLE_CHEMICAL", 65, 81], ["K2HPO4 \u02d93H2O", "SIMPLE_CHEMICAL", 145, 157], ["Dextrose", "SIMPLE_CHEMICAL", 169, 177], ["K2HPO4 \u02d93H2O", "SIMPLE_CHEMICAL", 304, 316], ["Dextrose", "SIMPLE_CHEMICAL", 328, 336], ["an apical low chloride buffer", "TREATMENT", 27, 56], ["mM sodium gluconate", "TREATMENT", 62, 81], ["5.0 mM HEPES", "TREATMENT", 83, 95], ["1.2 mM MgCl2", "TREATMENT", 97, 109], ["0.6 mM KH2PO4", "TREATMENT", 111, 124], ["4 mM CaCl2", "TREATMENT", 126, 136], ["10 mM Dextrose", "TREATMENT", 163, 177], ["pH", "TEST", 179, 181], ["a basal high chloride buffer", "TREATMENT", 196, 224], ["NaCl", "TEST", 233, 237], ["HEPES", "TEST", 246, 251], ["MgCl2", "TEST", 260, 265], ["0.6 mM KH2PO4", "TREATMENT", 267, 280], ["CaCl2", "TEST", 289, 294], ["K2HPO4", "TEST", 304, 310], ["10 mM Dextrose", "TREATMENT", 322, 336], ["pH", "TEST", 338, 340]]], ["Both buffers were continuously stirred, gassed with 95% O2 and 5% CO2 and maintained at 37\u00b0C. These buffers were to maintain a chloride gradient across the epithelial monolayer.", [["epithelial monolayer", "ANATOMY", 156, 176], ["O2", "CHEMICAL", 56, 58], ["CO2", "CHEMICAL", 66, 69], ["chloride", "CHEMICAL", 127, 135], ["O2", "CHEMICAL", 56, 58], ["CO2", "CHEMICAL", 66, 69], ["chloride", "CHEMICAL", 127, 135], ["O2", "SIMPLE_CHEMICAL", 56, 58], ["CO2", "SIMPLE_CHEMICAL", 66, 69], ["chloride", "SIMPLE_CHEMICAL", 127, 135], ["epithelial monolayer", "CELL", 156, 176], ["epithelial monolayer", "CELL_TYPE", 156, 176], ["95% O2", "TREATMENT", 52, 58], ["5% CO2", "TREATMENT", 63, 69], ["a chloride gradient", "TEST", 125, 144], ["epithelial monolayer", "OBSERVATION", 156, 176]]], ["The TEER was measured with an open circuit by applying an electrical pulse across the epithelial monolayer.", [["epithelial monolayer", "ANATOMY", 86, 106], ["epithelial monolayer", "CELL", 86, 106], ["epithelial monolayer", "CELL_TYPE", 86, 106], ["The TEER", "TEST", 0, 8], ["an open circuit", "TREATMENT", 27, 42], ["an electrical pulse", "TEST", 55, 74], ["open circuit", "OBSERVATION", 30, 42], ["epithelial monolayer", "OBSERVATION", 86, 106]]], ["Short circuit currents (ISC) were measured by applying an epithelial voltage clamp.", [["epithelial", "ANATOMY", 58, 68], ["epithelial", "TISSUE", 58, 68], ["an epithelial voltage clamp", "TREATMENT", 55, 82], ["epithelial", "OBSERVATION", 58, 68], ["voltage clamp", "OBSERVATION", 69, 82]]], ["For all the experiments, 100 \u00b5M of amiloride was added to the apical side to block sodium channels.", [["apical", "ANATOMY", 62, 68], ["amiloride", "CHEMICAL", 35, 44], ["sodium", "CHEMICAL", 83, 89], ["amiloride", "CHEMICAL", 35, 44], ["sodium", "CHEMICAL", 83, 89], ["amiloride", "SIMPLE_CHEMICAL", 35, 44], ["sodium", "SIMPLE_CHEMICAL", 83, 89], ["sodium channels", "PROTEIN", 83, 98], ["amiloride", "TREATMENT", 35, 44], ["apical", "ANATOMY_MODIFIER", 62, 68]]], ["Anion currents were induced by apical addition of 100 \u00b5M adenosine.", [["adenosine", "CHEMICAL", 57, 66], ["adenosine", "CHEMICAL", 57, 66], ["Anion", "SIMPLE_CHEMICAL", 0, 5], ["adenosine", "SIMPLE_CHEMICAL", 57, 66], ["100 \u00b5M adenosine", "TREATMENT", 50, 66], ["apical", "ANATOMY_MODIFIER", 31, 37]]], ["The A2BAR blockade was achieved by apical application of 50 \u00b5M alloxazine.", [["apical", "ANATOMY", 35, 41], ["alloxazine", "CHEMICAL", 63, 73], ["alloxazine", "CHEMICAL", 63, 73], ["A2BAR", "GENE_OR_GENE_PRODUCT", 4, 9], ["alloxazine", "SIMPLE_CHEMICAL", 63, 73], ["A2BAR", "PROTEIN", 4, 9], ["The A2BAR blockade", "TREATMENT", 0, 18], ["50 \u00b5M alloxazine", "TREATMENT", 57, 73]]], ["To differentiate between chloride and bicarbonate currents, 100 \u00b5M bumetanide was used basally to block chloride transport.", [["chloride", "CHEMICAL", 25, 33], ["bicarbonate", "CHEMICAL", 38, 49], ["bumetanide", "CHEMICAL", 67, 77], ["chloride", "CHEMICAL", 104, 112], ["chloride", "CHEMICAL", 25, 33], ["bicarbonate", "CHEMICAL", 38, 49], ["bumetanide", "CHEMICAL", 67, 77], ["chloride", "CHEMICAL", 104, 112], ["chloride", "SIMPLE_CHEMICAL", 25, 33], ["bicarbonate", "SIMPLE_CHEMICAL", 38, 49], ["bumetanide", "SIMPLE_CHEMICAL", 67, 77], ["chloride", "SIMPLE_CHEMICAL", 104, 112], ["chloride", "TREATMENT", 25, 33], ["bicarbonate currents", "TREATMENT", 38, 58], ["bumetanide", "TREATMENT", 67, 77], ["block chloride transport", "TREATMENT", 98, 122]]], ["Acetazolamide (20 \u00b5M) or DNDS (4,4\u2032-dinitro stilbene-2,2\u2032-disulfonate) (100 \u00b5M) was employed apically to block bicarbonate transport.", [["Acetazolamide", "CHEMICAL", 0, 13], ["DNDS", "CHEMICAL", 25, 29], ["4,4\u2032-dinitro stilbene-2,2\u2032-disulfonate", "CHEMICAL", 31, 69], ["bicarbonate", "CHEMICAL", 111, 122], ["Acetazolamide", "CHEMICAL", 0, 13], ["DNDS", "CHEMICAL", 25, 29], ["4,4\u2032-dinitro stilbene-2,2\u2032-disulfonate", "CHEMICAL", 31, 69], ["bicarbonate", "CHEMICAL", 111, 122], ["Acetazolamide", "SIMPLE_CHEMICAL", 0, 13], ["DNDS", "SIMPLE_CHEMICAL", 25, 29], ["4,4\u2032-dinitro stilbene-2,2\u2032-disulfonate", "SIMPLE_CHEMICAL", 31, 69], ["bicarbonate", "SIMPLE_CHEMICAL", 111, 122], ["Acetazolamide", "TREATMENT", 0, 13], ["DNDS", "TREATMENT", 25, 29], ["dinitro stilbene", "TREATMENT", 36, 52], ["block bicarbonate transport", "TREATMENT", 105, 132]]], ["Further, to inhibit epithelial phosphodiesterases, 100 \u00b5M of IBMX (3-isobutyl-1-methylxanthine) or 50 \u00b5M papaverine was added apically.Intracellular cAMP Measurement ::: Materials and MethodsThe air-liquid interface cultures of Calu-3 cells were exposed to either 0 mM or 100 mM of ethanol at the basolateral side for 24 hours.", [["epithelial", "ANATOMY", 20, 30], ["Intracellular", "ANATOMY", 135, 148], ["air-liquid interface cultures", "ANATOMY", 195, 224], ["Calu-3 cells", "ANATOMY", 228, 240], ["basolateral", "ANATOMY", 297, 308], ["IBMX", "CHEMICAL", 61, 65], ["3-isobutyl-1-methylxanthine", "CHEMICAL", 67, 94], ["papaverine", "CHEMICAL", 105, 115], ["cAMP", "CHEMICAL", 149, 153], ["ethanol", "CHEMICAL", 282, 289], ["IBMX", "CHEMICAL", 61, 65], ["3-isobutyl-1-methylxanthine", "CHEMICAL", 67, 94], ["papaverine", "CHEMICAL", 105, 115], ["cAMP", "CHEMICAL", 149, 153], ["ethanol", "CHEMICAL", 282, 289], ["epithelial", "CELL", 20, 30], ["IBMX", "SIMPLE_CHEMICAL", 61, 65], ["3-isobutyl-1-methylxanthine", "SIMPLE_CHEMICAL", 67, 94], ["papaverine", "SIMPLE_CHEMICAL", 105, 115], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 135, 148], ["cAMP", "SIMPLE_CHEMICAL", 149, 153], ["Calu-3 cells", "CELL", 228, 240], ["ethanol", "SIMPLE_CHEMICAL", 282, 289], ["epithelial phosphodiesterases", "PROTEIN", 20, 49], ["Calu-3 cells", "CELL_LINE", 228, 240], ["epithelial phosphodiesterases", "TEST", 20, 49], ["IBMX", "TEST", 61, 65], ["isobutyl", "TREATMENT", 69, 77], ["methylxanthine)", "TREATMENT", 80, 95], ["50 \u00b5M papaverine", "TREATMENT", 99, 115], ["Intracellular cAMP Measurement", "TEST", 135, 165], ["The air-liquid interface cultures", "TEST", 191, 224], ["Calu", "TEST", 228, 232], ["air-liquid interface", "OBSERVATION", 195, 215]]], ["On the apical surface the cells were stimulated with 100 \u00b5M of adenosine.", [["apical surface", "ANATOMY", 7, 21], ["cells", "ANATOMY", 26, 31], ["adenosine", "CHEMICAL", 63, 72], ["adenosine", "CHEMICAL", 63, 72], ["apical surface", "CELLULAR_COMPONENT", 7, 21], ["cells", "CELL", 26, 31], ["adenosine", "SIMPLE_CHEMICAL", 63, 72], ["adenosine", "TREATMENT", 63, 72], ["apical", "ANATOMY_MODIFIER", 7, 13], ["surface", "ANATOMY_MODIFIER", 14, 21]]], ["The cells were washed with PBS containing 100 \u00b5M IBMX to inhibit phosphodiesterases that might degrade cAMP.", [["cells", "ANATOMY", 4, 9], ["IBMX", "CHEMICAL", 49, 53], ["cAMP", "CHEMICAL", 103, 107], ["IBMX", "CHEMICAL", 49, 53], ["cAMP", "CHEMICAL", 103, 107], ["cells", "CELL", 4, 9], ["IBMX", "SIMPLE_CHEMICAL", 49, 53], ["cAMP", "SIMPLE_CHEMICAL", 103, 107], ["PBS", "TREATMENT", 27, 30], ["100 \u00b5M IBMX", "TREATMENT", 42, 53], ["phosphodiesterases", "TREATMENT", 65, 83]]], ["The cells were lysed and cAMP was measured by cAMP immunoassay (R&D Systems, Minneapolis, MN).", [["cells", "ANATOMY", 4, 9], ["cAMP", "CHEMICAL", 25, 29], ["cAMP", "CHEMICAL", 46, 50], ["cAMP", "CHEMICAL", 25, 29], ["cAMP", "CHEMICAL", 46, 50], ["cells", "CELL", 4, 9], ["cAMP", "SIMPLE_CHEMICAL", 25, 29], ["cAMP", "SIMPLE_CHEMICAL", 46, 50], ["cAMP", "TEST", 25, 29], ["cAMP immunoassay", "TEST", 46, 62]]], ["IBMX (100 \u00b5M) was also included in the lysis buffer.", [["IBMX", "CHEMICAL", 0, 4], ["IBMX", "CHEMICAL", 0, 4], ["IBMX", "SIMPLE_CHEMICAL", 0, 4], ["IBMX", "TEST", 0, 4], ["the lysis buffer", "TREATMENT", 35, 51]]], ["The samples were read at 450 nm using a spectrophotometer (BioTEK, Winooski, VT).", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["a spectrophotometer (BioTEK", "TREATMENT", 38, 65]]], ["All the treatments were carried out in quadruplicates.Statistical Analysis ::: Materials and MethodsData presented represent mean of multiple experiments and error bars indicate standard deviation from the mean.", [["All the treatments", "TREATMENT", 0, 18], ["MethodsData", "TEST", 93, 104], ["standard deviation", "PROBLEM", 178, 196], ["multiple", "OBSERVATION_MODIFIER", 133, 141], ["standard deviation", "OBSERVATION", 178, 196]]], ["Where indicated, the data points were analyzed by Student's t-test or One-way ANOVA test.", [["Student's t-test", "TEST", 50, 66], ["ANOVA test", "TEST", 78, 88]]], ["The P values smaller than 0.05 were considered statistically significant.Ethanol suppresses adenosine-activated ion transport by airway epithelia ::: ResultsTo explore if ethanol affects adenosine-activated ion transport function of airway epithelium, we employed air-liquid interface cultures of Calu-3 cells, a system widely used to investigate airway epithelial electrophysiological properties [27], [28].", [["airway epithelia", "ANATOMY", 129, 145], ["airway epithelium", "ANATOMY", 233, 250], ["air-liquid interface cultures", "ANATOMY", 264, 293], ["Calu-3 cells", "ANATOMY", 297, 309], ["airway epithelial", "ANATOMY", 347, 364], ["Ethanol", "CHEMICAL", 73, 80], ["adenosine", "CHEMICAL", 92, 101], ["ethanol", "CHEMICAL", 171, 178], ["adenosine", "CHEMICAL", 187, 196], ["Ethanol", "CHEMICAL", 73, 80], ["adenosine", "CHEMICAL", 92, 101], ["ethanol", "CHEMICAL", 171, 178], ["adenosine", "CHEMICAL", 187, 196], ["Ethanol", "SIMPLE_CHEMICAL", 73, 80], ["adenosine", "SIMPLE_CHEMICAL", 92, 101], ["ion", "SIMPLE_CHEMICAL", 112, 115], ["airway epithelia", "TISSUE", 129, 145], ["ethanol", "SIMPLE_CHEMICAL", 171, 178], ["adenosine", "SIMPLE_CHEMICAL", 187, 196], ["ion", "SIMPLE_CHEMICAL", 207, 210], ["airway epithelium", "TISSUE", 233, 250], ["Calu-3 cells", "CELL", 297, 309], ["airway epithelial", "TISSUE", 347, 364], ["Calu-3 cells", "CELL_LINE", 297, 309], ["The P values", "TEST", 0, 12], ["Ethanol suppresses adenosine", "TREATMENT", 73, 101], ["air-liquid interface cultures", "TEST", 264, 293], ["Calu", "TEST", 297, 301], ["airway", "ANATOMY", 129, 135], ["airway", "ANATOMY", 233, 239]]], ["The cultured epithelia were exposed basolaterally for 24 hours to different concentrations of ethanol (0, 25, 50 and 100 mM) and adenosine-induced transepithelial ion transport was assessed by measuring ISC with an Ussing chamber apparatus.", [["epithelia", "ANATOMY", 13, 22], ["transepithelial", "ANATOMY", 147, 162], ["ethanol", "CHEMICAL", 94, 101], ["adenosine", "CHEMICAL", 129, 138], ["ethanol", "CHEMICAL", 94, 101], ["adenosine", "CHEMICAL", 129, 138], ["epithelia", "TISSUE", 13, 22], ["ethanol", "SIMPLE_CHEMICAL", 94, 101], ["adenosine", "SIMPLE_CHEMICAL", 129, 138], ["transepithelial ion", "SIMPLE_CHEMICAL", 147, 166], ["The cultured epithelia", "PROBLEM", 0, 22], ["ethanol", "TEST", 94, 101], ["adenosine-induced transepithelial ion transport", "TREATMENT", 129, 176], ["an Ussing chamber apparatus", "TREATMENT", 212, 239], ["epithelia", "ANATOMY_MODIFIER", 13, 22], ["transepithelial ion", "OBSERVATION", 147, 166]]], ["Two buffers with asymmetric chloride were applied: apical low chloride (10.4 mM) and basolateral high chloride (139.8 mM).", [["basolateral", "ANATOMY", 85, 96], ["asymmetric chloride", "CHEMICAL", 17, 36], ["chloride", "CHEMICAL", 28, 36], ["chloride", "CHEMICAL", 62, 70], ["chloride", "CHEMICAL", 102, 110], ["chloride", "SIMPLE_CHEMICAL", 28, 36], ["chloride", "SIMPLE_CHEMICAL", 62, 70], ["basolateral high chloride", "SIMPLE_CHEMICAL", 85, 110], ["asymmetric chloride", "TREATMENT", 17, 36], ["apical low chloride", "TEST", 51, 70], ["basolateral high chloride", "TEST", 85, 110], ["apical", "ANATOMY_MODIFIER", 51, 57], ["low chloride", "OBSERVATION_MODIFIER", 58, 70]]], ["After voltage clamp, sodium channels were blocked by apical amiloride (100 \u00b5M) and ISC was stimulated by apical addition of adenosine (100 \u00b5M).", [["apical", "ANATOMY", 53, 59], ["apical", "ANATOMY", 105, 111], ["sodium", "CHEMICAL", 21, 27], ["amiloride", "CHEMICAL", 60, 69], ["adenosine", "CHEMICAL", 124, 133], ["sodium", "CHEMICAL", 21, 27], ["amiloride", "CHEMICAL", 60, 69], ["adenosine", "CHEMICAL", 124, 133], ["sodium", "SIMPLE_CHEMICAL", 21, 27], ["amiloride", "SIMPLE_CHEMICAL", 60, 69], ["adenosine", "SIMPLE_CHEMICAL", 124, 133], ["sodium channels", "PROTEIN", 21, 36], ["voltage clamp", "TREATMENT", 6, 19], ["sodium channels", "TREATMENT", 21, 36], ["apical amiloride", "TREATMENT", 53, 69], ["ISC", "TREATMENT", 83, 86], ["adenosine", "TREATMENT", 124, 133]]], ["As shown (Fig. 1), the ethanol exposure decreased adenosine-activated ISC in a dose-dependent manner.", [["ethanol", "CHEMICAL", 23, 30], ["adenosine", "CHEMICAL", 50, 59], ["ethanol", "CHEMICAL", 23, 30], ["adenosine", "CHEMICAL", 50, 59], ["ethanol", "SIMPLE_CHEMICAL", 23, 30], ["adenosine", "SIMPLE_CHEMICAL", 50, 59], ["ISC", "CELL", 70, 73], ["the ethanol exposure", "PROBLEM", 19, 39]]], ["Significant differences were detected by One-way ANOVA test between the control and the alcohol-exposed (50 mM and 100 mM) groups (p<0.05, n = 5).Ethanol suppresses adenosine-activated chloride transport ::: ResultsIt was previously documented that adenosine-stimulated anion secretion in airway epithelia is largely mediated by chloride transport [17], [29].", [["airway epithelia", "ANATOMY", 289, 305], ["alcohol", "CHEMICAL", 88, 95], ["Ethanol", "CHEMICAL", 146, 153], ["adenosine", "CHEMICAL", 165, 174], ["chloride", "CHEMICAL", 185, 193], ["adenosine", "CHEMICAL", 249, 258], ["chloride", "CHEMICAL", 329, 337], ["alcohol", "CHEMICAL", 88, 95], ["Ethanol", "CHEMICAL", 146, 153], ["adenosine", "CHEMICAL", 165, 174], ["chloride", "CHEMICAL", 185, 193], ["adenosine", "CHEMICAL", 249, 258], ["chloride", "CHEMICAL", 329, 337], ["alcohol", "SIMPLE_CHEMICAL", 88, 95], ["Ethanol", "SIMPLE_CHEMICAL", 146, 153], ["adenosine", "SIMPLE_CHEMICAL", 165, 174], ["chloride", "SIMPLE_CHEMICAL", 185, 193], ["adenosine", "SIMPLE_CHEMICAL", 249, 258], ["anion", "SIMPLE_CHEMICAL", 270, 275], ["airway epithelia", "TISSUE", 289, 305], ["chloride", "SIMPLE_CHEMICAL", 329, 337], ["One-way ANOVA test", "TEST", 41, 59], ["Ethanol suppresses adenosine", "TREATMENT", 146, 174], ["adenosine", "TREATMENT", 249, 258], ["stimulated anion secretion in airway epithelia", "PROBLEM", 259, 305], ["airway", "ANATOMY", 289, 295], ["epithelia", "ANATOMY_MODIFIER", 296, 305]]], ["To explore if the alcohol-suppressed ISC, as identified above, is actually a chloride current, we first confirmed chloride transport by Calu-3 epithelia in our experimental setting.", [["Calu-3 epithelia", "ANATOMY", 136, 152], ["alcohol", "CHEMICAL", 18, 25], ["chloride", "CHEMICAL", 77, 85], ["chloride", "CHEMICAL", 114, 122], ["alcohol", "CHEMICAL", 18, 25], ["chloride", "CHEMICAL", 77, 85], ["chloride", "CHEMICAL", 114, 122], ["alcohol", "SIMPLE_CHEMICAL", 18, 25], ["ISC", "CELL", 37, 40], ["chloride", "SIMPLE_CHEMICAL", 77, 85], ["chloride", "SIMPLE_CHEMICAL", 114, 122], ["Calu-3 epithelia", "TISSUE", 136, 152], ["chloride transport", "TEST", 114, 132], ["Calu", "TEST", 136, 140]]], ["To this end, the cultured Calu-3 epithelia without any alcohol exposure were subjected to ISC measurement in the presence of various inhibitors to block different ion channels.", [["Calu-3 epithelia", "ANATOMY", 26, 42], ["alcohol", "CHEMICAL", 55, 62], ["alcohol", "CHEMICAL", 55, 62], ["Calu-3 epithelia", "TISSUE", 26, 42], ["alcohol", "SIMPLE_CHEMICAL", 55, 62], ["the cultured Calu", "TEST", 13, 30], ["ISC measurement", "TEST", 90, 105], ["various inhibitors", "TREATMENT", 125, 143]]], ["Bumetanide (100 \u00b5M), a specific inhibitor for the Na+-K+-2Cl\u2212 cotransporter, was applied to the basolateral side of the Calu-3 epithelia after adenosine stimulation.", [["basolateral", "ANATOMY", 96, 107], ["Calu-3 epithelia", "ANATOMY", 120, 136], ["Bumetanide", "CHEMICAL", 0, 10], ["adenosine", "CHEMICAL", 143, 152], ["Bumetanide", "CHEMICAL", 0, 10], ["adenosine", "CHEMICAL", 143, 152], ["Bumetanide", "SIMPLE_CHEMICAL", 0, 10], ["Na+-K+-2Cl\u2212 cotransporter", "GENE_OR_GENE_PRODUCT", 50, 75], ["Calu-3 epithelia", "TISSUE", 120, 136], ["adenosine", "SIMPLE_CHEMICAL", 143, 152], ["Na+-K+-2Cl\u2212 cotransporter", "PROTEIN", 50, 75], ["Bumetanide", "TREATMENT", 0, 10], ["a specific inhibitor", "TREATMENT", 21, 41], ["the Na+-K+-2Cl\u2212 cotransporter", "TREATMENT", 46, 75], ["adenosine stimulation", "TREATMENT", 143, 164], ["basolateral", "ANATOMY_MODIFIER", 96, 107], ["Calu", "ANATOMY", 120, 124]]], ["This drug decreased ISC by \u223c58%, while acetazolamide, a carbonic anhydrase inhibitor, and DNDS, an inhibitor for Na+/HCO3\u2212 cotransporters and Cl\u2212/HCO3\u2212 exchangers, had no effect on ISC (Fig. 2A).", [["acetazolamide", "CHEMICAL", 39, 52], ["DNDS", "CHEMICAL", 90, 94], ["Na+", "CHEMICAL", 113, 116], ["HCO3", "CHEMICAL", 117, 121], ["Cl\u2212", "CHEMICAL", 142, 145], ["HCO3", "CHEMICAL", 146, 150], ["acetazolamide", "CHEMICAL", 39, 52], ["DNDS", "CHEMICAL", 90, 94], ["Na+", "CHEMICAL", 113, 116], ["HCO3", "CHEMICAL", 117, 121], ["Cl\u2212", "CHEMICAL", 142, 145], ["HCO3", "CHEMICAL", 146, 150], ["acetazolamide", "SIMPLE_CHEMICAL", 39, 52], ["carbonic anhydrase", "GENE_OR_GENE_PRODUCT", 56, 74], ["DNDS", "SIMPLE_CHEMICAL", 90, 94], ["Cl\u2212/HCO3\u2212", "SIMPLE_CHEMICAL", 142, 151], ["Na+/HCO3\u2212 cotransporters", "PROTEIN", 113, 137], ["acetazolamide", "TREATMENT", 39, 52], ["a carbonic anhydrase inhibitor", "TREATMENT", 54, 84], ["an inhibitor", "TREATMENT", 96, 108], ["Na+", "TEST", 113, 116], ["HCO3\u2212 cotransporters", "TREATMENT", 117, 137], ["Cl\u2212/HCO3\u2212 exchangers", "TREATMENT", 142, 162]]], ["These data suggest that the adenosine-stimulated anion current that is suppressed by alcohol is the chloride channel conductance.", [["adenosine", "CHEMICAL", 28, 37], ["alcohol", "CHEMICAL", 85, 92], ["chloride", "CHEMICAL", 100, 108], ["adenosine", "CHEMICAL", 28, 37], ["alcohol", "CHEMICAL", 85, 92], ["chloride", "CHEMICAL", 100, 108], ["adenosine", "SIMPLE_CHEMICAL", 28, 37], ["anion", "SIMPLE_CHEMICAL", 49, 54], ["alcohol", "SIMPLE_CHEMICAL", 85, 92], ["chloride", "SIMPLE_CHEMICAL", 100, 108], ["the adenosine", "TREATMENT", 24, 37], ["the chloride channel conductance", "TREATMENT", 96, 128]]], ["The result was further validated by measuring the adenosine-stimulated ISC with identical apical and basal chloride buffers.", [["apical", "ANATOMY", 90, 96], ["adenosine", "CHEMICAL", 50, 59], ["adenosine", "CHEMICAL", 50, 59], ["chloride", "CHEMICAL", 107, 115], ["adenosine", "SIMPLE_CHEMICAL", 50, 59], ["ISC", "CELL", 71, 74], ["apical", "MULTI-TISSUE_STRUCTURE", 90, 96], ["adenosine-stimulated ISC", "CELL_LINE", 50, 74], ["the adenosine-stimulated ISC", "TREATMENT", 46, 74], ["identical apical and basal chloride buffers", "TREATMENT", 80, 123], ["apical", "ANATOMY_MODIFIER", 90, 96], ["basal", "ANATOMY_MODIFIER", 101, 106], ["chloride buffers", "OBSERVATION", 107, 123]]], ["Without chloride gradient (Fig. 2B), adenosine-induced ISC was dropped significantly by Student's t-test (p<0.01, n = 5).", [["chloride", "CHEMICAL", 8, 16], ["adenosine", "CHEMICAL", 37, 46], ["chloride", "CHEMICAL", 8, 16], ["adenosine", "CHEMICAL", 37, 46], ["chloride", "SIMPLE_CHEMICAL", 8, 16], ["adenosine", "SIMPLE_CHEMICAL", 37, 46], ["chloride gradient", "PROBLEM", 8, 25], ["adenosine", "TREATMENT", 37, 46], ["Student's t-test", "TEST", 88, 104]]], ["The ISC was only \u223c8% of that measured with the asymmetric chloride buffers.The adenosine-stimulated chloride transport is mediated through the CFTR channel ::: ResultsCFTR has been found to be a major chloride channel in the airway epithelium responsible for adenosine-induced ion transport [30]#.", [["airway epithelium", "ANATOMY", 225, 242], ["adenosine", "CHEMICAL", 79, 88], ["chloride", "CHEMICAL", 100, 108], ["ResultsCFTR", "CHEMICAL", 160, 171], ["chloride", "CHEMICAL", 201, 209], ["adenosine", "CHEMICAL", 259, 268], ["chloride", "CHEMICAL", 58, 66], ["adenosine", "CHEMICAL", 79, 88], ["chloride", "CHEMICAL", 100, 108], ["chloride", "CHEMICAL", 201, 209], ["adenosine", "CHEMICAL", 259, 268], ["chloride", "SIMPLE_CHEMICAL", 58, 66], ["adenosine", "SIMPLE_CHEMICAL", 79, 88], ["chloride", "SIMPLE_CHEMICAL", 100, 108], ["CFTR", "GENE_OR_GENE_PRODUCT", 143, 147], ["ResultsCFTR", "GENE_OR_GENE_PRODUCT", 160, 171], ["chloride", "SIMPLE_CHEMICAL", 201, 209], ["airway epithelium", "TISSUE", 225, 242], ["adenosine", "SIMPLE_CHEMICAL", 259, 268], ["ion", "SIMPLE_CHEMICAL", 277, 280], ["CFTR channel", "PROTEIN", 143, 155], ["ResultsCFTR", "PROTEIN", 160, 171], ["The ISC", "TEST", 0, 7], ["the asymmetric chloride buffers", "TREATMENT", 43, 74], ["The adenosine-stimulated chloride transport", "TREATMENT", 75, 118], ["a major chloride channel in the airway epithelium", "PROBLEM", 193, 242], ["adenosine", "TREATMENT", 259, 268], ["chloride channel", "OBSERVATION", 201, 217], ["airway", "ANATOMY", 225, 231], ["epithelium", "ANATOMY_MODIFIER", 232, 242]]], ["To validate if CFTR is responsible for the observed adenosine-stimulated chloride transport in the Calu-3 epithelia, we applied CFTR channel inhibitor CFTRinh172 to the apical side of Calu-3 epithelia for 30 minutes, followed by adenosine stimulation.", [["Calu-3 epithelia", "ANATOMY", 99, 115], ["apical", "ANATOMY", 169, 175], ["Calu-3 epithelia", "ANATOMY", 184, 200], ["adenosine", "CHEMICAL", 52, 61], ["chloride", "CHEMICAL", 73, 81], ["adenosine", "CHEMICAL", 229, 238], ["adenosine", "CHEMICAL", 52, 61], ["chloride", "CHEMICAL", 73, 81], ["CFTRinh172", "CHEMICAL", 151, 161], ["adenosine", "CHEMICAL", 229, 238], ["CFTR", "GENE_OR_GENE_PRODUCT", 15, 19], ["adenosine", "SIMPLE_CHEMICAL", 52, 61], ["chloride", "SIMPLE_CHEMICAL", 73, 81], ["Calu-3 epithelia", "TISSUE", 99, 115], ["CFTR", "GENE_OR_GENE_PRODUCT", 128, 132], ["CFTRinh172", "SIMPLE_CHEMICAL", 151, 161], ["Calu-3 epithelia", "TISSUE", 184, 200], ["adenosine", "SIMPLE_CHEMICAL", 229, 238], ["CFTR", "PROTEIN", 15, 19], ["CFTR", "PROTEIN", 128, 132], ["CFTR", "PROBLEM", 15, 19], ["adenosine-stimulated chloride transport", "TREATMENT", 52, 91], ["CFTR channel inhibitor", "TREATMENT", 128, 150], ["adenosine stimulation", "TREATMENT", 229, 250], ["apical", "ANATOMY_MODIFIER", 169, 175]]], ["The chloride conductance was decreased by \u223c76% when CFTR was inhibited (Fig. 3), which is significantly lower than that of the no drug control (p<0.01, n = 5).", [["chloride", "CHEMICAL", 4, 12], ["chloride", "CHEMICAL", 4, 12], ["chloride", "SIMPLE_CHEMICAL", 4, 12], ["CFTR", "GENE_OR_GENE_PRODUCT", 52, 56], ["CFTR", "PROTEIN", 52, 56], ["The chloride conductance", "TEST", 0, 24], ["CFTR", "TEST", 52, 56]]], ["To seek a second approach to confirm the result, CFBE41o cells, an airway epithelial cell line derived from a cystic fibrosis (CF) patient with homozygous \u0394F508 mutations in CFTR, were used [24].", [["CFBE41o cells", "ANATOMY", 49, 62], ["airway epithelial cell line", "ANATOMY", 67, 94], ["cystic fibrosis", "DISEASE", 110, 125], ["CF", "DISEASE", 127, 129], ["CFBE41o cells", "CELL", 49, 62], ["airway epithelial cell line", "CELL", 67, 94], ["cystic fibrosis", "PATHOLOGICAL_FORMATION", 110, 125], ["patient", "ORGANISM", 131, 138], ["CFTR", "GENE_OR_GENE_PRODUCT", 174, 178], ["CFBE41o cells", "CELL_LINE", 49, 62], ["airway epithelial cell line", "CELL_LINE", 67, 94], ["CFTR", "PROTEIN", 174, 178], ["patient", "SPECIES", 131, 138], ["an airway epithelial cell line", "TREATMENT", 64, 94], ["a cystic fibrosis", "PROBLEM", 108, 125], ["homozygous \u0394F508 mutations in CFTR", "PROBLEM", 144, 178], ["airway", "ANATOMY", 67, 73], ["epithelial cell line", "OBSERVATION", 74, 94], ["cystic", "OBSERVATION_MODIFIER", 110, 116], ["fibrosis", "OBSERVATION", 117, 125]]], ["Strikingly, adenosine failed to elicit any chloride currents across the CF epithelia (p<0.01, N = 4).", [["CF epithelia", "ANATOMY", 72, 84], ["adenosine", "CHEMICAL", 12, 21], ["chloride", "CHEMICAL", 43, 51], ["adenosine", "CHEMICAL", 12, 21], ["chloride", "CHEMICAL", 43, 51], ["adenosine", "SIMPLE_CHEMICAL", 12, 21], ["chloride", "SIMPLE_CHEMICAL", 43, 51], ["CF epithelia", "TISSUE", 72, 84], ["adenosine", "TREATMENT", 12, 21], ["any chloride currents", "PROBLEM", 39, 60], ["the CF epithelia", "PROBLEM", 68, 84], ["CF epithelia", "ANATOMY", 72, 84]]], ["Thus, the currents under our experimental condition and drug profile are CFTR-mediated chloride conductance.", [["chloride", "CHEMICAL", 87, 95], ["chloride", "CHEMICAL", 87, 95], ["CFTR", "GENE_OR_GENE_PRODUCT", 73, 77], ["chloride", "SIMPLE_CHEMICAL", 87, 95], ["CFTR", "PROTEIN", 73, 77], ["drug profile", "TEST", 56, 68], ["CFTR-mediated chloride conductance", "TREATMENT", 73, 107]]], ["These data altogether confirmed that in airway epithelial cells ethanol-suppression of chloride transport is mediated through CFTR, a cAMP-activated chloride channel.A2BAR predominantly regulates the adenosine-induced chloride secretion in Calu-3 cells ::: ResultsThe aforementioned data suggest that the negative modulation of epithelial chloride secretion by ethanol is likely through the adenosine-adenosine receptor signaling pathway.", [["airway epithelial cells", "ANATOMY", 40, 63], ["Calu-3 cells", "ANATOMY", 240, 252], ["epithelial", "ANATOMY", 328, 338], ["ethanol", "CHEMICAL", 64, 71], ["chloride", "CHEMICAL", 87, 95], ["cAMP", "CHEMICAL", 134, 138], ["chloride", "CHEMICAL", 149, 157], ["adenosine", "CHEMICAL", 200, 209], ["chloride", "CHEMICAL", 218, 226], ["chloride", "CHEMICAL", 339, 347], ["ethanol", "CHEMICAL", 361, 368], ["adenosine", "CHEMICAL", 391, 400], ["adenosine", "CHEMICAL", 401, 410], ["ethanol", "CHEMICAL", 64, 71], ["chloride", "CHEMICAL", 87, 95], ["cAMP", "CHEMICAL", 134, 138], ["chloride", "CHEMICAL", 149, 157], ["adenosine", "CHEMICAL", 200, 209], ["chloride", "CHEMICAL", 218, 226], ["chloride", "CHEMICAL", 339, 347], ["ethanol", "CHEMICAL", 361, 368], ["adenosine", "CHEMICAL", 391, 400], ["adenosine", "CHEMICAL", 401, 410], ["airway epithelial cells", "CELL", 40, 63], ["ethanol", "SIMPLE_CHEMICAL", 64, 71], ["chloride", "SIMPLE_CHEMICAL", 87, 95], ["CFTR", "GENE_OR_GENE_PRODUCT", 126, 130], ["cAMP", "SIMPLE_CHEMICAL", 134, 138], ["chloride", "SIMPLE_CHEMICAL", 149, 157], ["A2BAR", "GENE_OR_GENE_PRODUCT", 166, 171], ["adenosine", "SIMPLE_CHEMICAL", 200, 209], ["chloride", "SIMPLE_CHEMICAL", 218, 226], ["Calu-3 cells", "CELL", 240, 252], ["epithelial", "TISSUE", 328, 338], ["chloride", "SIMPLE_CHEMICAL", 339, 347], ["ethanol", "SIMPLE_CHEMICAL", 361, 368], ["adenosine-adenosine receptor", "GENE_OR_GENE_PRODUCT", 391, 419], ["airway epithelial cells", "CELL_TYPE", 40, 63], ["CFTR", "PROTEIN", 126, 130], ["cAMP-activated chloride channel", "PROTEIN", 134, 165], ["A2BAR", "PROTEIN", 166, 171], ["Calu-3 cells", "CELL_LINE", 240, 252], ["These data", "TEST", 0, 10], ["chloride transport", "TREATMENT", 87, 105], ["a cAMP-activated chloride channel", "TREATMENT", 132, 165], ["the adenosine", "TREATMENT", 196, 209], ["induced chloride secretion", "PROBLEM", 210, 236], ["epithelial chloride secretion", "PROBLEM", 328, 357], ["the adenosine-adenosine receptor signaling pathway", "TREATMENT", 387, 437], ["airway", "ANATOMY", 40, 46], ["epithelial cells", "OBSERVATION", 47, 63], ["epithelial chloride", "OBSERVATION", 328, 347]]], ["Up to date, four different adenosine receptors have been identified: A1, A2A, A2B and A3 receptors [31].", [["adenosine", "CHEMICAL", 27, 36], ["adenosine", "CHEMICAL", 27, 36], ["adenosine receptors", "GENE_OR_GENE_PRODUCT", 27, 46], ["A1", "GENE_OR_GENE_PRODUCT", 69, 71], ["A2A", "GENE_OR_GENE_PRODUCT", 73, 76], ["A2B", "GENE_OR_GENE_PRODUCT", 78, 81], ["A3 receptors", "GENE_OR_GENE_PRODUCT", 86, 98], ["adenosine receptors", "PROTEIN", 27, 46], ["A1", "PROTEIN", 69, 71], ["A2A", "PROTEIN", 73, 76], ["A2B", "PROTEIN", 78, 81], ["A3 receptors", "PROTEIN", 86, 98], ["different adenosine receptors", "TREATMENT", 17, 46], ["A2A", "TEST", 73, 76], ["A2B", "TEST", 78, 81]]], ["In airway epithelial cells, A2BAR predominantly regulate CFTR function [18].", [["airway epithelial cells", "ANATOMY", 3, 26], ["airway epithelial cells", "CELL", 3, 26], ["A2BAR", "GENE_OR_GENE_PRODUCT", 28, 33], ["CFTR", "GENE_OR_GENE_PRODUCT", 57, 61], ["airway epithelial cells", "CELL_TYPE", 3, 26], ["A2BAR", "PROTEIN", 28, 33], ["CFTR", "PROTEIN", 57, 61], ["airway", "ANATOMY", 3, 9], ["epithelial cells", "OBSERVATION", 10, 26]]], ["Here, we wanted to examine if the same signaling pathway is involved in the alcohol-induced inhibition of CFTR-mediated chloride transport.", [["alcohol", "CHEMICAL", 76, 83], ["chloride", "CHEMICAL", 120, 128], ["alcohol", "CHEMICAL", 76, 83], ["chloride", "CHEMICAL", 120, 128], ["alcohol", "SIMPLE_CHEMICAL", 76, 83], ["CFTR", "GENE_OR_GENE_PRODUCT", 106, 110], ["chloride", "SIMPLE_CHEMICAL", 120, 128], ["CFTR", "PROTEIN", 106, 110], ["CFTR-mediated chloride transport", "TREATMENT", 106, 138]]], ["To this end, alloxazine (50 \u00b5M), a commonly used A2BAR specific blocker, was applied to the apical buffer after adenosine stimulation.", [["alloxazine", "CHEMICAL", 13, 23], ["adenosine", "CHEMICAL", 112, 121], ["alloxazine", "CHEMICAL", 13, 23], ["adenosine", "CHEMICAL", 112, 121], ["alloxazine", "SIMPLE_CHEMICAL", 13, 23], ["A2BAR", "SIMPLE_CHEMICAL", 49, 54], ["adenosine", "SIMPLE_CHEMICAL", 112, 121], ["alloxazine", "TREATMENT", 13, 23], ["A2BAR specific blocker", "TREATMENT", 49, 71], ["adenosine stimulation", "TREATMENT", 112, 133], ["apical", "ANATOMY_MODIFIER", 92, 98]]], ["The data (Figure 4) demonstrate that \u223c75% adenosine-stimulated epithelial ISC was reduced by alloxazine, indicating that A2BAR was largely responsible for the adenosine-mediated chloride secretion.Ethanol exposure affects CFTR-mediated chloride secretion through modulation of cellular cAMP level ::: ResultsUpon adenosine binding, the A2BAR signals through Gs protein to activate adenylyl cyclase and raises intracellular cAMP [13], [32].", [["epithelial", "ANATOMY", 63, 73], ["cellular", "ANATOMY", 277, 285], ["intracellular", "ANATOMY", 409, 422], ["adenosine", "CHEMICAL", 42, 51], ["alloxazine", "CHEMICAL", 93, 103], ["A2BAR", "CHEMICAL", 121, 126], ["adenosine", "CHEMICAL", 159, 168], ["chloride", "CHEMICAL", 178, 186], ["Ethanol", "CHEMICAL", 197, 204], ["chloride", "CHEMICAL", 236, 244], ["cAMP", "CHEMICAL", 286, 290], ["adenosine", "CHEMICAL", 313, 322], ["cAMP", "CHEMICAL", 423, 427], ["adenosine", "CHEMICAL", 42, 51], ["alloxazine", "CHEMICAL", 93, 103], ["adenosine", "CHEMICAL", 159, 168], ["chloride", "CHEMICAL", 178, 186], ["Ethanol", "CHEMICAL", 197, 204], ["chloride", "CHEMICAL", 236, 244], ["cAMP", "CHEMICAL", 286, 290], ["adenosine", "CHEMICAL", 313, 322], ["adenylyl", "CHEMICAL", 381, 389], ["cAMP", "CHEMICAL", 423, 427], ["adenosine", "SIMPLE_CHEMICAL", 42, 51], ["epithelial", "CELL", 63, 73], ["alloxazine", "SIMPLE_CHEMICAL", 93, 103], ["A2BAR", "GENE_OR_GENE_PRODUCT", 121, 126], ["adenosine", "SIMPLE_CHEMICAL", 159, 168], ["chloride", "SIMPLE_CHEMICAL", 178, 186], ["Ethanol", "SIMPLE_CHEMICAL", 197, 204], ["CFTR", "GENE_OR_GENE_PRODUCT", 222, 226], ["chloride", "SIMPLE_CHEMICAL", 236, 244], ["cellular", "CELL", 277, 285], ["cAMP", "SIMPLE_CHEMICAL", 286, 290], ["adenosine", "SIMPLE_CHEMICAL", 313, 322], ["A2BAR", "GENE_OR_GENE_PRODUCT", 336, 341], ["Gs", "GENE_OR_GENE_PRODUCT", 358, 360], ["adenylyl cyclase", "GENE_OR_GENE_PRODUCT", 381, 397], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 409, 422], ["cAMP", "SIMPLE_CHEMICAL", 423, 427], ["stimulated epithelial ISC", "CELL_LINE", 52, 77], ["A2BAR", "PROTEIN", 121, 126], ["CFTR", "PROTEIN", 222, 226], ["A2BAR", "PROTEIN", 336, 341], ["Gs protein", "PROTEIN", 358, 368], ["adenylyl cyclase", "PROTEIN", 381, 397], ["adenosine", "TEST", 42, 51], ["alloxazine", "TREATMENT", 93, 103], ["A2BAR", "PROBLEM", 121, 126], ["the adenosine-mediated chloride secretion", "PROBLEM", 155, 196], ["chloride secretion", "PROBLEM", 236, 254], ["cellular cAMP level", "TEST", 277, 296], ["adenosine binding", "TEST", 313, 330], ["the A2BAR signals", "TEST", 332, 349], ["Gs protein", "TEST", 358, 368], ["adenylyl cyclase", "TEST", 381, 397], ["intracellular cAMP", "TEST", 409, 427], ["epithelial ISC", "OBSERVATION", 63, 77]]], ["Because CFTR is a cAMP-activated chloride channel, we hypothesized that ethanol inhibits adenosine-stimulated cAMP production to cause a reduced CFTR channel activity.", [["cAMP", "CHEMICAL", 18, 22], ["chloride", "CHEMICAL", 33, 41], ["ethanol", "CHEMICAL", 72, 79], ["adenosine", "CHEMICAL", 89, 98], ["cAMP", "CHEMICAL", 110, 114], ["cAMP", "CHEMICAL", 18, 22], ["chloride", "CHEMICAL", 33, 41], ["ethanol", "CHEMICAL", 72, 79], ["adenosine", "CHEMICAL", 89, 98], ["cAMP", "CHEMICAL", 110, 114], ["CFTR", "GENE_OR_GENE_PRODUCT", 8, 12], ["cAMP", "SIMPLE_CHEMICAL", 18, 22], ["chloride", "SIMPLE_CHEMICAL", 33, 41], ["ethanol", "SIMPLE_CHEMICAL", 72, 79], ["adenosine", "SIMPLE_CHEMICAL", 89, 98], ["cAMP", "SIMPLE_CHEMICAL", 110, 114], ["CFTR", "GENE_OR_GENE_PRODUCT", 145, 149], ["CFTR", "PROTEIN", 8, 12], ["CFTR", "PROTEIN", 145, 149], ["activated chloride channel", "TREATMENT", 23, 49], ["adenosine", "TREATMENT", 89, 98], ["a reduced CFTR channel activity", "PROBLEM", 135, 166]]], ["To test this hypothesis, air-liquid interface cultures of Calu-3 cells were exposed basolaterally to either 0 mM or 100 mM of ethanol for 24 hours.", [["air-liquid interface cultures", "ANATOMY", 25, 54], ["Calu-3 cells", "ANATOMY", 58, 70], ["basolaterally", "ANATOMY", 84, 97], ["ethanol", "CHEMICAL", 126, 133], ["ethanol", "CHEMICAL", 126, 133], ["Calu-3 cells", "CELL", 58, 70], ["ethanol", "SIMPLE_CHEMICAL", 126, 133], ["air-liquid interface cultures", "CELL_LINE", 25, 54], ["Calu-3 cells", "CELL_LINE", 58, 70], ["air-liquid interface cultures", "TEST", 25, 54], ["Calu", "TEST", 58, 62]]], ["These cells were apically stimulated with 100 \u00b5M of adenosine as described above for 10 minutes, the time point at which the epithelial ISC was at its peak levels.", [["cells", "ANATOMY", 6, 11], ["epithelial", "ANATOMY", 125, 135], ["adenosine", "CHEMICAL", 52, 61], ["adenosine", "CHEMICAL", 52, 61], ["cells", "CELL", 6, 11], ["adenosine", "SIMPLE_CHEMICAL", 52, 61], ["epithelial", "CELL", 125, 135], ["epithelial ISC", "CELL_TYPE", 125, 139], ["adenosine", "TREATMENT", 52, 61], ["epithelial ISC", "ANATOMY", 125, 139]]], ["Then, the cells were lysed and the levels of cellular cAMP assayed.", [["cells", "ANATOMY", 10, 15], ["cellular", "ANATOMY", 45, 53], ["cAMP", "CHEMICAL", 54, 58], ["cAMP", "CHEMICAL", 54, 58], ["cells", "CELL", 10, 15], ["cellular", "CELL", 45, 53], ["cAMP", "SIMPLE_CHEMICAL", 54, 58], ["the cells", "TREATMENT", 6, 15], ["the levels", "TEST", 31, 41], ["cellular cAMP", "TEST", 45, 58]]], ["The results demonstrate that ethanol pre-treatment significantly decreased adenosine-stimulated cAMP levels (p<0.05, n = 5) (Fig. 5A).", [["ethanol", "CHEMICAL", 29, 36], ["adenosine", "CHEMICAL", 75, 84], ["cAMP", "CHEMICAL", 96, 100], ["ethanol", "CHEMICAL", 29, 36], ["adenosine", "CHEMICAL", 75, 84], ["cAMP", "CHEMICAL", 96, 100], ["ethanol", "SIMPLE_CHEMICAL", 29, 36], ["adenosine", "SIMPLE_CHEMICAL", 75, 84], ["cAMP", "SIMPLE_CHEMICAL", 96, 100], ["ethanol pre-treatment", "TREATMENT", 29, 50], ["adenosine", "TEST", 75, 84], ["stimulated cAMP levels", "TEST", 85, 107]]], ["In addition, to test whether the decrease in cAMP was in fact causing the suppression of adenosine-stimulated chloride transport by ethanol, Sp-cAMPS, a cell permeable and phosphodiesterase-resistant cAMP analogue, was used to directly activate PKA which then activates the CFTR channel.", [["cell", "ANATOMY", 153, 157], ["cAMP", "CHEMICAL", 45, 49], ["adenosine", "CHEMICAL", 89, 98], ["chloride", "CHEMICAL", 110, 118], ["ethanol", "CHEMICAL", 132, 139], ["-cAMPS", "CHEMICAL", 143, 149], ["cAMP", "CHEMICAL", 200, 204], ["cAMP", "CHEMICAL", 45, 49], ["adenosine", "CHEMICAL", 89, 98], ["chloride", "CHEMICAL", 110, 118], ["ethanol", "CHEMICAL", 132, 139], ["cAMP", "CHEMICAL", 200, 204], ["cAMP", "SIMPLE_CHEMICAL", 45, 49], ["adenosine", "SIMPLE_CHEMICAL", 89, 98], ["chloride", "SIMPLE_CHEMICAL", 110, 118], ["ethanol", "SIMPLE_CHEMICAL", 132, 139], ["Sp-cAMPS", "SIMPLE_CHEMICAL", 141, 149], ["cell", "CELL", 153, 157], ["cAMP", "SIMPLE_CHEMICAL", 200, 204], ["PKA", "GENE_OR_GENE_PRODUCT", 245, 248], ["CFTR", "GENE_OR_GENE_PRODUCT", 274, 278], ["Sp-cAMPS", "PROTEIN", 141, 149], ["PKA", "PROTEIN", 245, 248], ["CFTR channel", "PROTEIN", 274, 286], ["the decrease in cAMP", "PROBLEM", 29, 49], ["adenosine-stimulated chloride transport", "TREATMENT", 89, 128], ["a cell permeable", "TREATMENT", 151, 167], ["phosphodiesterase-resistant cAMP analogue", "TREATMENT", 172, 213], ["PKA", "TEST", 245, 248], ["decrease", "OBSERVATION_MODIFIER", 33, 41]]], ["As shown inFigure 5B, the alcohol-treated Calu-3 cells in the presence of 10 \u00b5M Sp-cAMPS obliterated the ethanol suppressive effect on adenosine-induced chloride secretion (p<0.05, n = 6).", [["Calu-3 cells", "ANATOMY", 42, 54], ["alcohol", "CHEMICAL", 26, 33], ["Sp-cAMPS", "CHEMICAL", 80, 88], ["ethanol", "CHEMICAL", 105, 112], ["adenosine", "CHEMICAL", 135, 144], ["chloride", "CHEMICAL", 153, 161], ["alcohol", "CHEMICAL", 26, 33], ["ethanol", "CHEMICAL", 105, 112], ["adenosine", "CHEMICAL", 135, 144], ["chloride", "CHEMICAL", 153, 161], ["alcohol", "SIMPLE_CHEMICAL", 26, 33], ["Calu-3 cells", "CELL", 42, 54], ["Sp-cAMPS", "SIMPLE_CHEMICAL", 80, 88], ["ethanol", "SIMPLE_CHEMICAL", 105, 112], ["adenosine", "SIMPLE_CHEMICAL", 135, 144], ["chloride", "SIMPLE_CHEMICAL", 153, 161], ["Calu-3 cells", "CELL_LINE", 42, 54], ["adenosine", "TREATMENT", 135, 144], ["induced chloride secretion", "PROBLEM", 145, 171]]], ["Thus, we conclude that ethanol inhibits CFTR-mediated chloride secretion by directly affecting the cellular cAMP level instead of the downstream PKA enzyme.Ethanol-suppression of chloride secretion in airway epithelial cells can be restored by phosphodiesterase inhibitors ::: ResultsBased on the data that ethanol impairs the adenosine-activated chloride secretion by reducing the cellular cAMP level, we chose to block endogenous cAMP degradation pharmacologically to counteract the alcohol-suppressive effect on chloride secretion.", [["cellular", "ANATOMY", 99, 107], ["airway epithelial cells", "ANATOMY", 201, 224], ["cellular", "ANATOMY", 382, 390], ["ethanol", "CHEMICAL", 23, 30], ["chloride", "CHEMICAL", 54, 62], ["cAMP", "CHEMICAL", 108, 112], ["Ethanol", "CHEMICAL", 156, 163], ["chloride", "CHEMICAL", 179, 187], ["ethanol", "CHEMICAL", 307, 314], ["adenosine", "CHEMICAL", 327, 336], ["chloride", "CHEMICAL", 347, 355], ["cAMP", "CHEMICAL", 391, 395], ["cAMP", "CHEMICAL", 432, 436], ["alcohol", "CHEMICAL", 485, 492], ["chloride", "CHEMICAL", 515, 523], ["ethanol", "CHEMICAL", 23, 30], ["chloride", "CHEMICAL", 54, 62], ["cAMP", "CHEMICAL", 108, 112], ["Ethanol", "CHEMICAL", 156, 163], ["chloride", "CHEMICAL", 179, 187], ["ethanol", "CHEMICAL", 307, 314], ["adenosine", "CHEMICAL", 327, 336], ["chloride", "CHEMICAL", 347, 355], ["cAMP", "CHEMICAL", 391, 395], ["cAMP", "CHEMICAL", 432, 436], ["alcohol", "CHEMICAL", 485, 492], ["chloride", "CHEMICAL", 515, 523], ["ethanol", "SIMPLE_CHEMICAL", 23, 30], ["CFTR", "GENE_OR_GENE_PRODUCT", 40, 44], ["chloride", "SIMPLE_CHEMICAL", 54, 62], ["cellular", "CELL", 99, 107], ["cAMP", "SIMPLE_CHEMICAL", 108, 112], ["PKA", "GENE_OR_GENE_PRODUCT", 145, 148], ["Ethanol", "SIMPLE_CHEMICAL", 156, 163], ["chloride", "SIMPLE_CHEMICAL", 179, 187], ["airway epithelial cells", "CELL", 201, 224], ["ethanol", "SIMPLE_CHEMICAL", 307, 314], ["adenosine", "SIMPLE_CHEMICAL", 327, 336], ["chloride", "SIMPLE_CHEMICAL", 347, 355], ["cellular", "CELL", 382, 390], ["cAMP", "SIMPLE_CHEMICAL", 391, 395], ["cAMP", "SIMPLE_CHEMICAL", 432, 436], ["alcohol", "SIMPLE_CHEMICAL", 485, 492], ["chloride", "SIMPLE_CHEMICAL", 515, 523], ["CFTR", "PROTEIN", 40, 44], ["PKA enzyme", "PROTEIN", 145, 155], ["airway epithelial cells", "CELL_TYPE", 201, 224], ["chloride secretion", "PROBLEM", 54, 72], ["the cellular cAMP level", "TEST", 95, 118], ["the downstream PKA enzyme", "TEST", 130, 155], ["Ethanol", "TREATMENT", 156, 163], ["chloride secretion in airway epithelial cells", "PROBLEM", 179, 224], ["phosphodiesterase inhibitors", "TREATMENT", 244, 272], ["activated chloride secretion", "PROBLEM", 337, 365], ["the cellular cAMP level", "TEST", 378, 401], ["endogenous cAMP degradation", "TREATMENT", 421, 448], ["chloride secretion", "PROBLEM", 515, 533], ["airway", "ANATOMY", 201, 207], ["epithelial cells", "OBSERVATION", 208, 224]]], ["Air-liquid interface cultures of Calu-3 cells were similarly exposed to ethanol for 24 hours and treated with 100 \u00b5M of non-specific phosphodiesterase inhibitor IBMX along with adenosine stimulation.", [["Calu-3 cells", "ANATOMY", 33, 45], ["ethanol", "CHEMICAL", 72, 79], ["IBMX", "CHEMICAL", 161, 165], ["adenosine", "CHEMICAL", 177, 186], ["ethanol", "CHEMICAL", 72, 79], ["IBMX", "CHEMICAL", 161, 165], ["adenosine", "CHEMICAL", 177, 186], ["Calu-3 cells", "CELL", 33, 45], ["ethanol", "SIMPLE_CHEMICAL", 72, 79], ["IBMX", "SIMPLE_CHEMICAL", 161, 165], ["adenosine", "SIMPLE_CHEMICAL", 177, 186], ["Air-liquid interface cultures", "CELL_LINE", 0, 29], ["Calu-3 cells", "CELL_LINE", 33, 45], ["Air-liquid interface cultures", "TEST", 0, 29], ["Calu", "TEST", 33, 37], ["non-specific phosphodiesterase inhibitor IBMX", "TREATMENT", 120, 165], ["adenosine stimulation", "TREATMENT", 177, 198]]], ["The data inFigure 6indicate that IBMX almost completely restored the ethanol suppression of Calu-3 chloride secretion (p<0.05, n = 4).", [["IBMX", "CHEMICAL", 33, 37], ["ethanol", "CHEMICAL", 69, 76], ["Calu-3 chloride", "CHEMICAL", 92, 107], ["IBMX", "CHEMICAL", 33, 37], ["ethanol", "CHEMICAL", 69, 76], ["Calu-3 chloride", "CHEMICAL", 92, 107], ["IBMX", "SIMPLE_CHEMICAL", 33, 37], ["ethanol", "SIMPLE_CHEMICAL", 69, 76], ["Calu-3", "GENE_OR_GENE_PRODUCT", 92, 98], ["The data inFigure", "TEST", 0, 17], ["IBMX", "PROBLEM", 33, 37], ["Calu", "TEST", 92, 96]]], ["Papaverine is a clinically used phosphodiesterase inhibitor.", [["Papaverine", "CHEMICAL", 0, 10], ["Papaverine", "CHEMICAL", 0, 10], ["Papaverine", "SIMPLE_CHEMICAL", 0, 10], ["Papaverine", "TREATMENT", 0, 10], ["phosphodiesterase inhibitor", "TREATMENT", 32, 59]]], ["This drug also overcame the inhibitory effect of ethanol on adenosine-induced transepithelial chloride conductance (p<0.05, n = 4) (Fig. 6).", [["transepithelial", "ANATOMY", 78, 93], ["ethanol", "CHEMICAL", 49, 56], ["adenosine", "CHEMICAL", 60, 69], ["chloride", "CHEMICAL", 94, 102], ["ethanol", "CHEMICAL", 49, 56], ["adenosine", "CHEMICAL", 60, 69], ["chloride", "CHEMICAL", 94, 102], ["ethanol", "SIMPLE_CHEMICAL", 49, 56], ["adenosine", "SIMPLE_CHEMICAL", 60, 69], ["transepithelial chloride", "SIMPLE_CHEMICAL", 78, 102], ["adenosine", "TREATMENT", 60, 69], ["transepithelial chloride conductance", "TREATMENT", 78, 114]]], ["These results not only confirm that ethanol modulates adenosine-cAMP signaling but also suggest that phosphodiesterase inhibitors may be useful as the potential therapeutic agents for improving the airway epithelial ion transport and mucociliary clearance in alcoholic patients.DiscussionAirway epithelial cells not only constitute the physical barrier that separates airway lumen from interstitial compartments, but also actively participate in innate and adaptive immunity to protect the host from pulmonary infections [33].", [["airway epithelial", "ANATOMY", 198, 215], ["mucociliary", "ANATOMY", 234, 245], ["epithelial cells", "ANATOMY", 295, 311], ["airway lumen", "ANATOMY", 368, 380], ["interstitial compartments", "ANATOMY", 386, 411], ["pulmonary", "ANATOMY", 500, 509], ["ethanol", "CHEMICAL", 36, 43], ["adenosine", "CHEMICAL", 54, 63], ["cAMP", "CHEMICAL", 64, 68], ["pulmonary infections", "DISEASE", 500, 520], ["ethanol", "CHEMICAL", 36, 43], ["adenosine", "CHEMICAL", 54, 63], ["cAMP", "CHEMICAL", 64, 68], ["ethanol", "SIMPLE_CHEMICAL", 36, 43], ["adenosine", "SIMPLE_CHEMICAL", 54, 63], ["cAMP", "SIMPLE_CHEMICAL", 64, 68], ["phosphodiesterase inhibitors", "GENE_OR_GENE_PRODUCT", 101, 129], ["airway epithelial", "TISSUE", 198, 215], ["mucociliary", "MULTI-TISSUE_STRUCTURE", 234, 245], ["patients", "ORGANISM", 269, 277], ["DiscussionAirway epithelial cells", "CELL", 278, 311], ["airway lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 368, 380], ["interstitial compartments", "IMMATERIAL_ANATOMICAL_ENTITY", 386, 411], ["pulmonary", "ORGAN", 500, 509], ["DiscussionAirway epithelial cells", "CELL_TYPE", 278, 311], ["patients", "SPECIES", 269, 277], ["ethanol modulates adenosine", "TREATMENT", 36, 63], ["cAMP signaling", "PROBLEM", 64, 78], ["phosphodiesterase inhibitors", "TREATMENT", 101, 129], ["therapeutic agents", "TREATMENT", 161, 179], ["the airway epithelial ion transport", "TREATMENT", 194, 229], ["epithelial cells", "PROBLEM", 295, 311], ["innate and adaptive immunity", "TREATMENT", 446, 474], ["pulmonary infections", "PROBLEM", 500, 520], ["airway", "ANATOMY", 198, 204], ["epithelial", "ANATOMY_MODIFIER", 205, 215], ["epithelial cells", "OBSERVATION", 295, 311], ["airway lumen", "OBSERVATION", 368, 380], ["interstitial", "ANATOMY_MODIFIER", 386, 398], ["pulmonary", "ANATOMY", 500, 509], ["infections", "OBSERVATION", 510, 520]]], ["Multiple defense systems have been evolved in airways.", [["airways", "ANATOMY", 46, 53], ["airways", "MULTI-TISSUE_STRUCTURE", 46, 53], ["Multiple defense systems", "PROBLEM", 0, 24], ["defense", "OBSERVATION", 9, 16], ["airways", "ANATOMY", 46, 53]]], ["First, the polarized airway epithelia have a mechanical clearance mechanism.", [["airway epithelia", "ANATOMY", 21, 37], ["airway epithelia", "TISSUE", 21, 37], ["a mechanical clearance mechanism", "TREATMENT", 43, 75], ["polarized", "ANATOMY_MODIFIER", 11, 20], ["airway", "ANATOMY", 21, 27], ["epithelia", "ANATOMY_MODIFIER", 28, 37], ["mechanical clearance", "OBSERVATION", 45, 65]]], ["Goblet cells or submucosal glands secrete mucus that entraps airborne particles and inhaled infectious agents.", [["Goblet cells", "ANATOMY", 0, 12], ["submucosal glands", "ANATOMY", 16, 33], ["mucus", "ANATOMY", 42, 47], ["Goblet cells", "CELL", 0, 12], ["submucosal glands", "ORGAN", 16, 33], ["mucus", "ORGANISM_SUBSTANCE", 42, 47], ["Goblet cells", "CELL_TYPE", 0, 12], ["Goblet cells", "PROBLEM", 0, 12], ["submucosal glands secrete mucus", "PROBLEM", 16, 47], ["inhaled infectious agents", "TREATMENT", 84, 109], ["submucosal glands", "ANATOMY", 16, 33]]], ["Synchronized ciliary movement sweeps inhaled particulate matter toward the mouth to be expectorated or swallowed [34]#.", [["ciliary", "ANATOMY", 13, 20], ["mouth", "ANATOMY", 75, 80], ["ciliary", "MULTI-TISSUE_STRUCTURE", 13, 20], ["mouth", "ORGANISM_SUBDIVISION", 75, 80], ["Synchronized ciliary movement sweeps inhaled", "TREATMENT", 0, 44], ["mouth", "ANATOMY", 75, 80]]], ["Second, airway epithelia secrete antimicrobial factors, such as lysozyme and \u03b2-defensins [35].", [["airway epithelia", "ANATOMY", 8, 24], ["airway epithelia", "TISSUE", 8, 24], ["lysozyme", "GENE_OR_GENE_PRODUCT", 64, 72], ["\u03b2-defensins", "GENE_OR_GENE_PRODUCT", 77, 88], ["antimicrobial factors", "PROTEIN", 33, 54], ["lysozyme", "PROTEIN", 64, 72], ["\u03b2-defensins", "PROTEIN", 77, 88], ["airway epithelia secrete antimicrobial factors", "PROBLEM", 8, 54], ["lysozyme and \u03b2-defensins", "TREATMENT", 64, 88], ["airway", "ANATOMY", 8, 14], ["epithelia", "ANATOMY_MODIFIER", 15, 24], ["antimicrobial factors", "OBSERVATION", 33, 54]]], ["Third, airways and alveoli are patrolled by phagocytic cells, most notably the alveolar macrophage, which can engulf microbes [36].", [["airways", "ANATOMY", 7, 14], ["alveoli", "ANATOMY", 19, 26], ["phagocytic cells", "ANATOMY", 44, 60], ["alveolar macrophage", "ANATOMY", 79, 98], ["airways", "MULTI-TISSUE_STRUCTURE", 7, 14], ["alveoli", "MULTI-TISSUE_STRUCTURE", 19, 26], ["phagocytic cells", "CELL", 44, 60], ["alveolar macrophage", "CELL", 79, 98], ["phagocytic cells", "CELL_TYPE", 44, 60], ["alveolar macrophage", "CELL_TYPE", 79, 98], ["Third, airways and alveoli", "PROBLEM", 0, 26], ["phagocytic cells", "PROBLEM", 44, 60], ["the alveolar macrophage", "PROBLEM", 75, 98], ["airways", "ANATOMY", 7, 14], ["alveoli", "ANATOMY", 19, 26], ["phagocytic cells", "OBSERVATION", 44, 60], ["alveolar macrophage", "OBSERVATION", 79, 98]]], ["Fourth, airways can recruit neutrophils and monocytes to sites of inflammation [37].", [["airways", "ANATOMY", 8, 15], ["neutrophils", "ANATOMY", 28, 39], ["monocytes", "ANATOMY", 44, 53], ["sites", "ANATOMY", 57, 62], ["inflammation", "DISEASE", 66, 78], ["airways", "MULTI-TISSUE_STRUCTURE", 8, 15], ["neutrophils", "CELL", 28, 39], ["monocytes", "CELL", 44, 53], ["neutrophils", "CELL_TYPE", 28, 39], ["monocytes", "CELL_TYPE", 44, 53], ["neutrophils", "TEST", 28, 39], ["monocytes", "TEST", 44, 53], ["inflammation", "PROBLEM", 66, 78], ["airways", "ANATOMY", 8, 15], ["neutrophils", "OBSERVATION", 28, 39], ["monocytes", "OBSERVATION_MODIFIER", 44, 53], ["inflammation", "OBSERVATION", 66, 78]]], ["Fifth, the acquired immune system, including antigen-stimulated T and B lymphocytes, provides cellular and humoral defenses for the airways [38], [39].", [["immune system", "ANATOMY", 20, 33], ["T", "ANATOMY", 64, 65], ["B lymphocytes", "ANATOMY", 70, 83], ["cellular", "ANATOMY", 94, 102], ["airways", "ANATOMY", 132, 139], ["antigen", "GENE_OR_GENE_PRODUCT", 45, 52], ["T", "CELL", 64, 65], ["B lymphocytes", "CELL", 70, 83], ["cellular", "CELL", 94, 102], ["airways", "MULTI-TISSUE_STRUCTURE", 132, 139], ["antigen-stimulated T and B lymphocytes", "CELL_TYPE", 45, 83], ["the acquired immune system", "TEST", 7, 33], ["antigen", "TEST", 45, 52], ["lymphocytes", "ANATOMY", 72, 83], ["humoral defenses", "OBSERVATION", 107, 123], ["airways", "ANATOMY", 132, 139]]], ["It is noteworthy that all the above-mentioned pulmonary defense mechanisms are executed in ASL, the thin film of liquid on top of the airway epithelia.", [["pulmonary", "ANATOMY", 46, 55], ["airway epithelia", "ANATOMY", 134, 150], ["pulmonary", "ORGAN", 46, 55], ["ASL", "MULTI-TISSUE_STRUCTURE", 91, 94], ["airway epithelia", "TISSUE", 134, 150], ["pulmonary defense mechanisms", "PROBLEM", 46, 74], ["the thin film", "TEST", 96, 109], ["pulmonary", "ANATOMY", 46, 55], ["defense", "OBSERVATION", 56, 63], ["airway", "ANATOMY", 134, 140], ["epithelia", "ANATOMY_MODIFIER", 141, 150]]], ["Therefore, ASL homeostasis is pivotal to lung host defense.", [["lung", "ANATOMY", 41, 45], ["ASL", "MULTI-TISSUE_STRUCTURE", 11, 14], ["lung", "ORGAN", 41, 45], ["ASL homeostasis", "TREATMENT", 11, 26], ["lung", "ANATOMY", 41, 45], ["host defense", "OBSERVATION", 46, 58]]], ["Here we provide the first evidence suggesting that ethanol exposure suppresses adenosine-stimulated chloride secretion that regulates ASL.DiscussionOur data demonstrate that ethanol affects adenosine-stimulated chloride secretion through CFTR.", [["ethanol", "CHEMICAL", 51, 58], ["adenosine", "CHEMICAL", 79, 88], ["chloride", "CHEMICAL", 100, 108], ["ethanol", "CHEMICAL", 174, 181], ["adenosine", "CHEMICAL", 190, 199], ["chloride", "CHEMICAL", 211, 219], ["ethanol", "CHEMICAL", 51, 58], ["adenosine", "CHEMICAL", 79, 88], ["chloride", "CHEMICAL", 100, 108], ["ethanol", "CHEMICAL", 174, 181], ["adenosine", "CHEMICAL", 190, 199], ["chloride", "CHEMICAL", 211, 219], ["ethanol", "SIMPLE_CHEMICAL", 51, 58], ["adenosine", "SIMPLE_CHEMICAL", 79, 88], ["chloride", "SIMPLE_CHEMICAL", 100, 108], ["ASL", "GENE_OR_GENE_PRODUCT", 134, 137], ["ethanol", "SIMPLE_CHEMICAL", 174, 181], ["adenosine", "SIMPLE_CHEMICAL", 190, 199], ["chloride", "SIMPLE_CHEMICAL", 211, 219], ["CFTR", "GENE_OR_GENE_PRODUCT", 238, 242], ["CFTR", "PROTEIN", 238, 242], ["ethanol exposure suppresses adenosine", "TREATMENT", 51, 88], ["stimulated chloride secretion", "PROBLEM", 89, 118], ["ethanol affects adenosine", "TREATMENT", 174, 199]]], ["On epithelial apical surface, adenosine binds to A2bAR, a predominant adenosine receptor present in airway epithelia [16].", [["epithelial apical surface", "ANATOMY", 3, 28], ["airway epithelia", "ANATOMY", 100, 116], ["adenosine", "CHEMICAL", 30, 39], ["adenosine", "CHEMICAL", 70, 79], ["adenosine", "CHEMICAL", 30, 39], ["adenosine", "CHEMICAL", 70, 79], ["epithelial apical surface", "CELLULAR_COMPONENT", 3, 28], ["adenosine", "SIMPLE_CHEMICAL", 30, 39], ["A2bAR", "GENE_OR_GENE_PRODUCT", 49, 54], ["adenosine receptor", "GENE_OR_GENE_PRODUCT", 70, 88], ["airway epithelia", "TISSUE", 100, 116], ["A2bAR", "PROTEIN", 49, 54], ["adenosine receptor", "PROTEIN", 70, 88], ["epithelial apical surface", "TREATMENT", 3, 28], ["adenosine binds", "TREATMENT", 30, 45], ["a predominant adenosine receptor", "TREATMENT", 56, 88], ["epithelial", "ANATOMY_MODIFIER", 3, 13], ["apical", "ANATOMY_MODIFIER", 14, 20], ["surface", "ANATOMY_MODIFIER", 21, 28], ["adenosine binds", "OBSERVATION", 30, 45], ["predominant", "OBSERVATION_MODIFIER", 58, 69], ["adenosine receptor", "OBSERVATION", 70, 88], ["airway", "ANATOMY", 100, 106], ["epithelia", "ANATOMY_MODIFIER", 107, 116]]], ["This receptor is coupled to Gs protein to activate adenylyl cyclase, which elevates intracellular cAMP and consequently activates PKA.", [["intracellular", "ANATOMY", 84, 97], ["cAMP", "CHEMICAL", 98, 102], ["adenylyl", "CHEMICAL", 51, 59], ["cAMP", "CHEMICAL", 98, 102], ["Gs", "GENE_OR_GENE_PRODUCT", 28, 30], ["adenylyl cyclase", "GENE_OR_GENE_PRODUCT", 51, 67], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 84, 97], ["cAMP", "SIMPLE_CHEMICAL", 98, 102], ["PKA", "GENE_OR_GENE_PRODUCT", 130, 133], ["Gs protein", "PROTEIN", 28, 38], ["adenylyl cyclase", "PROTEIN", 51, 67], ["PKA", "PROTEIN", 130, 133], ["Gs protein", "TEST", 28, 38], ["adenylyl cyclase", "TEST", 51, 67], ["intracellular cAMP", "PROBLEM", 84, 102]]], ["Then, CFTR is phosphorylated by PKA and the channel opens to permeate chloride [40]#.", [["chloride", "CHEMICAL", 70, 78], ["CFTR", "GENE_OR_GENE_PRODUCT", 6, 10], ["PKA", "GENE_OR_GENE_PRODUCT", 32, 35], ["CFTR", "PROTEIN", 6, 10], ["PKA", "PROTEIN", 32, 35], ["the channel opens to permeate chloride", "TREATMENT", 40, 78]]], ["More chloride in ASL will cause less Na+ absorption and more water retention, thus increasing ASL height and volume [15], [20].", [["chloride", "CHEMICAL", 5, 13], ["Na", "CHEMICAL", 37, 39], ["chloride", "CHEMICAL", 5, 13], ["Na+", "CHEMICAL", 37, 40], ["chloride", "SIMPLE_CHEMICAL", 5, 13], ["ASL", "SIMPLE_CHEMICAL", 17, 20], ["Na+", "SIMPLE_CHEMICAL", 37, 40], ["water", "SIMPLE_CHEMICAL", 61, 66], ["ASL", "SIMPLE_CHEMICAL", 94, 97], ["less Na+ absorption", "PROBLEM", 32, 51], ["more water retention", "PROBLEM", 56, 76], ["increasing ASL height and volume", "TREATMENT", 83, 115], ["more water retention", "OBSERVATION_MODIFIER", 56, 76]]], ["It is even speculated that adenosine is a sensor for ASL homeostasis.", [["adenosine", "CHEMICAL", 27, 36], ["adenosine", "CHEMICAL", 27, 36], ["adenosine", "SIMPLE_CHEMICAL", 27, 36], ["ASL", "SIMPLE_CHEMICAL", 53, 56], ["adenosine", "TREATMENT", 27, 36], ["ASL homeostasis", "TREATMENT", 53, 68]]], ["When ASL falls, adenosine levels increase in airways beyond their basal levels and activate A2BAR and CFTR channels [16], [29].", [["airways", "ANATOMY", 45, 52], ["adenosine", "CHEMICAL", 16, 25], ["adenosine", "CHEMICAL", 16, 25], ["adenosine", "SIMPLE_CHEMICAL", 16, 25], ["airways", "MULTI-TISSUE_STRUCTURE", 45, 52], ["A2BAR", "GENE_OR_GENE_PRODUCT", 92, 97], ["CFTR", "GENE_OR_GENE_PRODUCT", 102, 106], ["A2BAR", "PROTEIN", 92, 97], ["CFTR", "PROTEIN", 102, 106], ["ASL falls", "PROBLEM", 5, 14], ["adenosine levels", "TEST", 16, 32], ["their basal levels", "TEST", 60, 78], ["CFTR channels", "TEST", 102, 115], ["airways", "ANATOMY", 45, 52]]], ["Our data have linked ethanol-suppression of cAMP levels to attenuation of chloride secretion by airway epithelia.", [["airway epithelia", "ANATOMY", 96, 112], ["ethanol", "CHEMICAL", 21, 28], ["cAMP", "CHEMICAL", 44, 48], ["chloride", "CHEMICAL", 74, 82], ["ethanol", "CHEMICAL", 21, 28], ["cAMP", "CHEMICAL", 44, 48], ["chloride", "CHEMICAL", 74, 82], ["ethanol", "SIMPLE_CHEMICAL", 21, 28], ["cAMP", "SIMPLE_CHEMICAL", 44, 48], ["chloride", "SIMPLE_CHEMICAL", 74, 82], ["airway epithelia", "TISSUE", 96, 112], ["Our data", "TEST", 0, 8], ["cAMP levels", "TEST", 44, 55], ["chloride secretion", "PROBLEM", 74, 92], ["airway epithelia", "PROBLEM", 96, 112], ["chloride secretion", "OBSERVATION", 74, 92], ["airway epithelia", "OBSERVATION", 96, 112]]], ["Previous studies have documented that ethanol decreases ciliary beating and epithelial cell migration during wound repair which are associated with compromised cAMP signaling and PKA activation [21], [41].", [["ciliary", "ANATOMY", 56, 63], ["epithelial cell", "ANATOMY", 76, 91], ["wound", "ANATOMY", 109, 114], ["ethanol", "CHEMICAL", 38, 45], ["cAMP", "CHEMICAL", 160, 164], ["ethanol", "CHEMICAL", 38, 45], ["cAMP", "CHEMICAL", 160, 164], ["ethanol", "SIMPLE_CHEMICAL", 38, 45], ["epithelial cell", "CELL", 76, 91], ["wound", "PATHOLOGICAL_FORMATION", 109, 114], ["cAMP", "SIMPLE_CHEMICAL", 160, 164], ["PKA", "GENE_OR_GENE_PRODUCT", 179, 182], ["PKA", "PROTEIN", 179, 182], ["Previous studies", "TEST", 0, 16], ["ciliary beating", "PROBLEM", 56, 71], ["epithelial cell migration", "PROBLEM", 76, 101], ["wound repair", "TREATMENT", 109, 121], ["compromised cAMP signaling", "PROBLEM", 148, 174], ["PKA activation", "TEST", 179, 193], ["decreases", "OBSERVATION_MODIFIER", 46, 55], ["ciliary beating", "OBSERVATION", 56, 71], ["epithelial cell migration", "OBSERVATION", 76, 101], ["wound repair", "OBSERVATION", 109, 121]]], ["Moreover, alcohol is reported to upregulate the PDE4 enzyme expression as well as the enzymatic activity in epithelia [22] #, which results in accelerated cAMP degradation.", [["epithelia", "ANATOMY", 108, 117], ["alcohol", "CHEMICAL", 10, 17], ["cAMP", "CHEMICAL", 155, 159], ["alcohol", "CHEMICAL", 10, 17], ["cAMP", "CHEMICAL", 155, 159], ["alcohol", "SIMPLE_CHEMICAL", 10, 17], ["PDE4", "GENE_OR_GENE_PRODUCT", 48, 52], ["cAMP", "SIMPLE_CHEMICAL", 155, 159], ["PDE4", "PROTEIN", 48, 52], ["the enzymatic activity in epithelia", "PROBLEM", 82, 117], ["accelerated cAMP degradation", "PROBLEM", 143, 171], ["cAMP degradation", "OBSERVATION", 155, 171]]], ["Thus, our data are consistent with the data reported, indicating that alcohol modulates various cellular pathways by reducing cellular cAMP levels.DiscussionPulmonary mucociliary clearance is largely affected by three factors: 1) mucus production, 2) ciliary sweeping and, 3) ASL state.", [["cellular", "ANATOMY", 96, 104], ["cellular", "ANATOMY", 126, 134], ["mucociliary", "ANATOMY", 167, 178], ["mucus", "ANATOMY", 230, 235], ["ciliary", "ANATOMY", 251, 258], ["alcohol", "CHEMICAL", 70, 77], ["cAMP", "CHEMICAL", 135, 139], ["alcohol", "CHEMICAL", 70, 77], ["cAMP", "CHEMICAL", 135, 139], ["alcohol", "SIMPLE_CHEMICAL", 70, 77], ["cellular", "CELL", 96, 104], ["cellular", "CELL", 126, 134], ["cAMP", "SIMPLE_CHEMICAL", 135, 139], ["mucociliary", "MULTI-TISSUE_STRUCTURE", 167, 178], ["mucus", "TISSUE", 230, 235], ["ciliary", "MULTI-TISSUE_STRUCTURE", 251, 258], ["our data", "TEST", 6, 14], ["cellular cAMP levels", "TEST", 126, 146], ["DiscussionPulmonary mucociliary clearance", "PROBLEM", 147, 188], ["mucus production", "PROBLEM", 230, 246], ["ciliary sweeping and, 3) ASL state", "PROBLEM", 251, 285], ["consistent with", "UNCERTAINTY", 19, 34], ["cAMP levels", "OBSERVATION", 135, 146], ["ciliary", "ANATOMY", 251, 258]]], ["Studies on human bronchial epithelial cells have revealed that a 24-hour exposure with 100 mM of alcohol caused an 8-fold increase in trachea-bronchial mucin gene expression [42].", [["bronchial epithelial cells", "ANATOMY", 17, 43], ["trachea", "ANATOMY", 134, 141], ["alcohol", "CHEMICAL", 97, 104], ["alcohol", "CHEMICAL", 97, 104], ["human", "ORGANISM", 11, 16], ["bronchial epithelial cells", "CELL", 17, 43], ["alcohol", "SIMPLE_CHEMICAL", 97, 104], ["trachea", "MULTI-TISSUE_STRUCTURE", 134, 141], ["mucin", "GENE_OR_GENE_PRODUCT", 152, 157], ["human bronchial epithelial cells", "CELL_TYPE", 11, 43], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["Studies on human bronchial epithelial cells", "TEST", 0, 43], ["an 8-fold increase in trachea", "PROBLEM", 112, 141], ["bronchial", "ANATOMY", 17, 26], ["epithelial cells", "OBSERVATION", 27, 43], ["8-fold", "OBSERVATION_MODIFIER", 115, 121], ["increase", "OBSERVATION_MODIFIER", 122, 130], ["trachea", "ANATOMY", 134, 141], ["bronchial", "ANATOMY", 142, 151]]], ["Interestingly, experiments using bovine bronchial epithelial cells have established that alcohol exposure at 100 mM beyond 6 hours decreases ciliary beating frequency [22], [41].", [["bronchial epithelial cells", "ANATOMY", 40, 66], ["ciliary", "ANATOMY", 141, 148], ["alcohol", "CHEMICAL", 89, 96], ["alcohol", "CHEMICAL", 89, 96], ["bovine", "ORGANISM", 33, 39], ["bronchial epithelial cells", "CELL", 40, 66], ["alcohol", "SIMPLE_CHEMICAL", 89, 96], ["ciliary", "MULTI-TISSUE_STRUCTURE", 141, 148], ["bovine bronchial epithelial cells", "CELL_TYPE", 33, 66], ["bovine", "SPECIES", 33, 39], ["bovine", "SPECIES", 33, 39], ["bovine bronchial epithelial cells", "TREATMENT", 33, 66], ["ciliary beating frequency", "TEST", 141, 166], ["bronchial", "ANATOMY", 40, 49], ["epithelial cells", "OBSERVATION", 50, 66]]], ["A recent publication by Allen-Gipson and colleagues reports that purinergic stimulation of CBF requires A2BAR activation [43].", [["purinergic", "SIMPLE_CHEMICAL", 65, 75], ["CBF", "SIMPLE_CHEMICAL", 91, 94], ["A2BAR", "GENE_OR_GENE_PRODUCT", 104, 109], ["CBF", "PROTEIN", 91, 94], ["A2BAR", "PROTEIN", 104, 109]]], ["Similarly, in rats chronic alcohol administration decreased ciliary beating frequency and enhanced lung colonization of nasally administered S. pneumoniae[44] #.", [["ciliary", "ANATOMY", 60, 67], ["lung", "ANATOMY", 99, 103], ["alcohol", "CHEMICAL", 27, 34], ["alcohol", "CHEMICAL", 27, 34], ["rats", "ORGANISM", 14, 18], ["alcohol", "SIMPLE_CHEMICAL", 27, 34], ["ciliary", "MULTI-TISSUE_STRUCTURE", 60, 67], ["lung", "ORGAN", 99, 103], ["S. pneumoniae", "ORGANISM", 141, 154], ["rats", "SPECIES", 14, 18], ["S. pneumoniae", "SPECIES", 141, 154], ["S. pneumoniae", "SPECIES", 141, 154], ["decreased ciliary beating frequency", "PROBLEM", 50, 85], ["enhanced lung colonization", "PROBLEM", 90, 116], ["S. pneumoniae", "PROBLEM", 141, 154], ["chronic", "OBSERVATION_MODIFIER", 19, 26], ["alcohol", "OBSERVATION", 27, 34], ["ciliary beating", "OBSERVATION", 60, 75], ["lung", "ANATOMY", 99, 103], ["colonization", "OBSERVATION", 104, 116]]], ["Our current results demonstrate that 24-hour ethanol exposure reduces chloride secretion, which consequently alters ASL composition and volume.", [["ethanol", "CHEMICAL", 45, 52], ["chloride", "CHEMICAL", 70, 78], ["ethanol", "CHEMICAL", 45, 52], ["chloride", "CHEMICAL", 70, 78], ["ethanol", "SIMPLE_CHEMICAL", 45, 52], ["chloride", "SIMPLE_CHEMICAL", 70, 78], ["ASL", "SIMPLE_CHEMICAL", 116, 119], ["chloride secretion", "PROBLEM", 70, 88]]], ["Thus, alcohol affects all three mucociliary clearance components.DiscussionPharmacologically, blocking cAMP degradation has the potential of restoring ethanol-suppressed cellular cAMP levels and therefore epithelial functions.", [["mucociliary", "ANATOMY", 32, 43], ["cellular", "ANATOMY", 170, 178], ["epithelial", "ANATOMY", 205, 215], ["alcohol", "CHEMICAL", 6, 13], ["cAMP", "CHEMICAL", 103, 107], ["ethanol", "CHEMICAL", 151, 158], ["cAMP", "CHEMICAL", 179, 183], ["alcohol", "CHEMICAL", 6, 13], ["cAMP", "CHEMICAL", 103, 107], ["ethanol", "CHEMICAL", 151, 158], ["cAMP", "CHEMICAL", 179, 183], ["alcohol", "SIMPLE_CHEMICAL", 6, 13], ["mucociliary", "MULTI-TISSUE_STRUCTURE", 32, 43], ["cAMP", "SIMPLE_CHEMICAL", 103, 107], ["ethanol", "SIMPLE_CHEMICAL", 151, 158], ["cellular", "CELL", 170, 178], ["cAMP", "SIMPLE_CHEMICAL", 179, 183], ["epithelial", "TISSUE", 205, 215], ["blocking cAMP degradation", "PROBLEM", 94, 119], ["restoring ethanol", "TREATMENT", 141, 158], ["cellular cAMP levels", "TEST", 170, 190], ["epithelial functions", "PROBLEM", 205, 225], ["mucociliary clearance", "OBSERVATION", 32, 53], ["epithelial", "ANATOMY_MODIFIER", 205, 215]]], ["Phosphodiesterase inhibitors such as papaverine may improve mucociliary clearance in alcoholics by enhancing airway epithelial ion secretion and ciliary beating.", [["mucociliary", "ANATOMY", 60, 71], ["airway epithelial", "ANATOMY", 109, 126], ["ciliary", "ANATOMY", 145, 152], ["papaverine", "CHEMICAL", 37, 47], ["alcoholics", "DISEASE", 85, 95], ["papaverine", "CHEMICAL", 37, 47], ["Phosphodiesterase inhibitors", "GENE_OR_GENE_PRODUCT", 0, 28], ["papaverine", "SIMPLE_CHEMICAL", 37, 47], ["mucociliary", "ORGAN", 60, 71], ["airway epithelial", "TISSUE", 109, 126], ["ciliary", "MULTI-TISSUE_STRUCTURE", 145, 152], ["Phosphodiesterase inhibitors", "TREATMENT", 0, 28], ["papaverine", "TREATMENT", 37, 47], ["mucociliary clearance", "TEST", 60, 81], ["enhancing airway epithelial ion secretion", "PROBLEM", 99, 140], ["ciliary beating", "PROBLEM", 145, 160], ["airway", "ANATOMY", 109, 115], ["epithelial", "ANATOMY_MODIFIER", 116, 126], ["ion secretion", "OBSERVATION", 127, 140], ["ciliary beating", "OBSERVATION", 145, 160]]], ["Moreover, enhancement of airway epithelial ion secretion alters the composition of ASL.", [["airway epithelial", "ANATOMY", 25, 42], ["airway epithelial", "CELL", 25, 42], ["ASL", "PATHOLOGICAL_FORMATION", 83, 86], ["airway epithelial ion secretion", "PROBLEM", 25, 56], ["enhancement", "OBSERVATION_MODIFIER", 10, 21], ["airway", "ANATOMY", 25, 31], ["epithelial", "ANATOMY_MODIFIER", 32, 42], ["ion secretion", "OBSERVATION", 43, 56]]], ["Our laboratory has reported that extracellular chloride levels affect neutrophil microbial killing ability [45].", [["extracellular", "ANATOMY", 33, 46], ["neutrophil", "ANATOMY", 70, 80], ["chloride", "CHEMICAL", 47, 55], ["chloride", "CHEMICAL", 47, 55], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 46], ["chloride", "SIMPLE_CHEMICAL", 47, 55], ["neutrophil", "CELL", 70, 80], ["extracellular chloride levels", "TEST", 33, 62]]], ["Thus, increasing ASL chloride level by phosphodiesterase inhibitors may also improve phagocytic innate immunity in airways of alcoholics.DiscussionIn summary, ethanol exposure compromises chloride ion secretion which is pivotal to maintain ASL volume and composition.", [["airways", "ANATOMY", 115, 122], ["ASL chloride", "CHEMICAL", 17, 29], ["alcoholics", "DISEASE", 126, 136], ["ethanol", "CHEMICAL", 159, 166], ["chloride", "CHEMICAL", 188, 196], ["chloride", "CHEMICAL", 21, 29], ["ethanol", "CHEMICAL", 159, 166], ["chloride", "CHEMICAL", 188, 196], ["ASL chloride", "SIMPLE_CHEMICAL", 17, 29], ["airways", "MULTI-TISSUE_STRUCTURE", 115, 122], ["ethanol", "SIMPLE_CHEMICAL", 159, 166], ["chloride ion", "SIMPLE_CHEMICAL", 188, 200], ["ASL", "MULTI-TISSUE_STRUCTURE", 240, 243], ["increasing ASL chloride level", "TREATMENT", 6, 35], ["phosphodiesterase inhibitors", "TREATMENT", 39, 67], ["chloride ion secretion", "PROBLEM", 188, 210], ["airways", "ANATOMY", 115, 122]]], ["Such an effect may alter the properties of airway host defenses predisposing ethanol abusers to an increased risk of infection in the lung.", [["airway", "ANATOMY", 43, 49], ["lung", "ANATOMY", 134, 138], ["ethanol", "CHEMICAL", 77, 84], ["infection", "DISEASE", 117, 126], ["ethanol", "CHEMICAL", 77, 84], ["airway", "MULTI-TISSUE_STRUCTURE", 43, 49], ["ethanol", "SIMPLE_CHEMICAL", 77, 84], ["lung", "ORGAN", 134, 138], ["infection in the lung", "PROBLEM", 117, 138], ["airway", "ANATOMY", 43, 49], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["infection", "OBSERVATION", 117, 126], ["lung", "ANATOMY", 134, 138]]], ["Restoration of cellular cAMP level with phosphodiesterase inhibitors could potentially ameliorate mucociliary clearance by improving epithelial ion secretion and hence lung host defense.", [["cellular", "ANATOMY", 15, 23], ["mucociliary", "ANATOMY", 98, 109], ["epithelial ion", "ANATOMY", 133, 147], ["lung", "ANATOMY", 168, 172], ["cAMP", "CHEMICAL", 24, 28], ["cAMP", "CHEMICAL", 24, 28], ["cellular", "CELL", 15, 23], ["cAMP", "SIMPLE_CHEMICAL", 24, 28], ["mucociliary", "ORGAN", 98, 109], ["epithelial", "CELL", 133, 143], ["lung", "ORGAN", 168, 172], ["cellular cAMP level", "TEST", 15, 34], ["phosphodiesterase inhibitors", "TREATMENT", 40, 68], ["mucociliary clearance", "PROBLEM", 98, 119], ["improving epithelial ion secretion", "PROBLEM", 123, 157], ["cellular cAMP", "OBSERVATION", 15, 28], ["epithelial ion secretion", "OBSERVATION", 133, 157], ["lung", "ANATOMY", 168, 172], ["host defense", "OBSERVATION", 173, 185]]]], "PMC7382563": [["Digital health ::: IntroductionAccording to the World Health Organization (WHO), digital health or eHealth (short for \u201celectronic health\u201d) is defined as the cost-effective and secure use of information and communication technologies (ICTs) for health and health-related fields. mHealth (or \u201cmobile health\u201d), as a component of eHealth, involves the provision of health services and information via mobile technologies, such as mobile phones, tablet computers and Personal Digital Assistants (PDAs) [1].", [["communication technologies", "TREATMENT", 206, 232]]], ["As stated during the 71st World Health Assembly in Geneva (2018), mobile wireless technologies have the potential to revolutionize the interaction of citizens with national health services.", [["mobile wireless technologies", "TREATMENT", 66, 94]]], ["The use of simple and easily accessible digital technologies can improve quality and coverage of care, increase the access to health information and services, raise awareness and promote positive changes in health behaviors to prevent the onset of acute and chronic diseases [2\u20134].", [["simple and easily accessible digital technologies", "TREATMENT", 11, 60], ["coverage of care", "TREATMENT", 85, 101], ["positive changes in health behaviors", "PROBLEM", 187, 223], ["acute and chronic diseases", "PROBLEM", 248, 274], ["acute", "OBSERVATION_MODIFIER", 248, 253], ["chronic", "OBSERVATION_MODIFIER", 258, 265], ["diseases", "OBSERVATION", 266, 274]]], ["Several aspects of traditional health care will be changed by this digital health revolution: (a) the point of care will no longer be the clinic or laboratory, but the patient; (b) the approach to care will be based on the individual patient instead of patient groups with similar diseases; (c) the traditional hierarchy between doctor and patient (the former as an authority) based on prescriptions and orders will be replaced by a partnership-like collaboration (doctor as a guide); (d) patients\u2019 data will be determined as personal property, not that of any institution; (e) decisions will be based on the analysis of big data sets in addition to the doctors\u2019 experience; (f) the costs of care will be diminished [5].Digital health in Allergology ::: IntroductionDigital Health may also have a very positive impact on the management of allergic patients.", [["allergic", "DISEASE", 839, 847], ["patient", "ORGANISM", 168, 175], ["patient", "ORGANISM", 234, 241], ["patient", "ORGANISM", 253, 260], ["patient", "ORGANISM", 340, 347], ["patients", "ORGANISM", 489, 497], ["patients", "ORGANISM", 848, 856], ["patient", "SPECIES", 168, 175], ["patient", "SPECIES", 234, 241], ["patient", "SPECIES", 253, 260], ["patient", "SPECIES", 340, 347], ["patients", "SPECIES", 489, 497], ["patients", "SPECIES", 848, 856], ["traditional health care", "TREATMENT", 19, 42], ["similar diseases", "PROBLEM", 273, 289], ["the management", "TREATMENT", 821, 835], ["allergic patients", "PROBLEM", 839, 856], ["allergic", "OBSERVATION", 839, 847]]], ["As stated in a position paper by the American College of Allergy, Asthma and Immunology (ACAAI), allergic patients benefit from telemedicine, for example through a better patient-doctor collaboration, easy access and adherence to allergists\u2019 consultation as well as simplified prescription procedures.", [["Allergy", "DISEASE", 57, 64], ["Asthma", "DISEASE", 66, 72], ["allergic", "DISEASE", 97, 105], ["patients", "ORGANISM", 106, 114], ["patient", "ORGANISM", 171, 178], ["patients", "SPECIES", 106, 114], ["patient", "SPECIES", 171, 178], ["Asthma", "PROBLEM", 66, 72], ["allergic", "PROBLEM", 97, 105], ["telemedicine", "TREATMENT", 128, 140]]], ["This positive impact is especially important for patients living in rural or remote areas.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57]]], ["However, the authors also point out the need for improved regulations, certification programs, high attention to data protection, and the development of adequate reimbursement systems [6].", [["certification programs", "TREATMENT", 71, 93], ["data protection", "TREATMENT", 113, 128]]], ["The study group examined over 130 allergy-related apps and reported on the role of mHealth technologies in the area of allergic rhinoconjunctivitis, asthma, atopic dermatitis, chronic urticaria as well as food allergies, anaphylaxis, drug, and venom allergies [7].Apps for allergic rhinitis ::: IntroductionAlthough many apps are dedicated to the management and monitoring of allergic rhinitis, only few have been used in studies published in peer-reviewed international journals [7, 8].", [["venom", "ANATOMY", 244, 249], ["allergy", "DISEASE", 34, 41], ["allergic rhinoconjunctivitis", "DISEASE", 119, 147], ["asthma", "DISEASE", 149, 155], ["atopic dermatitis", "DISEASE", 157, 174], ["chronic urticaria", "DISEASE", 176, 193], ["food allergies", "DISEASE", 205, 219], ["anaphylaxis", "DISEASE", 221, 232], ["venom allergies", "DISEASE", 244, 259], ["allergic rhinitis", "DISEASE", 273, 290], ["allergic rhinitis", "DISEASE", 376, 393], ["venom", "ORGANISM_SUBSTANCE", 244, 249], ["The study", "TEST", 0, 9], ["mHealth technologies", "TREATMENT", 83, 103], ["allergic rhinoconjunctivitis", "PROBLEM", 119, 147], ["asthma", "PROBLEM", 149, 155], ["atopic dermatitis", "PROBLEM", 157, 174], ["chronic urticaria", "PROBLEM", 176, 193], ["food allergies", "PROBLEM", 205, 219], ["anaphylaxis", "PROBLEM", 221, 232], ["venom allergies", "PROBLEM", 244, 259], ["allergic rhinitis", "PROBLEM", 273, 290], ["the management", "TREATMENT", 343, 357], ["allergic rhinitis", "PROBLEM", 376, 393], ["allergic rhinoconjunctivitis", "OBSERVATION", 119, 147], ["asthma", "OBSERVATION", 149, 155], ["atopic dermatitis", "OBSERVATION", 157, 174], ["chronic", "OBSERVATION_MODIFIER", 176, 183], ["urticaria", "OBSERVATION", 184, 193], ["allergic rhinitis", "OBSERVATION", 273, 290], ["allergic rhinitis", "OBSERVATION", 376, 393]]], ["A very large collaborative network focused on rhinitis and its treatment is accumulating evidence through the worldwide use of MASK-Air (MASK standing for Mobile Airways Sentinel Network).", [["rhinitis", "DISEASE", 46, 54], ["A very large collaborative network", "PROBLEM", 0, 34], ["rhinitis", "PROBLEM", 46, 54], ["its treatment", "TREATMENT", 59, 72], ["MASK", "TREATMENT", 127, 131], ["Air (MASK standing", "TREATMENT", 132, 150], ["very", "OBSERVATION_MODIFIER", 2, 6], ["large", "OBSERVATION_MODIFIER", 7, 12], ["collaborative", "OBSERVATION", 13, 26], ["rhinitis", "OBSERVATION", 46, 54]]], ["This electronic clinical diary assesses nasal, ocular and lung symptoms, as well as work impairment and global health via a visual analogue scale (VAS) [9].", [["nasal", "ANATOMY", 40, 45], ["ocular", "ANATOMY", 47, 53], ["lung", "ANATOMY", 58, 62], ["nasal, ocular and lung symptoms", "DISEASE", 40, 71], ["nasal", "MULTI-TISSUE_STRUCTURE", 40, 45], ["lung", "ORGAN", 58, 62], ["nasal, ocular and lung symptoms", "PROBLEM", 40, 71], ["ocular", "ANATOMY", 47, 53], ["lung", "ANATOMY", 58, 62], ["symptoms", "OBSERVATION", 63, 71]]], ["MASK-Air has already accumulated real-life data from a large number of patients worldwide, whose analysis has led to innovative knowledge on productivity at work, innovative patterns of treatment, and new allergic disease phenotypes [10].", [["allergic disease", "DISEASE", 205, 221], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["treatment", "TREATMENT", 186, 195], ["new allergic disease phenotypes", "PROBLEM", 201, 232], ["Air", "OBSERVATION", 5, 8], ["large", "OBSERVATION_MODIFIER", 55, 60], ["allergic disease", "OBSERVATION", 205, 221]]], ["A model of individualized prediction of allergic rhinitis symptoms, named Patient\u2019s Hay-fever Diary (PHD), has been developed in Austria [11].", [["allergic rhinitis", "DISEASE", 40, 57], ["fever", "DISEASE", 88, 93], ["Patient", "SPECIES", 74, 81], ["allergic rhinitis symptoms", "PROBLEM", 40, 66], ["fever", "PROBLEM", 88, 93], ["allergic rhinitis", "OBSERVATION", 40, 57]]], ["By combining input from the patients (symptoms and medications) along with environmental information, an improved management of the disease is pursued through symptom forecasting [11].Apps for allergic rhinitis ::: IntroductionIn this review, we summarize the clinical and research experience that our group has gathered over the last decade with the platform \u201cAllergyMonitor\u201d, an eDiary for allergic rhinitis and allergen immunotherapy whose first version was developed in Rome, Italy, in 2009.", [["allergic rhinitis", "DISEASE", 193, 210], ["allergic rhinitis", "DISEASE", 392, 409], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["symptoms", "PROBLEM", 38, 46], ["medications", "TREATMENT", 51, 62], ["the disease", "PROBLEM", 128, 139], ["allergic rhinitis", "PROBLEM", 193, 210], ["allergic rhinitis", "PROBLEM", 392, 409], ["allergen immunotherapy", "TREATMENT", 414, 436], ["disease", "OBSERVATION", 132, 139], ["allergic rhinitis", "OBSERVATION", 193, 210], ["allergic rhinitis", "OBSERVATION", 392, 409]]], ["In the following sections, we shall illustrate the structure and content of the digital platform, show exemplary reports of clinical cases, an illustration of the scientific studies based on AllergyMonitor, the perspective of studies in progress and the implications for allergy practice in real-life settings.AllergyMonitor: targets, structure, functions ::: AllergyMonitorAllergymonitor (TPS software production, Rome, Italy) is an online service developed in 2009 with the aim of enabling the recording of clinical symptoms, drug consumption and adherence to allergen-specific sublingual immunotherapy (SLIT) as well as monitoring efficacy of SLIT or subcutaneous immunotherapy (SCIT) by patients with allergic rhino-conjunctivitis and/or asthma.", [["sections", "ANATOMY", 17, 25], ["sublingual", "ANATOMY", 580, 590], ["subcutaneous", "ANATOMY", 654, 666], ["allergy", "DISEASE", 271, 278], ["AllergyMonitorAllergymonitor", "CHEMICAL", 360, 388], ["allergic rhino-conjunctivitis", "DISEASE", 705, 734], ["asthma", "DISEASE", 742, 748], ["SLIT", "SIMPLE_CHEMICAL", 646, 650], ["patients", "ORGANISM", 691, 699], ["patients", "SPECIES", 691, 699], ["the digital platform", "TEST", 76, 96], ["the scientific studies", "TEST", 159, 181], ["allergy", "PROBLEM", 271, 278], ["clinical symptoms", "PROBLEM", 509, 526], ["allergen", "TREATMENT", 562, 570], ["specific sublingual immunotherapy (SLIT)", "TREATMENT", 571, 611], ["SLIT", "TREATMENT", 646, 650], ["subcutaneous immunotherapy (SCIT", "TREATMENT", 654, 686], ["allergic rhino", "PROBLEM", 705, 719], ["conjunctivitis", "PROBLEM", 720, 734], ["asthma", "PROBLEM", 742, 748], ["conjunctivitis", "OBSERVATION", 720, 734], ["asthma", "OBSERVATION", 742, 748]]], ["The system, available to everyone and straightforward to use, consists of two parts: a patient app (front end) and a website for the attending doctor (back-office), and the whole system is free during the actual Covid-19 pandemic.", [["patient", "ORGANISM", 87, 94], ["patient", "SPECIES", 87, 94], ["pandemic", "PROBLEM", 221, 229]]], ["The app, that patients can freely download form Google Play and Apple Store, is available in different languages.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["On a daily basis, the user is requested to fill a short and visually enhanced questionnaire about his/her symptoms of the eyes, nose and lungs, as well as a visual analogue scale on his/her general allergic condition.", [["eyes", "ANATOMY", 122, 126], ["nose", "ANATOMY", 128, 132], ["lungs", "ANATOMY", 137, 142], ["allergic condition", "DISEASE", 198, 216], ["eyes", "ORGAN", 122, 126], ["nose", "ORGANISM_SUBDIVISION", 128, 132], ["lungs", "ORGAN", 137, 142], ["her symptoms of the eyes, nose and lungs", "PROBLEM", 102, 142], ["a visual analogue scale", "TEST", 155, 178], ["her general allergic condition", "PROBLEM", 186, 216], ["eyes", "ANATOMY", 122, 126], ["nose", "ANATOMY", 128, 132], ["lungs", "ANATOMY", 137, 142]]], ["Once activated by the doctor via the back-office, the app user is also enabled to record his/her daily medication intake, adherence to sublingual immunotherapy and potentially occurring side effects.", [["sublingual immunotherapy", "TREATMENT", 135, 159], ["side effects", "PROBLEM", 186, 198]]], ["In order to provide a summary and feedback to the user, all entered data can be easily accessed within the app in summarized graphs showing the evolution of symptoms over time (Fig. 1).AllergyMonitor: targets, structure, functions ::: AllergyMonitorVia his/her back-office, the doctor is able to access a breakdown of all recorded data as well as individual patient reports accessible as different symptom (and medication) scores (Rhinoconjunctivitis Total Symptom Score (RTSS), average adjusted symptom score (AdSS), rescue medication score (RMS), average combined score (ACS)) and matched to local pollen monitoring data, which is retrieved using validated methodologies.", [["patient", "ORGANISM", 358, 365], ["patient", "SPECIES", 358, 365], ["symptoms", "PROBLEM", 157, 165], ["different symptom (and medication) scores (Rhinoconjunctivitis", "PROBLEM", 388, 450], ["Total Symptom Score", "TEST", 451, 470], ["RTSS", "TEST", 472, 476], ["average adjusted symptom score", "PROBLEM", 479, 509], ["local pollen monitoring data", "TEST", 594, 622]]], ["More specifically: pollen is collected in pollen traps, analyzed by aerobiologists, and this data is incorporated in AllergyMonitor.", [["pollen", "ANATOMY", 19, 25], ["pollen", "ORGAN", 19, 25], ["pollen", "OBSERVATION", 19, 25]]], ["A messaging system between doctor and patient based on e-mail, chat or SMS (short message service) facilitates direct communication.", [["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45]]], ["An automatic alert system points out missed days of recording to both, front end and back-office users.", [["An automatic alert system", "PROBLEM", 0, 25], ["back", "ANATOMY", 85, 89]]], ["Keeping in line with an approach of blended care, the back-office enables the doctor to configure each patient\u2019s front end individually by entering for example symptomatic drugs or adding an immunotherapy intake and side effects monitoring (Fig. 2).Clinical report ::: AllergyMonitorOn the basis of data registered via the front end (app), the software generates a printable report for the app user (Fig. 3).", [["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110], ["an approach of blended care", "TREATMENT", 21, 48], ["symptomatic drugs", "TREATMENT", 160, 177], ["an immunotherapy intake", "TREATMENT", 188, 211], ["side effects monitoring", "TEST", 216, 239]]], ["The report is divided into several sections:Doctor\u2019s prescription \u2013 recommended monitoring period, pharmacotherapy, allergen-specific immunotherapy;Symptoms vs pollen counts - Graphs illustrating the time-trends of selected symptom severity scores and pollen counts.Medication diary \u2013 A table illustrating the intake of drugs and/or SLIT during the monitoring period.Statistical summary \u2013 A series of indexes summarizing the patient\u2019s adherence to symptom recording, as well as drug and SLIT intake.Space for the doctor\u2019s comments \u2013 marked empty space for comments and notes from the treating physician.Clinical report ::: AllergyMonitorThe report produced by AllergyMonitor can be printed and given by the patient to the physician of his/her choice, but also directly sent by mail from the app to the doctor.", [["sections", "ANATOMY", 35, 43], ["pollen", "ANATOMY", 252, 258], ["patient", "ORGANISM", 425, 432], ["patient", "ORGANISM", 707, 714], ["patient", "SPECIES", 425, 432], ["patient", "SPECIES", 707, 714], ["pharmacotherapy", "TREATMENT", 99, 114], ["allergen", "TREATMENT", 116, 124], ["specific immunotherapy", "TREATMENT", 125, 147], ["Symptoms", "PROBLEM", 148, 156], ["pollen counts", "TEST", 160, 173], ["selected symptom severity scores", "PROBLEM", 215, 247], ["pollen counts", "TEST", 252, 265], ["drugs", "TREATMENT", 320, 325], ["SLIT", "TREATMENT", 333, 337], ["symptom recording", "TEST", 448, 465]]], ["The doctor can then base further clinical examinations and diagnostic or therapeutic prescriptions also on the data prospectively acquired by the patient during the monitoring period.", [["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 146, 153], ["clinical examinations", "TEST", 33, 54]]], ["The volume, reliability and precision of the information provided by the eDiary may represent a valuable and time-efficient add-on to the information retrospectively collected during an often short interview, frequently done months after the relevant clinical episodes and possibly influenced by a strong recall bias.Scientific studies ::: AllergyMonitorSince 2010, our group has used AllergyMonitor in a series of clinical studies on allergic rhinitis.", [["allergic rhinitis", "DISEASE", 435, 452], ["Scientific studies", "TEST", 317, 335], ["clinical studies", "TEST", 415, 431], ["allergic rhinitis", "PROBLEM", 435, 452], ["volume", "OBSERVATION_MODIFIER", 4, 10], ["allergic rhinitis", "OBSERVATION", 435, 452]]], ["The results of these have illustrated how the system can be deployed to support the etiological diagnosis, symptom prediction, adherence to therapy, and decision on AIT prescription for patients presenting with seasonal allergic diseases.Etiological diagnosis of seasonal allergic rhinitis (SAR) \u2013 The analysis of the allergic rhinitis symptom severity scores during pollen exposure can be used to evaluate the clinical relevance of a patient\u2019s sensitization to a specific pollen.", [["pollen", "ANATOMY", 473, 479], ["allergic diseases", "DISEASE", 220, 237], ["allergic rhinitis", "DISEASE", 272, 289], ["allergic rhinitis", "DISEASE", 318, 335], ["patients", "ORGANISM", 186, 194], ["patient", "ORGANISM", 435, 442], ["pollen", "ORGAN", 473, 479], ["patients", "SPECIES", 186, 194], ["patient", "SPECIES", 435, 442], ["therapy", "TREATMENT", 140, 147], ["AIT prescription", "TREATMENT", 165, 181], ["seasonal allergic diseases", "PROBLEM", 211, 237], ["seasonal allergic rhinitis", "PROBLEM", 263, 289], ["The analysis", "TEST", 298, 310], ["the allergic rhinitis symptom severity scores", "PROBLEM", 314, 359], ["a patient\u2019s sensitization", "TREATMENT", 433, 458], ["allergic diseases", "OBSERVATION", 220, 237], ["seasonal", "OBSERVATION_MODIFIER", 263, 271], ["allergic rhinitis", "OBSERVATION", 272, 289], ["allergic", "OBSERVATION_MODIFIER", 318, 326], ["rhinitis", "OBSERVATION", 327, 335]]], ["This statement has been exemplified by describing two patients suffering from SAR with similar diagnostic challenges [12].", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62]]], ["In both patients, no clear-cut decision could be reached based on a traditional allergological evaluation (clinical history, SPT,) plus molecular IgE assessment against relevant genuine and cross-reacting allergenic molecules (Ole e 1, Phl p1, Phl p 5).", [["patients", "ORGANISM", 8, 16], ["Ole e 1", "GENE_OR_GENE_PRODUCT", 227, 234], ["Phl p1", "GENE_OR_GENE_PRODUCT", 236, 242], ["IgE", "PROTEIN", 146, 149], ["cross-reacting allergenic molecules", "PROTEIN", 190, 225], ["Ole e 1", "PROTEIN", 227, 234], ["Phl p1", "PROTEIN", 236, 242], ["Phl p 5", "PROTEIN", 244, 251], ["patients", "SPECIES", 8, 16], ["a traditional allergological evaluation", "TEST", 66, 105], ["molecular IgE assessment", "TEST", 136, 160], ["relevant genuine and cross-reacting allergenic molecules", "PROBLEM", 169, 225]]], ["However, the prospective and consistent recording of nasal and conjunctival symptoms during the pollination period contributed fundamentally to the identification of the trigger-pollen (olive for patient one (Fig. 4a), grass pollen for patient two (Fig. 4b)).", [["nasal", "ANATOMY", 53, 58], ["conjunctival", "ANATOMY", 63, 75], ["nasal", "ORGANISM_SUBDIVISION", 53, 58], ["conjunctival", "ORGAN", 63, 75], ["olive", "ORGANISM_SUBDIVISION", 186, 191], ["patient", "ORGANISM", 196, 203], ["patient", "ORGANISM", 236, 243], ["patient", "SPECIES", 196, 203], ["patient", "SPECIES", 236, 243], ["nasal and conjunctival symptoms", "PROBLEM", 53, 84], ["nasal", "ANATOMY", 53, 58], ["conjunctival", "ANATOMY", 63, 75]]], ["To our knowledge, this was the first report of an etiological diagnosis of pollen allergy substantiated by a smartphone app.", [["pollen", "ANATOMY", 75, 81], ["pollen allergy", "DISEASE", 75, 89], ["pollen", "ORGAN", 75, 81], ["pollen allergy", "PROBLEM", 75, 89], ["pollen allergy", "OBSERVATION", 75, 89]]], ["The comparison of symptom severity scores (RTSS in this case) with pollen concentration data may therefore guide the doctor in the choice of the correct immunotherapy composition [12].Short-term prediction of allergic symptoms \u2013 We used AllergyMonitor to test the efficiency of a model to forecast symptoms of pollen-related SAR at individual patient level.", [["pollen", "ANATOMY", 67, 73], ["allergic symptoms", "DISEASE", 209, 226], ["pollen", "ORGANISM_SUBDIVISION", 310, 316], ["patient", "ORGANISM", 343, 350], ["patient", "SPECIES", 343, 350], ["symptom severity scores", "PROBLEM", 18, 41], ["pollen concentration data", "TEST", 67, 92], ["the correct immunotherapy composition", "TREATMENT", 141, 178], ["allergic symptoms", "PROBLEM", 209, 226], ["AllergyMonitor", "TEST", 237, 251], ["forecast symptoms", "PROBLEM", 289, 306], ["pollen", "PROBLEM", 310, 316], ["allergic", "OBSERVATION", 209, 217]]], ["We analyzed prospectively recorded symptom and medication data (April to June 2010\u20132011) of 21 Italian children affected by allergic rhinoconjunctivitis.", [["allergic rhinoconjunctivitis", "DISEASE", 124, 152], ["children", "ORGANISM", 103, 111], ["children", "SPECIES", 103, 111], ["allergic rhinoconjunctivitis", "PROBLEM", 124, 152], ["allergic rhinoconjunctivitis", "OBSERVATION", 124, 152]]], ["Using the average combined score (ACS) of symptoms and medication, we found that the short-term forecast of seasonal allergic rhinitis symptoms is possible even in highly poly-sensitized patients in geographic areas with complex pollen exposure.", [["pollen", "ANATOMY", 229, 235], ["ACS", "DISEASE", 34, 37], ["allergic rhinitis", "DISEASE", 117, 134], ["patients", "ORGANISM", 187, 195], ["pollen", "ORGANISM_SUBDIVISION", 229, 235], ["patients", "SPECIES", 187, 195], ["symptoms", "PROBLEM", 42, 50], ["medication", "TREATMENT", 55, 65], ["seasonal allergic rhinitis symptoms", "PROBLEM", 108, 143], ["complex pollen exposure", "PROBLEM", 221, 244], ["allergic rhinitis", "OBSERVATION", 117, 134], ["complex", "OBSERVATION_MODIFIER", 221, 228], ["pollen exposure", "OBSERVATION", 229, 244]]], ["We further concluded that predictive models must be tailored to the individual patient\u2019s allergic susceptibility.", [["allergic", "DISEASE", 89, 97], ["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["predictive models", "PROBLEM", 26, 43], ["allergic susceptibility", "PROBLEM", 89, 112]]], ["This may lead to a better use of anti-symptomatic drugs, especially considering their targeted intake before the expected raise of symptoms [13].Adherence to eDiary compilation - Several e-Diaries are available for pollen allergies in European countries, some of them also having been used in trials or observational studies [10, 14\u201318].", [["pollen allergies", "DISEASE", 215, 231], ["anti-symptomatic drugs", "TREATMENT", 33, 55], ["symptoms", "PROBLEM", 131, 139], ["eDiary compilation", "TREATMENT", 158, 176], ["pollen allergies", "PROBLEM", 215, 231], ["observational studies", "TEST", 303, 324]]], ["In most of the study settings, the respective app was directly downloaded by patients, with no or only occasional intervention of the allergist [18\u201320].", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["the study settings", "TEST", 11, 29]]], ["Although the use of mobile technologies permits an unprecedentedly easy collection of big data sets independent from geographic location and social differences, some observational studies were characterized by a poor adherence of their users to data recording, sometimes even dropping below 10% after only 2 weeks [10, 19].", [["mobile technologies", "TREATMENT", 20, 39], ["some observational studies", "TEST", 161, 187]]], ["As the role of the attending physician has been shown to be of great importance for medication-compliance in patients [21], we wondered whether this also holds true for the adherence to digital symptom diaries.", [["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["digital symptom diaries", "PROBLEM", 186, 209]]], ["In an Italian bi-center study involving 101 children and 93 adults, patients were instructed very clearly on the use of AllergyMonitor and received personal reminders via phone in addition to automated alert messages in case of missed recording [22].", [["children", "ORGANISM", 44, 52], ["adults", "ORGANISM", 60, 66], ["patients", "ORGANISM", 68, 76], ["children", "SPECIES", 44, 52], ["patients", "SPECIES", 68, 76]]], ["Interestingly, the individual adherence level in week 2 and 3 was able to predict a patient\u2019s overall adherence to monitoring with enough confidence (Spearman\u2019s p -0.55, P < .001 in both centers).", [["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["Spearman\u2019s", "TEST", 150, 160], ["p", "TEST", 161, 162]]], ["We concluded that adherence to daily recording of an eDiary, provided that it is prescribed and eagerly motivated by a physician in a blended care setting, is very high.Adherence to drug therapy \u2013 As an important cause for treatment failure in asthma and rhinitis is suboptimal adherence to local corticosteroids [23], we hypothesized that the use of a monitoring app with a reminder system might be able to optimize also medication-compliance and by this the clinical management of respiratory allergic diseases.", [["respiratory", "ANATOMY", 483, 494], ["asthma", "DISEASE", 244, 250], ["rhinitis", "DISEASE", 255, 263], ["respiratory allergic diseases", "DISEASE", 483, 512], ["corticosteroids", "CHEMICAL", 297, 312], ["drug therapy", "TREATMENT", 182, 194], ["treatment failure", "PROBLEM", 223, 240], ["asthma", "PROBLEM", 244, 250], ["rhinitis", "PROBLEM", 255, 263], ["local corticosteroids", "TREATMENT", 291, 312], ["a monitoring app", "TEST", 351, 367], ["a reminder system", "TREATMENT", 373, 390], ["respiratory allergic diseases", "PROBLEM", 483, 512], ["drug therapy", "OBSERVATION", 182, 194], ["important cause for", "UNCERTAINTY", 203, 222], ["asthma", "OBSERVATION", 244, 250], ["rhinitis", "OBSERVATION", 255, 263], ["respiratory", "ANATOMY", 483, 494], ["allergic diseases", "OBSERVATION", 495, 512]]], ["The need to take medications regularly to obtain maximum effect even when asymptomatic is a particular problem for chronic diseases with episodic symptom occurrence, such as seasonal allergic rhinitis (hay fever).", [["allergic rhinitis", "DISEASE", 183, 200], ["hay fever", "DISEASE", 202, 211], ["medications", "TREATMENT", 17, 28], ["asymptomatic", "PROBLEM", 74, 86], ["chronic diseases", "PROBLEM", 115, 131], ["episodic symptom occurrence", "PROBLEM", 137, 164], ["seasonal allergic rhinitis", "PROBLEM", 174, 200], ["fever", "PROBLEM", 206, 211], ["allergic rhinitis", "OBSERVATION", 183, 200]]], ["The reasons for suboptimal adherence are complex, but the key to successful management is good education both in the rationale for treatment and inhaler technique.", [["treatment and inhaler technique", "TREATMENT", 131, 162]]], ["Telemedicine has found its way into most corners of health care, but there is relatively little published on its potential role in allergic disease.", [["allergic disease", "DISEASE", 131, 147], ["allergic disease", "PROBLEM", 131, 147], ["allergic disease", "OBSERVATION", 131, 147]]], ["Therefore, we have undertaken an original study looking at the value of telemonitoring on adherence to daily treatment with topical corticosteroids in children with severe hay fever [15].", [["hay fever", "DISEASE", 172, 181], ["children", "ORGANISM", 151, 159], ["children", "SPECIES", 151, 159], ["an original study", "TEST", 30, 47], ["daily treatment", "TREATMENT", 103, 118], ["topical corticosteroids", "TREATMENT", 124, 147], ["severe hay fever", "PROBLEM", 165, 181]]], ["The study demonstrated an improvement in both adherence to daily drug medication and disease knowledge.", [["The study", "TEST", 0, 9], ["daily drug medication", "TREATMENT", 59, 80], ["disease knowledge", "PROBLEM", 85, 102], ["improvement", "OBSERVATION_MODIFIER", 26, 37], ["both", "OBSERVATION_MODIFIER", 41, 45], ["adherence", "OBSERVATION_MODIFIER", 46, 55]]], ["No improvement was seen in disease control, but pollen counts were low during the study period (Fig. 6).Adherence to Sublingual Immunotherapy \u2013 The only disease-modifying treatment option for allergic rhinoconjunctivitis and asthma so far is an allergen-specific immunotherapy [24], which is mostly administered as repeated subcutaneous injections or the daily intake of sublingual tablets/drops.", [["pollen", "ANATOMY", 48, 54], ["subcutaneous", "ANATOMY", 324, 336], ["sublingual", "ANATOMY", 371, 381], ["allergic rhinoconjunctivitis", "DISEASE", 192, 220], ["asthma", "DISEASE", 225, 231], ["disease control", "TREATMENT", 27, 42], ["pollen counts", "TEST", 48, 61], ["Sublingual Immunotherapy", "TREATMENT", 117, 141], ["The only disease", "PROBLEM", 144, 160], ["modifying treatment option", "TREATMENT", 161, 187], ["allergic rhinoconjunctivitis", "PROBLEM", 192, 220], ["asthma", "PROBLEM", 225, 231], ["an allergen-specific immunotherapy", "TREATMENT", 242, 276], ["repeated subcutaneous injections", "TREATMENT", 315, 347], ["sublingual tablets/drops", "TREATMENT", 371, 395], ["improvement", "OBSERVATION_MODIFIER", 3, 14], ["disease", "OBSERVATION", 27, 34], ["disease", "OBSERVATION", 153, 160]]], ["One of the most relevant problems linked to the long-term daily administration of sublingual immunotherapy (SLIT) is poor compliance and a high dropout rate.", [["sublingual", "ANATOMY", 82, 92], ["sublingual immunotherapy", "TREATMENT", 82, 106], ["a high dropout rate", "PROBLEM", 137, 156]]], ["Only 50 and 20% of the patients starting the treatment with SLIT continue its daily administration in the second and third year of treatment, respectively [25].", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["the treatment", "TREATMENT", 41, 54], ["SLIT", "TREATMENT", 60, 64], ["treatment", "TREATMENT", 131, 140]]], ["When comparing long-term adherence of a small group of patients undergoing SLIT with usual care support versus a group of patients receiving SLIT plus digital adherence monitoring via AllergyMonitor, we observed a clear reduction in the drop-out rate in the second year of therapy among 28 patients with digital support [26].", [["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 122, 130], ["patients", "ORGANISM", 290, 298], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 122, 130], ["patients", "SPECIES", 290, 298], ["usual care support", "TREATMENT", 85, 103], ["SLIT plus digital adherence monitoring", "TREATMENT", 141, 179], ["a clear reduction", "PROBLEM", 212, 229], ["therapy", "TREATMENT", 273, 280], ["digital support", "TREATMENT", 304, 319], ["small", "OBSERVATION_MODIFIER", 40, 45], ["reduction", "OBSERVATION_MODIFIER", 220, 229]]], ["(Fig. 7)Comparison of disease severity scores \u2013 To assess the impact of different methodological approaches on the interpretation of digitally and prospectively collected data, we used several different symptom severity scores to analyze the data sets of two pediatric cohorts.", [["disease severity scores", "PROBLEM", 22, 45], ["several different symptom severity scores", "PROBLEM", 185, 226]]], ["In brief, 76 children with SAR from Ascoli Piceno (Italy) and 29 grass pollen allergic participants from Berlin (Germany), were asked to monitor their daily symptoms via the app during a period of 2 months within the local grass pollen season.", [["pollen allergic", "DISEASE", 71, 86], ["children", "ORGANISM", 13, 21], ["children", "SPECIES", 13, 21], ["participants", "SPECIES", 87, 99], ["their daily symptoms", "PROBLEM", 145, 165]]], ["We then prospectively compared six different severity scores for allergic rhinitis (AR) against pollen counts at both population and individual level (Fig. 8) [14], namely the Rhinoconjunctivitis Total Symptom Score (RTSS), the Adjusted Rhinoconjunctivitis Total Symptom Score (method: last observation carried forward) adjRTSS [LOCF], Adjusted Rhinoconjunctivitis Total Symptom Score (method: worst case) adjRTSS [WC] (rhinoconjunctivitis total symptom score [worst case]), the Rhino-conjunctivitis Allergy-Control-SCORE (RC-ACS\u00a9) the average combined score (ACS), and the average adjusted symptom score (AdSS).", [["pollen", "ANATOMY", 96, 102], ["allergic rhinitis", "DISEASE", 65, 82], ["rhinoconjunctivitis", "DISEASE", 420, 439], ["conjunctivitis", "DISEASE", 485, 499], ["ACS", "DISEASE", 560, 563], ["allergic rhinitis", "PROBLEM", 65, 82], ["AR", "PROBLEM", 84, 86], ["pollen counts", "TEST", 96, 109], ["the Rhinoconjunctivitis", "PROBLEM", 172, 195], ["Total Symptom Score", "TEST", 196, 215], ["RTSS", "TEST", 217, 221], ["the Adjusted Rhinoconjunctivitis", "PROBLEM", 224, 256], ["Adjusted Rhinoconjunctivitis", "PROBLEM", 336, 364], ["total symptom score", "TEST", 440, 459], ["the Rhino-conjunctivitis Allergy", "PROBLEM", 475, 507], ["allergic rhinitis", "OBSERVATION", 65, 82], ["conjunctivitis", "OBSERVATION", 485, 499]]], ["We found that the disease severity scores for SAR tend to provide similar results at population level but often produce heterogeneous slopes in individual patients.", [["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["the disease severity scores", "PROBLEM", 14, 41], ["disease", "OBSERVATION", 18, 25], ["heterogeneous", "OBSERVATION_MODIFIER", 120, 133], ["slopes", "OBSERVATION_MODIFIER", 134, 140]]], ["On this basis, we concluded that the choice of the disease severity score might have only a low impact on the outcome of a large clinical trial, but it may be crucial for the management of individual patients [14].Clinical routine and future perspectives ::: AllergyMonitorThe use of AllergyMonitor in routine clinical practice started in 2009 in the Pediatric Allergy Unit of the Pertini Hospital in Rome.", [["Allergy", "DISEASE", 259, 266], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 200, 208], ["the disease severity score", "PROBLEM", 47, 73], ["Allergy", "PROBLEM", 259, 266], ["AllergyMonitor", "TREATMENT", 284, 298]]], ["During 10 years of activity, about 9500 patients seeking care for allergic rhinitis in this hospital have used the eDiary.", [["allergic rhinitis", "DISEASE", 66, 83], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["allergic rhinitis", "PROBLEM", 66, 83]]], ["On the other hand, about 130 allergists and pediatricians in 10 countries have prescribed the use of the app among their patients for clinical and/or research purposes.", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["research purposes", "TEST", 150, 167]]], ["Individual user feedback from doctors shows, that the most appreciated benefits of prospectively collected clinical data plus pollen counts is the increased diagnostic precision especially for poly-sensitized patients but also the improved adherence to SLIT (Fig. 9).", [["pollen", "ANATOMY", 126, 132], ["poly", "CHEMICAL", 193, 197], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 209, 217], ["pollen counts", "TEST", 126, 139]]], ["As one of the main benefits of AllergyMonitor is the interaction and feedback from the doctor, the initiative to introduce AllergyMonitor into the patients\u2019routine comes predominantly from the medical teams.", [["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155]]]], "PMC7439087": [["IntroductionInfectious diseases are the demons with which human beings have been fighting since the beginning of human history.", [["IntroductionInfectious diseases", "DISEASE", 0, 31], ["human", "ORGANISM", 58, 63], ["human", "ORGANISM", 113, 118], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 113, 118], ["IntroductionInfectious diseases", "PROBLEM", 0, 31]]], ["Several epidemics have occurred in the history of China.", [["Several epidemics", "PROBLEM", 0, 17], ["epidemics", "OBSERVATION", 8, 17]]], ["But, fortunately, no large numbers of casualties have occurred, due to the prevalence of Traditional Chinese Medicine (TCM).", [["Traditional Chinese Medicine", "TREATMENT", 89, 117], ["large", "OBSERVATION_MODIFIER", 21, 26], ["numbers", "OBSERVATION_MODIFIER", 27, 34]]], ["During the epidemic period of severe acute respiratory syndrome (SARS), TCM played a vital role in fighting the epidemic (Luo et al., 2019), and the Chinese medical community accumulated valuable TCM experience (Li et al. 2020; Liu and Wang, 2004).", [["acute respiratory syndrome", "DISEASE", 37, 63], ["SARS", "DISEASE", 65, 69], ["TCM", "CHEMICAL", 72, 75], ["severe acute respiratory syndrome", "PROBLEM", 30, 63], ["SARS", "PROBLEM", 65, 69], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["respiratory syndrome", "OBSERVATION", 43, 63]]], ["What is the essence of infectious diseases?", [["infectious diseases", "DISEASE", 23, 42], ["infectious diseases", "PROBLEM", 23, 42], ["infectious", "OBSERVATION", 23, 33]]], ["Is it possible to cure the disease as long as the virus is eliminated?", [["the disease", "PROBLEM", 23, 34], ["the virus", "PROBLEM", 46, 55], ["disease", "OBSERVATION", 27, 34]]], ["TCM believes that the essence of infectious diseases is not viruses, but \u201cgrumpiness.\u201d", [["infectious diseases", "DISEASE", 33, 52], ["grumpiness", "DISEASE", 74, 84], ["infectious diseases", "PROBLEM", 33, 52], ["viruses", "PROBLEM", 60, 67], ["infectious", "OBSERVATION", 33, 43], ["not", "UNCERTAINTY", 56, 59], ["viruses", "OBSERVATION", 60, 67]]], ["\u201cGrumpiness\u201d is a kind of evil that appears at the same time as abnormal weather.", [["abnormal weather", "PROBLEM", 64, 80]]], ["\u201cGrumpiness\u201d has the characteristics of strong pathogenicity, strong infectivity, entry route to human body through the mouth and nose, and specific lesion location.", [["body", "ANATOMY", 103, 107], ["mouth", "ANATOMY", 120, 125], ["nose", "ANATOMY", 130, 134], ["lesion", "ANATOMY", 149, 155], ["human", "ORGANISM", 97, 102], ["body", "ORGANISM_SUBDIVISION", 103, 107], ["mouth", "ORGANISM_SUBDIVISION", 120, 125], ["nose", "ORGANISM_SUBDIVISION", 130, 134], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["strong pathogenicity", "PROBLEM", 40, 60], ["strong infectivity", "PROBLEM", 62, 80], ["strong", "OBSERVATION_MODIFIER", 40, 46], ["pathogenicity", "OBSERVATION", 47, 60], ["strong", "OBSERVATION_MODIFIER", 62, 68], ["infectivity", "OBSERVATION", 69, 80], ["mouth", "ANATOMY", 120, 125], ["nose", "ANATOMY", 130, 134], ["lesion", "OBSERVATION", 149, 155]]], ["The current research data show that the novel coronavirus disease (COVID-19), which was prevalent in Wuhan in December 2019 (Cui et al., 2019; Li et al., 2020b; Zhu et al., 2020), has the characteristics of an epidemic due to its infectiousness, which is in line with the category of \u201cplague\u201d in febrile disease.", [["coronavirus disease", "DISEASE", 46, 65], ["plague", "DISEASE", 285, 291], ["febrile disease", "DISEASE", 296, 311], ["coronavirus", "ORGANISM", 46, 57], ["The current research data", "TEST", 0, 25], ["the novel coronavirus disease", "PROBLEM", 36, 65], ["COVID", "TEST", 67, 72], ["an epidemic", "PROBLEM", 207, 218], ["its infectiousness", "PROBLEM", 226, 244], ["febrile disease", "PROBLEM", 296, 311], ["coronavirus disease", "OBSERVATION", 46, 65], ["epidemic", "OBSERVATION", 210, 218], ["infectiousness", "OBSERVATION", 230, 244], ["plague", "OBSERVATION_MODIFIER", 285, 291], ["febrile disease", "OBSERVATION", 296, 311]]], ["SARS-CoV2 can be understood as the \u201coutcry\u201d in Wen Xie, which is of great significance for screening susceptible people.IntroductionA current meta-analysis also showed that the main clinical symptoms of COVID-19 patients are fever (88.5%), cough (68.6%), myalgia or fatigue (35.8%), expectoration (28.2%), and dyspnea (21.9%).", [["SARS", "DISEASE", 0, 4], ["COVID", "DISEASE", 203, 208], ["fever", "DISEASE", 225, 230], ["cough", "DISEASE", 240, 245], ["myalgia", "DISEASE", 255, 262], ["fatigue", "DISEASE", 266, 273], ["expectoration", "DISEASE", 283, 296], ["dyspnea", "DISEASE", 310, 317], ["people", "ORGANISM", 113, 119], ["patients", "ORGANISM", 212, 220], ["people", "SPECIES", 113, 119], ["patients", "SPECIES", 212, 220], ["IntroductionA current meta-analysis", "TEST", 120, 155], ["the main clinical symptoms", "PROBLEM", 173, 199], ["COVID", "TEST", 203, 208], ["fever", "PROBLEM", 225, 230], ["cough", "PROBLEM", 240, 245], ["myalgia", "PROBLEM", 255, 262], ["fatigue", "PROBLEM", 266, 273], ["expectoration", "TEST", 283, 296], ["dyspnea", "PROBLEM", 310, 317], ["main", "OBSERVATION_MODIFIER", 177, 181]]], ["The minor symptoms include headache or dizziness (12.1%), diarrhea (4.8%), and nausea and vomiting (3.9%) (Li et al., 2020a).", [["headache", "DISEASE", 27, 35], ["dizziness", "DISEASE", 39, 48], ["diarrhea", "DISEASE", 58, 66], ["nausea", "DISEASE", 79, 85], ["vomiting", "DISEASE", 90, 98], ["The minor symptoms", "PROBLEM", 0, 18], ["headache", "PROBLEM", 27, 35], ["dizziness", "PROBLEM", 39, 48], ["diarrhea", "PROBLEM", 58, 66], ["nausea", "PROBLEM", 79, 85], ["vomiting", "PROBLEM", 90, 98]]], ["The data showed that although patients with COVID-19 had fever (mainly in the early stage of disease), the fever was not high and had the characteristic of \u201cheat not rising.\u201d", [["fever", "DISEASE", 57, 62], ["fever", "DISEASE", 107, 112], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["The data", "TEST", 0, 8], ["COVID", "TEST", 44, 49], ["fever", "PROBLEM", 57, 62], ["disease", "PROBLEM", 93, 100], ["the fever", "PROBLEM", 103, 112], ["\u201cheat", "PROBLEM", 156, 161], ["disease", "OBSERVATION", 93, 100]]], ["In addition, patients have symptoms such as fatigue, tiredness, diarrhea, and thickly coated tongue (Tian et al., 2020), which are consistent with the characteristics of heavy turbidity, stickiness, and depression in TCM.", [["tongue", "ANATOMY", 93, 99], ["fatigue", "DISEASE", 44, 51], ["tiredness", "DISEASE", 53, 62], ["diarrhea", "DISEASE", 64, 72], ["stickiness", "DISEASE", 187, 197], ["depression", "DISEASE", 203, 213], ["patients", "ORGANISM", 13, 21], ["tongue", "ORGAN", 93, 99], ["TCM", "CELL_TYPE", 217, 220], ["patients", "SPECIES", 13, 21], ["symptoms", "PROBLEM", 27, 35], ["fatigue", "PROBLEM", 44, 51], ["tiredness", "PROBLEM", 53, 62], ["diarrhea", "PROBLEM", 64, 72], ["thickly coated tongue", "PROBLEM", 78, 99], ["heavy turbidity", "PROBLEM", 170, 185], ["stickiness", "PROBLEM", 187, 197], ["depression in TCM", "PROBLEM", 203, 220], ["tongue", "ANATOMY", 93, 99], ["consistent with", "UNCERTAINTY", 131, 146], ["heavy", "OBSERVATION_MODIFIER", 170, 175], ["turbidity", "OBSERVATION", 176, 185]]], ["Thus, people who are cold or wet are very susceptible to the virus.", [["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12], ["cold", "PROBLEM", 21, 25], ["the virus", "PROBLEM", 57, 66], ["virus", "OBSERVATION", 61, 66]]], ["In addition, sex workers may be heavily affected.IntroductionThe spread of infectious disease among health care workers during an epidemic is another consequence of its widespread distribution.", [["infectious disease", "DISEASE", 75, 93], ["infectious", "OBSERVATION_MODIFIER", 75, 85], ["widespread", "OBSERVATION_MODIFIER", 169, 179], ["distribution", "OBSERVATION_MODIFIER", 180, 192]]], ["What has become absolutely clear is that the use of isolation clothing, masks, and eye masks is an effective method to prevent the spread.", [["eye", "ANATOMY", 83, 86], ["eye", "ORGAN", 83, 86], ["isolation clothing", "TREATMENT", 52, 70], ["masks", "TREATMENT", 72, 77], ["eye masks", "TREATMENT", 83, 92], ["an effective method", "TREATMENT", 96, 115], ["clear", "OBSERVATION", 27, 32], ["eye", "ANATOMY", 83, 86]]], ["However, this method puts stress on the supply of materials for this equipment.", [["this equipment", "TREATMENT", 64, 78]]], ["If there is widespread need, and the protective articles are not replaced in a timely way, infection of medical staff may occur.", [["infection", "DISEASE", 91, 100], ["widespread", "OBSERVATION_MODIFIER", 12, 22], ["infection", "OBSERVATION", 91, 100]]], ["The medical staff consumed a Ganjiang Gancao decoction or other preventive prescriptions to prevent the infectious disease.", [["Ganjiang Gancao decoction", "CHEMICAL", 29, 54], ["infectious disease", "DISEASE", 104, 122], ["a Ganjiang Gancao decoction", "TREATMENT", 27, 54], ["preventive prescriptions", "TREATMENT", 64, 88], ["the infectious disease", "PROBLEM", 100, 122], ["infectious", "OBSERVATION", 104, 114]]], ["This gratifying result was confirmed in the prevention and treatment of SARS in 2003 (Luo et al., 2020).", [["SARS", "DISEASE", 72, 76], ["treatment", "TREATMENT", 59, 68], ["SARS", "PROBLEM", 72, 76]]], ["Youke Wu, a famous Chinese medicine practitioner in the Qing Dynasty of China, systematically furthered the understanding and treatment of infectious diseases and completed the first monograph on infectious diseases of TCM, entitled \u201cPlague Theory\u201d.", [["infectious diseases", "DISEASE", 139, 158], ["infectious diseases", "DISEASE", 196, 215], ["TCM", "DISEASE", 219, 222], ["infectious diseases", "PROBLEM", 139, 158], ["infectious", "OBSERVATION", 139, 149]]], ["In view of the law of transmission of infectious diseases, it is believed that the progress of the disease in the human body can be divided into four steps: defense, qi, nutrient, and blood.", [["body", "ANATOMY", 120, 124], ["blood", "ANATOMY", 184, 189], ["infectious diseases", "DISEASE", 38, 57], ["human", "ORGANISM", 114, 119], ["body", "ORGANISM_SUBDIVISION", 120, 124], ["blood", "ORGANISM_SUBSTANCE", 184, 189], ["human", "SPECIES", 114, 119], ["human", "SPECIES", 114, 119], ["infectious diseases", "PROBLEM", 38, 57], ["the disease in the human body", "PROBLEM", 95, 124], ["infectious", "OBSERVATION", 38, 48], ["disease", "OBSERVATION", 99, 106]]], ["These steps can be used to summarize the superficial and deep levels of pathological changes and the severity of these changes.", [["pathological changes", "PROBLEM", 72, 92], ["deep", "ANATOMY_MODIFIER", 57, 61], ["pathological", "OBSERVATION", 72, 84]]], ["Wei Fen syndrome belongs to the category of exogenous exterior syndrome, which is the initial stage of pathological changes caused by exogenous heat evil invading the human body.", [["body", "ANATOMY", 173, 177], ["exterior syndrome", "DISEASE", 54, 71], ["human", "ORGANISM", 167, 172], ["body", "ORGANISM_SUBDIVISION", 173, 177], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["Wei Fen syndrome", "PROBLEM", 0, 16], ["exogenous exterior syndrome", "PROBLEM", 44, 71], ["pathological changes", "PROBLEM", 103, 123], ["syndrome", "OBSERVATION", 8, 16], ["exogenous exterior syndrome", "OBSERVATION", 44, 71], ["pathological", "OBSERVATION", 103, 115], ["exogenous heat evil", "OBSERVATION", 134, 153], ["human", "ANATOMY", 167, 172], ["body", "ANATOMY_MODIFIER", 173, 177]]], ["Qi Fen syndrome refers to the stage of abnormal qi movement in human viscera or tissues without blood circulation.", [["viscera", "ANATOMY", 69, 76], ["tissues", "ANATOMY", 80, 87], ["blood", "ANATOMY", 96, 101], ["abnormal qi movement", "DISEASE", 39, 59], ["human", "ORGANISM", 63, 68], ["viscera", "ORGAN", 69, 76], ["tissues", "TISSUE", 80, 87], ["blood", "ORGANISM_SUBSTANCE", 96, 101], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["Qi Fen syndrome", "PROBLEM", 0, 15], ["abnormal qi movement in human viscera", "PROBLEM", 39, 76], ["Fen syndrome", "OBSERVATION", 3, 15], ["abnormal", "OBSERVATION_MODIFIER", 39, 47], ["qi movement", "OBSERVATION", 48, 59], ["human viscera", "ANATOMY", 63, 76], ["tissues", "ANATOMY", 80, 87]]], ["In Wei Fen and Qi Fen, the disease location is mainly in the lung, stomach, intestine, and gallbladder, and most of these diseases are functional disorders of the human body.", [["lung", "ANATOMY", 61, 65], ["stomach", "ANATOMY", 67, 74], ["intestine", "ANATOMY", 76, 85], ["gallbladder", "ANATOMY", 91, 102], ["body", "ANATOMY", 169, 173], ["disorders of the human body", "DISEASE", 146, 173], ["lung", "ORGAN", 61, 65], ["stomach", "ORGAN", 67, 74], ["intestine", "ORGAN", 76, 85], ["gallbladder", "ORGAN", 91, 102], ["human", "ORGANISM", 163, 168], ["body", "ORGANISM_SUBDIVISION", 169, 173], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 163, 168], ["the disease location", "PROBLEM", 23, 43], ["these diseases", "PROBLEM", 116, 130], ["functional disorders of the human body", "PROBLEM", 135, 173], ["disease", "OBSERVATION", 27, 34], ["lung", "ANATOMY", 61, 65], ["stomach", "ANATOMY", 67, 74], ["intestine", "ANATOMY", 76, 85], ["gallbladder", "ANATOMY", 91, 102], ["diseases", "OBSERVATION", 122, 130], ["human body", "ANATOMY_MODIFIER", 163, 173]]], ["Ying Fen syndrome refers to the stage of pathogenic heat in Ying Fen caused by the invasion of pathogenic heat.", [["Fen syndrome", "DISEASE", 5, 17], ["Fen syndrome", "PROBLEM", 5, 17], ["pathogenic heat", "PROBLEM", 41, 56], ["pathogenic heat", "PROBLEM", 95, 110], ["syndrome", "OBSERVATION", 9, 17], ["invasion", "OBSERVATION", 83, 91], ["pathogenic heat", "OBSERVATION", 95, 110]]], ["The stage of main pathological change is burning Ying Yin, which is the third stage of pathological change caused by the invasion of pathogenic factors.", [["pathogenic factors", "PROTEIN", 133, 151], ["main pathological change", "PROBLEM", 13, 37], ["burning Ying Yin", "PROBLEM", 41, 57], ["pathological change", "PROBLEM", 87, 106], ["the invasion of pathogenic factors", "PROBLEM", 117, 151], ["stage", "OBSERVATION_MODIFIER", 4, 9], ["main", "OBSERVATION_MODIFIER", 13, 17], ["pathological", "OBSERVATION_MODIFIER", 18, 30], ["change", "OBSERVATION", 31, 37], ["burning", "OBSERVATION_MODIFIER", 41, 48], ["Ying Yin", "OBSERVATION_MODIFIER", 49, 57], ["third stage", "OBSERVATION_MODIFIER", 72, 83], ["pathological", "OBSERVATION", 87, 99], ["invasion", "OBSERVATION_MODIFIER", 121, 129], ["pathogenic", "OBSERVATION_MODIFIER", 133, 143]]], ["Blood Fen syndrome refers to the development of pathogenic heat to blood Fen, resulting in hyperactivity of blood heat.", [["Blood", "ANATOMY", 0, 5], ["blood", "ANATOMY", 67, 72], ["blood", "ANATOMY", 108, 113], ["Fen syndrome", "DISEASE", 6, 18], ["Fen", "CHEMICAL", 73, 76], ["hyperactivity", "DISEASE", 91, 104], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 67, 72], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["Blood Fen syndrome", "PROBLEM", 0, 18], ["pathogenic heat", "PROBLEM", 48, 63], ["blood Fen", "TEST", 67, 76], ["hyperactivity of blood heat", "PROBLEM", 91, 118], ["Fen syndrome", "OBSERVATION", 6, 18], ["hyperactivity", "OBSERVATION", 91, 104]]], ["Blood consumption is a stage of major pathological change and the fourth stage in the course of disease.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood consumption", "TEST", 0, 17], ["major pathological change", "PROBLEM", 32, 57], ["disease", "PROBLEM", 96, 103], ["major", "OBSERVATION_MODIFIER", 32, 37], ["pathological", "OBSERVATION", 38, 50], ["fourth stage", "OBSERVATION_MODIFIER", 66, 78], ["course", "OBSERVATION_MODIFIER", 86, 92], ["disease", "OBSERVATION", 96, 103]]], ["The main pathological change in this stage is organ parenchyma damage.", [["organ parenchyma", "ANATOMY", 46, 62], ["organ parenchyma damage", "DISEASE", 46, 69], ["organ parenchyma", "MULTI-TISSUE_STRUCTURE", 46, 62], ["The main pathological change", "PROBLEM", 0, 28], ["organ parenchyma damage", "PROBLEM", 46, 69], ["main", "OBSERVATION_MODIFIER", 4, 8], ["pathological", "OBSERVATION", 9, 21], ["organ", "ANATOMY", 46, 51], ["parenchyma", "ANATOMY_MODIFIER", 52, 62], ["damage", "OBSERVATION", 63, 69]]], ["This four-step TCM method of defense, qi, nutrient, and blood explains why no case progressed from mild to severe in the treatment of COVID-19 by TCM.IntroductionThe present review summarizes the advantages of TCM in the prevention and treatment of COVID-19 and answers the following scientific questions: (1) How can we understand the origin of unprecedented new infectious diseases? (2) Why is the TCM so effective for preventing the spread of highly infectious viruses? (3) Which methods of TCM have achieved good results in the treatment of COVID-19? (4) What are the scientific nature and molecular mechanism of TCM in the treatment of COVID-19? (5) For the patients cured by TCM, will they recover Yang, have sequelae, or need to continue taking medicine after recovery?Understanding how COVID-19 is a plague ::: TCM knowledge of COVID-19Infectious diseases are often associated with viruses, such as in the cases of Severe Acute Respiratory Syndrome (SARS) in 2003, Middle East respiratory syndrome (MERS) in 2012, and COVID-19 in 2019.", [["blood", "ANATOMY", 56, 61], ["COVID-19", "CHEMICAL", 134, 142], ["infectious diseases", "DISEASE", 364, 383], ["Acute Respiratory Syndrome", "DISEASE", 930, 956], ["SARS", "DISEASE", 958, 962], ["Middle East respiratory syndrome", "DISEASE", 973, 1005], ["COVID-19", "CHEMICAL", 134, 142], ["COVID-19", "CHEMICAL", 545, 553], ["COVID-19", "CHEMICAL", 641, 649], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["patients", "ORGANISM", 663, 671], ["COVID-19Infectious", "GENE_OR_GENE_PRODUCT", 836, 854], ["COVID-19", "DNA", 794, 802], ["patients", "SPECIES", 663, 671], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 923, 963], ["COVID", "TEST", 134, 139], ["TCM", "TREATMENT", 210, 213], ["COVID", "TEST", 249, 254], ["unprecedented new infectious diseases", "PROBLEM", 346, 383], ["highly infectious viruses", "PROBLEM", 446, 471], ["COVID", "TEST", 545, 550], ["COVID", "TEST", 641, 646], ["COVID", "TEST", 836, 841], ["19Infectious diseases", "PROBLEM", 842, 863], ["viruses", "PROBLEM", 890, 897], ["Severe Acute Respiratory Syndrome", "PROBLEM", 923, 956], ["SARS", "PROBLEM", 958, 962], ["Middle East respiratory syndrome", "PROBLEM", 973, 1005], ["COVID", "TEST", 1026, 1031], ["mild", "OBSERVATION_MODIFIER", 99, 103], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["new", "OBSERVATION_MODIFIER", 360, 363], ["infectious", "OBSERVATION", 364, 374], ["highly", "OBSERVATION_MODIFIER", 446, 452], ["infectious", "OBSERVATION", 453, 463], ["viruses", "OBSERVATION", 890, 897], ["Severe", "OBSERVATION_MODIFIER", 923, 929], ["Acute", "OBSERVATION_MODIFIER", 930, 935], ["Respiratory Syndrome", "OBSERVATION", 936, 956], ["Middle", "ANATOMY_MODIFIER", 973, 979], ["respiratory syndrome", "OBSERVATION", 985, 1005]]], ["The pathogens associated with these diseases are all coronaviruses.", [["The pathogens", "PROBLEM", 0, 13], ["these diseases", "PROBLEM", 30, 44], ["all coronaviruses", "PROBLEM", 49, 66], ["pathogens", "OBSERVATION", 4, 13], ["diseases", "OBSERVATION", 36, 44]]], ["But, TCM does not consider viruses to be the main cause of infectious diseases.", [["infectious diseases", "DISEASE", 59, 78], ["TCM", "CELL_TYPE", 5, 8], ["viruses", "PROBLEM", 27, 34], ["infectious diseases", "PROBLEM", 59, 78], ["infectious", "OBSERVATION", 59, 69]]], ["As long as the disease is cured, the virus will die out naturally.", [["the disease", "PROBLEM", 11, 22], ["the virus", "PROBLEM", 33, 42], ["disease", "OBSERVATION", 15, 22]]], ["Further, a negative virus test does not indicate recovery.", [["a negative virus test", "TEST", 9, 30]]], ["COVID-19 belongs to the category of \u2018epidemic\u2019 disease in TCM (Wang et al., 2020).", [["COVID-19", "DNA", 0, 8], ["COVID", "TEST", 0, 5], ["disease", "OBSERVATION", 47, 54]]], ["Plagues have their own properties, and a plague corresponds to a nature (Yang et al. 2020).Understanding how COVID-19 is a plague ::: TCM knowledge of COVID-19COVID-19 was categorized as a cold and dampness epidemic (Sun et al. 2020), and the pathogenic factors are found in the body's mucous membranes (Han et al. 2020).", [["body", "ANATOMY", 279, 283], ["mucous membranes", "ANATOMY", 286, 302], ["COVID-19COVID-19", "CHEMICAL", 151, 167], ["body", "ORGANISM_SUBDIVISION", 279, 283], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 286, 302], ["COVID-19", "DNA", 109, 117], ["COVID-19COVID-19", "DNA", 151, 167], ["COVID", "TEST", 151, 156], ["a cold and dampness epidemic", "PROBLEM", 187, 215], ["the pathogenic factors", "PROBLEM", 239, 261], ["dampness", "OBSERVATION", 198, 206], ["body", "ANATOMY", 279, 283], ["mucous membranes", "ANATOMY", 286, 302]]], ["Dampness should be paid more attention to in this epidemic (Li et al. 2020; Zheng et al. 2020).", [["Dampness", "DISEASE", 0, 8], ["Dampness", "PROBLEM", 0, 8]]], ["The complexity of COVID-19 lies in the fact that damp evil is dominant and dryness evil is contained (Fan et al. 2020).Understanding how COVID-19 is a plague ::: TCM knowledge of COVID-19In addition, some patients have been infected with the disease without obvious symptoms, which makes the prevention and control of the epidemic more difficult.", [["COVID-19In", "CHEMICAL", 179, 189], ["COVID-19In", "GENE_OR_GENE_PRODUCT", 179, 189], ["patients", "ORGANISM", 205, 213], ["COVID-19", "DNA", 18, 26], ["COVID-19", "DNA", 137, 145], ["patients", "SPECIES", 205, 213], ["COVID", "TEST", 18, 23], ["dominant", "PROBLEM", 62, 70], ["dryness evil", "PROBLEM", 75, 87], ["COVID", "TEST", 179, 184], ["the disease", "PROBLEM", 238, 249], ["obvious symptoms", "PROBLEM", 258, 274], ["the epidemic", "PROBLEM", 318, 330], ["complexity", "OBSERVATION_MODIFIER", 4, 14], ["damp evil", "OBSERVATION", 49, 58], ["dominant", "OBSERVATION_MODIFIER", 62, 70], ["infected", "OBSERVATION", 224, 232]]], ["TCM also has a treatment plan for patients who have been infected with the disease without symptoms (Liu et al. 2020).Focus on organs other than lungs ::: TCM knowledge of COVID-19Treating patients as an organic whole is the prerequisite for TCM to treat all diseases.", [["organs", "ANATOMY", 127, 133], ["lungs", "ANATOMY", 145, 150], ["COVID-19Treating", "CHEMICAL", 172, 188], ["patients", "ORGANISM", 34, 42], ["organs", "ORGAN", 127, 133], ["lungs", "ORGAN", 145, 150], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 189, 197], ["a treatment plan", "TREATMENT", 13, 29], ["the disease", "PROBLEM", 71, 82], ["symptoms", "PROBLEM", 91, 99], ["COVID", "TEST", 172, 177], ["TCM", "TREATMENT", 242, 245], ["all diseases", "PROBLEM", 255, 267], ["infected", "OBSERVATION", 57, 65], ["lungs", "ANATOMY", 145, 150]]], ["COVID-19 is primarily located in the lungs, but there are exterior and interior relationships between the lungs and the large intestine (Xia and Huang, 2020).Focus on organs other than lungs ::: TCM knowledge of COVID-19The connection between the spleen, stomach, and lungs is extremely strong and should be attended to during treatment (Ding et al. 2020; Wen and Zhang, 2020).", [["lungs", "ANATOMY", 37, 42], ["lungs", "ANATOMY", 106, 111], ["intestine", "ANATOMY", 126, 135], ["organs", "ANATOMY", 167, 173], ["lungs", "ANATOMY", 185, 190], ["spleen", "ANATOMY", 247, 253], ["stomach", "ANATOMY", 255, 262], ["lungs", "ANATOMY", 268, 273], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["lungs", "ORGAN", 37, 42], ["lungs", "ORGAN", 106, 111], ["intestine", "ORGAN", 126, 135], ["organs", "ORGAN", 167, 173], ["lungs", "ORGAN", 185, 190], ["COVID-19", "CELL", 212, 220], ["spleen", "ORGAN", 247, 253], ["stomach", "ORGAN", 255, 262], ["lungs", "ORGAN", 268, 273], ["COVID-19", "DNA", 0, 8], ["COVID", "TEST", 0, 5], ["COVID", "TEST", 212, 217], ["treatment", "TREATMENT", 327, 336], ["lungs", "ANATOMY", 37, 42], ["exterior", "ANATOMY_MODIFIER", 58, 66], ["interior", "ANATOMY_MODIFIER", 71, 79], ["lungs", "ANATOMY", 106, 111], ["large intestine", "ANATOMY", 120, 135], ["lungs", "ANATOMY", 185, 190], ["spleen", "ANATOMY", 247, 253], ["stomach", "ANATOMY", 255, 262], ["lungs", "ANATOMY", 268, 273], ["strong", "OBSERVATION", 287, 293]]], ["More importantly, TCM also attaches great importance to liver damage caused by COVID-19 (Chai et al., 2020; Liu, 2003).", [["liver", "ANATOMY", 56, 61], ["TCM", "CHEMICAL", 18, 21], ["liver damage", "DISEASE", 56, 68], ["COVID-19", "CHEMICAL", 79, 87], ["COVID-19", "CHEMICAL", 79, 87], ["liver", "ORGAN", 56, 61], ["liver damage", "PROBLEM", 56, 68], ["COVID", "TEST", 79, 84], ["liver", "ANATOMY", 56, 61], ["damage", "OBSERVATION", 62, 68]]], ["During the SARS epidemic, it was recognized that the receptor angiotensin converting enzyme II (ACE2) was activated during the viral infection and subsequently caused a dysfunction in blood clotting.", [["blood", "ANATOMY", 184, 189], ["SARS", "DISEASE", 11, 15], ["angiotensin", "CHEMICAL", 62, 73], ["viral infection", "DISEASE", 127, 142], ["dysfunction in blood clotting", "DISEASE", 169, 198], ["angiotensin converting enzyme II", "GENE_OR_GENE_PRODUCT", 62, 94], ["ACE2", "GENE_OR_GENE_PRODUCT", 96, 100], ["blood", "ORGANISM_SUBSTANCE", 184, 189], ["receptor angiotensin converting enzyme II", "PROTEIN", 53, 94], ["ACE2", "PROTEIN", 96, 100], ["the SARS epidemic", "PROBLEM", 7, 24], ["the receptor angiotensin", "TREATMENT", 49, 73], ["the viral infection", "PROBLEM", 123, 142], ["a dysfunction in blood clotting", "PROBLEM", 167, 198], ["viral infection", "OBSERVATION", 127, 142], ["dysfunction", "OBSERVATION", 169, 180], ["blood clotting", "OBSERVATION", 184, 198]]], ["This finding suggested that we should also pay attention to the relationship between the heart and the lungs (Xian et al. 2020).TCM treatment strategy for COVID-19 ::: TCM knowledge of COVID-19TCM divides the disease into four stages according to the law of disease transmission: early stage, advanced stage, critical stage, and recovery stage.", [["heart", "ANATOMY", 89, 94], ["lungs", "ANATOMY", 103, 108], ["COVID-19TCM", "CHEMICAL", 185, 196], ["heart", "ORGAN", 89, 94], ["lungs", "ORGAN", 103, 108], ["COVID-19TCM", "CELL", 185, 196], ["COVID-19TCM", "DNA", 185, 196], ["COVID", "TEST", 155, 160], ["COVID", "TEST", 185, 190], ["the disease into four stages", "PROBLEM", 205, 233], ["early stage", "PROBLEM", 280, 291], ["advanced stage", "PROBLEM", 293, 307], ["critical stage", "PROBLEM", 309, 323], ["heart", "ANATOMY", 89, 94], ["lungs", "ANATOMY", 103, 108], ["disease", "OBSERVATION", 209, 216], ["early stage", "OBSERVATION_MODIFIER", 280, 291], ["advanced stage", "OBSERVATION_MODIFIER", 293, 307], ["critical stage", "OBSERVATION_MODIFIER", 309, 323]]], ["In the early stage, the common syndromes of COVID-19 were the syndrome of dampness repressing the defensive qi of the lungs or of wind heat attacking the lungs.", [["lungs", "ANATOMY", 118, 123], ["lungs", "ANATOMY", 154, 159], ["COVID", "DISEASE", 44, 49], ["lungs", "ORGAN", 118, 123], ["lungs", "ORGAN", 154, 159], ["COVID", "TEST", 44, 49], ["dampness", "PROBLEM", 74, 82], ["early stage", "OBSERVATION_MODIFIER", 7, 18], ["common syndromes", "ANATOMY", 24, 40], ["dampness", "OBSERVATION", 74, 82], ["defensive", "OBSERVATION_MODIFIER", 98, 107], ["lungs", "ANATOMY", 118, 123], ["wind heat", "OBSERVATION", 130, 139], ["lungs", "ANATOMY", 154, 159]]], ["The primary treatment is dredging the exterior and penetrating the pathogen, ventilating the lung qi for lowering adverse qi, and treatment against the cold in the Taiyang meridian (Wang et al., 2020; Xiao et al. 2020).", [["lung", "ANATOMY", 93, 97], ["lung", "ORGAN", 93, 97], ["The primary treatment", "TREATMENT", 0, 21], ["the exterior", "TREATMENT", 34, 46], ["penetrating the pathogen", "TREATMENT", 51, 75], ["lowering adverse qi", "TREATMENT", 105, 124], ["treatment", "TREATMENT", 130, 139], ["dredging", "OBSERVATION", 25, 33], ["penetrating", "OBSERVATION_MODIFIER", 51, 62], ["pathogen", "OBSERVATION", 67, 75], ["lung", "ANATOMY", 93, 97]]], ["In the advanced stage, the common syndromes were the syndrome of dampness blocking the lungs and stomach or pathogenic heat accumulating in the lungs.", [["lungs", "ANATOMY", 87, 92], ["stomach", "ANATOMY", 97, 104], ["lungs", "ANATOMY", 144, 149], ["lungs", "ORGAN", 87, 92], ["stomach", "ORGAN", 97, 104], ["lungs", "ORGAN", 144, 149], ["the common syndromes", "PROBLEM", 23, 43], ["dampness blocking the lungs and stomach", "PROBLEM", 65, 104], ["pathogenic heat accumulating in the lungs", "PROBLEM", 108, 149], ["advanced stage", "OBSERVATION_MODIFIER", 7, 21], ["common syndromes", "ANATOMY", 27, 43], ["syndrome", "OBSERVATION", 53, 61], ["dampness", "OBSERVATION", 65, 73], ["lungs", "ANATOMY", 87, 92], ["stomach", "ANATOMY", 97, 104], ["pathogenic heat", "OBSERVATION", 108, 123], ["lungs", "ANATOMY", 144, 149]]], ["The main treatment is increasing clear qi and lowering adverse qi (Shao et al. 2020; Xue et al. 2020).", [["The main treatment", "TREATMENT", 0, 18], ["main", "OBSERVATION_MODIFIER", 4, 8], ["treatment", "OBSERVATION", 9, 18], ["increasing", "OBSERVATION_MODIFIER", 22, 32], ["clear", "OBSERVATION", 33, 38]]], ["Then, in the critical stage, the common syndromes were the syndrome of epidemic virus closing the lungs, or internal block and outward desertion.", [["lungs", "ANATOMY", 98, 103], ["lungs", "ORGAN", 98, 103], ["the common syndromes", "PROBLEM", 29, 49], ["the syndrome", "PROBLEM", 55, 67], ["epidemic virus closing the lungs", "PROBLEM", 71, 103], ["internal block and outward desertion", "PROBLEM", 108, 144], ["common syndromes", "ANATOMY", 33, 49], ["epidemic virus", "OBSERVATION", 71, 85], ["lungs", "ANATOMY", 98, 103], ["internal block", "OBSERVATION", 108, 122], ["outward", "OBSERVATION_MODIFIER", 127, 134], ["desertion", "OBSERVATION", 135, 144]]], ["The treatment should allow the Yang to recover and open the orifices to induce resuscitation (Bai et al. 2020; Ma et al. 2020; Xiao et al. 2020).", [["The treatment", "TREATMENT", 0, 13], ["resuscitation", "TREATMENT", 79, 92]]], ["Finally, the common syndromes in the recovery stage were the syndromes of qi deficiency of the lungs and spleen.", [["lungs", "ANATOMY", 95, 100], ["spleen", "ANATOMY", 105, 111], ["lungs", "ORGAN", 95, 100], ["spleen", "ORGAN", 105, 111], ["the common syndromes", "PROBLEM", 9, 29], ["the syndromes", "PROBLEM", 57, 70], ["qi deficiency of the lungs and spleen", "PROBLEM", 74, 111], ["common syndromes", "ANATOMY", 13, 29], ["qi deficiency", "OBSERVATION", 74, 87], ["lungs", "ANATOMY", 95, 100], ["spleen", "ANATOMY", 105, 111]]], ["In addition, in the treatment of plague, both evil and positive are emphasized by TCM (Shao et al. 2020).Prediction based on five movements and six qi ::: TCM prevention of COVID-19Based on the theory of \u201cfive movements and six qi,\u201d the science of disaster prediction in ancient China can be used to predict the effect of natural climate change on human organ function based on the combination of the five movements of the sky and the six qi of the earth.", [["organ", "ANATOMY", 354, 359], ["plague", "DISEASE", 33, 39], ["COVID-19Based", "CHEMICAL", 173, 186], ["human", "ORGANISM", 348, 353], ["organ", "ORGAN", 354, 359], ["human", "SPECIES", 348, 353], ["human", "SPECIES", 348, 353], ["plague", "PROBLEM", 33, 39], ["COVID", "TEST", 173, 178], ["disaster prediction", "TREATMENT", 248, 267], ["natural climate change", "TREATMENT", 322, 344], ["human organ function", "TREATMENT", 348, 368]]], ["Further, based on the theory of \u201c3-year epidemic formation,\u201d it is proposed that if the migration and operation of the climate is abnormal, an epidemic will occur in approximately 3 years (Liu et al., 2013).", [["the migration", "PROBLEM", 84, 97], ["abnormal", "PROBLEM", 130, 138]]], ["The Spring Festival of 2020 was affected by excessive jinyun, the minister fire of shaoyin being the celestial manager and the influence of zhuqi and keqi, the lungs (the five element is gold) and liver (the five element is wood) are easily out of balance, and the functions of the spleen are gradually recovering (Li and Du, 2020; Yang and Yu, 2020).", [["lungs", "ANATOMY", 160, 165], ["liver", "ANATOMY", 197, 202], ["wood", "ANATOMY", 224, 228], ["spleen", "ANATOMY", 282, 288], ["shaoyin", "CHEMICAL", 83, 90], ["lungs", "ORGAN", 160, 165], ["liver", "ORGAN", 197, 202], ["spleen", "ORGAN", 282, 288], ["zhuqi", "TREATMENT", 140, 145], ["lungs", "ANATOMY", 160, 165], ["liver", "ANATOMY", 197, 202], ["spleen", "ANATOMY", 282, 288], ["gradually", "OBSERVATION_MODIFIER", 293, 302]]], ["In other words, TCM can make relatively accurate predictions before the outbreak of the disease, allowing the hospitals to make emergency plans.Prevention using TCM decoction ::: TCM prevention of COVID-19For people who are isolated at home in the community, a TCM decoction can be used for prevention.", [["TCM decoction", "CHEMICAL", 261, 274], ["people", "ORGANISM", 209, 215], ["TCM", "CELL_TYPE", 16, 19], ["people", "SPECIES", 209, 215], ["the disease", "PROBLEM", 84, 95], ["COVID", "TEST", 197, 202], ["a TCM decoction", "TREATMENT", 259, 274]]], ["The composition of the prescription is mainly aromatic and is used to avoid filth and improve autoimmunity (Ali et al., 2013; Angenent et al., 1986; Hosain et al., 1969).", [["autoimmunity", "DISEASE", 94, 106]]], ["COVID-19 prevention prescriptions based on the theory of \u201cNatural Factor\u201d were used to maintain vital qi (Li and Qiu, 2020).", [["COVID-19 prevention prescriptions", "TREATMENT", 0, 33]]], ["Modern pharmacological studies have shown that TCM ingredients are effective in clearing away heat and detoxifying, as well as in relieving surface dampness, thereby inhibiting the virus.", [["surface", "ANATOMY", 140, 147], ["Modern pharmacological studies", "TEST", 0, 30], ["TCM ingredients", "TREATMENT", 47, 62], ["relieving surface dampness", "PROBLEM", 130, 156], ["the virus", "PROBLEM", 177, 186], ["effective", "OBSERVATION_MODIFIER", 67, 76], ["dampness", "OBSERVATION", 148, 156]]], ["As early as the 1970s, the study of TCM against the influenza virus has been undertaken in China.", [["TCM", "CHEMICAL", 36, 39], ["influenza virus", "DISEASE", 52, 67], ["influenza virus", "ORGANISM", 52, 67], ["influenza virus", "SPECIES", 52, 67], ["the study", "TEST", 23, 32], ["TCM", "TREATMENT", 36, 39], ["the influenza virus", "PROBLEM", 48, 67]]], ["There are two ways that TCM acts as an antiviral.", [["TCM", "CHEMICAL", 24, 27], ["an antiviral", "TREATMENT", 36, 48]]], ["The first is by directly inhibiting the virus, primarily by heat clearing and detoxifying.", [["the virus", "PROBLEM", 36, 45], ["virus", "OBSERVATION", 40, 45], ["clearing", "OBSERVATION", 65, 73]]], ["Lonicera, Folium Isatidis, and Scutellaria are used for inhibition.", [["Lonicera", "CHEMICAL", 0, 8], ["Lonicera", "SIMPLE_CHEMICAL", 0, 8], ["Folium Isatidis", "ORGANISM", 10, 25], ["Lonicera", "TREATMENT", 0, 8], ["Folium Isatidis", "TREATMENT", 10, 25], ["Scutellaria", "TREATMENT", 31, 42], ["Folium Isatidis", "OBSERVATION", 10, 25]]], ["The second is to indirectly play an antiviral role or inhibit the virus-mediated inflammatory response by regulating the immune function of the body.", [["body", "ANATOMY", 144, 148], ["body", "ORGANISM_SUBDIVISION", 144, 148], ["the virus", "PROBLEM", 62, 71], ["inflammatory response", "PROBLEM", 81, 102], ["antiviral", "OBSERVATION", 36, 45], ["inflammatory", "OBSERVATION", 81, 93], ["body", "ANATOMY", 144, 148]]], ["Astragalus, Salvia, Acanthopanax senticosus, and Gentiana are used as antivirals and induce interferon and immunoglobulin.", [["Gentiana", "CHEMICAL", 49, 57], ["Astragalus", "ORGANISM_SUBSTANCE", 0, 10], ["Acanthopanax senticosus", "ORGANISM", 20, 43], ["Gentiana", "ORGANISM", 49, 57], ["interferon", "GENE_OR_GENE_PRODUCT", 92, 102], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 107, 121], ["interferon", "PROTEIN", 92, 102], ["immunoglobulin", "PROTEIN", 107, 121], ["Acanthopanax senticosus", "SPECIES", 20, 43], ["Acanthopanax senticosus", "SPECIES", 20, 43], ["Astragalus", "TREATMENT", 0, 10], ["Salvia", "TREATMENT", 12, 18], ["Acanthopanax senticosus", "TREATMENT", 20, 43], ["Gentiana", "TREATMENT", 49, 57], ["antivirals", "TREATMENT", 70, 80], ["interferon", "TREATMENT", 92, 102], ["immunoglobulin", "TREATMENT", 107, 121], ["Salvia", "ANATOMY", 12, 18]]], ["TCM focuses on the overall regulation of the body.", [["body", "ANATOMY", 45, 49], ["body", "ORGANISM_SUBDIVISION", 45, 49], ["TCM", "CELL_TYPE", 0, 3], ["body", "ANATOMY", 45, 49]]], ["Thus, TCM can play a multi-target role in the regulation of the body's systems (Gao and Wang, 2018).Prevention of disease with herbal incense ::: TCM prevention of COVID-19Sachets are made of aromatic herbs.", [["body", "ANATOMY", 64, 68], ["TCM", "CHEMICAL", 6, 9], ["TCM", "CHEMICAL", 146, 149], ["COVID-19Sachets", "CHEMICAL", 164, 179], ["body", "ORGANISM_SUBDIVISION", 64, 68], ["COVID-19Sachets", "SIMPLE_CHEMICAL", 164, 179], ["TCM", "CELL_TYPE", 6, 9], ["disease", "PROBLEM", 114, 121], ["COVID", "TEST", 164, 169], ["aromatic herbs", "PROBLEM", 192, 206], ["disease", "OBSERVATION", 114, 121], ["aromatic herbs", "OBSERVATION", 192, 206]]], ["For those who have not been infected with the virus but have been exposed, the most simple and effective method of TCM prevention is by the traditional aromatherapy method with herbs such as Atractylodes lanceolata, Phellodendron amurense, and Artemisia argyi, which have a significant preventive effect (Liang et al., 2003).", [["Atractylodes lanceolata", "CHEMICAL", 191, 214], ["Atractylodes lanceolata", "ORGANISM", 191, 214], ["Phellodendron amurense", "ORGANISM", 216, 238], ["Artemisia argyi", "ORGANISM", 244, 259], ["Atractylodes lanceolata", "SPECIES", 191, 214], ["Phellodendron amurense", "SPECIES", 216, 238], ["Artemisia argyi", "SPECIES", 244, 259], ["Atractylodes lanceolata", "SPECIES", 191, 214], ["Phellodendron amurense", "SPECIES", 216, 238], ["Artemisia argyi", "SPECIES", 244, 259], ["the virus", "PROBLEM", 42, 51], ["TCM prevention", "TREATMENT", 115, 129], ["herbs", "TREATMENT", 177, 182], ["Atractylodes lanceolata", "TREATMENT", 191, 214], ["Phellodendron amurense", "TREATMENT", 216, 238], ["infected", "OBSERVATION", 28, 36], ["most simple", "OBSERVATION_MODIFIER", 79, 90], ["significant", "OBSERVATION_MODIFIER", 274, 285]]], ["In addition, the herbs can be made into a sachet to \u201cavoid poisonous gas\u201d (Zhang et al. 2020; Zhang et al., 2003), which is an important principle in TCM (Liu, 2003).Prevention of infection among medical staff ::: TCM prevention of COVID-19Insufficient protection increases the risk of COVID-19 in frontline medical staff (Fu et al., 2020).", [["infection", "DISEASE", 180, 189], ["COVID-19Insufficient", "CHEMICAL", 232, 252], ["poisonous gas", "PROBLEM", 59, 72], ["infection", "PROBLEM", 180, 189], ["COVID", "TEST", 232, 237], ["COVID", "TEST", 286, 291], ["infection", "OBSERVATION", 180, 189]]], ["Moreover, once masks, goggles, and protective clothing are contaminated, they cannot be used again.Prevention of infection among medical staff ::: TCM prevention of COVID-19In TCM hospitals, or hospitals based on TCM treatment methods, medical staff take one or two decoctions every day and burn Artemisia argyi or Atractylodes lanceolata in the hospital to cut off the transmission route.Prevention of infection among medical staff ::: TCM prevention of COVID-19As reported by CCTV4, 1250 medical staff in Tongxu County Hospital (Henan province) drank Chinese medicine decoctions and burned Artemisia argyi in the hospital corridor.", [["infection", "DISEASE", 113, 122], ["COVID-19In TCM", "CHEMICAL", 165, 179], ["Atractylodes lanceolata", "CHEMICAL", 315, 338], ["infection", "DISEASE", 403, 412], ["COVID-19As", "CHEMICAL", 455, 465], ["Artemisia argyi", "ORGANISM", 296, 311], ["Atractylodes lanceolata", "ORGANISM", 315, 338], ["COVID-19As", "SIMPLE_CHEMICAL", 455, 465], ["Artemisia argyi", "SPECIES", 296, 311], ["Atractylodes lanceolata", "SPECIES", 315, 338], ["Artemisia argyi", "SPECIES", 592, 607], ["Artemisia argyi", "SPECIES", 296, 311], ["Atractylodes lanceolata", "SPECIES", 315, 338], ["Artemisia argyi", "SPECIES", 592, 607], ["goggles", "TREATMENT", 22, 29], ["protective clothing", "TREATMENT", 35, 54], ["infection", "PROBLEM", 113, 122], ["COVID", "TEST", 165, 170], ["TCM treatment methods", "TREATMENT", 213, 234], ["burn Artemisia argyi", "TREATMENT", 291, 311], ["Atractylodes lanceolata", "TREATMENT", 315, 338], ["infection", "PROBLEM", 403, 412], ["COVID", "TEST", 455, 460], ["Chinese medicine decoctions", "TREATMENT", 553, 580], ["burned Artemisia", "PROBLEM", 585, 601], ["infection", "OBSERVATION", 113, 122], ["infection", "OBSERVATION", 403, 412], ["burned Artemisia", "OBSERVATION", 585, 601]]], ["With regard to masks, disposable masks were used for medical personnel, and N95 masks were not used (Hao et al., 2012).", [["disposable masks", "TREATMENT", 22, 38], ["N95 masks", "TREATMENT", 76, 85]]], ["In Jingzhou (Hubei province), the worst-hit area of the epidemic, 580 medical staff came from Jingzhou TCM Hospital, and none of them were infected by the disease.", [["disease", "OBSERVATION", 155, 162]]], ["In addition, the hospital produces 25,000 preventive Chinese patented medicines for distribution to other hospitals every day (Zhang et al., 2017).", [["preventive Chinese patented medicines", "TREATMENT", 42, 79]]], ["In Wuhan, where the epidemic was most severe, Jiangxia Fangcai Hospital also achieved zero infections among medical staff (Seah et al., 1973).", [["infections", "DISEASE", 91, 101]]], ["Moreover, in Huanggang, Huangshi (Hubei province), and Guangzhou (Guangdong province), TCM methods were used to prevent the epidemic, and there was zero infection among the medical staff there as well.", [["infection", "DISEASE", 153, 162], ["TCM methods", "TREATMENT", 87, 98], ["zero infection", "PROBLEM", 148, 162], ["infection", "OBSERVATION", 153, 162]]], ["However, more than 3000 medical staff without TCM prevention were infected.", [["TCM prevention", "TREATMENT", 46, 60], ["infected", "PROBLEM", 66, 74], ["infected", "OBSERVATION", 66, 74]]], ["Considering the similarity between the COVID-19 epidemic and the SARS epidemic in 2003, it is pertinent to compare the outcomes among medical personnel in China.", [["SARS", "DISEASE", 65, 69], ["the COVID", "TEST", 35, 44]]], ["Three studies were identified including one controlled study (Lau et al., 2005) and two single cohort studies (Luo et al., 2020) conducted during the SARS epidemic.", [["SARS", "DISEASE", 150, 154], ["Three studies", "TEST", 0, 13], ["one controlled study", "TEST", 40, 60], ["single cohort studies", "TEST", 88, 109], ["the SARS epidemic", "PROBLEM", 146, 163]]], ["Lau et al designed a controlled study to evaluate an herbal formula for prevention of SARS (no herbal intervention in the control group) and conducted it in Hong Kong, China.", [["SARS", "DISEASE", 86, 90], ["a controlled study", "TEST", 19, 37], ["an herbal formula", "TREATMENT", 50, 67], ["SARS", "PROBLEM", 86, 90], ["herbal intervention", "TREATMENT", 95, 114]]], ["The sample size was 16,437 (1063 in the herbal group and 15,374 in the control group), and all participants were hospital care workers including doctors, nurses, and other staff.", [["participants", "SPECIES", 95, 107], ["The sample size", "TEST", 0, 15], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["The results showed that none of the participants who took a modified formula of Yupingfeng Powder and Sangju Decoction contracted SARS, whereas 64 of 15,347 (0.4%) in the control group were infected with SARS (P=0.035).", [["Yupingfeng Powder", "CHEMICAL", 80, 97], ["Sangju Decoction", "CHEMICAL", 102, 118], ["SARS", "DISEASE", 130, 134], ["SARS", "DISEASE", 204, 208], ["participants", "ORGANISM", 36, 48], ["participants", "SPECIES", 36, 48], ["a modified formula of Yupingfeng Powder", "TREATMENT", 58, 97], ["Sangju Decoction", "TREATMENT", 102, 118], ["SARS", "PROBLEM", 204, 208]]], ["There were 19 cases (1.8%) of minor adverse effects after 14 days of taking the herbal medicine, including diarrhea, sore throat, dizziness, and nausea.", [["diarrhea", "DISEASE", 107, 115], ["sore throat", "DISEASE", 117, 128], ["dizziness", "DISEASE", 130, 139], ["nausea", "DISEASE", 145, 151], ["minor adverse effects", "PROBLEM", 30, 51], ["the herbal medicine", "TREATMENT", 76, 95], ["diarrhea", "PROBLEM", 107, 115], ["sore throat", "PROBLEM", 117, 128], ["dizziness", "PROBLEM", 130, 139], ["nausea", "PROBLEM", 145, 151], ["sore throat", "ANATOMY", 117, 128], ["dizziness", "OBSERVATION", 130, 139]]], ["Both single cohort studies were conducted in Beijing, China, with sample sizes of 3561 and 163, respectively.", [["Both single cohort studies", "TEST", 0, 26], ["sample sizes", "TEST", 66, 78]]], ["All participants were medical staff from two hospitals in which SARS patients were recruited and treated during the study period (Luo et al., 2020).", [["SARS", "DISEASE", 64, 68], ["patients", "ORGANISM", 69, 77], ["participants", "SPECIES", 4, 16], ["patients", "SPECIES", 69, 77]]], ["One of the studies included only first-line medical staff treating SARS.", [["SARS", "DISEASE", 67, 71], ["the studies", "TEST", 7, 18], ["SARS", "PROBLEM", 67, 71]]], ["The courses of taking the herbal formulae for prevention were 6 days and 12 to 25 days for the two cohort studies, respectively.", [["the herbal formulae", "TREATMENT", 22, 41], ["the two cohort studies", "TEST", 91, 113]]], ["The decoctions used in these studies were both a classic formula of Yupingfeng Powder and some heat-clearing and detoxifying herbs.", [["The decoctions", "TREATMENT", 0, 14], ["these studies", "TEST", 23, 36], ["a classic formula of Yupingfeng Powder", "TREATMENT", 47, 85], ["some heat", "TREATMENT", 90, 99]]], ["The results of the two studies showed that none of the participants who took the preventive herbal medicine contracted SARS.TCM decoction ::: TCM treatment of COVID-19A TCM study was performed to accurately identify patients infected with COVID-19 (Yu et al. 2020).", [["SARS", "DISEASE", 119, 123], ["TCM", "CHEMICAL", 142, 145], ["COVID-19A TCM", "CHEMICAL", 159, 172], ["patients", "ORGANISM", 216, 224], ["participants", "SPECIES", 55, 67], ["patients", "SPECIES", 216, 224], ["the two studies", "TEST", 15, 30], ["TCM treatment", "TREATMENT", 142, 155], ["COVID", "TREATMENT", 159, 164], ["19A TCM study", "TEST", 165, 178], ["COVID", "TEST", 239, 244]]], ["In the Wanzhou District (Chongqing), 225 common and severe COVID-19 cases were analyzed.", [["severe COVID", "TEST", 52, 64]]], ["Based on TCM theory, the core pathogenesis of COVID-19 is dampness, heat, toxins, and deficiency, and the main treatment principle is strengthening the lungs to prevent dampness, clearing away heat and detoxification, supplementing qi, and nourishing Yin (Gong et al. 2020).", [["lungs", "ANATOMY", 152, 157], ["COVID-19", "CHEMICAL", 46, 54], ["dampness", "DISEASE", 169, 177], ["lungs", "ORGAN", 152, 157], ["COVID", "TEST", 46, 51], ["dampness", "PROBLEM", 58, 66], ["heat", "PROBLEM", 68, 72], ["toxins", "PROBLEM", 74, 80], ["deficiency", "PROBLEM", 86, 96], ["the main treatment principle", "TREATMENT", 102, 130], ["dampness", "PROBLEM", 169, 177], ["dampness", "OBSERVATION", 58, 66], ["main", "OBSERVATION_MODIFIER", 106, 110], ["lungs", "ANATOMY", 152, 157], ["dampness", "OBSERVATION", 169, 177]]], ["Further, there were 209 cases of COVID-19 in Chongqing City with cough (70.81%) and fever (55.50%) as the common symptoms.", [["cough", "DISEASE", 65, 70], ["fever", "DISEASE", 84, 89], ["COVID", "TEST", 33, 38], ["cough", "PROBLEM", 65, 70], ["fever", "PROBLEM", 84, 89], ["the common symptoms", "PROBLEM", 102, 121]]], ["The primary clinical TCM pathogens are heat obstructing lung syndrome (30.14%), dampness obstructing syndrome (16.27%), and cold dampness stagnating lung syndrome (11.96%) (Ran et al. 2020).", [["lung", "ANATOMY", 56, 60], ["lung", "ANATOMY", 149, 153], ["obstructing lung syndrome", "DISEASE", 44, 69], ["dampness obstructing syndrome", "DISEASE", 80, 109], ["dampness stagnating lung syndrome", "DISEASE", 129, 162], ["lung", "ORGAN", 56, 60], ["lung", "ORGAN", 149, 153], ["The primary clinical TCM pathogens", "PROBLEM", 0, 34], ["heat obstructing lung syndrome", "PROBLEM", 39, 69], ["dampness obstructing syndrome", "PROBLEM", 80, 109], ["cold dampness stagnating lung syndrome", "PROBLEM", 124, 162], ["heat", "OBSERVATION_MODIFIER", 39, 43], ["obstructing", "OBSERVATION_MODIFIER", 44, 55], ["lung", "ANATOMY", 56, 60], ["syndrome", "OBSERVATION", 61, 69], ["dampness", "OBSERVATION_MODIFIER", 80, 88], ["obstructing", "OBSERVATION_MODIFIER", 89, 100], ["syndrome", "OBSERVATION", 101, 109], ["cold", "OBSERVATION_MODIFIER", 124, 128], ["dampness", "OBSERVATION", 129, 137], ["lung", "ANATOMY", 149, 153], ["syndrome", "OBSERVATION", 154, 162]]], ["In Hunan province, by the end of February 25, 2020, a total of 1016 patients were diagnosed, and 981 of these patients were treated with TCM as part of their treatment, accounting for 96.56%.", [["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 110, 118], ["TCM", "TREATMENT", 137, 140], ["their treatment", "TREATMENT", 152, 167]]], ["Of these patients, 779 patients (95.76%) were discharged, and 233 patients were hospitalized.", [["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 66, 74]]], ["Among them, 233 patients were treated with TCM, accounting for 100% (Huang et al. 2020).", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["TCM", "TREATMENT", 43, 46]]], ["Another study of 52 confirmed cases of COVID-19 used TCM intervention (Chen et al. 2020).", [["COVID", "DISEASE", 39, 44], ["Another study", "TEST", 0, 13], ["COVID", "TEST", 39, 44], ["TCM intervention", "TREATMENT", 53, 69]]], ["Except for one death in the extreme stage, the rest of the cases improved or were discharged.", [["death", "DISEASE", 15, 20]]], ["Qingfei Paidu decoction was most commonly used in COVID-19 treatment.", [["Qingfei Paidu decoction", "CHEMICAL", 0, 23], ["COVID-19", "CHEMICAL", 50, 58], ["COVID-19", "CHEMICAL", 50, 58], ["COVID-19", "SIMPLE_CHEMICAL", 50, 58], ["Qingfei Paidu decoction", "TREATMENT", 0, 23]]], ["Ninety-eight cases of COVID-19 in Sichuan province treated using Qingfei Paidu decoction were analyzed.", [["COVID", "TREATMENT", 22, 27], ["Qingfei Paidu decoction", "TREATMENT", 65, 88]]], ["After 9 days of treatment with Qingfei Paidu decoction, the total effective rate was 92.09%, the recovery rate was 41.13%, and the significant efficacy rate was 26.92% (Wang et al. 2020).", [["Qingfei Paidu decoction", "CHEMICAL", 31, 54], ["treatment", "TREATMENT", 16, 25], ["Qingfei Paidu decoction", "TREATMENT", 31, 54], ["the recovery rate", "TEST", 93, 110], ["the significant efficacy rate", "TEST", 127, 156], ["significant", "OBSERVATION_MODIFIER", 131, 142]]], ["In another case, in which six patients were treated using Lung-toxin Dispelling Formula (1 version) in combination with Western medicine for 16 days, the polymerase chain reaction (PCR) tests came back negative, and the average hospitalization time was 20 days.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["Lung-toxin Dispelling Formula", "TREATMENT", 58, 87], ["Western medicine", "TREATMENT", 120, 136], ["the polymerase chain reaction", "PROBLEM", 150, 179], ["PCR) tests", "TEST", 181, 191], ["Lung", "ANATOMY", 58, 62]]], ["All six patients were cured and discharged (Li et al. 2020).", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16]]], ["A case of COVID-19 in Changchun that was treated using integrated TCM and Western medicine for 7 days resulted in the patient's rent recovery and discharge (Zhao et al. 2020).", [["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125], ["COVID", "TEST", 10, 15]]], ["Outside Hubei, 87% of patients who were cured using TCM and discharged participated in the treatment of cases.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30]]], ["There may be a positive correlation between the cure rate of COVID-19 and the rate of TCM use, but there are other factors that affect the cure rate of COVID-19.", [["COVID-19", "CHEMICAL", 152, 160], ["COVID", "TEST", 61, 66], ["COVID", "TEST", 152, 157], ["positive", "OBSERVATION", 15, 23]]], ["Ang et al. (2020) summarized and analyzed the herbal formulae provided by the guidelines for their pattern identifications (PIs) and compositions of herbs to treat patients with COVID-19.", [["Ang", "CHEMICAL", 0, 3], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["the herbal formulae", "TREATMENT", 42, 61], ["herbs", "TREATMENT", 149, 154], ["COVID", "TEST", 178, 183]]], ["In the frequency analysis of herbs, Glycyrrhizae Radix et Rhizoma, Armeniacae Semen Amarum, Ephedrae Herba, and Gypsum Fibrosum were found to be the herbs with the highest frequency of use in the Chinese guidelines.Acupuncture ::: TCM treatment of COVID-19As an important part of TCM, acupuncture and moxibustion therapy have made vital contributions in the history of anti-epidemic action in China.", [["Glycyrrhizae Radix et Rhizoma", "CHEMICAL", 36, 65], ["COVID-19As", "CHEMICAL", 248, 258], ["Armeniacae", "ORGANISM", 67, 77], ["Semen Amarum", "ORGANISM", 78, 90], ["Ephedrae Herba", "ORGANISM", 92, 106], ["Gypsum Fibrosum", "ORGANISM", 112, 127], ["COVID-19As", "SIMPLE_CHEMICAL", 248, 258], ["Armeniacae", "SPECIES", 67, 77], ["herbs", "TREATMENT", 29, 34], ["Glycyrrhizae Radix et Rhizoma", "TREATMENT", 36, 65], ["Armeniacae Semen Amarum", "TREATMENT", 67, 90], ["Ephedrae Herba", "TREATMENT", 92, 106], ["Gypsum Fibrosum", "PROBLEM", 112, 127], ["Acupuncture", "TREATMENT", 215, 226], ["TCM treatment", "TREATMENT", 231, 244], ["COVID", "TREATMENT", 248, 253], ["TCM", "TREATMENT", 280, 283], ["acupuncture", "TREATMENT", 285, 296], ["moxibustion therapy", "TREATMENT", 301, 320], ["anti-epidemic action", "TREATMENT", 369, 389], ["herbs", "ANATOMY", 29, 34], ["Gypsum Fibrosum", "OBSERVATION", 112, 127]]], ["Modern clinical and experimental studies have shown that acupuncture and moxibustion therapy can regulate the human immune function, preventing inflammation and infection.", [["inflammation", "DISEASE", 144, 156], ["infection", "DISEASE", 161, 170], ["human", "ORGANISM", 110, 115], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["Modern clinical and experimental studies", "TEST", 0, 40], ["acupuncture", "TREATMENT", 57, 68], ["moxibustion therapy", "TREATMENT", 73, 92], ["inflammation", "PROBLEM", 144, 156], ["infection", "PROBLEM", 161, 170], ["inflammation", "OBSERVATION", 144, 156], ["infection", "OBSERVATION", 161, 170]]], ["In the current epidemic of COVID-19, acupuncture and moxibustion therapy were actively used for both prevention and treatment.", [["COVID-19", "CHEMICAL", 27, 35], ["COVID", "TEST", 27, 32], ["acupuncture", "TREATMENT", 37, 48], ["moxibustion therapy", "TREATMENT", 53, 72], ["treatment", "TREATMENT", 116, 125]]], ["According to Guidelines on Acupuncture and Moxibustion Intervention for COVID-19 (second edition) (Lin et al. 2020), acupuncture and moxibustion intervention was divided into three phases: medical observation phase (suspected cases), clinical treatment phase (confirmed cases), and convalescence phase.", [["Acupuncture", "TREATMENT", 27, 38], ["Moxibustion Intervention", "TREATMENT", 43, 67], ["COVID", "TEST", 72, 77], ["acupuncture", "TREATMENT", 117, 128], ["moxibustion intervention", "TREATMENT", 133, 157], ["medical observation phase", "TEST", 189, 214], ["clinical treatment phase", "TEST", 234, 258]]], ["In the medical observation phase, the main points were Fengmen (BLl2), Feishu (BLl3), Pishu (BL20), Hegu (LI4), Quchi (LI11), Chize (LU5), Yuji (LU10), Qihai (CV6), Zusanli (ST36), and Sanyinjiao (SP6).", [["SP6", "GENE_OR_GENE_PRODUCT", 197, 200], ["Qihai (CV6)", "TREATMENT", 152, 163], ["Zusanli (ST36)", "TREATMENT", 165, 179], ["Sanyinjiao (SP6", "TREATMENT", 185, 200], ["Hegu", "ANATOMY", 100, 104], ["Zusanli", "ANATOMY", 165, 172]]], ["The purpose was to stimulate the vital qi and the functions of the lungs and spleen, enhancing the viscera's defense.", [["lungs", "ANATOMY", 67, 72], ["spleen", "ANATOMY", 77, 83], ["viscera", "ANATOMY", 99, 106], ["lungs", "ORGAN", 67, 72], ["spleen", "ORGAN", 77, 83], ["viscera", "ORGAN", 99, 106], ["the vital qi", "TEST", 29, 41], ["lungs", "ANATOMY", 67, 72], ["spleen", "ANATOMY", 77, 83], ["viscera", "ANATOMY", 99, 106]]], ["During the clinical treatment phase, the main points chosen were as follows: Hegu (LI4), Taichong (LR3), Tiantu (CV22), Chize (LU5), Kongzui (LU6), Zusanli (ST36), Sanyinjiao (SP6), Dazhu (BLll), Fengmen (BLl2), Feishu (BLl3), Xinshu (BLl5), Geshu (BL17), Zhongfu (LU1), Danzhong (CVl7), Qihai (CV6), Guanyuan (CV4), and Zhongwan (CVl2), in order to stimulate the vital qi of the lungs and spleen, protect the viscera, and dispel pathogens.", [["lungs", "ANATOMY", 380, 385], ["spleen", "ANATOMY", 390, 396], ["viscera", "ANATOMY", 410, 417], ["Zusanli (ST36", "ORGANISM", 148, 161], ["SP6", "ORGANISM", 176, 179], ["lungs", "ORGAN", 380, 385], ["spleen", "ORGAN", 390, 396], ["viscera", "ORGAN", 410, 417], ["Hegu", "TEST", 77, 81], ["Taichong", "TEST", 89, 97], ["Tiantu (CV22", "TEST", 105, 117], ["Chize", "TEST", 120, 125], ["Zusanli (ST36", "TREATMENT", 148, 161], ["Sanyinjiao (SP6", "TREATMENT", 164, 179], ["Zhongwan (CVl2)", "TREATMENT", 321, 336], ["dispel pathogens", "PROBLEM", 423, 439], ["main", "OBSERVATION_MODIFIER", 41, 45], ["Zusanli", "ANATOMY", 148, 155], ["Sanyinjiao", "ANATOMY", 164, 174], ["lungs", "ANATOMY", 380, 385], ["spleen", "ANATOMY", 390, 396], ["viscera", "ANATOMY", 410, 417]]], ["In the convalescence phase, the main points were Neiguan (PC6), Zusanli (ST36), Zhongwan (CVl2), Tianshu (ST25), and Qihai (CV6).", [["Neiguan (PC6", "TREATMENT", 49, 61], ["Zusanli (ST36", "TREATMENT", 64, 77], ["Zhongwan (CVl2)", "TREATMENT", 80, 95], ["main", "OBSERVATION_MODIFIER", 32, 36], ["Zusanli", "ANATOMY", 64, 71]]], ["The aim in this phase is to remove residual virus, restore vitality, and repair the functions of the lungs and spleen.", [["lungs", "ANATOMY", 101, 106], ["spleen", "ANATOMY", 111, 117], ["lungs", "ORGAN", 101, 106], ["spleen", "ORGAN", 111, 117], ["residual virus", "PROBLEM", 35, 49], ["repair", "TREATMENT", 73, 79], ["virus", "OBSERVATION", 44, 49], ["lungs", "ANATOMY", 101, 106], ["spleen", "ANATOMY", 111, 117]]], ["Scholars have provided other ideas for prevention and treatment of COVID-19.", [["COVID", "TEST", 67, 72]]], ["Lin Shiyu (Lin et al. 2020) selected Dazhui (DU14), Fengmen (BLl2), Shaoshang (LU11), Yuji (LU10), Lidui (ST45), and Neiting (ST44) can be used as part of a fire needle treatment plan to prevent COVID-19 and relieve patients\u2019 symptoms.", [["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["Lidui (ST45)", "TREATMENT", 99, 111], ["Neiting (ST44)", "TREATMENT", 117, 131], ["a fire needle treatment", "TREATMENT", 155, 178], ["COVID", "TEST", 195, 200], ["patients\u2019 symptoms", "PROBLEM", 216, 234]]], ["Liu Kaiping (Liu et al. 2020) suggested that moxibustion not only effectively prevents and treats COVID-19, but also improves the quality of life of patients.", [["COVID-19", "CHEMICAL", 98, 106], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["moxibustion", "TREATMENT", 45, 56], ["COVID", "TEST", 98, 103]]], ["After the comparative induction and analysis of relevant references, Zhang et al. (2020) pointed out that moxibustion on Dazhui (DU14) and Quchi (LI11) could be selected for fever; moxibustion on Dazhui (DU14), Feishu (BL13), and Dingchuan (EX-B1) could be selected for cough; moxibustion on Zusanli (ST36), Guanyuan (CV4), and Qihai (CV6) could be used for fatigue; and moxibustion on Zhongwan (CV12), Zusanli (ST36), and Tianshu (ST25) could be used for upper digestive system discomfort.", [["upper digestive system", "ANATOMY", 456, 478], ["fever", "DISEASE", 174, 179], ["cough", "DISEASE", 270, 275], ["fatigue", "DISEASE", 358, 365], ["upper digestive system discomfort", "DISEASE", 456, 489], ["EX-B1", "CELL", 241, 246], ["upper digestive", "ORGANISM_SUBDIVISION", 456, 471], ["system", "ORGANISM_SUBDIVISION", 472, 478], ["Quchi (LI11)", "TREATMENT", 139, 151], ["fever", "PROBLEM", 174, 179], ["moxibustion", "PROBLEM", 181, 192], ["Dingchuan (EX-B1)", "TREATMENT", 230, 247], ["cough", "PROBLEM", 270, 275], ["moxibustion", "TREATMENT", 277, 288], ["Zusanli (ST36", "TREATMENT", 292, 305], ["fatigue", "PROBLEM", 358, 365], ["moxibustion", "TREATMENT", 371, 382], ["Zhongwan (CV12)", "TREATMENT", 386, 401], ["Zusanli (ST36", "TREATMENT", 403, 416], ["Tianshu (ST25)", "TREATMENT", 423, 437], ["upper digestive system discomfort", "PROBLEM", 456, 489], ["Zusanli", "ANATOMY", 292, 299], ["Zusanli", "ANATOMY", 403, 410], ["upper", "ANATOMY_MODIFIER", 456, 461], ["digestive system", "ANATOMY", 462, 478], ["discomfort", "OBSERVATION", 479, 489]]], ["Besides, Yang et al. (2020) suggested that Ren and Du meridian moxibustion can play an important role in the prevention of new COVID-19 infectionsand in preventing recurrence after recovery.Acupuncture ::: TCM treatment of COVID-19Although there are only a few clinical reports about acupuncture and moxibustion treatment in COVID-19 patients, it is expected to be a safe and effective adjuvant therapy.Treatment by Chinese patented medicine ::: TCM treatment of COVID-19Chinese patented medicine is widely used in all stages of COVID-19 because of its convenience and good taste.", [["COVID-19 infectionsand", "CHEMICAL", 127, 149], ["TCM", "CHEMICAL", 446, 449], ["COVID-19Chinese", "CHEMICAL", 463, 478], ["patients", "ORGANISM", 334, 342], ["patients", "SPECIES", 334, 342], ["COVID-19", "SPECIES", 127, 135], ["Du meridian moxibustion", "TREATMENT", 51, 74], ["new COVID-19 infectionsand", "PROBLEM", 123, 149], ["Acupuncture", "TREATMENT", 190, 201], ["TCM treatment", "TREATMENT", 206, 219], ["COVID", "TEST", 223, 228], ["acupuncture", "TREATMENT", 284, 295], ["moxibustion treatment", "TREATMENT", 300, 321], ["effective adjuvant therapy", "TREATMENT", 376, 402], ["TCM treatment", "TREATMENT", 446, 459], ["COVID-19Chinese patented medicine", "TREATMENT", 463, 496], ["COVID", "TREATMENT", 529, 534]]], ["At present, the COVID-19 diagnosis and treatment plan (trial version 7) includes Chinese medicine.", [["treatment plan (trial version", "TREATMENT", 39, 68], ["Chinese medicine", "TREATMENT", 81, 97]]], ["During the medical observation period, the clinical manifestation is fatigue.", [["fatigue", "DISEASE", 69, 76], ["fatigue", "PROBLEM", 69, 76], ["fatigue", "OBSERVATION", 69, 76]]], ["In case of gastrointestinal discomfort, Huoxiang Zhengqi (capsule, pill, water, or oral liquid) is recommended as the Chinese patented medicine with the most effectiveness.", [["gastrointestinal", "ANATOMY", 11, 27], ["capsule", "ANATOMY", 58, 65], ["oral", "ANATOMY", 83, 87], ["gastrointestinal discomfort", "DISEASE", 11, 38], ["Zhengqi", "CHEMICAL", 49, 56], ["gastrointestinal", "ORGAN", 11, 27], ["oral", "ORGANISM_SUBDIVISION", 83, 87], ["gastrointestinal discomfort", "PROBLEM", 11, 38], ["Huoxiang Zhengqi (capsule, pill, water, or oral liquid)", "TREATMENT", 40, 95], ["the Chinese patented medicine", "TREATMENT", 114, 143], ["gastrointestinal", "ANATOMY", 11, 27], ["discomfort", "OBSERVATION", 28, 38]]], ["In cases of fatigue with fever, a combination of Jinhua Qinggan granules, Lianhua Qingwen capsules (granules), and Shufeng Jiedu capsules (granules) are recommended as the Chinese patented medicines with the most effectiveness.", [["granules", "ANATOMY", 100, 108], ["granules", "ANATOMY", 139, 147], ["fatigue", "DISEASE", 12, 19], ["fever", "DISEASE", 25, 30], ["granules", "ORGANISM_SUBSTANCE", 100, 108], ["granules", "ORGANISM_SUBSTANCE", 139, 147], ["fatigue", "PROBLEM", 12, 19], ["fever", "PROBLEM", 25, 30], ["Jinhua Qinggan granules", "TREATMENT", 49, 72], ["Lianhua Qingwen capsules", "TREATMENT", 74, 98], ["Shufeng Jiedu capsules", "TREATMENT", 115, 137], ["the Chinese patented medicines", "TREATMENT", 168, 198]]], ["In the clinical treatment period, Qingfei Paidu decoction is used for the treatment of mild, regular, and severe patients.", [["Qingfei Paidu decoction", "CHEMICAL", 34, 57], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["Qingfei Paidu decoction", "TREATMENT", 34, 57], ["the treatment", "TREATMENT", 70, 83], ["mild, regular, and severe patients", "PROBLEM", 87, 121], ["mild", "OBSERVATION_MODIFIER", 87, 91], ["severe", "OBSERVATION_MODIFIER", 106, 112]]], ["In addition, the corresponding prescriptions are recommended for different syndromes of mild, regular, severe, and critical patients; for severe and critical patients, Xiyanping injection, Xuebijing injection, Reduning injection, Tanreqing injection, and Xingnaojing injection are recommended (Chen et al. 2020).", [["Xiyanping", "CHEMICAL", 168, 177], ["Xuebijing", "CHEMICAL", 189, 198], ["Tanreqing", "CHEMICAL", 230, 239], ["Xingnaojing", "CHEMICAL", 255, 266], ["patients", "ORGANISM", 124, 132], ["patients", "ORGANISM", 158, 166], ["Xiyanping", "SIMPLE_CHEMICAL", 168, 177], ["patients", "SPECIES", 124, 132], ["patients", "SPECIES", 158, 166], ["different syndromes of mild, regular, severe, and critical patients", "PROBLEM", 65, 132], ["Xiyanping injection", "TREATMENT", 168, 187], ["Xuebijing injection", "TREATMENT", 189, 208], ["Reduning injection", "TREATMENT", 210, 228], ["Tanreqing injection", "TREATMENT", 230, 249], ["Xingnaojing injection", "TREATMENT", 255, 276], ["mild", "OBSERVATION_MODIFIER", 88, 92], ["severe", "OBSERVATION_MODIFIER", 103, 109]]], ["The possible mechanism of Huoxiang Zhengqi in the prevention and treatment of COVID-19 has been discussed.", [["Zhengqi", "CHEMICAL", 35, 42], ["COVID-19", "CHEMICAL", 78, 86], ["COVID-19", "CHEMICAL", 78, 86], ["Huoxiang Zhengqi", "TREATMENT", 26, 42], ["treatment of COVID", "TREATMENT", 65, 83], ["possible", "UNCERTAINTY", 4, 12]]], ["Huoxiang Zhengqi can increase the level of anti-inflammatory cytokine IL-10, regulate the inflammation-related NF-\u03baB pathway, suppress excessive inflammatory response, and resist a variety of viruses.", [["Zhengqi", "CHEMICAL", 9, 16], ["inflammation", "DISEASE", 90, 102], ["IL-10", "GENE_OR_GENE_PRODUCT", 70, 75], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 111, 116], ["anti-inflammatory cytokine IL-10", "PROTEIN", 43, 75], ["NF-\u03baB", "PROTEIN", 111, 116], ["Huoxiang Zhengqi", "TREATMENT", 0, 16], ["anti-inflammatory cytokine IL", "TREATMENT", 43, 72], ["the inflammation", "PROBLEM", 86, 102], ["excessive inflammatory response", "PROBLEM", 135, 166], ["inflammation", "OBSERVATION", 90, 102], ["excessive", "OBSERVATION_MODIFIER", 135, 144], ["inflammatory", "OBSERVATION", 145, 157], ["viruses", "OBSERVATION", 192, 199]]], ["There is in vitro experimental evidence that Huoxiang Zhengqi has a significant inhibitory effect on COVID-19 pathogens (Wang et al., 2020; Huo et al. 2020).", [["Zhengqi", "CHEMICAL", 54, 61], ["Huoxiang", "ORGANISM", 45, 53], ["Zhengqi", "SIMPLE_CHEMICAL", 54, 61], ["significant", "OBSERVATION_MODIFIER", 68, 79]]], ["TCM injection is widely used in the treatment of COVID-19 (Wang, 2019).", [["TCM", "CHEMICAL", 0, 3], ["TCM injection", "TREATMENT", 0, 13], ["COVID", "TEST", 49, 54]]], ["There are still some risks of the use of TCM injections.", [["TCM injections", "TREATMENT", 41, 55]]], ["Attention should be paid to its safety, especially standardization, combination, adverse reactions, and use in special populations (Lin and Zhang, 2020; Xiang et al. 2020; Yang et al. 2020; Zhao et al. 2020).Classic pharmacology in animal experiments ::: Therapeutic pharmacology and mechanismDue to time limitations, there have been few animal experiments related to COVID-19.", [["COVID-19", "CHEMICAL", 368, 376], ["adverse reactions", "PROBLEM", 81, 98], ["Therapeutic pharmacology", "TREATMENT", 255, 279], ["COVID", "TEST", 368, 373], ["few", "OBSERVATION_MODIFIER", 334, 337]]], ["Compound Qinlan Oral Liquid has a certain pharmacological effect in the rat model when combining COVID-19 disease with epidemic toxin closed lung syndrome, through inhibiting virus replication, improving gastrointestinal function, improving immunity, and decreasing inflammatory factor expression.", [["lung", "ANATOMY", 141, 145], ["gastrointestinal", "ANATOMY", 204, 220], ["COVID-19 disease", "DISEASE", 97, 113], ["lung syndrome", "DISEASE", 141, 154], ["rat", "ORGANISM", 72, 75], ["lung", "ORGAN", 141, 145], ["gastrointestinal", "ORGAN", 204, 220], ["inflammatory factor", "PROTEIN", 266, 285], ["rat", "SPECIES", 72, 75], ["rat", "SPECIES", 72, 75], ["Compound Qinlan Oral Liquid", "TREATMENT", 0, 27], ["combining COVID-19 disease", "PROBLEM", 87, 113], ["epidemic toxin closed lung syndrome", "PROBLEM", 119, 154], ["inhibiting virus replication", "TREATMENT", 164, 192], ["decreasing inflammatory factor expression", "PROBLEM", 255, 296], ["lung", "ANATOMY", 141, 145], ["syndrome", "OBSERVATION", 146, 154], ["improving", "OBSERVATION_MODIFIER", 194, 203], ["gastrointestinal function", "OBSERVATION", 204, 229], ["decreasing", "OBSERVATION_MODIFIER", 255, 265], ["inflammatory", "OBSERVATION_MODIFIER", 266, 278]]], ["A therapeutic effect was found in Compound Qinlan Oral Liquid in treating a combination of COVID-19 pneumonia with pestilence attacking lung syndrome (Bao et al. 2020).", [["lung", "ANATOMY", 136, 140], ["COVID-19", "CHEMICAL", 91, 99], ["pneumonia", "DISEASE", 100, 109], ["pestilence", "CHEMICAL", 115, 125], ["lung syndrome", "DISEASE", 136, 149], ["lung", "ORGAN", 136, 140], ["A therapeutic effect", "PROBLEM", 0, 20], ["Compound Qinlan Oral Liquid", "TREATMENT", 34, 61], ["COVID", "TREATMENT", 91, 96], ["pneumonia", "PROBLEM", 100, 109], ["pestilence attacking lung syndrome", "PROBLEM", 115, 149], ["therapeutic effect", "OBSERVATION", 2, 20], ["pneumonia", "OBSERVATION", 100, 109], ["lung", "ANATOMY", 136, 140], ["syndrome", "OBSERVATION", 141, 149]]], ["Reyanning Mixture could treat COVID-19 in mice with epidemic toxin closed lung syndrome.", [["lung", "ANATOMY", 74, 78], ["COVID-19", "CHEMICAL", 30, 38], ["lung syndrome", "DISEASE", 74, 87], ["COVID-19", "CHEMICAL", 30, 38], ["mice", "ORGANISM", 42, 46], ["lung", "ORGAN", 74, 78], ["mice", "SPECIES", 42, 46], ["mice", "SPECIES", 42, 46], ["Reyanning Mixture", "TREATMENT", 0, 17], ["COVID", "TEST", 30, 35], ["epidemic toxin closed lung syndrome", "PROBLEM", 52, 87], ["lung", "ANATOMY", 74, 78], ["syndrome", "OBSERVATION", 79, 87]]], ["It has significant effects such as improving the gastrointestinal function and enhancing the autoimmune function of mice, and decreasing the expression of inflammatory factors in vivo, which would offer reference for clinical research (Bao et al. 2020).Network pharmacology ::: Therapeutic pharmacology and mechanismAt the molecular level, TCM compounds play an all-round and integral role in regulating the body through multi-component and multi-target processes.", [["gastrointestinal", "ANATOMY", 49, 65], ["body", "ANATOMY", 408, 412], ["gastrointestinal", "ORGAN", 49, 65], ["mice", "ORGANISM", 116, 120], ["body", "ORGANISM_SUBDIVISION", 408, 412], ["inflammatory factors", "PROTEIN", 155, 175], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 116, 120], ["inflammatory factors", "PROBLEM", 155, 175], ["Therapeutic pharmacology", "TREATMENT", 278, 302], ["significant", "OBSERVATION_MODIFIER", 7, 18], ["effects", "OBSERVATION", 19, 26], ["gastrointestinal", "ANATOMY", 49, 65], ["autoimmune", "OBSERVATION", 93, 103], ["inflammatory", "OBSERVATION_MODIFIER", 155, 167]]], ["The herb-target interaction network analysis helps to disclose the molecular mechanisms of TCM (Hopkins, 2008; Zhao et al., 2019).Network pharmacology ::: Therapeutic pharmacology and mechanismThe national Health Commission and the State Administration of traditional Chinese medicine jointly issued a notice recommending Qing Fei Pai Du Tang (QFPDT) to be used all over the country (Feng et al., 2019).", [["Therapeutic pharmacology", "TREATMENT", 155, 179], ["traditional Chinese medicine", "TREATMENT", 256, 284], ["Qing Fei Pai Du Tang (QFPDT)", "TREATMENT", 322, 350]]], ["Zhao Jing (Zhao et al. 2020) explored the mechanism of QFPDT in the treatment of COVID-19 with a network pharmacology analysis, by regulating a series of proteins co-expressed with ACE2 and a series of signaling pathways.", [["QFPDT", "CHEMICAL", 55, 60], ["COVID-19", "CHEMICAL", 81, 89], ["QFPDT", "SIMPLE_CHEMICAL", 55, 60], ["ACE2", "GENE_OR_GENE_PRODUCT", 181, 185], ["ACE2", "PROTEIN", 181, 185], ["COVID", "TEST", 81, 86], ["a network pharmacology analysis", "TEST", 95, 126], ["ACE2", "TEST", 181, 185]]], ["QFPDT may act as an antiviral agent by targeting ribosomal proteins that are necessary for viral replication, thus inhibiting viral mRNA translation and inhibiting a group of proteins that interact with viral proteins.", [["ribosomal", "ANATOMY", 49, 58], ["QFPDT", "CHEMICAL", 0, 5], ["QFPDT", "SIMPLE_CHEMICAL", 0, 5], ["ribosomal proteins", "PROTEIN", 49, 67], ["viral mRNA", "RNA", 126, 136], ["viral proteins", "PROTEIN", 203, 217], ["QFPDT", "TREATMENT", 0, 5], ["an antiviral agent", "TREATMENT", 17, 35], ["targeting ribosomal proteins", "TREATMENT", 39, 67], ["viral replication", "PROBLEM", 91, 108], ["viral mRNA translation", "PROBLEM", 126, 148], ["viral proteins", "PROBLEM", 203, 217]]], ["Xu et al. (2020) predicted that the first five active ingredients of QFPDT in the treatment of COVID-19 were quercetin, luteolin, kaempferol, naringin, and isorrine.", [["QFPDT", "CHEMICAL", 69, 74], ["COVID-19", "CHEMICAL", 95, 103], ["quercetin", "CHEMICAL", 109, 118], ["luteolin", "CHEMICAL", 120, 128], ["kaempferol", "CHEMICAL", 130, 140], ["naringin", "CHEMICAL", 142, 150], ["isorrine", "CHEMICAL", 156, 164], ["QFPDT", "CHEMICAL", 69, 74], ["COVID-19", "CHEMICAL", 95, 103], ["quercetin", "CHEMICAL", 109, 118], ["luteolin", "CHEMICAL", 120, 128], ["kaempferol", "CHEMICAL", 130, 140], ["naringin", "CHEMICAL", 142, 150], ["isorrine", "CHEMICAL", 156, 164], ["QFPDT", "SIMPLE_CHEMICAL", 69, 74], ["COVID-19", "SIMPLE_CHEMICAL", 95, 103], ["quercetin", "SIMPLE_CHEMICAL", 109, 118], ["luteolin", "SIMPLE_CHEMICAL", 120, 128], ["kaempferol", "SIMPLE_CHEMICAL", 130, 140], ["naringin", "SIMPLE_CHEMICAL", 142, 150], ["isorrine", "SIMPLE_CHEMICAL", 156, 164], ["QFPDT", "TREATMENT", 69, 74], ["COVID", "TEST", 95, 100], ["quercetin", "TREATMENT", 109, 118], ["luteolin", "TREATMENT", 120, 128], ["kaempferol", "TREATMENT", 130, 140], ["naringin", "TREATMENT", 142, 150], ["isorrine", "TREATMENT", 156, 164]]], ["QFPDT mainly regulates targets such as MAPK1, MAPK3, MAPK8, MAPK14, IL-6, RELA, and STA T1, and signaling pathways such as TNF and NF-\u03baB to inhibit inflammatory response, regulate immune function, reduce lung injury, and protect nerve function, thus effectively treating COVID-19.", [["lung", "ANATOMY", 204, 208], ["nerve", "ANATOMY", 229, 234], ["QFPDT", "CHEMICAL", 0, 5], ["lung injury", "DISEASE", 204, 215], ["COVID-19", "CHEMICAL", 271, 279], ["QFPDT", "SIMPLE_CHEMICAL", 0, 5], ["MAPK1", "GENE_OR_GENE_PRODUCT", 39, 44], ["MAPK3", "GENE_OR_GENE_PRODUCT", 46, 51], ["MAPK8", "GENE_OR_GENE_PRODUCT", 53, 58], ["MAPK14", "GENE_OR_GENE_PRODUCT", 60, 66], ["IL-6", "GENE_OR_GENE_PRODUCT", 68, 72], ["RELA", "GENE_OR_GENE_PRODUCT", 74, 78], ["STA T1", "GENE_OR_GENE_PRODUCT", 84, 90], ["TNF", "GENE_OR_GENE_PRODUCT", 123, 126], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 131, 136], ["lung", "ORGAN", 204, 208], ["nerve", "MULTI-TISSUE_STRUCTURE", 229, 234], ["QFPDT", "PROTEIN", 0, 5], ["MAPK1", "PROTEIN", 39, 44], ["MAPK3", "PROTEIN", 46, 51], ["MAPK8", "PROTEIN", 53, 58], ["MAPK14", "PROTEIN", 60, 66], ["RELA", "PROTEIN", 74, 78], ["STA T1", "PROTEIN", 84, 90], ["TNF", "PROTEIN", 123, 126], ["NF-\u03baB", "PROTEIN", 131, 136], ["MAPK1", "TEST", 39, 44], ["MAPK3", "TEST", 46, 51], ["MAPK8", "TEST", 53, 58], ["MAPK14", "TEST", 60, 66], ["IL", "TEST", 68, 70], ["RELA", "TEST", 74, 78], ["STA T1", "TEST", 84, 90], ["signaling pathways", "PROBLEM", 96, 114], ["TNF", "TEST", 123, 126], ["NF", "TEST", 131, 133], ["inflammatory response", "PROBLEM", 148, 169], ["immune function", "TEST", 180, 195], ["lung injury", "PROBLEM", 204, 215], ["COVID", "TEST", 271, 276], ["lung", "ANATOMY", 204, 208], ["injury", "OBSERVATION", 209, 215], ["nerve", "ANATOMY", 229, 234]]], ["Moreover, it was reported that the components with high oral availability of Qingfei oral solution had good molecular docking results with the targets of RdRp, 3Clpro, and PLpr, and could be used to treat viral pneumonia with fever and cough symptoms by regulating multiple signaling pathways (Yao et al., 2020).Network pharmacology ::: Therapeutic pharmacology and mechanismDa-Yuan-Yin is the original prescription of QFPDT and provincial anti-COVID-19 prescriptions.", [["oral", "ANATOMY", 56, 60], ["oral", "ANATOMY", 85, 89], ["Qingfei", "CHEMICAL", 77, 84], ["viral pneumonia", "DISEASE", 205, 220], ["fever", "DISEASE", 226, 231], ["cough", "DISEASE", 236, 241], ["oral", "ORGANISM_SUBDIVISION", 56, 60], ["oral", "ORGANISM_SUBDIVISION", 85, 89], ["RdRp", "GENE_OR_GENE_PRODUCT", 154, 158], ["3Clpro", "GENE_OR_GENE_PRODUCT", 160, 166], ["PLpr", "GENE_OR_GENE_PRODUCT", 172, 176], ["QFPDT", "SIMPLE_CHEMICAL", 419, 424], ["RdRp", "PROTEIN", 154, 158], ["PLpr", "PROTEIN", 172, 176], ["Qingfei oral solution", "TREATMENT", 77, 98], ["RdRp", "TREATMENT", 154, 158], ["3Clpro", "TREATMENT", 160, 166], ["PLpr", "TREATMENT", 172, 176], ["viral pneumonia", "PROBLEM", 205, 220], ["fever", "PROBLEM", 226, 231], ["cough symptoms", "PROBLEM", 236, 250], ["Therapeutic pharmacology", "TREATMENT", 337, 361], ["mechanismDa-Yuan", "TREATMENT", 366, 382], ["QFPDT", "TREATMENT", 419, 424], ["provincial anti-COVID", "TREATMENT", 429, 450], ["pneumonia", "OBSERVATION", 211, 220]]], ["Based on network pharmacology and the molecular docking method, Zong et al. (2020) pointed out that the active compounds in Da-Yuan-Yin may regulate multiple signaling pathways by binding ACE2 and acting on targets such as prostaglandin-endoperoxide synthase 2 (PTGS2), heat shock protein 90 alpha family class a member 1 (HSP90AA1), and estrogen receptor 1 (ESR1) to inhibit COVID-19.", [["Da-Yuan-Yin", "CHEMICAL", 124, 135], ["prostaglandin-endoperoxide", "CHEMICAL", 223, 249], ["estrogen", "CHEMICAL", 338, 346], ["prostaglandin-endoperoxide", "CHEMICAL", 223, 249], ["estrogen", "CHEMICAL", 338, 346], ["ACE2", "GENE_OR_GENE_PRODUCT", 188, 192], ["prostaglandin-endoperoxide synthase 2", "GENE_OR_GENE_PRODUCT", 223, 260], ["PTGS2", "GENE_OR_GENE_PRODUCT", 262, 267], ["heat shock protein 90 alpha family class a member 1", "GENE_OR_GENE_PRODUCT", 270, 321], ["HSP90AA1", "GENE_OR_GENE_PRODUCT", 323, 331], ["estrogen receptor 1", "GENE_OR_GENE_PRODUCT", 338, 357], ["ESR1", "GENE_OR_GENE_PRODUCT", 359, 363], ["COVID-19", "GENE_OR_GENE_PRODUCT", 376, 384], ["ACE2", "PROTEIN", 188, 192], ["prostaglandin-endoperoxide synthase 2", "PROTEIN", 223, 260], ["PTGS2", "PROTEIN", 262, 267], ["heat shock protein 90 alpha family class a member 1", "PROTEIN", 270, 321], ["HSP90AA1", "PROTEIN", 323, 331], ["estrogen receptor 1", "PROTEIN", 338, 357], ["ESR1", "PROTEIN", 359, 363], ["COVID-19", "PROTEIN", 376, 384], ["prostaglandin-endoperoxide synthase", "TREATMENT", 223, 258], ["heat shock protein", "TREATMENT", 270, 288], ["estrogen receptor", "TREATMENT", 338, 355], ["COVID", "TEST", 376, 381], ["active", "OBSERVATION_MODIFIER", 104, 110]]], ["On the other hand, as a Chinese patented medicine based on Da-Yuan-Yin, Qingfei Dayuan Granules\u2019 main active ingredients had good binding properties to the receptor according to the molecular docking results (Xiang et al. 2020).", [["a Chinese patented medicine", "TREATMENT", 22, 49]]], ["The series Chinese patented medicines of Huoxiang Zhengqi, including Huoxiang Zhengqi oral liquid, are recommended as preventive drugs for COVID-19 patients with gastrointestinal discomfort and fatigue during medical observation.", [["oral", "ANATOMY", 86, 90], ["gastrointestinal", "ANATOMY", 162, 178], ["Zhengqi", "CHEMICAL", 50, 57], ["gastrointestinal discomfort", "DISEASE", 162, 189], ["fatigue", "DISEASE", 194, 201], ["patients", "ORGANISM", 148, 156], ["gastrointestinal", "ORGANISM_SUBDIVISION", 162, 178], ["patients", "SPECIES", 148, 156], ["The series Chinese patented medicines", "TREATMENT", 0, 37], ["Huoxiang Zhengqi", "TREATMENT", 41, 57], ["Huoxiang Zhengqi oral liquid", "TREATMENT", 69, 97], ["preventive drugs", "TREATMENT", 118, 134], ["COVID", "TREATMENT", 139, 144], ["gastrointestinal discomfort", "PROBLEM", 162, 189], ["fatigue", "PROBLEM", 194, 201], ["medical observation", "TEST", 209, 228], ["gastrointestinal", "ANATOMY", 162, 178], ["discomfort", "OBSERVATION", 179, 189]]], ["Based on network pharmacology and the molecular docking method, Deng yanjun (Deng et al. 2020) suggested that the compounds in Huoxiang Zhengqi Oral Liquid can combine with ACE2 binding to PTGS2, heat shock protein 90 alpha family class b member 1 (HSP90AB1), calmodulin regulated spectrin associated protein family member 2 (CAMSAP2), and other targets to regulate multiple signaling pathways, thus exerting a preventive or therapeutic effect on COVID-19.", [["ACE2", "GENE_OR_GENE_PRODUCT", 173, 177], ["PTGS2", "GENE_OR_GENE_PRODUCT", 189, 194], ["heat shock protein 90 alpha family class b member 1", "GENE_OR_GENE_PRODUCT", 196, 247], ["HSP90AB1", "GENE_OR_GENE_PRODUCT", 249, 257], ["calmodulin regulated spectrin associated protein family member 2", "GENE_OR_GENE_PRODUCT", 260, 324], ["CAMSAP2", "GENE_OR_GENE_PRODUCT", 326, 333], ["ACE2", "PROTEIN", 173, 177], ["PTGS2", "PROTEIN", 189, 194], ["heat shock protein 90 alpha family class b member 1", "PROTEIN", 196, 247], ["HSP90AB1", "PROTEIN", 249, 257], ["calmodulin regulated spectrin associated protein family member 2", "PROTEIN", 260, 324], ["CAMSAP2", "PROTEIN", 326, 333], ["Huoxiang Zhengqi Oral Liquid", "TREATMENT", 127, 155], ["ACE2 binding", "PROBLEM", 173, 185], ["heat shock protein", "TREATMENT", 196, 214], ["COVID", "TEST", 447, 452]]], ["In addition, based on the analysis of network pharmacology, huanglian jiedu soup (Wang et al. 2020), Qingwen Baidu Yin (Zhang et al. 2020), and Xue's Wuye Lugen Decoction Tea Drink (Xiang and L\u00fc, 2020) may also have a therapeutic effect on COVID-19.DiscussionThe Chinese method is the only one that has been proven successful, said Bruce Elwald, senior adviser to the director general of the World Health Organization on February 24.", [["huanglian jiedu soup", "TREATMENT", 60, 80], ["COVID", "TEST", 240, 245]]], ["At present, more than 200 countries in the world have experienced COVID-19 outbreaks.", [["COVID", "TEST", 66, 71]]], ["Another advantage of TCM to treat COVID-19 is that the rate of relapse of COVID-19 is lower than that when Western medicine is used.", [["COVID", "DISEASE", 34, 39], ["COVID-19", "CHEMICAL", 74, 82], ["COVID", "TEST", 34, 39], ["COVID", "TEST", 74, 79]]], ["The total rate of relapse of COVID-19 is approximately 0.1% of 8000 cases (Liu et al., 2016).", [["COVID", "DISEASE", 29, 34], ["COVID", "TEST", 29, 34], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["Although pharmacological studies have demonstrated the underlying mechanisms, targets, and biological pathways to treat COVID-19, the only two targets are cathepsin L (CL)-like proteases (CL3) and ACE2.", [["COVID", "DISEASE", 120, 125], ["COVID-19", "CHEMICAL", 120, 128], ["cathepsin L (CL)-like proteases", "GENE_OR_GENE_PRODUCT", 155, 186], ["CL3", "GENE_OR_GENE_PRODUCT", 188, 191], ["ACE2", "GENE_OR_GENE_PRODUCT", 197, 201], ["cathepsin L (CL)-like proteases", "PROTEIN", 155, 186], ["CL3", "PROTEIN", 188, 191], ["ACE2", "PROTEIN", 197, 201], ["pharmacological studies", "TEST", 9, 32], ["COVID", "TEST", 120, 125], ["cathepsin", "TEST", 155, 164], ["ACE2", "TEST", 197, 201]]], ["Cluster of differentiation 147 (CD147) is another host cell route that can be explored for possible pharmacological treatments (Suo et al., 2016).DiscussionChinese medicine is playing a vital role in the global fight against COVID-19, and the demand for Chinese medicine has increased substantially (Zhang et al., 2020).", [["cell", "ANATOMY", 55, 59], ["Cluster of differentiation 147", "GENE_OR_GENE_PRODUCT", 0, 30], ["CD147", "GENE_OR_GENE_PRODUCT", 32, 37], ["host cell", "CELL", 50, 59], ["Cluster of differentiation 147", "PROTEIN", 0, 30], ["CD147", "PROTEIN", 32, 37], ["pharmacological treatments", "TREATMENT", 100, 126], ["Chinese medicine", "TREATMENT", 254, 270]]], ["Chinese medicine has resisted many large-scale epidemics in Chinese history and has continuously introduced the achievements of modern scientific development.", [["large", "OBSERVATION_MODIFIER", 35, 40]]], ["LYZ, XTZ, and BWX collected and analyzed literature and made charts.", [["XTZ", "CHEMICAL", 5, 8], ["BWX", "TREATMENT", 14, 17]]], ["All authors read and approved the manuscript.Uncited References:(Daily., 2020, Chen et al., 2020-05-30, Gu et al., 2020, News. and Astragali, 2020, Hubei University of Traditional Chinese Medicine.", [["Traditional Chinese Medicine", "TREATMENT", 168, 196], ["Astragali", "ANATOMY", 131, 140]]]], "6aec8eb0d50c1f0ead5a00a7554f2867e53c6a6f": [["BackgroundMiddle East respiratory syndrome coronavirus (MERS-CoV) is a severe respiratory infection which has infected over 1888 people in 27 countries [1] .", [["respiratory", "ANATOMY", 78, 89], ["Middle East respiratory syndrome coronavirus", "DISEASE", 10, 54], ["respiratory infection", "DISEASE", 78, 99], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 10, 54], ["MERS-CoV", "ORGANISM", 56, 64], ["people", "SPECIES", 129, 135], ["Middle East respiratory syndrome coronavirus", "SPECIES", 10, 54], ["MERS-CoV", "SPECIES", 56, 64], ["BackgroundMiddle East respiratory syndrome coronavirus", "PROBLEM", 0, 54], ["a severe respiratory infection", "PROBLEM", 69, 99], ["Middle", "ANATOMY_MODIFIER", 10, 16], ["respiratory syndrome", "OBSERVATION", 22, 42], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["respiratory", "ANATOMY", 78, 89], ["infection", "OBSERVATION", 90, 99]]], ["Since its first discovery in Saudi Arabia in 2012 [2] , MERS-CoV has spread to neighboring Gulf countries (Table 1) and reached as far as South East Asia, Europe and North America.", [["MERS-CoV", "ORGANISM", 56, 64], ["MERS-CoV", "SPECIES", 56, 64]]], ["Arabian Gulf countries bear the heaviest burden of the epidemic and with 1549 cases and 643 fatalities, Saudi Arabia is considered the epicentre of MERS-CoV [3] .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 148, 156], ["MERS-CoV", "SPECIES", 148, 156]]], ["To date, camels are considered to be the zoonotic source of the virus [4] .", [["camels", "ORGANISM", 9, 15], ["the virus", "PROBLEM", 60, 69]]], ["Recent data obtained from Saudi Arabian Ministry of Health (MoH) showed that about 41% of the MERS-CoV patients had a history of exposure to camels [5] .", [["MERS-CoV", "ORGANISM", 94, 102], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["MERS-CoV", "SPECIES", 94, 102]]], ["This epidemic poses great public health challenge to the Middle East particularly in view of the fact that the region traditionally hosts large gatherings such as Hajj pilgrimage.", [["Middle", "ANATOMY_MODIFIER", 57, 63]]], ["In order to limit the spread of the epidemic, many important strategies have been introduced from international public health agencies including the World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC).", [["Disease Control", "TREATMENT", 204, 219]]], ["These recommendations include facemask use, hand hygiene, cough etiquette, and avoidance of close contact with camels and consumption of their raw products [6, 7] , needing public participation and subsequent investigation to quantify their uptake and effects.", [["hand", "ANATOMY", 44, 48], ["hand", "ORGANISM_SUBDIVISION", 44, 48], ["facemask use", "TREATMENT", 30, 42], ["hand hygiene", "TREATMENT", 44, 56], ["cough etiquette", "TREATMENT", 58, 73], ["subsequent investigation", "TEST", 198, 222]]], ["Few studies have attempted to examine the knowledge and practices around MERS-CoV among members of the public and health care workers (HCWs) and that is only in Saudi Arabia, the hotspot of MERS-CoV [8] [9] [10] [11] .", [["MERS-CoV", "ORGANISM", 73, 81], ["MERS-CoV", "SPECIES", 73, 81], ["Few studies", "TEST", 0, 11]]], ["However, no study has compared public understanding and behaviors around MERS-CoV across the Gulf countries.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 73, 81], ["MERS-CoV", "SPECIES", 73, 81], ["study", "TEST", 12, 17]]], ["Also, no study has explored knowledge and practices about the risk of camel exposure among the general public.", [["camel", "ORGANISM", 70, 75], ["camel", "SPECIES", 70, 75], ["study", "TEST", 9, 14]]], ["Such data are required for transnational comparisons, designing mitigation plans, research and sharing accountability across the countries.", [["mitigation plans", "TREATMENT", 64, 80]]], ["Moreover, it can also provide lessons for the future in relation to public willingness to adopt prevention behaviors and support related policies against emerging diseases.", [["emerging diseases", "PROBLEM", 154, 171]]], ["To this end, we have conducted a cross-sectional study to examine public awareness about MERS-CoV and compare public adoption of preventive practices including non-pharmaceutical behaviors (e.g. hand hygiene) and exposure to camels in response to the epidemic MERS-CoV among residents of Gulf Cooperation Council (GCC) countries.Study design and recruitment methodThis was a cross-sectional survey among people aged \u226516 years and living in GCC countries, namely, Saudi Arabia, Kuwait, the United Arab Emirates (UAE), Qatar, Bahrain and Oman.", [["hand", "ANATOMY", 195, 199], ["MERS-CoV", "ORGANISM", 89, 97], ["hand", "ORGANISM_SUBDIVISION", 195, 199], ["MERS-CoV", "ORGANISM", 260, 268], ["people", "ORGANISM", 404, 410], ["people", "SPECIES", 404, 410], ["MERS-CoV", "SPECIES", 89, 97], ["MERS-CoV", "SPECIES", 260, 268], ["a cross-sectional study", "TEST", 31, 54], ["preventive practices", "TREATMENT", 129, 149], ["non-pharmaceutical behaviors", "PROBLEM", 160, 188], ["Study design", "TEST", 329, 341], ["recruitment method", "TREATMENT", 346, 364]]], ["The GI is a smartphone app that was published in apple app store in November 2014, to be used as a research data collection platform for cross-sectional and cohort studies targeting users from the GCC countries.", [["apple", "SPECIES", 49, 54], ["cohort studies", "TEST", 157, 171], ["GI", "ANATOMY", 4, 6]]], ["Registered participants who have the app installed on their smartphone devices (voluntarily) received push-notifications (short messages [SMS]-like function) from the app inviting them to open the app and participate in the study, and also reminders were sent to those who did not complete the survey questions [12] .", [["participants", "SPECIES", 11, 23], ["the study", "TEST", 220, 229]]], ["This method was tested successfully in previous studies [13] [14] [15] .Study design and recruitment methodAfter the first push-notification, a reminder was sent once every week to those who did not complete the survey questions.", [["[13] [14] [15]", "SIMPLE_CHEMICAL", 56, 70], ["previous studies", "TEST", 39, 55], ["recruitment method", "TREATMENT", 89, 107]]], ["As the data were obtained electronically no user could submit their responses with missing vital information.", [["the data", "TEST", 3, 11]]], ["Electronic informed consent was obtained from all individual participants included in the study.Study design and recruitment methodData on socio-demographic characteristics of the respondents, perceptions regarding MERS-CoV, and understanding of its risk (24) from exposure to camels or their raw products were collected in a questionnaire.", [["camels", "ORGANISM", 277, 283], ["participants", "SPECIES", 61, 73], ["MERS-CoV", "SPECIES", 215, 223], ["the study", "TEST", 86, 95], ["Study design", "TEST", 96, 108]]], ["The questionnaire also assessed the respondents' adoption of protective behaviors including avoidance of contact with camels, consumption of raw camel milk and meat and adherence of using non-pharmaceutical behaviors such as facemask use and hand hygiene.Sample sizeAssuming that at least 50% of the members of public in GCC countries will have the right knowledge about MERS-CoV [8, 9] , and considering an error margin of 10% to be acceptable for this survey, a minimum sample size of 480 was considered sufficient for this survey, but we aimed to recruit as many participants as possible within the survey period even after the minimum sample size was achieved.Statistical analysisStatistical analysis was performed using the Statistical Package for Social Sciences (SPSS) v. 23 .0 (SPSS, Inc., Chicago, IL, USA).DemographicsA total of 2741 individuals downloaded the app, of whom 1812 (66%) individuals aged 16-75 (median 27) years participated in the study.", [["milk", "ANATOMY", 151, 155], ["meat", "ANATOMY", 160, 164], ["hand", "ANATOMY", 242, 246], ["camel", "ORGANISM", 145, 150], ["milk", "ORGANISM_SUBSTANCE", 151, 155], ["meat", "ORGANISM_SUBDIVISION", 160, 164], ["hand", "ORGANISM_SUBDIVISION", 242, 246], ["individuals", "ORGANISM", 844, 855], ["individuals", "ORGANISM", 895, 906], ["camel", "SPECIES", 145, 150], ["participants", "SPECIES", 566, 578], ["camel", "SPECIES", 145, 150], ["MERS-CoV", "SPECIES", 371, 379], ["non-pharmaceutical behaviors", "TREATMENT", 188, 216], ["Sample", "TEST", 255, 261], ["an error margin", "TEST", 405, 420], ["a minimum sample size", "TEST", 462, 483], ["Statistical analysisStatistical analysis", "TEST", 664, 704], ["the study", "TEST", 952, 961], ["right", "ANATOMY_MODIFIER", 349, 354]]], ["A large proportion (61%) of participants were from Saudi Arabia, the others were from five other participating countries ( Table 2) .Participants' knowledge and perception about MERS-CoVAll respondents were generally aware of MERS-CoV; mass media (TV, magazines, newspapers) was reported to be the main information source (70%).", [["participants", "ORGANISM", 28, 40], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 226, 234], ["participants", "SPECIES", 28, 40], ["Participants", "SPECIES", 133, 145], ["MERS-CoV", "SPECIES", 226, 234], ["CoV", "PROBLEM", 231, 234], ["mass media", "PROBLEM", 236, 246], ["large", "OBSERVATION_MODIFIER", 2, 7], ["proportion", "OBSERVATION_MODIFIER", 8, 18]]], ["Thirty seven per cent of respondents stated that MERS-CoV affects the respiratory tract, 23% named other body parts (e.g. brain, stomach and kidneys), while the remaining 40% reported not to know this (Table 3) .Participants' knowledge and perception about MERS-CoVLess than half (44%) of respondents reported that the disease is severe and serious for everyone, 33% stated it to be serious only for those with 'at risk' conditions while 23% stated that the disease is not serious for anyone (Table 3) .", [["respiratory tract", "ANATOMY", 70, 87], ["body parts", "ANATOMY", 105, 115], ["brain", "ANATOMY", 122, 127], ["stomach", "ANATOMY", 129, 136], ["kidneys", "ANATOMY", 141, 148], ["MERS-CoV", "ORGANISM", 49, 57], ["respiratory tract", "ORGANISM_SUBDIVISION", 70, 87], ["body", "ORGANISM_SUBDIVISION", 105, 109], ["brain", "ORGAN", 122, 127], ["stomach", "ORGAN", 129, 136], ["kidneys", "ORGAN", 141, 148], ["Participants", "SPECIES", 212, 224], ["MERS-CoV", "SPECIES", 49, 57], ["the respiratory tract", "PROBLEM", 66, 87], ["respiratory tract", "ANATOMY", 70, 87], ["brain", "ANATOMY", 122, 127], ["stomach", "ANATOMY", 129, 136], ["kidneys", "ANATOMY", 141, 148], ["disease", "OBSERVATION", 319, 326], ["severe", "OBSERVATION_MODIFIER", 330, 336]]], ["Saudi Arabian participants were 4 times more likely to report MERS-CoV as a serious disease compared to those from other countries (aOR: 4.6, 95% CI: 2.7-8.1, p < 0.01).Participants' knowledge and perception about MERS-CoVOver two thirds (67%) of respondents were either \"not concerned\" or \"slightly concerned\" about MERS-CoV; the following reasons were stated for this: believing that they were under Allah's (God's) protection (40%) and MERS-CoV was not a fatal disease (29%), considering MERS-CoV to be a media propaganda (26%), and holding that they were not at risk of exposure to camels (5%).", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 62, 70], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 317, 325], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 439, 447], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 491, 499], ["participants", "SPECIES", 14, 26], ["Participants", "SPECIES", 169, 181], ["MERS-CoV", "SPECIES", 62, 70], ["MERS-CoV", "SPECIES", 317, 325], ["MERS-CoV", "SPECIES", 439, 447], ["MERS-CoV", "SPECIES", 491, 499], ["a serious disease", "PROBLEM", 74, 91], ["aOR", "TEST", 132, 135], ["CI", "TEST", 146, 148], ["p", "TEST", 159, 160], ["a fatal disease", "PROBLEM", 456, 471], ["a media propaganda", "TREATMENT", 506, 524]]], ["On the other hand, 33% of respondents were highly or moderately concerned about MERS-CoV (Table 3) ; the following reasons were given: having poor immunity (37%), reports of several cases in the same city or country (28%), infected cases among family members or friends (26%) and high risk occupation (e.g., being a HCW) (9%).", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 80, 88], ["MERS-CoV", "SPECIES", 80, 88]]], ["Those with chronic conditions (OR: 1.7, 95% CI: 1.1-1.7, p < 0.01) were more likely to be concerned of contracting MERS-CoV, however, males (aOR: 0.6, 95% CI:0.4-0.9, p = 0.01) and participants who thought MERS-CoV was serious only for individuals with high risk conditions were less likely to be concerned about the disease (aOR: 0.6, 95% CI: 0.4-0.8, p = 0.01).Participants' knowledge and practices about MERS-CoV and its transmissionHuman-to-human transmission Majority (79%) of respondents rightly stated that MERS-CoV can transmit through droplet spread via sneezing or coughing from an infected person however, 21% reported that the disease transmits through direct contact with an infected person.", [["Human-to-human transmission", "DISEASE", 436, 463], ["MERS-CoV", "ORGANISM", 115, 123], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 206, 214], ["MERS-CoV", "ORGANISM", 407, 415], ["Human", "ORGANISM", 436, 441], ["human", "ORGANISM", 445, 450], ["MERS-CoV", "ORGANISM", 514, 522], ["participants", "SPECIES", 181, 193], ["Participants", "SPECIES", 363, 375], ["Human", "SPECIES", 436, 441], ["human", "SPECIES", 445, 450], ["person", "SPECIES", 601, 607], ["person", "SPECIES", 697, 703], ["MERS-CoV", "SPECIES", 115, 123], ["MERS-CoV", "SPECIES", 206, 214], ["MERS-CoV", "SPECIES", 407, 415], ["human", "SPECIES", 445, 450], ["MERS-CoV", "SPECIES", 514, 522], ["chronic conditions", "PROBLEM", 11, 29], ["CI", "TEST", 44, 46], ["p", "TEST", 57, 58], ["contracting MERS", "PROBLEM", 103, 119], ["aOR", "TEST", 141, 144], ["CI", "TEST", 155, 157], ["CoV", "PROBLEM", 211, 214], ["high risk conditions", "PROBLEM", 253, 273], ["the disease", "PROBLEM", 313, 324], ["aOR", "TEST", 326, 329], ["CI", "TEST", 340, 342], ["sneezing", "PROBLEM", 563, 571], ["coughing", "PROBLEM", 575, 583], ["the disease transmits", "PROBLEM", 635, 656], ["chronic", "OBSERVATION_MODIFIER", 11, 18], ["MERS", "OBSERVATION", 115, 119], ["infected", "OBSERVATION", 592, 600], ["infected", "OBSERVATION", 688, 696]]], ["Other respondents reported several other modes of transmission (e.g., through air, contaminated food and contaminated surfaces), however their awareness varied by country ( Participants' compliance with protective measures is summarized in Table 3 .", [["protective measures", "TREATMENT", 203, 222]]], ["The most commonly practised protective behavior was hand hygiene (e.g., hand washing with water or disinfectants), adopted by 40% to 50% of respondents (Table 4 ).", [["hand", "ANATOMY", 52, 56], ["hand", "ANATOMY", 72, 76], ["hand", "ORGANISM_SUBDIVISION", 52, 56], ["hand", "ORGANISM_SUBDIVISION", 72, 76], ["disinfectants", "TREATMENT", 99, 112]]], ["Students (aOR: 2.9, 95% CI: 2.1-4.2, p < 0.01), government employees (aOR: 1.7, 95% CI: 1.2-2.5, p < 0.01), and residents of Saudi Arabia (aOR: 2.3, 95% CI: 1.8-3.1, p < 0.01) and Bahrain (aOR: 2.4, 95% CI: 1.5-3.9, p < 0.01) were more likely to comply with hand hygiene.Participants' knowledge and practices about MERS-CoV and its transmissionOverall, 39% of participants intended to avoid close contact with sick individuals who exhibited flu-like symptoms (e.g., coughing and sneezing) ( Wearing facemask in crowded public places was practised by 24% of respondents.", [["hand", "ANATOMY", 258, 262], ["flu-like symptoms", "DISEASE", 441, 458], ["coughing", "DISEASE", 466, 474], ["sneezing", "DISEASE", 479, 487], ["hand", "ORGANISM_SUBDIVISION", 258, 262], ["MERS-CoV", "ORGANISM", 315, 323], ["Participants", "SPECIES", 271, 283], ["participants", "SPECIES", 360, 372], ["MERS-CoV", "SPECIES", 315, 323], ["aOR", "TEST", 10, 13], ["CI", "TEST", 24, 26], ["p", "TEST", 37, 38], ["CI", "TEST", 84, 86], ["aOR", "TEST", 139, 142], ["CI", "TEST", 153, 155], ["p", "TEST", 166, 167], ["Bahrain", "TEST", 180, 187], ["aOR", "TEST", 189, 192], ["CI", "TEST", 203, 205], ["p", "TEST", 216, 217], ["flu-like symptoms", "PROBLEM", 441, 458], ["coughing", "PROBLEM", 466, 474], ["sneezing", "PROBLEM", 479, 487], ["facemask", "TREATMENT", 499, 507]]], ["Only those with postgraduate qualification were more likely to use facemask in crowded places than others (aOR: 2.8, 95% CI: 1.8-4.4, p < 0.01).", [["facemask", "TREATMENT", 67, 75], ["aOR", "TEST", 107, 110], ["CI", "TEST", 121, 123], ["p", "TEST", 134, 135]]], ["However, males (aOR: 0.6, 95% CI: 0.5-0.9, p = 0.01) and those who were aged between 37 to 55 years (aOR: 0.3, 95% CI: 0.3-0.8, p < 0.01) were less likely to use facemask in crowded places.Zoonotic transmissionOnly 12% of respondents reported that MERS-CoV transmits through close contact with infected camels; those with postgraduate education (aOR: 1.8, 95% CI: 1.1-3.3, p = 0.04) were more likely to report that MERS-CoV transmits through camels, however, people in UAE (aOR: 0.4, 95% CI: 0.2-0.7, p < 0.01) and Kuwait (aOR: 0.5, 95% CI: 0.3-0.7, p < 0.01) were less likely to report so.", [["MERS-CoV", "ORGANISM", 248, 256], ["MERS-CoV", "ORGANISM", 415, 423], ["camels", "ORGANISM", 442, 448], ["people", "ORGANISM", 459, 465], ["people", "SPECIES", 459, 465], ["MERS-CoV", "SPECIES", 248, 256], ["aOR", "TEST", 16, 19], ["CI", "TEST", 30, 32], ["CI", "TEST", 115, 117], ["facemask", "TREATMENT", 162, 170], ["Zoonotic transmissionOnly", "TREATMENT", 189, 214], ["CI", "TEST", 360, 362], ["UAE", "TEST", 469, 472], ["aOR", "TEST", 474, 477], ["CI", "TEST", 488, 490], ["aOR", "TEST", 523, 526], ["CI", "TEST", 537, 539]]], ["Respondents also reported other modes of transmission, including consumption of raw camel milk (18%) and meat (62%), however their awareness varied by country (Table 3 ).Zoonotic transmissionIn addition, only 22% of respondents believed that camels are the zoonotic reservoir of MERS-CoV, whereas the remaining 78% did not believe or are unsure if camels were a reservoir (Table 3) .", [["meat", "ANATOMY", 105, 109], ["camel", "ORGANISM", 84, 89], ["milk", "ORGANISM_SUBSTANCE", 90, 94], ["meat", "ORGANISM_SUBDIVISION", 105, 109], ["camels", "ORGANISM", 242, 248], ["MERS-CoV", "ORGANISM", 279, 287], ["camels", "ORGANISM", 348, 354], ["camel", "SPECIES", 84, 89], ["camel", "SPECIES", 84, 89], ["MERS-CoV", "SPECIES", 279, 287]]], ["Interestingly, of those who were aware that the disease can transmit through close contact with camels only 31% (65/209) believed that camels are the zoonotic reservoir of MERS-CoV.", [["camels", "ORGANISM", 135, 141], ["MERS-CoV", "ORGANISM", 172, 180], ["MERS-CoV", "SPECIES", 172, 180], ["the disease", "PROBLEM", 44, 55]]], ["Those who were concerned about contracting MERS-CoV (aOR: 1.6, 95% CI: 1.2-2.1, p < 0.01) and those who thought MERS-CoV to be a severe disease only for those with high-risk conditions (aOR: 1.5, 95% CI: 1.1-2.1, p < 0.01) were more likely to believe that camels are the zoonotic source.", [["MERS-CoV", "DISEASE", 43, 51], ["MERS-CoV", "ORGANISM", 43, 51], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 112, 120], ["camels", "ORGANISM", 256, 262], ["MERS-CoV", "SPECIES", 43, 51], ["MERS-CoV", "SPECIES", 112, 120], ["CI", "TEST", 67, 69], ["p", "TEST", 80, 81], ["CoV", "PROBLEM", 117, 120], ["a severe disease", "PROBLEM", 127, 143], ["high-risk conditions", "PROBLEM", 164, 184], ["CI", "TEST", 200, 202], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["disease", "OBSERVATION", 136, 143], ["zoonotic", "OBSERVATION_MODIFIER", 271, 279]]], ["However, residents of KSA (aOR: 0.03, 95% CI: 0.01-0.07, p < 0.01), UAE (aOR: 0.01, 95% CI: 0.004-0.02, p < 0.01) and Kuwait (aOR: 0.03, 95% CI: 0.01-0.07, p < 0.01) were less likely to believe that camels are the main zoonotic source compared to respondents from the other countries.Zoonotic transmissionParticipants' compliance to the protective measures is summarized in Table 4 .", [["camels", "ORGANISM", 199, 205], ["CI", "TEST", 42, 44], ["UAE", "TEST", 68, 71], ["aOR", "TEST", 73, 76], ["CI", "TEST", 88, 90], ["p", "TEST", 104, 105], ["aOR", "TEST", 126, 129], ["CI", "TEST", 141, 143], ["Zoonotic transmissionParticipants", "TREATMENT", 284, 317], ["the protective measures", "TREATMENT", 333, 356], ["main", "OBSERVATION_MODIFIER", 214, 218], ["zoonotic", "OBSERVATION_MODIFIER", 219, 227]]], ["Those who were aware that MERS-CoV can transmit through close contact with camels (aOR: 1.3, 95% CI: 1.1-1.7, p < 0.01) and those who thought the disease to be severe for everyone (aOR: 1.5, 95% CI: 1.1-2.1, p = 0.01) were more likely to avoid camel contact.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 26, 34], ["camel", "ORGANISM", 244, 249], ["MERS-CoV", "SPECIES", 26, 34], ["CI", "TEST", 97, 99], ["the disease", "PROBLEM", 142, 153], ["CI", "TEST", 195, 197], ["disease", "OBSERVATION", 146, 153]]], ["In contrast, males (aOR: 0.4, 95% CI: 0.3-0.6, p < 0.01), those with chronic medical conditions (aOR: 0.7, 95% CI: 0.5-0.9, p = 0.01), and residents of Saudi Arabia (aOR: 0.3, 95% CI: 0.2-0.5, p < 0.01) and UAE (aOR: 0.5, 95% CI: 0.3-0.9, p < 0.01) were less likely to avoid close contact with camels.Zoonotic transmissionAbout a quarter of respondents intended to avoid consumption of raw camel products including milk (28%) and meat (22%).", [["milk", "ANATOMY", 415, 419], ["meat", "ANATOMY", 430, 434], ["camel", "ORGANISM", 390, 395], ["milk", "ORGANISM_SUBSTANCE", 415, 419], ["meat", "ORGANISM_SUBDIVISION", 430, 434], ["milk", "SPECIES", 415, 419], ["camel", "SPECIES", 390, 395], ["aOR", "TEST", 20, 23], ["CI", "TEST", 34, 36], ["chronic medical conditions", "PROBLEM", 69, 95], ["aOR", "TEST", 97, 100], ["CI", "TEST", 111, 113], ["aOR", "TEST", 166, 169], ["CI", "TEST", 180, 182], ["p", "TEST", 193, 194], ["UAE", "TEST", 207, 210], ["aOR", "TEST", 212, 215], ["CI", "TEST", 226, 228], ["chronic", "OBSERVATION_MODIFIER", 69, 76]]], ["Residents of Oman (aOR: 1.8, 95% CI: 1.1-3.3, p < 0.01) and individuals who were generally concerned about MERS-CoV (aOR: 1.7, 95% CI: 1.4-2.2, p < 0.01) were more likely to avoid consumption of raw camel products.DiscussionThis is the first in-depth study involving participants from six Middle East countries showing that public perception and practices surrounding MERS-CoV vary widely among the public within these countries.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 107, 115], ["camel", "ORGANISM", 199, 204], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 368, 376], ["participants", "SPECIES", 267, 279], ["MERS-CoV", "SPECIES", 107, 115], ["camel", "SPECIES", 199, 204], ["MERS-CoV", "SPECIES", 368, 376], ["CI", "TEST", 33, 35], ["aOR", "TEST", 117, 120], ["CI", "TEST", 131, 133]]], ["There was a discrepancy between the respondents' perception about MERS-CoV and their actual compliance with preventive measures against it.DiscussionOverall participants' awareness about the MERS-CoV outbreak in the Middle East recorded in this survey is comparable to other surveys conducted among the general public in Saudi Arabia which showed that over 97% respondents were generally aware of MERS-CoV [8, 16] , but public awareness in this study was much higher than that among Hajj pilgrims to Saudi Arabia [17] [18] [19] [20] .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 66, 74], ["MERS-CoV", "ORGANISM", 191, 199], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 397, 405], ["participants", "SPECIES", 157, 169], ["MERS-CoV", "SPECIES", 66, 74], ["MERS-CoV", "SPECIES", 191, 199], ["MERS-CoV", "SPECIES", 397, 405], ["preventive measures", "TREATMENT", 108, 127], ["this study", "TEST", 440, 450]]], ["However, participants' specific knowledge about the mode of transmission was lower and differed depending on the modalities of transmission; for example, overall 79% participants knew that MERS-CoV transmits through coughing or sneezing (i.e., through large droplets) which is comparable to 72%-91% Saudi public knowing that coughing or sneezing spread MERS-CoV [8, 9, 16] .", [["coughing", "DISEASE", 216, 224], ["coughing", "DISEASE", 325, 333], ["sneezing", "DISEASE", 337, 345], ["participants", "ORGANISM", 166, 178], ["MERS-CoV", "ORGANISM", 189, 197], ["participants", "SPECIES", 9, 21], ["participants", "SPECIES", 166, 178], ["MERS-CoV", "SPECIES", 189, 197], ["MERS-CoV", "SPECIES", 353, 361], ["coughing", "PROBLEM", 216, 224], ["sneezing", "PROBLEM", 228, 236], ["coughing", "PROBLEM", 325, 333], ["sneezing", "PROBLEM", 337, 345]]], ["Conversely, this survey shows that only 21% of participants (24% of Saudi Arabian respondents) believed that MERS-CoV transmits through close contact with infected person, which is comparable to 31% Saudi citizens believing so, but much lower compared to another study which demonstrated that >70% Saudi people considered MERS-CoV to spread from person to person via close contact such as shaking hands with an infected person [8, 9] , but without sustained community transmission [8] ; this difference may suggest that in-depth knowledge of MERS-CoV transmission is very much individual, and people build on learning about this from their background knowledge and life experiences.", [["participants", "ORGANISM", 47, 59], ["MERS-CoV", "ORGANISM", 109, 117], ["people", "ORGANISM", 304, 310], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 322, 330], ["MERS-CoV", "ORGANISM", 542, 550], ["people", "ORGANISM", 593, 599], ["participants", "SPECIES", 47, 59], ["person", "SPECIES", 164, 170], ["people", "SPECIES", 304, 310], ["person", "SPECIES", 346, 352], ["person", "SPECIES", 356, 362], ["person", "SPECIES", 420, 426], ["people", "SPECIES", 593, 599], ["MERS-CoV", "SPECIES", 109, 117], ["MERS-CoV", "SPECIES", 322, 330], ["MERS-CoV", "SPECIES", 542, 550], ["another study", "TEST", 255, 268]]], ["For example, surveys involving healthcare workers have shown that 64% of dental students and 88% of hospital HCWs were aware that MERS-CoV can transmit through close contact like caring for and/or living in the same house with infected persons, indicating that persons with better understanding of the disease were more aware of its transmission [10, 11] .DiscussionIn this study we found that there is inter-country variability of public perception of MERS-CoV in GCC countries, for example participants from Oman reported more accurate knowledge about the infection and complied better with most preventive measures than the participants from the other countries.", [["infection", "DISEASE", 558, 567], ["HCWs", "ORGANISM", 109, 113], ["MERS-CoV", "ORGANISM", 130, 138], ["persons", "ORGANISM", 236, 243], ["persons", "ORGANISM", 261, 268], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 453, 461], ["participants", "ORGANISM", 492, 504], ["persons", "SPECIES", 236, 243], ["persons", "SPECIES", 261, 268], ["participants", "SPECIES", 492, 504], ["participants", "SPECIES", 627, 639], ["MERS-CoV", "SPECIES", 130, 138], ["MERS-CoV", "SPECIES", 453, 461], ["the disease", "PROBLEM", 298, 309], ["this study", "TEST", 369, 379], ["the infection", "PROBLEM", 554, 567], ["infection", "OBSERVATION", 558, 567]]], ["This inter-country variability of public perception of MERS-CoV in GCC countries resembles the transnational differences in adoption of preventive behaviors against H1N1 pandemic influenza in 2009 [21] .", [["H1N1", "DISEASE", 165, 169], ["influenza", "DISEASE", 179, 188], ["MERS-CoV", "ORGANISM", 55, 63], ["H1N1 pandemic influenza", "SPECIES", 165, 188], ["MERS-CoV", "SPECIES", 55, 63], ["MERS", "PROBLEM", 55, 59], ["H1N1 pandemic influenza", "PROBLEM", 165, 188]]], ["This variability could be related to an array of factors that affect behavior adoption, including the burden of disease, government mitigation plans, cost and availability of interventions, and the media's portrayal of the disease [21] ; and the public's level of understanding may correspond with the degree of stringency imposed by health authorities [22] .DiscussionMost participants (overall 40%) perceived MERS-CoV to be severe for all, but again there was inter-country variation: respondents from Saudi Arabia were about five times more likely to report so compared to respondents from other countries.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 411, 419], ["participants", "SPECIES", 374, 386], ["MERS-CoV", "SPECIES", 411, 419], ["disease", "PROBLEM", 112, 119], ["interventions", "TREATMENT", 175, 188], ["the disease", "PROBLEM", 219, 230], ["disease", "OBSERVATION", 112, 119], ["disease", "OBSERVATION", 223, 230]]], ["In contrast, a survey involving Saudi Arabian people demonstrated that 47.6% respondents believed the elderly people to be at special risk of MERS-CoV [8] and another Saudi Arabian survey showed that 80% respondents were not seriously worried about MERS-CoV [16] .", [["people", "ORGANISM", 110, 116], ["MERS-CoV", "ORGANISM", 142, 150], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 249, 257], ["people", "SPECIES", 46, 52], ["people", "SPECIES", 110, 116], ["MERS-CoV", "SPECIES", 142, 150], ["MERS-CoV", "SPECIES", 249, 257]]], ["In our study no participant from Bahrain and Qatar expressed significant concern presumably because of very low case burden in those countries.DiscussionAn interesting relationship was observed when the nexus between public understanding about the transmission of MERS-CoV on exposure to camels or their raw products and people's beliefs about camels being a zoonotic source was considered against their practice around the avoidance of close camel contact or abstention from consumption of raw camel products.", [["MERS-CoV", "ORGANISM", 264, 272], ["camels", "ORGANISM", 288, 294], ["people", "ORGANISM", 321, 327], ["camels", "ORGANISM", 344, 350], ["camel", "ORGANISM", 443, 448], ["people", "SPECIES", 321, 327], ["MERS-CoV", "SPECIES", 264, 272], ["camel", "SPECIES", 495, 500], ["our study", "TEST", 3, 12]]], ["Only 12% respondents said that MERS-CoV can be acquired by coming in direct contact with infected camels yet 56% participants avoided camel contact.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 31, 39], ["camels", "ORGANISM", 98, 104], ["camel", "ORGANISM", 134, 139], ["participants", "SPECIES", 113, 125], ["MERS-CoV", "SPECIES", 31, 39]]], ["On the contrary, respectively 18% and 62% believed that it can be acquired by consuming raw milk and meat, yet only 22% respondents believed camels to be a zoonotic reservoir, and up to 28% participants avoided raw camel products.", [["milk", "ANATOMY", 92, 96], ["meat", "ANATOMY", 101, 105], ["milk", "ORGANISM_SUBSTANCE", 92, 96], ["meat", "ORGANISM_SUBDIVISION", 101, 105], ["camels", "ORGANISM", 141, 147], ["participants", "SPECIES", 190, 202], ["camel", "SPECIES", 215, 220], ["a zoonotic reservoir", "TREATMENT", 154, 174]]], ["This observation remains difficult to explain fully, however other surveys involving Saudi public and trainee HCWs have shown that about 50% respondents believed camels to be the source of MERS-CoV [8, 9, 11] .", [["camels", "ORGANISM", 162, 168], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 189, 197], ["MERS-CoV", "SPECIES", 189, 197]]], ["From the example of avoiding camel contact, a unique observation was that there was an upward transition from peoples' awareness to action.", [["an upward transition", "PROBLEM", 84, 104]]], ["The framework of this model sets forward stages of health behavior change in an individual and the factors that lead people to move from one stage to another such as beliefs, perceived susceptibility, perceived severity, perceived barriers, motivation, and cues to action [23] .", [["people", "SPECIES", 117, 123]]], ["Paradoxically, however, more respondents (56%) avoided camels while only a small proportion (12%) was aware of the acquisition of MERS-CoV from camels.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 130, 138], ["camels", "ORGANISM", 144, 150], ["MERS-CoV", "SPECIES", 130, 138]]], ["This is likely because, contact with camel or consumption of its raw products (milk, liver, meat, and urine) is associated with other exotic infections such as brucellosis, plague, and rift valley fever [24] [25] [26] , so some respondents may have avoided exposure to camel to prevent other non-MERS diseases.DiscussionResults from this study also found hand hygiene (\u226544%) and cough etiquette (46%) to be more popular measures, while facemask use in crowded places was less popular reported by only 24% of participants.", [["milk", "ANATOMY", 79, 83], ["liver", "ANATOMY", 85, 90], ["meat", "ANATOMY", 92, 96], ["urine", "ANATOMY", 102, 107], ["hand", "ANATOMY", 355, 359], ["infections", "DISEASE", 141, 151], ["brucellosis", "DISEASE", 160, 171], ["plague", "DISEASE", 173, 179], ["fever", "DISEASE", 197, 202], ["cough", "DISEASE", 379, 384], ["camel", "ORGANISM", 37, 42], ["milk", "ORGANISM_SUBDIVISION", 79, 83], ["liver", "ORGAN", 85, 90], ["meat", "ORGANISM_SUBDIVISION", 92, 96], ["urine", "ORGANISM_SUBSTANCE", 102, 107], ["camel", "ORGANISM", 269, 274], ["hand", "ORGANISM_SUBDIVISION", 355, 359], ["milk", "SPECIES", 79, 83], ["participants", "SPECIES", 508, 520], ["camel", "SPECIES", 269, 274], ["its raw products", "TREATMENT", 61, 77], ["other exotic infections", "PROBLEM", 128, 151], ["brucellosis", "PROBLEM", 160, 171], ["plague", "PROBLEM", 173, 179], ["rift valley fever", "PROBLEM", 185, 202], ["other non-MERS diseases", "PROBLEM", 286, 309], ["this study", "TEST", 333, 343], ["cough etiquette", "PROBLEM", 379, 394], ["liver", "ANATOMY", 85, 90], ["infections", "OBSERVATION", 141, 151], ["brucellosis", "OBSERVATION", 160, 171]]], ["Other surveys conducted in Saudi Arabia demonstrated that 74%-94% participants practised hand washing [9] , and between 81% and 93% practised respiratory etiquette in order to protect from MERS-CoV [9] .", [["hand", "ANATOMY", 89, 93], ["participants", "ORGANISM", 66, 78], ["participants", "SPECIES", 66, 78], ["MERS-CoV", "SPECIES", 189, 197]]], ["The use of facemask varies widely: a recent survey conducted in Riyadh reported that 75% participants used facemask in crowded places while a country-wide survey demonstrated that 11% used facemasks in public places [8, 9] .", [["participants", "SPECIES", 89, 101], ["facemask", "TREATMENT", 107, 115]]], ["This is likely because hand hygiene and cough etiquette are easy to implement, culturally acceptable among Arabic people and complement Muslims' daily washing five times a day before prayers [27] .DiscussionThis study shows that being well-educated (e.g., having a university qualification), a government employee, or a resident of certain countries (e.g., Saudi Arabia) were significantly associated with better awareness of MERS-CoV, and higher compliance with preventive measures.", [["hand", "ANATOMY", 23, 27], ["hand", "ORGANISM_SUBDIVISION", 23, 27], ["people", "ORGANISM", 114, 120], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 426, 434], ["people", "SPECIES", 114, 120], ["MERS-CoV", "SPECIES", 426, 434], ["cough", "PROBLEM", 40, 45], ["This study", "TEST", 207, 217], ["preventive measures", "TREATMENT", 463, 482], ["likely because", "UNCERTAINTY", 8, 22]]], ["Similarly, in another survey involving Saudi citizens, respondents who reported to be aware of MERS-CoV were more likely to have at least high school level education, but surprisingly more likely to be unemployed or employed in health care sector [16] .DiscussionInterestingly, this study also revealed that most participants who had no or only slight concern regarding catching MERS- CoV implied that no major calamity will befall them so long as they remain under God's protection, some other participants had genuine misperception about MERS-CoV: about one third of respondents thought that MERS-CoV was not fatal, and over a quarter believed that it was a mere media propaganda.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 95, 103], ["MERS- CoV", "ORGANISM", 379, 388], ["MERS-CoV", "ORGANISM", 540, 548], ["MERS-CoV", "ORGANISM", 594, 602], ["participants", "SPECIES", 313, 325], ["participants", "SPECIES", 495, 507], ["MERS-CoV", "SPECIES", 95, 103], ["MERS- CoV", "SPECIES", 379, 388], ["MERS-CoV", "SPECIES", 540, 548], ["MERS-CoV", "SPECIES", 594, 602], ["this study", "TEST", 278, 288], ["God's protection", "TREATMENT", 466, 482]]], ["Other surveys involving Saudi public showed that faith in God was a strong resilience factor against serious emerging infectious threats, and a survey involving Australian Hajj pilgrims has shown that some people misinterpret this faith in God to such an extent that they use it as an excuse to miss out recommended vaccinations [28, 29] .DiscussionThis study indicates that the use of smartphone applications to track the change in health behavior among public is feasible.", [["people", "ORGANISM", 206, 212], ["people", "SPECIES", 206, 212], ["This study", "TEST", 349, 359], ["smartphone applications", "TREATMENT", 386, 409], ["infectious", "OBSERVATION", 118, 128]]], ["Smartphones are increasingly becoming an essential part of modern life, for example in Saudi Arabia about 70% of mobile users own smartphones [30] .", [["Smartphones", "TREATMENT", 0, 11]]], ["A few studies have demonstrated the usefulness of using electronic surveys, including by using mobile devices, in conducting surveys with promising results [31] [32] [33] [34] .", [["[31] [32] [33] [34]", "SIMPLE_CHEMICAL", 156, 175], ["A few studies", "TEST", 0, 13], ["electronic surveys", "TEST", 56, 74], ["mobile devices", "TREATMENT", 95, 109]]], ["For instance, in a comparative study of pen and paper survey versus smart phone data collection, Zhang et al. [32] demonstrated that much data recording and entry errors were prevented in smart phone surveys (while in pen-paper based surveys 65% of the data did not match and needed to be rechecked subsequently).", [["a comparative study", "TEST", 17, 36]]], ["This study shows that using smartphones allows fast communication with target population, saves time and effort, and is cheap.", [["This study", "TEST", 0, 10]]], ["However, using smartphones in social and epidemiological research works has not yet gained much popularity and deserves further evaluation to confirm its effectiveness.DiscussionThis study demonstrates that despite being aware of MERS-CoV epidemic many individuals in GCC countries lack proper knowledge about its transmission and prevention, and not fully compliant with preventive measures.", [["MERS-CoV", "ORGANISM", 230, 238], ["MERS-CoV", "SPECIES", 230, 238], ["further evaluation", "TEST", 120, 138], ["This study", "TEST", 178, 188], ["preventive measures", "TREATMENT", 372, 391]]], ["There are significant opportunities to improve public perception, and compliance with preventive health measures against MERS-CoV among people of GCC countries.", [["MERS-CoV", "ORGANISM", 121, 129], ["people", "ORGANISM", 136, 142], ["people", "SPECIES", 136, 142], ["MERS-CoV", "SPECIES", 121, 129], ["preventive health measures", "TREATMENT", 86, 112], ["significant", "OBSERVATION_MODIFIER", 10, 21]]], ["To some extent, this could be achieved by supplying the public with up-to-date, culturally appropriate health information.DiscussionThis study has some limitations.", [["This study", "TEST", 132, 142], ["some extent", "OBSERVATION_MODIFIER", 3, 14]]], ["As a cross sectional study, no follow up was conducted, and public perception assessed at a point of time may not be representative of their consistent beliefs or practices, this is particularly true for their exposure to camels; second, the cohort was skewed toward male since 82% of the participants were male; third, the data were self-reported and the actual behaviors practised may be different; fourth, the number of participants from one country (Oman) was too low to allow sub-group analysis which might have biased the comparison; fifth, no question was asked about the respondents' urban or rural dwelling hence stratification of data based on rural and urban regions was not possible, sixth, the study may have excluded people with limited or no access to smartphones leading to potential selection bias, finally, although smartphone use is gradually becoming ubiquitous, as a survey tool it too introduces bias resulting from intrinsic factors related to its users.", [["participants", "ORGANISM", 289, 301], ["people", "ORGANISM", 731, 737], ["participants", "SPECIES", 289, 301], ["participants", "SPECIES", 423, 435], ["people", "SPECIES", 731, 737], ["a cross sectional study", "TEST", 3, 26], ["sub-group analysis", "TEST", 481, 499], ["rural dwelling", "TREATMENT", 601, 615], ["the study", "TEST", 703, 712], ["intrinsic factors", "PROBLEM", 938, 955]]], ["Despite these limitations this study has provided unique data on public perceptions and practices surrounding MERS-CoV.DiscussionTo conclude, this study highlights that many people in GCC countries lack accurate understanding about MERS-CoV transmission, biology and prevention, and are not fully compliant with preventive measures.", [["MERS-CoV", "ORGANISM", 110, 118], ["people", "ORGANISM", 174, 180], ["MERS-CoV", "ORGANISM", 232, 240], ["people", "SPECIES", 174, 180], ["MERS-CoV", "SPECIES", 110, 118], ["MERS-CoV", "SPECIES", 232, 240], ["this study", "TEST", 26, 36], ["this study", "TEST", 142, 152], ["preventive measures", "TREATMENT", 312, 331]]], ["There is considerable variation between countries; people from countries with higher disease burden seem to be more aware of the disease.FundingNone required.Competing interestsAuthor H.R. has received research grants from Pfizer and Novartis for consulting or serving on an advisory board.", [["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57], ["higher disease burden", "PROBLEM", 78, 99], ["the disease", "PROBLEM", 125, 136], ["considerable", "OBSERVATION_MODIFIER", 9, 21], ["variation", "OBSERVATION_MODIFIER", 22, 31], ["disease", "OBSERVATION", 129, 136]]], ["The other Authors (A.S.A., M.H.B., T.M.A. and N.F.B.) have declared no conflict of interest in relation to this work.Ethical approvalThis study was reviewed and approved by the Human Research Ethics Committee at King Saud University (Ethics Ref No: 4/2016), Riyadh, Saudi Arabia.", [["Human", "ORGANISM", 177, 182], ["Human", "SPECIES", 177, 182], ["Ethical approval", "TREATMENT", 117, 133], ["This study", "TEST", 133, 143]]], ["Participation was voluntary and electronic informed consent was obtained from all individual participants included in the study.", [["participants", "SPECIES", 93, 105], ["the study", "TEST", 118, 127]]]], "PMC7245234": [["INTRODUCTIONIn December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China.", [["pneumonia", "DISEASE", 57, 66], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["pneumonia", "PROBLEM", 57, 66], ["pneumonia", "OBSERVATION", 57, 66]]], ["1 Since then, the novel coronavirus disease 2019 (Covid-19) has rapidly spread across the world leading the World Health Organization (WHO) to declare a global pandemic on 11 March 2020.", [["coronavirus disease", "DISEASE", 24, 43], ["Covid-19", "CHEMICAL", 50, 58], ["coronavirus", "ORGANISM", 24, 35], ["coronavirus disease 2019 (Covid-19", "SPECIES", 24, 58], ["the novel coronavirus disease", "PROBLEM", 14, 43], ["Covid", "TEST", 50, 55], ["coronavirus disease", "OBSERVATION", 24, 43]]], ["The surge in the number of people seeking medical treatment has temporarily overwhelmed health services, leading to concerns regarding the allocation of scarce resources such as intensive care facilities.", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33], ["medical treatment", "TREATMENT", 42, 59]]], ["2,3", [["2,3", "CHEMICAL", 0, 3], ["2,3", "SIMPLE_CHEMICAL", 0, 3]]]], "PMC5899082": [["IntroductionApolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like type 3 (APOBEC3) proteins are Zn2+ - dependent cytidine deaminases that belong to the APOBEC superfamily.", [["cytidine", "CHEMICAL", 124, 132], ["Zn2+", "CHEMICAL", 107, 111], ["cytidine", "CHEMICAL", 124, 132], ["IntroductionApolipoprotein B", "GENE_OR_GENE_PRODUCT", 0, 28], ["catalytic polypeptide-like type 3", "GENE_OR_GENE_PRODUCT", 50, 83], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 85, 92], ["Zn2+", "SIMPLE_CHEMICAL", 107, 111], ["cytidine deaminases", "SIMPLE_CHEMICAL", 124, 143], ["APOBEC", "GENE_OR_GENE_PRODUCT", 163, 169], ["IntroductionApolipoprotein B mRNA-editing enzyme", "PROTEIN", 0, 48], ["catalytic polypeptide-like type 3 (APOBEC3) proteins", "PROTEIN", 50, 102], ["Zn2+ - dependent cytidine deaminases", "PROTEIN", 107, 143], ["APOBEC superfamily", "PROTEIN", 163, 181], ["IntroductionApolipoprotein", "TEST", 0, 26], ["editing enzyme", "TEST", 34, 48], ["catalytic polypeptide", "TEST", 50, 71], ["Zn2", "TEST", 107, 110], ["dependent cytidine deaminases", "PROBLEM", 114, 143], ["cytidine deaminases", "OBSERVATION", 124, 143]]], ["APOBEC3 enzymes are considered to be part of the intrinsic defense system in eukaryotic cells, and can inhibit replication of some viruses and restrict mobile genetic elements.", [["cells", "ANATOMY", 88, 93], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 0, 7], ["eukaryotic cells", "CELL", 77, 93], ["APOBEC3 enzymes", "PROTEIN", 0, 15], ["eukaryotic cells", "CELL_TYPE", 77, 93], ["mobile genetic elements", "DNA", 152, 175], ["APOBEC3 enzymes", "TEST", 0, 15], ["some viruses", "PROBLEM", 126, 138], ["considered to be", "UNCERTAINTY", 20, 36], ["intrinsic defense system", "OBSERVATION", 49, 73], ["eukaryotic cells", "OBSERVATION", 77, 93], ["some", "OBSERVATION_MODIFIER", 126, 130], ["viruses", "OBSERVATION", 131, 138]]], ["All APOBEC3 proteins share a cytidine-deaminase domain, which is identifiable by the primary amino acid motif His-Xaa-Glu-Xaa23\u201328-Pro-Cys-Xaa2\u20134-Cys, in which Zn2+ is coordinated.", [["cytidine", "CHEMICAL", 29, 37], ["amino acid", "CHEMICAL", 93, 103], ["Glu-Xaa23\u201328-Pro-Cys-Xaa2\u20134-Cys", "CHEMICAL", 118, 149], ["Zn2", "CHEMICAL", 160, 163], ["cytidine", "CHEMICAL", 29, 37], ["amino acid", "CHEMICAL", 93, 103], ["His-Xaa-Glu-Xaa23\u201328-Pro-Cys-Xaa2\u20134-Cys", "CHEMICAL", 110, 149], ["Zn2+", "CHEMICAL", 160, 164], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 4, 11], ["cytidine", "SIMPLE_CHEMICAL", 29, 37], ["amino acid", "AMINO_ACID", 93, 103], ["His-Xaa-Glu-Xaa23\u201328-Pro-Cys-Xaa2\u20134-Cys", "SIMPLE_CHEMICAL", 110, 149], ["Zn2+", "SIMPLE_CHEMICAL", 160, 164], ["APOBEC3 proteins", "PROTEIN", 4, 20], ["cytidine-deaminase domain", "PROTEIN", 29, 54], ["primary amino acid motif", "PROTEIN", 85, 109], ["Zn2", "PROTEIN", 160, 163], ["a cytidine-deaminase domain", "TEST", 27, 54], ["Xaa-", "TEST", 114, 118], ["Glu", "TEST", 118, 121], ["Xaa", "TEST", 122, 125], ["Cys", "TEST", 135, 138]]], ["Deamination of cytidine results in its conversion to uridine.", [["cytidine", "CHEMICAL", 15, 23], ["uridine", "CHEMICAL", 53, 60], ["cytidine", "CHEMICAL", 15, 23], ["uridine", "CHEMICAL", 53, 60], ["cytidine", "SIMPLE_CHEMICAL", 15, 23], ["uridine", "SIMPLE_CHEMICAL", 53, 60], ["Deamination of cytidine", "TREATMENT", 0, 23], ["uridine", "TREATMENT", 53, 60]]], ["During this process, the ammonium group on C4 of cytidine undergoes nucleophilic attack by an activated water molecule and the APOBEC3 glutamate residue.IntroductionA single copy of a gene encoding APOBEC3 is found in the genomes of rodents, cats, pigs and sheeps, with two genes in the genomes of cows, three the genomes of dogs and horses and seven genes in the human genome, encoding A3A, A3B, A3C, A3D, A3F, A3G and A3H1.", [["sheeps", "ANATOMY", 257, 263], ["ammonium", "CHEMICAL", 25, 33], ["cytidine", "CHEMICAL", 49, 57], ["glutamate", "CHEMICAL", 135, 144], ["ammonium", "CHEMICAL", 25, 33], ["cytidine", "CHEMICAL", 49, 57], ["glutamate", "CHEMICAL", 135, 144], ["ammonium", "SIMPLE_CHEMICAL", 25, 33], ["cytidine", "SIMPLE_CHEMICAL", 49, 57], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 127, 134], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 198, 205], ["cats", "ORGANISM", 242, 246], ["pigs", "ORGANISM", 248, 252], ["sheeps", "CANCER", 257, 263], ["cows", "ORGANISM_SUBDIVISION", 298, 302], ["dogs", "ORGANISM", 325, 329], ["horses", "ORGANISM_SUBDIVISION", 334, 340], ["human", "ORGANISM", 364, 369], ["A3A", "GENE_OR_GENE_PRODUCT", 387, 390], ["A3B", "GENE_OR_GENE_PRODUCT", 392, 395], ["A3C", "GENE_OR_GENE_PRODUCT", 397, 400], ["A3D", "GENE_OR_GENE_PRODUCT", 402, 405], ["A3F", "GENE_OR_GENE_PRODUCT", 407, 410], ["A3G", "GENE_OR_GENE_PRODUCT", 412, 415], ["A3H1", "GENE_OR_GENE_PRODUCT", 420, 424], ["APOBEC3", "PROTEIN", 198, 205], ["human genome", "DNA", 364, 376], ["A3A", "PROTEIN", 387, 390], ["A3B", "PROTEIN", 392, 395], ["A3C", "PROTEIN", 397, 400], ["A3D", "PROTEIN", 402, 405], ["A3F", "PROTEIN", 407, 410], ["A3G", "PROTEIN", 412, 415], ["A3H1", "PROTEIN", 420, 424], ["cats", "SPECIES", 242, 246], ["pigs", "SPECIES", 248, 252], ["cows", "SPECIES", 298, 302], ["dogs", "SPECIES", 325, 329], ["human", "SPECIES", 364, 369], ["pigs", "SPECIES", 248, 252], ["human", "SPECIES", 364, 369], ["cytidine", "TREATMENT", 49, 57], ["nucleophilic attack", "PROBLEM", 68, 87], ["an activated water molecule", "TREATMENT", 91, 118], ["the APOBEC3 glutamate residue", "PROBLEM", 123, 152], ["a gene encoding APOBEC3", "TREATMENT", 182, 205], ["A3G", "TREATMENT", 412, 415], ["A3H1", "TREATMENT", 420, 424], ["nucleophilic attack", "OBSERVATION", 68, 87], ["APOBEC3", "OBSERVATION", 127, 134], ["glutamate residue", "OBSERVATION", 135, 152], ["human genome", "ANATOMY", 364, 376]]], ["The mechanisms and selective pressures that led to the APOBEC3 gene expansion in humans are unclear, but it is believed that all the genes originated from duplication of a single-copy primordial APOBEC3 gene.", [["APOBEC3", "GENE_OR_GENE_PRODUCT", 55, 62], ["humans", "ORGANISM", 81, 87], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 195, 202], ["APOBEC3 gene", "DNA", 55, 67], ["single-copy primordial APOBEC3 gene", "DNA", 172, 207], ["humans", "SPECIES", 81, 87], ["humans", "SPECIES", 81, 87], ["selective pressures", "TEST", 19, 38], ["the APOBEC3 gene expansion", "PROBLEM", 51, 77], ["a single-copy primordial APOBEC3 gene", "TREATMENT", 170, 207], ["selective", "OBSERVATION_MODIFIER", 19, 28], ["pressures", "OBSERVATION_MODIFIER", 29, 38], ["APOBEC3 gene", "OBSERVATION", 55, 67], ["expansion", "OBSERVATION_MODIFIER", 68, 77], ["primordial APOBEC3 gene", "OBSERVATION", 184, 207]]], ["This multiplication may have provided protection from genomic instability caused by human endogenous retroviruses and retrotransposons2.IntroductionThe best-studied protein within the human APOBEC3 family is A3G.", [["genomic instability", "DISEASE", 54, 73], ["human", "ORGANISM", 84, 89], ["retroviruses", "ORGANISM", 101, 113], ["retrotransposons2", "GENE_OR_GENE_PRODUCT", 118, 135], ["human", "ORGANISM", 184, 189], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 190, 197], ["A3G", "GENE_OR_GENE_PRODUCT", 208, 211], ["human APOBEC3 family", "PROTEIN", 184, 204], ["A3G", "PROTEIN", 208, 211], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 184, 189], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 184, 189], ["genomic instability", "PROBLEM", 54, 73], ["human endogenous retroviruses", "PROBLEM", 84, 113], ["genomic instability", "OBSERVATION", 54, 73], ["endogenous retroviruses", "OBSERVATION", 90, 113], ["human APOBEC3", "ANATOMY", 184, 197]]], ["Its function as an antiviral factor was discovered in 2002 through cDNA-transfer experiments that were designed to identify a cellular suppressor of an HIV-1 accessory protein, the virion infectivity factor (Vif).", [["cellular", "ANATOMY", 126, 134], ["cellular", "CELL", 126, 134], ["HIV-1", "ORGANISM", 152, 157], ["Vif", "GENE_OR_GENE_PRODUCT", 208, 211], ["antiviral factor", "PROTEIN", 19, 35], ["HIV-1 accessory protein", "PROTEIN", 152, 175], ["virion infectivity factor", "PROTEIN", 181, 206], ["Vif", "PROTEIN", 208, 211], ["HIV-1", "SPECIES", 152, 157], ["HIV-1", "SPECIES", 152, 157], ["an antiviral factor", "PROBLEM", 16, 35], ["an HIV", "TEST", 149, 155], ["the virion infectivity factor", "PROBLEM", 177, 206]]], ["The primary antiretroviral activity of A3G requires its encapsidation into HIV-1 particles, and involves cytidine deamination of the reverse-transcribed first viral DNA strand, with mutations becoming fixed as G to A changes upon second-strand synthesis.", [["cytidine", "CHEMICAL", 105, 113], ["cytidine", "CHEMICAL", 105, 113], ["A3G", "GENE_OR_GENE_PRODUCT", 39, 42], ["HIV-1 particles", "ORGANISM", 75, 90], ["cytidine", "SIMPLE_CHEMICAL", 105, 113], ["DNA", "CELLULAR_COMPONENT", 165, 168], ["A3G", "PROTEIN", 39, 42], ["reverse-transcribed first viral DNA strand", "DNA", 133, 175], ["HIV-1", "SPECIES", 75, 80], ["HIV-1", "SPECIES", 75, 80], ["The primary antiretroviral activity of A3G", "TREATMENT", 0, 42], ["cytidine deamination", "TREATMENT", 105, 125], ["mutations", "PROBLEM", 182, 191], ["second-strand synthesis", "TREATMENT", 230, 253], ["antiretroviral activity", "OBSERVATION", 12, 35], ["cytidine deamination", "OBSERVATION", 105, 125]]], ["Mutational frequencies can exceed 10% of all G residues (hypermutation), and may result in inhibition of viral replication.", [["Mutational frequencies", "PROBLEM", 0, 22], ["viral replication", "TREATMENT", 105, 122], ["viral replication", "OBSERVATION", 105, 122]]], ["This activity is blocked by Vif protein, which specifically binds to and ubiquitinates A3G, directing it for degradation in the proteasome1,3,4.", [["Vif", "GENE_OR_GENE_PRODUCT", 28, 31], ["A3G", "GENE_OR_GENE_PRODUCT", 87, 90], ["proteasome1", "GENE_OR_GENE_PRODUCT", 128, 139], ["Vif protein", "PROTEIN", 28, 39], ["A3G", "PROTEIN", 87, 90], ["Vif protein", "PROBLEM", 28, 39], ["A3G", "TREATMENT", 87, 90]]], ["Other APOBEC3 proteins have been found to affect a wide variety of viruses, including other retroviruses (e.g., simian immunodeficiency virus (SIV), equine infectious anemia virus (EIAV), murine leukemia virus (MLV), foamy viruses), and DNA viruses (e.g., hepatitis B virus, parvovirus)5\u201314.", [["simian immunodeficiency virus (SIV)", "DISEASE", 112, 147], ["equine infectious anemia virus (EIAV), murine leukemia virus (MLV), foamy viruses", "DISEASE", 149, 230], ["hepatitis B", "DISEASE", 256, 267], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 6, 13], ["retroviruses", "ORGANISM", 92, 104], ["simian immunodeficiency virus", "ORGANISM", 112, 141], ["SIV", "ORGANISM", 143, 146], ["equine infectious anemia virus", "ORGANISM", 149, 179], ["EIAV", "ORGANISM", 181, 185], ["murine leukemia virus", "ORGANISM", 188, 209], ["MLV", "ORGANISM", 211, 214], ["foamy viruses", "ORGANISM", 217, 230], ["DNA", "CELLULAR_COMPONENT", 237, 240], ["hepatitis B virus", "ORGANISM", 256, 273], ["parvovirus", "ORGANISM", 275, 285], ["APOBEC3 proteins", "PROTEIN", 6, 22], ["simian immunodeficiency virus", "SPECIES", 112, 141], ["equine infectious anemia virus", "SPECIES", 149, 179], ["EIAV", "SPECIES", 181, 185], ["murine", "SPECIES", 188, 194], ["leukemia virus", "SPECIES", 195, 209], ["hepatitis B virus", "SPECIES", 256, 273], ["simian immunodeficiency virus", "SPECIES", 112, 141], ["SIV", "SPECIES", 143, 146], ["equine infectious anemia virus", "SPECIES", 149, 179], ["EIAV", "SPECIES", 181, 185], ["murine leukemia virus", "SPECIES", 188, 209], ["MLV", "SPECIES", 211, 214], ["foamy viruses", "SPECIES", 217, 230], ["hepatitis B virus", "SPECIES", 256, 273], ["Other APOBEC3 proteins", "PROBLEM", 0, 22], ["a wide variety of viruses", "PROBLEM", 49, 74], ["other retroviruses", "PROBLEM", 86, 104], ["simian immunodeficiency virus", "PROBLEM", 112, 141], ["equine infectious anemia virus (EIAV)", "PROBLEM", 149, 186], ["murine leukemia virus (MLV)", "PROBLEM", 188, 215], ["foamy viruses", "PROBLEM", 217, 230], ["DNA viruses", "PROBLEM", 237, 248], ["hepatitis B virus, parvovirus)", "TREATMENT", 256, 286], ["wide", "OBSERVATION_MODIFIER", 51, 55], ["variety", "OBSERVATION_MODIFIER", 56, 63], ["viruses", "OBSERVATION", 67, 74], ["infectious", "OBSERVATION_MODIFIER", 156, 166], ["murine leukemia virus", "OBSERVATION", 188, 209], ["foamy viruses", "OBSERVATION", 217, 230]]], ["As well as the inhibition of viral replication by hypermutation, APOBEC3-induced mutations also cause degradation of viral genomic material, mediated by cellular DNA-repair mechanisms15.IntroductionThe RNA-editing capability of APOBEC3 proteins was identified in 200416, since when extensive mutational activity of A3A on RNA transcripts in monocytes and macrophages has been demonstrated17.", [["cellular", "ANATOMY", 153, 161], ["monocytes", "ANATOMY", 341, 350], ["macrophages", "ANATOMY", 355, 366], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 65, 72], ["cellular", "CELL", 153, 161], ["DNA", "CELLULAR_COMPONENT", 162, 165], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 228, 235], ["A3A", "GENE_OR_GENE_PRODUCT", 315, 318], ["monocytes", "CELL", 341, 350], ["macrophages", "CELL", 355, 366], ["APOBEC3", "PROTEIN", 65, 72], ["APOBEC3 proteins", "PROTEIN", 228, 244], ["A3A", "PROTEIN", 315, 318], ["RNA transcripts", "RNA", 322, 337], ["monocytes", "CELL_TYPE", 341, 350], ["macrophages", "CELL_TYPE", 355, 366], ["viral replication", "TREATMENT", 29, 46], ["hypermutation", "PROBLEM", 50, 63], ["APOBEC3-induced mutations", "PROBLEM", 65, 90], ["viral genomic material", "PROBLEM", 117, 139], ["repair mechanisms", "TREATMENT", 166, 183], ["APOBEC3 proteins", "PROBLEM", 228, 244], ["extensive mutational activity of A3A", "PROBLEM", 282, 318], ["RNA transcripts in monocytes", "PROBLEM", 322, 350], ["macrophages", "PROBLEM", 355, 366], ["viral replication", "OBSERVATION", 29, 46], ["viral genomic material", "OBSERVATION", 117, 139], ["cellular DNA", "OBSERVATION", 153, 165], ["monocytes", "ANATOMY", 341, 350]]], ["Our current understanding of the APOBEC3 proteins suggests that they may also constitute an innate defense system against RNA viruses.", [["APOBEC3", "GENE_OR_GENE_PRODUCT", 33, 40], ["APOBEC3 proteins", "PROTEIN", 33, 49], ["the APOBEC3 proteins", "TEST", 29, 49], ["RNA viruses", "PROBLEM", 122, 133]]], ["For example, A3G known to be involved in restriction of three RNA pathogens (the mumps, measles and respiratory syncytial viruses), but whether this effect is associated with cytidine deamination is not yet known18.IntroductionMembers of the family Coronaviridae are positive-strand RNA viruses with large genomes, ranging in size from 27 to 32 kb.", [["mumps", "DISEASE", 81, 86], ["measles", "DISEASE", 88, 95], ["respiratory syncytial viruses", "DISEASE", 100, 129], ["cytidine", "CHEMICAL", 175, 183], ["cytidine", "CHEMICAL", 175, 183], ["A3G", "GENE_OR_GENE_PRODUCT", 13, 16], ["respiratory syncytial viruses", "ORGANISM", 100, 129], ["cytidine", "SIMPLE_CHEMICAL", 175, 183], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 249, 262], ["A3G", "PROTEIN", 13, 16], ["respiratory syncytial viruses", "SPECIES", 100, 129], ["A3G", "TREATMENT", 13, 16], ["three RNA pathogens", "PROBLEM", 56, 75], ["the mumps", "PROBLEM", 77, 86], ["measles and respiratory syncytial viruses", "PROBLEM", 88, 129], ["cytidine deamination", "TREATMENT", 175, 195], ["the family Coronaviridae", "TEST", 238, 262], ["strand RNA viruses", "PROBLEM", 276, 294], ["large genomes", "PROBLEM", 300, 313], ["A3G", "OBSERVATION", 13, 16], ["three", "OBSERVATION_MODIFIER", 56, 61], ["RNA pathogens", "OBSERVATION", 62, 75], ["respiratory", "ANATOMY", 100, 111], ["syncytial viruses", "OBSERVATION", 112, 129], ["strand RNA viruses", "OBSERVATION", 276, 294], ["large", "OBSERVATION_MODIFIER", 300, 305], ["genomes", "OBSERVATION", 306, 313], ["ranging", "OBSERVATION_MODIFIER", 315, 322], ["size", "OBSERVATION_MODIFIER", 326, 330]]], ["Six human coronaviruses (HCoVs) have been identified, four of which (HCoV-OC43, HCoV-229E, HCoV-NL63 and HCoV-HKU1) circulate continuously in human populations.", [["human", "ORGANISM", 4, 9], ["coronaviruses", "ORGANISM", 10, 23], ["HCoVs", "GENE_OR_GENE_PRODUCT", 25, 30], ["HCoV-OC43", "ORGANISM", 69, 78], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 80, 89], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 91, 100], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 105, 114], ["human", "ORGANISM", 142, 147], ["HCoV", "PROTEIN", 91, 95], ["NL63", "PROTEIN", 96, 100], ["HCoV", "PROTEIN", 105, 109], ["HKU1", "PROTEIN", 110, 114], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 142, 147], ["human coronaviruses", "SPECIES", 4, 23], ["human", "SPECIES", 142, 147], ["Six human coronaviruses (HCoVs", "TEST", 0, 30], ["HCoV", "TEST", 69, 73], ["OC43", "TEST", 74, 78], ["HCoV", "TEST", 80, 84], ["HCoV", "TEST", 91, 95], ["NL63", "TEST", 96, 100], ["HCoV", "TEST", 105, 109], ["coronaviruses", "OBSERVATION", 10, 23]]], ["These four viruses cause the common cold in otherwise healthy adults, and may cause more severe symptoms in young, elderly and immunocompromised individuals19\u201322.", [["severe symptoms", "PROBLEM", 89, 104], ["viruses", "OBSERVATION", 11, 18]]], ["Other coronaviruses that infect humans can cause severe and life-threatening diseases.", [["coronaviruses", "ORGANISM", 6, 19], ["humans", "ORGANISM", 32, 38], ["humans", "SPECIES", 32, 38], ["humans", "SPECIES", 32, 38], ["severe and life-threatening diseases", "PROBLEM", 49, 85], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["threatening", "OBSERVATION_MODIFIER", 65, 76], ["diseases", "OBSERVATION", 77, 85]]], ["In 2002, severe acute respiratory syndrome coronavirus (SARS-CoV) emerged and affected ~8,000 individuals, causing ~800 deaths23,24.", [["acute respiratory syndrome coronavirus", "DISEASE", 16, 54], ["SARS-CoV)", "DISEASE", 56, 65], ["deaths", "DISEASE", 120, 126], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 9, 54], ["SARS-CoV", "ORGANISM", 56, 64], ["severe acute respiratory syndrome coronavirus", "SPECIES", 9, 54], ["SARS-CoV", "SPECIES", 56, 64], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 9, 54], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["acute", "OBSERVATION_MODIFIER", 16, 21], ["respiratory syndrome coronavirus", "OBSERVATION", 22, 54]]], ["Middle East respiratory syndrome coronavirus (MERS-CoV) is the most recently identified coronaviruse that infects humans.", [["Middle East respiratory syndrome coronavirus", "DISEASE", 0, 44], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 0, 44], ["MERS-CoV", "ORGANISM", 46, 54], ["coronaviruse", "CANCER", 88, 100], ["humans", "ORGANISM", 114, 120], ["humans", "SPECIES", 114, 120], ["Middle East respiratory syndrome coronavirus", "SPECIES", 0, 44], ["MERS-CoV", "SPECIES", 46, 54], ["humans", "SPECIES", 114, 120], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 0, 44], ["respiratory syndrome", "OBSERVATION", 12, 32], ["infects", "OBSERVATION", 106, 113]]], ["MERS-CoV was isolated in 2012 and is associated with severe pneumonia and renal failure, with a mortality rate of ~30%25,26.IntroductionHCoV-NL63 was identified in 2004 and is distributed worldwide, with highest prevalence during winter and early spring in temperate climate27.", [["renal", "ANATOMY", 74, 79], ["pneumonia", "DISEASE", 60, 69], ["renal failure", "DISEASE", 74, 87], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["renal", "ORGAN", 74, 79], ["NL63", "DNA", 141, 145], ["MERS-CoV", "SPECIES", 0, 8], ["severe pneumonia", "PROBLEM", 53, 69], ["renal failure", "PROBLEM", 74, 87], ["a mortality rate", "TEST", 94, 110], ["IntroductionHCoV", "TEST", 124, 140], ["associated with", "UNCERTAINTY", 37, 52], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["pneumonia", "OBSERVATION", 60, 69], ["renal", "ANATOMY", 74, 79], ["failure", "OBSERVATION", 80, 87]]], ["HCoV-NL63 accounts for a considerable number of hospitalisations among children <18 years of age, the elderly and immunocompromised individuals19.", [["HCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["children", "ORGANISM", 71, 79], ["HCoV", "PROTEIN", 0, 4], ["NL63", "PROTEIN", 5, 9], ["children", "SPECIES", 71, 79], ["HCoV", "SPECIES", 0, 4], ["HCoV", "TEST", 0, 4], ["immunocompromised individuals", "PROBLEM", 114, 143]]], ["A notable characteristics of coronaviruses is that their genomes are highly U/A-rich and C/G-poor.", [["coronaviruses", "ORGANISM", 29, 42], ["C/G", "GENE_OR_GENE_PRODUCT", 89, 92], ["coronaviruses", "PROBLEM", 29, 42], ["C/G", "PROBLEM", 89, 92], ["notable", "OBSERVATION_MODIFIER", 2, 9], ["coronaviruses", "OBSERVATION", 29, 42]]], ["For example, HCoV-NL63 has 39% U and 27% A content, with only 14% C and 20%, G nucleotides28.", [["nucleotides", "CHEMICAL", 79, 90], ["HCoV", "GENE_OR_GENE_PRODUCT", 13, 17], ["HCoV", "PROTEIN", 13, 17], ["NL63", "DNA", 18, 22], ["HCoV", "TEST", 13, 17], ["NL63", "TEST", 18, 22], ["U", "TEST", 31, 32], ["A content", "TEST", 41, 50], ["G nucleotides", "TEST", 77, 90]]], ["One possibility is that, over an evolutionary timescale, genomes of coronaviruses might have been shaped by cytidine deamination.", [["cytidine", "CHEMICAL", 108, 116], ["cytidine", "CHEMICAL", 108, 116], ["coronaviruses", "ORGANISM", 68, 81], ["cytidine", "SIMPLE_CHEMICAL", 108, 116], ["coronaviruses", "PROBLEM", 68, 81], ["cytidine deamination", "TREATMENT", 108, 128], ["coronaviruses", "OBSERVATION", 68, 81], ["cytidine deamination", "OBSERVATION", 108, 128]]], ["Our aim, therefore, was to determine whether APOBEC3 proteins might be responsible for this modification.", [["APOBEC3", "GENE_OR_GENE_PRODUCT", 45, 52], ["APOBEC3 proteins", "PROTEIN", 45, 61], ["APOBEC3 proteins", "PROBLEM", 45, 61], ["this modification", "TREATMENT", 87, 104]]], ["Our results demonstrate that three of the APOBEC3 proteins (A3C, A3F and A3H) can inhibit coronaviral infection in vitro.APOBEC3-family gene expression is upregulated in HCoV-NL63-infected cells ::: ResultsModulation of human APOBEC3-family transcript levels in human airway epithelium (HAE) cultures during coronavirus infection was evaluated by quantitative RT-PCR (qRT-PCR) with primers and standards developed in our lab.", [["coronaviral", "ANATOMY", 90, 101], ["HCoV-NL63", "ANATOMY", 170, 179], ["cells", "ANATOMY", 189, 194], ["airway epithelium", "ANATOMY", 268, 285], ["HAE", "ANATOMY", 287, 290], ["cultures", "ANATOMY", 292, 300], ["coronaviral infection", "DISEASE", 90, 111], ["HAE", "DISEASE", 287, 290], ["coronavirus infection", "DISEASE", 308, 329], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 42, 49], ["A3C", "GENE_OR_GENE_PRODUCT", 60, 63], ["A3F", "GENE_OR_GENE_PRODUCT", 65, 68], ["A3H", "GENE_OR_GENE_PRODUCT", 73, 76], ["coronaviral", "CANCER", 90, 101], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 121, 128], ["HCoV-NL63", "CELL", 170, 179], ["cells", "CELL", 189, 194], ["human", "ORGANISM", 220, 225], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 226, 233], ["human", "ORGANISM", 262, 267], ["airway epithelium", "TISSUE", 268, 285], ["HAE) cultures", "CELL", 287, 300], ["coronavirus", "ORGANISM", 308, 319], ["APOBEC3 proteins", "PROTEIN", 42, 58], ["A3C", "PROTEIN", 60, 63], ["A3F", "PROTEIN", 65, 68], ["A3H", "PROTEIN", 73, 76], ["APOBEC3", "PROTEIN", 121, 128], ["HCoV-NL63-infected cells", "CELL_LINE", 170, 194], ["human APOBEC3", "PROTEIN", 220, 233], ["human airway epithelium (HAE) cultures", "CELL_LINE", 262, 300], ["human", "SPECIES", 220, 225], ["human", "SPECIES", 262, 267], ["coronavirus", "SPECIES", 308, 319], ["HCoV", "SPECIES", 170, 174], ["human", "SPECIES", 220, 225], ["human", "SPECIES", 262, 267], ["coronavirus", "SPECIES", 308, 319], ["the APOBEC3 proteins", "TEST", 38, 58], ["A3C", "TEST", 60, 63], ["coronaviral infection in vitro", "PROBLEM", 90, 120], ["HCoV", "TEST", 170, 174], ["cultures", "TEST", 292, 300], ["coronavirus infection", "PROBLEM", 308, 329], ["quantitative RT", "TEST", 347, 362], ["PCR", "TEST", 363, 366], ["qRT", "TEST", 368, 371], ["PCR", "TEST", 372, 375], ["primers", "TEST", 382, 389], ["coronaviral", "OBSERVATION_MODIFIER", 90, 101], ["infection", "OBSERVATION", 102, 111], ["infected cells", "OBSERVATION", 180, 194], ["human APOBEC3", "OBSERVATION", 220, 233], ["airway", "ANATOMY", 268, 274]]], ["The level of each APOBEC3 mRNA was analysed in fully differentiated cells from healthy adults, and a high level of expression was observed for six out of seven human APOBEC3 genes (Fig. 1a).", [["cells", "ANATOMY", 68, 73], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 18, 25], ["cells", "CELL", 68, 73], ["human", "ORGANISM", 160, 165], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 166, 173], ["APOBEC3 mRNA", "RNA", 18, 30], ["differentiated cells", "CELL_TYPE", 53, 73], ["human APOBEC3 genes", "DNA", 160, 179], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 160, 165], ["each APOBEC3 mRNA", "TEST", 13, 30], ["APOBEC3 mRNA", "OBSERVATION", 18, 30], ["APOBEC3 genes", "OBSERVATION", 166, 179]]], ["The same six genes (APOBEC3A, APOBEC3C, APOBEC3D, APOBEC3F, APOBEC3G and APOBEC3H) were expressed during HCoV-NL63 infection, and these genes were analysed in subsequent experiments.APOBEC3-family gene expression is upregulated in HCoV-NL63-infected cells ::: ResultsHAE cultures were infected with HCoV-NL63 and cultured for 5 days at 32 \u00b0C. As a control, HAE cultures were infected with influenza A H3N2 virus, which induces considerable upregulation of APOBEC3G30.", [["HCoV-NL63", "ANATOMY", 231, 240], ["cells", "ANATOMY", 250, 255], ["HAE cultures", "ANATOMY", 357, 369], ["infection", "DISEASE", 115, 124], ["HAE", "DISEASE", 357, 360], ["APOBEC3A", "GENE_OR_GENE_PRODUCT", 20, 28], ["APOBEC3C", "GENE_OR_GENE_PRODUCT", 30, 38], ["APOBEC3D", "GENE_OR_GENE_PRODUCT", 40, 48], ["APOBEC3F", "GENE_OR_GENE_PRODUCT", 50, 58], ["APOBEC3G", "GENE_OR_GENE_PRODUCT", 60, 68], ["APOBEC3H", "GENE_OR_GENE_PRODUCT", 73, 81], ["HCoV", "GENE_OR_GENE_PRODUCT", 105, 109], ["NL63", "GENE_OR_GENE_PRODUCT", 110, 114], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 182, 189], ["HCoV-NL63", "CELL", 231, 240], ["cells", "CELL", 250, 255], ["ResultsHAE cultures", "CELL", 260, 279], ["HCoV-NL63", "CELL", 299, 308], ["HAE cultures", "CELL", 357, 369], ["influenza A H3N2 virus", "ORGANISM", 389, 411], ["APOBEC3G30", "GENE_OR_GENE_PRODUCT", 456, 466], ["APOBEC3A", "DNA", 20, 28], ["APOBEC3C", "DNA", 30, 38], ["APOBEC3D", "DNA", 40, 48], ["APOBEC3F", "DNA", 50, 58], ["APOBEC3G", "DNA", 60, 68], ["APOBEC3H", "DNA", 73, 81], ["APOBEC3", "PROTEIN", 182, 189], ["HCoV-NL63-infected cells", "CELL_LINE", 231, 255], ["ResultsHAE cultures", "CELL_LINE", 260, 279], ["HCoV", "PROTEIN", 299, 303], ["NL63", "DNA", 304, 308], ["HAE cultures", "CELL_LINE", 357, 369], ["APOBEC3G30", "PROTEIN", 456, 466], ["influenza A H3N2 virus", "SPECIES", 389, 411], ["HCoV", "SPECIES", 105, 109], ["HCoV", "SPECIES", 231, 235], ["HCoV", "SPECIES", 299, 303], ["influenza A H3N2 virus", "SPECIES", 389, 411], ["APOBEC3A", "TEST", 20, 28], ["APOBEC3C", "TEST", 30, 38], ["APOBEC3D", "TEST", 40, 48], ["APOBEC3F", "TEST", 50, 58], ["APOBEC3G", "TEST", 60, 68], ["HCoV", "TEST", 105, 109], ["NL63 infection", "PROBLEM", 110, 124], ["HCoV", "TEST", 231, 235], ["ResultsHAE cultures", "TEST", 260, 279], ["HCoV", "TEST", 299, 303], ["HAE cultures", "TEST", 357, 369], ["influenza", "PROBLEM", 389, 398], ["A H3N2 virus", "PROBLEM", 399, 411], ["APOBEC3G30", "TREATMENT", 456, 466], ["APOBEC3G", "OBSERVATION", 60, 68], ["infection", "OBSERVATION", 115, 124], ["infected cells", "OBSERVATION", 241, 255]]], ["RT-qPCR analysis of total RNA extracted from infected cells revealed upregulation of APOBEC3A, APOBEC3C, APOBEC3D and APOBEC3F transcripts in HCoV-NL63-infected cells relative to mock-infected cells, with an almost 100-fold increase in APOBEC3A expression (Fig. 1b).", [["cells", "ANATOMY", 54, 59], ["HCoV-NL63", "ANATOMY", 142, 151], ["cells", "ANATOMY", 161, 166], ["cells", "ANATOMY", 193, 198], ["cells", "CELL", 54, 59], ["APOBEC3A", "GENE_OR_GENE_PRODUCT", 85, 93], ["APOBEC3C", "GENE_OR_GENE_PRODUCT", 95, 103], ["APOBEC3D", "GENE_OR_GENE_PRODUCT", 105, 113], ["APOBEC3F", "GENE_OR_GENE_PRODUCT", 118, 126], ["HCoV-NL63", "CELL", 142, 151], ["cells", "CELL", 161, 166], ["cells", "CELL", 193, 198], ["APOBEC3A", "GENE_OR_GENE_PRODUCT", 236, 244], ["APOBEC3A, APOBEC3C, APOBEC3D and APOBEC3F transcripts", "RNA", 85, 138], ["HCoV-NL63-infected cells", "CELL_LINE", 142, 166], ["mock-infected cells", "CELL_TYPE", 179, 198], ["APOBEC3A", "PROTEIN", 236, 244], ["HCoV", "SPECIES", 142, 146], ["RT-qPCR analysis", "TEST", 0, 16], ["total RNA", "PROBLEM", 20, 29], ["infected cells", "PROBLEM", 45, 59], ["APOBEC3A", "TEST", 85, 93], ["APOBEC3C", "TEST", 95, 103], ["APOBEC3D", "TEST", 105, 113], ["HCoV", "TEST", 142, 146], ["infected cells", "PROBLEM", 152, 166], ["infected cells", "PROBLEM", 184, 198], ["infected cells", "OBSERVATION", 45, 59], ["upregulation", "OBSERVATION_MODIFIER", 69, 81], ["infected cells", "OBSERVATION", 152, 166], ["infected cells", "OBSERVATION", 184, 198]]], ["As anticipated, APOBEC3G was upregulated in the influenza-infected cells, and APOBEC3H expression also increased (Fig. 1c).Expression of APOBEC3 proteins in cultured cells ::: ResultsPlasmids encoding individual APOBEC3 proteins were prepared and transfected into 293T cells, which were cultured and analysed for protein expression by western blotting (Fig. 2a, Supplementary Figure 1).", [["cells", "ANATOMY", 67, 72], ["cells", "ANATOMY", 166, 171], ["293T cells", "ANATOMY", 264, 274], ["influenza-infected", "DISEASE", 48, 66], ["APOBEC3G", "GENE_OR_GENE_PRODUCT", 16, 24], ["cells", "CELL", 67, 72], ["APOBEC3H", "GENE_OR_GENE_PRODUCT", 78, 86], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 137, 144], ["cells", "CELL", 166, 171], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 212, 219], ["293T cells", "CELL", 264, 274], ["APOBEC3G", "PROTEIN", 16, 24], ["influenza-infected cells", "CELL_TYPE", 48, 72], ["APOBEC3H", "PROTEIN", 78, 86], ["APOBEC3 proteins", "PROTEIN", 137, 153], ["cultured cells", "CELL_LINE", 157, 171], ["APOBEC3 proteins", "PROTEIN", 212, 228], ["293T cells", "CELL_LINE", 264, 274], ["APOBEC3G", "TREATMENT", 16, 24], ["the influenza-infected cells", "PROBLEM", 44, 72], ["APOBEC3H expression", "PROBLEM", 78, 97], ["APOBEC3 proteins in cultured cells", "PROBLEM", 137, 171], ["ResultsPlasmids encoding individual APOBEC3 proteins", "PROBLEM", 176, 228], ["protein expression", "PROBLEM", 313, 331], ["infected cells", "OBSERVATION", 58, 72], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["APOBEC3 proteins", "OBSERVATION", 137, 153], ["APOBEC3 proteins", "OBSERVATION", 212, 228]]], ["For expression in the naturally permissive LLC-Mk2 cell line, in which the DNA transfection efficiency is very low (data not shown), mRNA transcripts encoding APOBEC3 proteins or green fluorescent protein (GFP) were prepared by in vitro transcription.", [["LLC-Mk2 cell line", "ANATOMY", 43, 60], ["LLC-Mk2 cell line", "CELL", 43, 60], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 159, 166], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 179, 204], ["GFP", "GENE_OR_GENE_PRODUCT", 206, 209], ["LLC-Mk2 cell line", "CELL_LINE", 43, 60], ["mRNA transcripts", "RNA", 133, 149], ["APOBEC3 proteins", "PROTEIN", 159, 175], ["green fluorescent protein", "PROTEIN", 179, 204], ["GFP", "PROTEIN", 206, 209], ["Mk2 cell line", "TREATMENT", 47, 60], ["the DNA transfection efficiency", "TEST", 71, 102], ["mRNA transcripts encoding APOBEC3 proteins", "PROBLEM", 133, 175], ["green fluorescent protein (GFP", "PROBLEM", 179, 209], ["Mk2 cell line", "OBSERVATION", 47, 60], ["transfection efficiency", "OBSERVATION", 79, 102]]], ["Transfection of LLC-Mk2 cells was efficient, reaching ~80% for the control GFP mRNA (Fig. 2b).", [["LLC-Mk2 cells", "ANATOMY", 16, 29], ["LLC-Mk2 cells", "CELL", 16, 29], ["GFP", "GENE_OR_GENE_PRODUCT", 75, 78], ["LLC-Mk2 cells", "CELL_LINE", 16, 29], ["GFP mRNA", "RNA", 75, 83], ["LLC", "ANATOMY", 16, 19], ["Mk2 cells", "OBSERVATION", 20, 29]]], ["Expression of HA-tagged APOBEC3 proteins in mRNA transfected LLC-Mk2 cells, measured by flow cytometry, was similar for all proteins (Fig. 2c).Human APOBEC3 proteins A3C, A3F and A3H inhibit HCoV-NL63 replication ::: ResultsmRNA-transfected LLC-Mk2 cells were infected with HCoV-NL63 and cultured for 5 days at 32 \u00b0C. No cytopathic effect (CPE) was observed in cells expressing A3C, A3F and A3H proteins, but CPE was observed in untransfected or GFP-transfected cells, and in cells expressing A3A, A3DE and A3G (Fig. 3a).", [["LLC-Mk2 cells", "ANATOMY", 61, 74], ["HCoV-NL63", "ANATOMY", 191, 200], ["LLC-Mk2 cells", "ANATOMY", 241, 254], ["HCoV-NL63", "ANATOMY", 274, 283], ["cells", "ANATOMY", 361, 366], ["cells", "ANATOMY", 462, 467], ["cells", "ANATOMY", 476, 481], ["HA", "GENE_OR_GENE_PRODUCT", 14, 16], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 24, 31], ["LLC-Mk2 cells", "CELL", 61, 74], ["Human", "ORGANISM", 143, 148], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 149, 156], ["A3C", "GENE_OR_GENE_PRODUCT", 166, 169], ["A3F", "GENE_OR_GENE_PRODUCT", 171, 174], ["A3H", "GENE_OR_GENE_PRODUCT", 179, 182], ["HCoV", "GENE_OR_GENE_PRODUCT", 191, 195], ["NL63", "GENE_OR_GENE_PRODUCT", 196, 200], ["ResultsmRNA", "GENE_OR_GENE_PRODUCT", 217, 228], ["LLC-Mk2 cells", "CELL", 241, 254], ["HCoV-NL63", "CELL", 274, 283], ["cells", "CELL", 361, 366], ["A3C", "GENE_OR_GENE_PRODUCT", 378, 381], ["A3F", "GENE_OR_GENE_PRODUCT", 383, 386], ["A3H", "GENE_OR_GENE_PRODUCT", 391, 394], ["GFP", "GENE_OR_GENE_PRODUCT", 446, 449], ["cells", "CELL", 462, 467], ["cells", "CELL", 476, 481], ["A3A", "GENE_OR_GENE_PRODUCT", 493, 496], ["A3DE", "GENE_OR_GENE_PRODUCT", 498, 502], ["A3G", "GENE_OR_GENE_PRODUCT", 507, 510], ["Fig. 3a", "GENE_OR_GENE_PRODUCT", 512, 519], ["HA", "PROTEIN", 14, 16], ["APOBEC3 proteins", "PROTEIN", 24, 40], ["mRNA", "RNA", 44, 48], ["LLC-Mk2 cells", "CELL_LINE", 61, 74], ["Human APOBEC3 proteins", "PROTEIN", 143, 165], ["A3C", "PROTEIN", 166, 169], ["A3F", "PROTEIN", 171, 174], ["A3H", "PROTEIN", 179, 182], ["ResultsmRNA-transfected LLC-Mk2 cells", "CELL_LINE", 217, 254], ["HCoV", "PROTEIN", 274, 278], ["NL63", "DNA", 279, 283], ["A3C", "PROTEIN", 378, 381], ["A3F", "PROTEIN", 383, 386], ["A3H proteins", "PROTEIN", 391, 403], ["GFP-transfected cells", "CELL_LINE", 446, 467], ["A3A", "PROTEIN", 493, 496], ["A3DE", "PROTEIN", 498, 502], ["A3G", "PROTEIN", 507, 510], ["Fig. 3a", "PROTEIN", 512, 519], ["Human", "SPECIES", 143, 148], ["Human", "SPECIES", 143, 148], ["HCoV", "SPECIES", 191, 195], ["HCoV", "SPECIES", 274, 278], ["HA", "PROBLEM", 14, 16], ["tagged APOBEC3 proteins", "TEST", 17, 40], ["mRNA transfected LLC", "TEST", 44, 64], ["Mk2 cells", "TEST", 65, 74], ["flow cytometry", "TEST", 88, 102], ["Human APOBEC3 proteins", "TEST", 143, 165], ["A3C", "TEST", 166, 169], ["A3F", "TEST", 171, 174], ["A3H", "TEST", 179, 182], ["HCoV", "TEST", 191, 195], ["ResultsmRNA", "TEST", 217, 228], ["Mk2 cells", "PROBLEM", 245, 254], ["HCoV", "TEST", 274, 278], ["cytopathic effect (CPE", "PROBLEM", 321, 343], ["A3C", "TEST", 378, 381], ["A3H proteins", "PROBLEM", 391, 403], ["CPE", "PROBLEM", 409, 412], ["GFP", "TEST", 446, 449], ["transfected cells", "PROBLEM", 450, 467], ["LLC", "ANATOMY", 61, 64], ["Mk2 cells", "OBSERVATION", 65, 74], ["flow cytometry", "OBSERVATION", 88, 102], ["LLC", "ANATOMY", 241, 244], ["Mk2 cells", "OBSERVATION", 245, 254], ["cytopathic", "OBSERVATION_MODIFIER", 321, 331], ["effect", "OBSERVATION_MODIFIER", 332, 338], ["transfected cells", "OBSERVATION", 450, 467]]], ["Analysis of HCoV-NL63 replication showed a 1.5\u20132 log reduction in virus yield in cells expressing A3C, A3F and A3H, relative to the control sample.", [["cells", "ANATOMY", 81, 86], ["HCoV", "GENE_OR_GENE_PRODUCT", 12, 16], ["cells", "CELL", 81, 86], ["A3C", "GENE_OR_GENE_PRODUCT", 98, 101], ["A3F", "GENE_OR_GENE_PRODUCT", 103, 106], ["A3H", "GENE_OR_GENE_PRODUCT", 111, 114], ["HCoV", "DNA", 12, 16], ["A3C", "PROTEIN", 98, 101], ["A3F", "PROTEIN", 103, 106], ["A3H", "PROTEIN", 111, 114], ["HCoV", "SPECIES", 12, 16], ["Analysis", "TEST", 0, 8], ["HCoV", "TEST", 12, 16], ["NL63 replication", "TEST", 17, 33], ["a 1.5\u20132 log reduction", "PROBLEM", 41, 62], ["A3C", "TEST", 98, 101]]], ["By contrast, HCoV-NL63 replication was not inhibited in cells expressing GFP, A3A, A3D or A3G (Fig. 3b).APOBEC3-mediated HCoV-NL63 restriction is associated with cytidine deamination ::: ResultsBecause HCoV-NL63 infection resulted in upregulation of expression of A3A, A3C, A3D and A3F and A3C, A3F and A3H all inhibited HCoV-NL63 replication, we tested whether this inhibition was the result of the catalytic activity of the APOBECs.", [["cells", "ANATOMY", 56, 61], ["HCoV-NL63", "ANATOMY", 321, 330], ["APOBECs", "ANATOMY", 426, 433], ["cytidine", "CHEMICAL", 162, 170], ["HCoV", "CHEMICAL", 202, 206], ["infection", "DISEASE", 212, 221], ["cytidine", "CHEMICAL", 162, 170], ["HCoV", "GENE_OR_GENE_PRODUCT", 13, 17], ["cells", "CELL", 56, 61], ["GFP", "GENE_OR_GENE_PRODUCT", 73, 76], ["A3A", "GENE_OR_GENE_PRODUCT", 78, 81], ["A3D", "GENE_OR_GENE_PRODUCT", 83, 86], ["A3G", "GENE_OR_GENE_PRODUCT", 90, 93], ["Fig. 3b", "GENE_OR_GENE_PRODUCT", 95, 102], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 104, 111], ["HCoV", "GENE_OR_GENE_PRODUCT", 121, 125], ["cytidine", "SIMPLE_CHEMICAL", 162, 170], ["HCoV", "GENE_OR_GENE_PRODUCT", 202, 206], ["A3A", "GENE_OR_GENE_PRODUCT", 264, 267], ["A3C", "GENE_OR_GENE_PRODUCT", 269, 272], ["A3D", "GENE_OR_GENE_PRODUCT", 274, 277], ["A3F", "GENE_OR_GENE_PRODUCT", 282, 285], ["A3C", "GENE_OR_GENE_PRODUCT", 290, 293], ["A3F", "GENE_OR_GENE_PRODUCT", 295, 298], ["A3H", "GENE_OR_GENE_PRODUCT", 303, 306], ["HCoV-NL63", "CELL", 321, 330], ["APOBECs", "GENE_OR_GENE_PRODUCT", 426, 433], ["HCoV", "PROTEIN", 13, 17], ["GFP", "PROTEIN", 73, 76], ["A3A", "PROTEIN", 78, 81], ["A3D", "PROTEIN", 83, 86], ["A3G", "PROTEIN", 90, 93], ["Fig. 3b", "PROTEIN", 95, 102], ["APOBEC3", "PROTEIN", 104, 111], ["HCoV", "DNA", 121, 125], ["NL63", "DNA", 126, 130], ["A3A", "PROTEIN", 264, 267], ["A3C", "PROTEIN", 269, 272], ["A3D", "PROTEIN", 274, 277], ["A3F", "PROTEIN", 282, 285], ["A3C", "PROTEIN", 290, 293], ["A3F", "PROTEIN", 295, 298], ["A3H", "PROTEIN", 303, 306], ["APOBECs", "PROTEIN", 426, 433], ["HCoV", "SPECIES", 13, 17], ["HCoV", "SPECIES", 321, 325], ["HCoV", "TEST", 13, 17], ["GFP", "TEST", 73, 76], ["A3A", "TEST", 78, 81], ["APOBEC3", "TEST", 104, 111], ["NL63 restriction", "PROBLEM", 126, 142], ["HCoV", "TEST", 202, 206], ["NL63 infection", "PROBLEM", 207, 221], ["A3A", "TEST", 264, 267], ["A3C", "TEST", 269, 272], ["A3D", "TEST", 274, 277], ["A3F", "TEST", 282, 285], ["A3C", "TEST", 290, 293], ["A3F", "TEST", 295, 298], ["A3H", "TEST", 303, 306], ["NL63 replication", "TREATMENT", 326, 342], ["cytidine deamination", "OBSERVATION", 162, 182], ["infection", "OBSERVATION", 212, 221]]], ["Plasmids encoding variants of A3C, A3F and A3H with Glu \u2192 Gln substitutions in the catalytic site were prepared31 and mRNAs encoding active or inactive proteins were transfected into LLC-Mk2 cells, which were infected with HCoV-NL63 and cultured prior to visualisation of viral proteins with specific antibodies.", [["LLC-Mk2 cells", "ANATOMY", 183, 196], ["HCoV-NL63", "ANATOMY", 223, 232], ["Glu", "CHEMICAL", 52, 55], ["Gln", "CHEMICAL", 58, 61], ["Glu", "CHEMICAL", 52, 55], ["Gln", "CHEMICAL", 58, 61], ["A3C", "GENE_OR_GENE_PRODUCT", 30, 33], ["A3F", "GENE_OR_GENE_PRODUCT", 35, 38], ["A3H", "GENE_OR_GENE_PRODUCT", 43, 46], ["Glu", "AMINO_ACID", 52, 55], ["Gln", "AMINO_ACID", 58, 61], ["prepared31", "GENE_OR_GENE_PRODUCT", 103, 113], ["LLC-Mk2 cells", "CELL", 183, 196], ["HCoV-NL63", "CELL", 223, 232], ["A3C", "PROTEIN", 30, 33], ["A3F", "PROTEIN", 35, 38], ["A3H", "PROTEIN", 43, 46], ["catalytic site", "DNA", 83, 97], ["prepared31 and", "RNA", 103, 117], ["mRNAs", "RNA", 118, 123], ["inactive proteins", "PROTEIN", 143, 160], ["LLC-Mk2 cells", "CELL_LINE", 183, 196], ["HCoV", "PROTEIN", 223, 227], ["viral proteins", "PROTEIN", 272, 286], ["specific antibodies", "PROTEIN", 292, 311], ["HCoV", "SPECIES", 223, 227], ["Glu", "TEST", 52, 55], ["Gln substitutions in the catalytic site", "PROBLEM", 58, 97], ["mRNAs encoding active or inactive proteins", "PROBLEM", 118, 160], ["Mk2 cells", "TEST", 187, 196], ["HCoV", "TEST", 223, 227], ["NL63", "TREATMENT", 228, 232], ["visualisation", "TEST", 255, 268], ["viral proteins", "PROBLEM", 272, 286], ["substitutions", "OBSERVATION_MODIFIER", 62, 75], ["LLC", "ANATOMY", 183, 186], ["Mk2 cells", "OBSERVATION", 187, 196], ["viral proteins", "OBSERVATION", 272, 286]]], ["The percentages of HCoV-NL63-infected cells were measured by flow cytometry.", [["cells", "ANATOMY", 38, 43], ["HCoV", "GENE_OR_GENE_PRODUCT", 19, 23], ["NL63", "GENE_OR_GENE_PRODUCT", 24, 28], ["cells", "CELL", 38, 43], ["HCoV-NL63-infected cells", "CELL_LINE", 19, 43], ["HCoV", "SPECIES", 19, 23], ["The percentages", "TEST", 0, 15], ["HCoV", "TEST", 19, 23], ["infected cells", "PROBLEM", 29, 43], ["flow cytometry", "TEST", 61, 75], ["infected cells", "OBSERVATION", 29, 43], ["flow cytometry", "OBSERVATION", 61, 75]]], ["Wild-type APOBEC3 proteins resulted in pronounced reductions in HCoV-NL63 infection rates, whereas catalytically inactive proteins produced moderate inhibition, with infection rates that were not significantly different from those in controls (Fig. 4a).", [["infection", "DISEASE", 74, 83], ["infection", "DISEASE", 166, 175], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 10, 17], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 64, 73], ["Wild-type APOBEC3 proteins", "PROTEIN", 0, 26], ["catalytically inactive proteins", "PROTEIN", 99, 130], ["HCoV", "SPECIES", 64, 68], ["type APOBEC3 proteins", "PROBLEM", 5, 26], ["pronounced reductions in HCoV", "PROBLEM", 39, 68], ["NL63 infection rates", "PROBLEM", 69, 89], ["catalytically inactive proteins", "PROBLEM", 99, 130], ["moderate inhibition", "PROBLEM", 140, 159], ["infection rates", "PROBLEM", 166, 181], ["pronounced", "OBSERVATION_MODIFIER", 39, 49], ["reductions", "OBSERVATION_MODIFIER", 50, 60], ["infection", "OBSERVATION", 74, 83], ["moderate", "OBSERVATION_MODIFIER", 140, 148], ["infection", "OBSERVATION", 166, 175], ["significantly different", "OBSERVATION_MODIFIER", 196, 219]]], ["Western blot analysis showed an even expression of all proteins, showing that the inhibitory effect did not result from unequal mRNA translation (Fig. 4b, Supplementary Figure 2).", [["Western blot analysis", "TEST", 0, 21], ["all proteins", "PROBLEM", 51, 63], ["the inhibitory effect", "PROBLEM", 78, 99], ["unequal mRNA translation", "PROBLEM", 120, 144]]], ["This level of inhibition of HCoV-NL63 replication by catalytically inactive proteins required transfection of 3 \u00b5g of mRNA, whereas for active proteins, inhibition was achieved with transfection of 1 \u00b5g of mRNA.APOBEC3-mediated HCoV-NL63 restriction is associated with cytidine deamination ::: ResultsNext, we tested the activity of APOBEC3 proteins in vitro.", [["cytidine", "CHEMICAL", 269, 277], ["cytidine", "CHEMICAL", 269, 277], ["HCoV", "GENE_OR_GENE_PRODUCT", 28, 32], ["NL63", "GENE_OR_GENE_PRODUCT", 33, 37], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 211, 218], ["HCoV", "GENE_OR_GENE_PRODUCT", 228, 232], ["cytidine", "SIMPLE_CHEMICAL", 269, 277], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 333, 340], ["catalytically inactive proteins", "PROTEIN", 53, 84], ["mRNA", "RNA", 118, 122], ["mRNA", "RNA", 206, 210], ["APOBEC3", "PROTEIN", 211, 218], ["HCoV", "DNA", 228, 232], ["NL63", "DNA", 233, 237], ["APOBEC3 proteins", "PROTEIN", 333, 349], ["HCoV", "SPECIES", 28, 32], ["HCoV", "TEST", 28, 32], ["NL63 replication", "TREATMENT", 33, 49], ["catalytically inactive proteins", "PROBLEM", 53, 84], ["transfection", "TREATMENT", 94, 106], ["mRNA", "TREATMENT", 118, 122], ["active proteins", "PROBLEM", 136, 151], ["transfection", "TREATMENT", 182, 194], ["APOBEC3", "TEST", 211, 218], ["NL63 restriction", "PROBLEM", 233, 249], ["APOBEC3 proteins", "TREATMENT", 333, 349], ["cytidine deamination", "OBSERVATION", 269, 289]]], ["A DNA template containing several possible sites for cytidine deamination (GC-rich domains) was used for in vitro transcription, producing RNA that was incubated with lysates from 293T cells overexpressing A3C protein or GFP.", [["lysates", "ANATOMY", 167, 174], ["293T cells", "ANATOMY", 180, 190], ["cytidine", "CHEMICAL", 53, 61], ["cytidine", "CHEMICAL", 53, 61], ["DNA", "CELLULAR_COMPONENT", 2, 5], ["cytidine", "SIMPLE_CHEMICAL", 53, 61], ["lysates", "ORGANISM_SUBSTANCE", 167, 174], ["293T cells", "CELL", 180, 190], ["A3C", "GENE_OR_GENE_PRODUCT", 206, 209], ["GFP", "GENE_OR_GENE_PRODUCT", 221, 224], ["DNA template", "DNA", 2, 14], ["293T cells", "CELL_LINE", 180, 190], ["A3C protein", "PROTEIN", 206, 217], ["GFP", "PROTEIN", 221, 224], ["A DNA template", "TREATMENT", 0, 14], ["cytidine deamination", "TREATMENT", 53, 73], ["GC-rich domains", "TREATMENT", 75, 90], ["lysates", "TEST", 167, 174], ["A3C protein", "TEST", 206, 217], ["GFP", "TEST", 221, 224], ["cytidine deamination", "OBSERVATION", 53, 73]]], ["The RNA was then isolated, reverse transcribed, amplified by PCR and sequenced, revealing several C \u2192 C/T changes following incubation with A3C (but not GFP) cell lysate (Fig. 4c).", [["cell lysate", "ANATOMY", 158, 169], ["A3C", "SIMPLE_CHEMICAL", 140, 143], ["GFP", "GENE_OR_GENE_PRODUCT", 153, 156], ["A3C", "PROTEIN", 140, 143], ["GFP", "PROTEIN", 153, 156], ["PCR", "TEST", 61, 64], ["several C \u2192 C/T changes", "PROBLEM", 90, 113], ["A3C", "TREATMENT", 140, 143], ["cell lysate", "TEST", 158, 169]]], ["However, hypermutation did not occur, and no pattern was identified in the nucleotide changes.APOBEC3-mediated HCoV-NL63 restriction is associated with cytidine deamination ::: ResultsTo examine the progressive accumulation of mutations, we performed a series of virus passages on cells expressing A3C, A3F or A3H.", [["cells", "ANATOMY", 281, 286], ["nucleotide", "CHEMICAL", 75, 85], ["cytidine", "CHEMICAL", 152, 160], ["nucleotide", "CHEMICAL", 75, 85], ["cytidine", "CHEMICAL", 152, 160], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 94, 101], ["HCoV", "GENE_OR_GENE_PRODUCT", 111, 115], ["cytidine", "SIMPLE_CHEMICAL", 152, 160], ["cells", "CELL", 281, 286], ["A3C", "GENE_OR_GENE_PRODUCT", 298, 301], ["A3F", "GENE_OR_GENE_PRODUCT", 303, 306], ["A3H", "GENE_OR_GENE_PRODUCT", 310, 313], ["APOBEC3", "PROTEIN", 94, 101], ["HCoV", "DNA", 111, 115], ["NL63", "DNA", 116, 120], ["A3C", "PROTEIN", 298, 301], ["A3F", "PROTEIN", 303, 306], ["A3H", "PROTEIN", 310, 313], ["hypermutation", "PROBLEM", 9, 22], ["the nucleotide changes", "PROBLEM", 71, 93], ["APOBEC3", "TEST", 94, 101], ["NL63 restriction", "PROBLEM", 116, 132], ["the progressive accumulation of mutations", "PROBLEM", 195, 236], ["virus passages", "TREATMENT", 263, 277], ["hypermutation", "OBSERVATION", 9, 22], ["cytidine deamination", "OBSERVATION", 152, 172]]], ["Notably, after the first passage, the inhibitory effect of the three APOBECs diminished, and no decline in virus yield was seen (data not shown).", [["APOBECs", "GENE_OR_GENE_PRODUCT", 69, 76], ["the three APOBECs diminished", "PROBLEM", 59, 87], ["decline in virus yield", "PROBLEM", 96, 118], ["diminished", "OBSERVATION", 77, 87], ["no", "UNCERTAINTY", 93, 95]]], ["Cell-culture supernatants were collected after four passages of HCoV-NL63, and several regions of the viral RNA genome were sequenced.", [["Cell", "ANATOMY", 0, 4], ["supernatants", "ANATOMY", 13, 25], ["Cell", "CELL", 0, 4], ["HCoV-NL63", "CELL", 64, 73], ["HCoV", "DNA", 64, 68], ["NL63", "DNA", 69, 73], ["viral RNA genome", "DNA", 102, 118], ["HCoV", "SPECIES", 64, 68], ["Cell-culture supernatants", "TEST", 0, 25], ["HCoV", "TEST", 64, 68], ["the viral RNA genome", "PROBLEM", 98, 118], ["viral RNA genome", "OBSERVATION", 102, 118]]], ["Point mutations (G \u2192 A or C \u2192 T) were identified in the genes encoding the 1ab polyprotein and spike protein in virus passaged in APOBEC3-expressing cells, but not in wild-type cells.", [["cells", "ANATOMY", 149, 154], ["wild-type cells", "ANATOMY", 167, 182], ["G \u2192 A", "GENE_OR_GENE_PRODUCT", 17, 22], ["C \u2192 T", "GENE_OR_GENE_PRODUCT", 26, 31], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 130, 137], ["cells", "CELL", 149, 154], ["cells", "CELL", 177, 182], ["1ab polyprotein", "PROTEIN", 75, 90], ["spike protein", "PROTEIN", 95, 108], ["APOBEC3-expressing cells", "CELL_LINE", 130, 154], ["wild-type cells", "CELL_TYPE", 167, 182], ["Point mutations", "TEST", 0, 15], ["the 1ab polyprotein", "TEST", 71, 90], ["spike protein in virus", "PROBLEM", 95, 117], ["expressing cells", "PROBLEM", 138, 154], ["expressing cells", "OBSERVATION", 138, 154], ["type cells", "OBSERVATION", 172, 182]]], ["These mutations were not specific to virus collected from cells expressing A3C, A3F or A3H, but were also identified in virus passaged in cells expressing A3A, ADE or A3G.APOBEC3-mediated HCoV-NL63 restriction is associated with cytidine deamination ::: ResultsTo identify whether APOBEC3 protein were capable of inducing hypermutation, we used a recombinant GC-rich HCoV-229E virus (ic229E-GC), into which we had introduced silent mutations (either A \u2192 G or T \u2192 C) in the A/T-rich region of nsp6, resulting in a potential \u2018hot-spot\u2019 for cytidine deamination.", [["cells", "ANATOMY", 58, 63], ["cells", "ANATOMY", 138, 143], ["cytidine", "CHEMICAL", 229, 237], ["cytidine", "CHEMICAL", 538, 546], ["cytidine", "CHEMICAL", 229, 237], ["cytidine", "CHEMICAL", 538, 546], ["cells", "CELL", 58, 63], ["A3C", "GENE_OR_GENE_PRODUCT", 75, 78], ["A3F", "GENE_OR_GENE_PRODUCT", 80, 83], ["A3H", "GENE_OR_GENE_PRODUCT", 87, 90], ["cells", "CELL", 138, 143], ["A3A", "GENE_OR_GENE_PRODUCT", 155, 158], ["A3G", "GENE_OR_GENE_PRODUCT", 167, 170], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 171, 178], ["HCoV", "GENE_OR_GENE_PRODUCT", 188, 192], ["cytidine", "SIMPLE_CHEMICAL", 229, 237], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 281, 288], ["GC-rich HCoV-229E virus", "ORGANISM", 359, 382], ["ic229E-GC", "CELL", 384, 393], ["A \u2192 G", "GENE_OR_GENE_PRODUCT", 450, 455], ["T \u2192 C", "GENE_OR_GENE_PRODUCT", 459, 464], ["nsp6", "GENE_OR_GENE_PRODUCT", 492, 496], ["cytidine", "SIMPLE_CHEMICAL", 538, 546], ["A3C", "PROTEIN", 75, 78], ["A3F", "PROTEIN", 80, 83], ["A3H", "PROTEIN", 87, 90], ["A3A", "PROTEIN", 155, 158], ["ADE", "PROTEIN", 160, 163], ["A3G", "PROTEIN", 167, 170], ["APOBEC3", "PROTEIN", 171, 178], ["HCoV", "DNA", 188, 192], ["NL63", "DNA", 193, 197], ["APOBEC3 protein", "PROTEIN", 281, 296], ["A/T-rich region", "DNA", 473, 488], ["nsp6", "DNA", 492, 496], ["HCoV-229E virus", "SPECIES", 367, 382], ["These mutations", "PROBLEM", 0, 15], ["A3C", "TEST", 75, 78], ["virus", "PROBLEM", 120, 125], ["APOBEC3", "TEST", 171, 178], ["NL63 restriction", "PROBLEM", 193, 209], ["APOBEC3 protein", "PROBLEM", 281, 296], ["inducing hypermutation", "PROBLEM", 313, 335], ["a recombinant GC", "TEST", 345, 361], ["silent mutations", "PROBLEM", 425, 441], ["a potential \u2018hot-spot", "PROBLEM", 511, 532], ["cytidine deamination", "TREATMENT", 538, 558], ["virus passaged", "OBSERVATION", 120, 134], ["cytidine deamination", "OBSERVATION", 229, 249]]], ["The virus was propagated and titrated to determine the 50% tissue-culture infective dose (TCID50) in naturally permissive Huh-7 cells.", [["tissue", "ANATOMY", 59, 65], ["Huh-7 cells", "ANATOMY", 122, 133], ["tissue", "TISSUE", 59, 65], ["Huh-7 cells", "CELL", 122, 133], ["Huh-7 cells", "CELL_LINE", 122, 133], ["Huh-7", "SPECIES", 122, 127], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9]]], ["The effectiveness of mRNA transfection in Huh-7 cells was confirmed by detection of green fluorescence in cells transfected with GFP mRNA.", [["Huh-7 cells", "ANATOMY", 42, 53], ["cells", "ANATOMY", 106, 111], ["Huh-7 cells", "CELL", 42, 53], ["cells", "CELL", 106, 111], ["GFP", "GENE_OR_GENE_PRODUCT", 129, 132], ["Huh-7 cells", "CELL_LINE", 42, 53], ["GFP mRNA", "RNA", 129, 137], ["mRNA transfection", "TEST", 21, 38], ["Huh", "TEST", 42, 45], ["green fluorescence in cells", "PROBLEM", 84, 111], ["GFP mRNA", "TEST", 129, 137], ["mRNA transfection", "OBSERVATION", 21, 38], ["green fluorescence", "OBSERVATION", 84, 102], ["GFP mRNA", "OBSERVATION", 129, 137]]], ["Huh-7 cells were then transfected with mRNA encoding an APOBEC3 protein, infected with ic229E-GC at 400 TCID50 per ml and cultured for 5 days.", [["Huh-7 cells", "ANATOMY", 0, 11], ["Huh-7 cells", "CELL", 0, 11], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 56, 63], ["Huh-7 cells", "CELL_LINE", 0, 11], ["mRNA", "RNA", 39, 43], ["APOBEC3 protein", "PROTEIN", 56, 71], ["Huh", "TEST", 0, 3], ["GC", "TREATMENT", 94, 96], ["7 cells", "OBSERVATION_MODIFIER", 4, 11]]], ["Pronounced inhibition of viral infection occurred in cells expressing A3C, A3F or A3H (data not shown).", [["cells", "ANATOMY", 53, 58], ["viral infection", "DISEASE", 25, 40], ["cells", "CELL", 53, 58], ["A3C", "GENE_OR_GENE_PRODUCT", 70, 73], ["A3F", "GENE_OR_GENE_PRODUCT", 75, 78], ["A3H", "GENE_OR_GENE_PRODUCT", 82, 85], ["A3C", "PROTEIN", 70, 73], ["A3F", "PROTEIN", 75, 78], ["A3H", "PROTEIN", 82, 85], ["viral infection", "PROBLEM", 25, 40], ["viral", "OBSERVATION_MODIFIER", 25, 30], ["infection", "OBSERVATION", 31, 40]]], ["After four passages of ic229E-GC, viral RNA was sequenced.", [["ic229E-GC", "CELL", 23, 32], ["ic229E", "DNA", 23, 29], ["viral RNA", "RNA", 34, 43], ["viral RNA", "PROBLEM", 34, 43], ["viral RNA", "OBSERVATION", 34, 43]]], ["No G \u2192 A or C \u2192 T mutations were identified within the GC-rich region in any of the samples.", [["samples", "ANATOMY", 84, 91], ["G \u2192 A", "GENE_OR_GENE_PRODUCT", 3, 8], ["C \u2192 T", "GENE_OR_GENE_PRODUCT", 12, 17], ["GC-rich region", "DNA", 55, 69], ["C \u2192 T mutations", "PROBLEM", 12, 27]]], ["However, ic229E-GC passaged in cells expressing A3F protein showed considerable sequence heterogeneity, compared with passaged in GFP-positive cells, indicating a possible A3F deaminase activity (Fig. 4d).APOBEC3 proteins interact with the HCoV-NL63 nucleoprotein ::: ResultsOur results demonstrated that, although cytidine deamination was involved in inhibition of coronavirus by APOBEC3 proteins, deaminase mutants retained some anti-coronaviral activity, suggesting that an additional mechanism may be involved in APOBEC3-mediated coronavirus restriction.", [["cells", "ANATOMY", 31, 36], ["cells", "ANATOMY", 143, 148], ["cytidine", "CHEMICAL", 315, 323], ["cytidine", "CHEMICAL", 315, 323], ["ic229E", "GENE_OR_GENE_PRODUCT", 9, 15], ["cells", "CELL", 31, 36], ["A3F", "GENE_OR_GENE_PRODUCT", 48, 51], ["GFP", "GENE_OR_GENE_PRODUCT", 130, 133], ["cells", "CELL", 143, 148], ["A3F deaminase", "GENE_OR_GENE_PRODUCT", 172, 185], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 205, 212], ["HCoV", "GENE_OR_GENE_PRODUCT", 240, 244], ["cytidine", "SIMPLE_CHEMICAL", 315, 323], ["coronavirus", "ORGANISM", 366, 377], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 381, 388], ["anti-coronaviral", "CANCER", 431, 447], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 517, 524], ["coronavirus", "ORGANISM", 534, 545], ["ic229E", "PROTEIN", 9, 15], ["A3F protein", "PROTEIN", 48, 59], ["GFP-positive cells", "CELL_LINE", 130, 148], ["A3F deaminase", "PROTEIN", 172, 185], ["APOBEC3 proteins", "PROTEIN", 205, 221], ["HCoV", "PROTEIN", 240, 244], ["NL63 nucleoprotein", "PROTEIN", 245, 263], ["APOBEC3 proteins", "PROTEIN", 381, 397], ["deaminase mutants", "PROTEIN", 399, 416], ["APOBEC3", "PROTEIN", 517, 524], ["A3F protein", "TEST", 48, 59], ["considerable sequence heterogeneity", "PROBLEM", 67, 102], ["GFP", "TEST", 130, 133], ["positive cells", "PROBLEM", 134, 148], ["A3F deaminase activity", "PROBLEM", 172, 194], ["the HCoV", "TEST", 236, 244], ["cytidine deamination", "PROBLEM", 315, 335], ["coronavirus", "PROBLEM", 366, 377], ["APOBEC3 proteins", "PROBLEM", 381, 397], ["deaminase mutants", "PROBLEM", 399, 416], ["an additional mechanism", "PROBLEM", 474, 497], ["APOBEC3-mediated coronavirus restriction", "TREATMENT", 517, 557], ["positive cells", "OBSERVATION", 134, 148], ["anti-coronaviral activity", "OBSERVATION", 431, 456]]], ["We therefore analysed the interactions between APOBEC3 proteins (A3C, A3F and A3H) and HCoV-NL63 nucleocapsid protein (HCoV-NL63-N), which is the most abundant viral structural protein.", [["APOBEC3", "GENE_OR_GENE_PRODUCT", 47, 54], ["A3C", "GENE_OR_GENE_PRODUCT", 65, 68], ["A3F", "GENE_OR_GENE_PRODUCT", 70, 73], ["A3H", "GENE_OR_GENE_PRODUCT", 78, 81], ["HCoV-NL63 nucleocapsid", "GENE_OR_GENE_PRODUCT", 87, 109], ["HCoV-NL63-N", "GENE_OR_GENE_PRODUCT", 119, 130], ["APOBEC3 proteins", "PROTEIN", 47, 63], ["A3C", "PROTEIN", 65, 68], ["A3F", "PROTEIN", 70, 73], ["A3H", "PROTEIN", 78, 81], ["HCoV", "PROTEIN", 87, 91], ["NL63 nucleocapsid protein", "PROTEIN", 92, 117], ["HCoV", "PROTEIN", 119, 123], ["NL63", "PROTEIN", 124, 128], ["N", "PROTEIN", 129, 130], ["viral structural protein", "PROTEIN", 160, 184], ["APOBEC3 proteins", "TEST", 47, 63], ["A3C", "TEST", 65, 68], ["A3F", "TEST", 70, 73], ["A3H", "TEST", 78, 81], ["HCoV", "TEST", 87, 91], ["nucleocapsid protein", "TEST", 97, 117], ["HCoV", "TEST", 119, 123], ["viral structural protein", "OBSERVATION", 160, 184]]], ["Human 293T cells were transiently transfected with plasmid DNA constructs for expression of individual HA-tagged APOBEC3 proteins (or their catalytically inactive derivatives) or GFP.", [["293T cells", "ANATOMY", 6, 16], ["plasmid", "ANATOMY", 51, 58], ["Human", "ORGANISM", 0, 5], ["293T cells", "CELL", 6, 16], ["DNA", "CELLULAR_COMPONENT", 59, 62], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 113, 120], ["GFP", "GENE_OR_GENE_PRODUCT", 179, 182], ["Human 293T cells", "CELL_LINE", 0, 16], ["plasmid DNA constructs", "DNA", 51, 73], ["HA", "PROTEIN", 103, 105], ["APOBEC3 proteins", "PROTEIN", 113, 129], ["catalytically inactive derivatives", "PROTEIN", 140, 174], ["GFP", "PROTEIN", 179, 182], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human 293T cells", "TREATMENT", 0, 16], ["plasmid DNA constructs", "TREATMENT", 51, 73], ["individual HA", "PROBLEM", 92, 105], ["tagged APOBEC3 proteins", "PROBLEM", 106, 129], ["their catalytically inactive derivatives", "PROBLEM", 134, 174], ["GFP", "PROBLEM", 179, 182]]], ["Cell lysates containing the expressed proteins were incubated with purified HCoV-NL63-N, and protein complexes were co-immunoprecipitated with anti-HA-tag resin.", [["Cell lysates", "ANATOMY", 0, 12], ["Cell lysates", "ORGANISM_SUBSTANCE", 0, 12], ["HCoV", "GENE_OR_GENE_PRODUCT", 76, 80], ["anti-HA", "GENE_OR_GENE_PRODUCT", 143, 150], ["HCoV", "PROTEIN", 76, 80], ["NL63", "PROTEIN", 81, 85], ["protein complexes", "PROTEIN", 93, 110], ["anti-HA", "PROTEIN", 143, 150], ["Cell lysates", "TEST", 0, 12], ["purified HCoV", "TEST", 67, 80], ["protein complexes", "PROBLEM", 93, 110], ["anti-HA-tag resin", "TREATMENT", 143, 160]]], ["Western-blot analysis demonstrated co-immunoprecipitation of HCoV-NL63-N with A3C, A3F and A3H, whereas no HCoV-NL63-N could be detected in samples incubated with GFP lysate.", [["samples", "ANATOMY", 140, 147], ["lysate", "ANATOMY", 167, 173], ["HCoV", "GENE_OR_GENE_PRODUCT", 61, 65], ["A3C", "GENE_OR_GENE_PRODUCT", 78, 81], ["A3F", "GENE_OR_GENE_PRODUCT", 83, 86], ["A3H", "GENE_OR_GENE_PRODUCT", 91, 94], ["HCoV", "GENE_OR_GENE_PRODUCT", 107, 111], ["NL63-N", "GENE_OR_GENE_PRODUCT", 112, 118], ["GFP", "GENE_OR_GENE_PRODUCT", 163, 166], ["HCoV", "PROTEIN", 61, 65], ["NL63", "PROTEIN", 66, 70], ["A3C", "DNA", 78, 81], ["A3F", "DNA", 83, 86], ["A3H", "DNA", 91, 94], ["HCoV", "PROTEIN", 107, 111], ["NL63", "DNA", 112, 116], ["HCoV", "SPECIES", 107, 111], ["blot analysis", "TEST", 8, 21], ["co-immunoprecipitation", "TEST", 35, 57], ["HCoV", "TEST", 61, 65], ["NL63", "TEST", 66, 70], ["A3C", "TEST", 78, 81], ["A3F", "TEST", 83, 86], ["A3H", "TEST", 91, 94], ["HCoV", "TEST", 107, 111], ["GFP lysate", "TEST", 163, 173]]], ["Notably, the catalytically inactive derivatives of A3C, A3F and A3H also bound to HCoV-NL63-N protein (Fig. 5a, Supplementary Figure 3).", [["A3C", "CHEMICAL", 51, 54], ["A3F", "CHEMICAL", 56, 59], ["A3C", "SIMPLE_CHEMICAL", 51, 54], ["A3F", "SIMPLE_CHEMICAL", 56, 59], ["A3H", "SIMPLE_CHEMICAL", 64, 67], ["HCoV", "GENE_OR_GENE_PRODUCT", 82, 86], ["A3C", "PROTEIN", 51, 54], ["A3F", "PROTEIN", 56, 59], ["A3H", "PROTEIN", 64, 67], ["HCoV", "PROTEIN", 82, 86], ["NL63", "PROTEIN", 87, 91], ["N protein", "PROTEIN", 92, 101], ["A3C", "TEST", 51, 54], ["A3F", "TEST", 56, 59], ["HCoV", "TEST", 82, 86], ["NL63", "TEST", 87, 91]]], ["On the other hand, we could not observe the same effect with other APOBEC3 proteins (A3A, A3D and A3G).APOBEC3 proteins interact with the HCoV-NL63 nucleoprotein ::: ResultsCo-localisation of A3C with HCoV-NL63-N was investigated by co-transfection of LLC-Mk2 cells with mRNAs encoding A3C and HCoV-NL63-N, followed by immunofluorescence staining and confocal microscopy.", [["LLC-Mk2 cells", "ANATOMY", 252, 265], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 67, 74], ["A3A", "GENE_OR_GENE_PRODUCT", 85, 88], ["A3D", "GENE_OR_GENE_PRODUCT", 90, 93], ["A3G", "GENE_OR_GENE_PRODUCT", 98, 101], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 103, 110], ["HCoV", "GENE_OR_GENE_PRODUCT", 138, 142], ["A3C", "GENE_OR_GENE_PRODUCT", 192, 195], ["HCoV", "GENE_OR_GENE_PRODUCT", 201, 205], ["LLC-Mk2 cells", "CELL", 252, 265], ["A3C", "GENE_OR_GENE_PRODUCT", 286, 289], ["APOBEC3 proteins", "PROTEIN", 67, 83], ["A3A", "PROTEIN", 85, 88], ["A3D", "PROTEIN", 90, 93], ["A3G", "PROTEIN", 98, 101], ["APOBEC3 proteins", "PROTEIN", 103, 119], ["HCoV", "PROTEIN", 138, 142], ["NL63 nucleoprotein", "PROTEIN", 143, 161], ["A3C", "PROTEIN", 192, 195], ["HCoV", "PROTEIN", 201, 205], ["NL63", "PROTEIN", 206, 210], ["LLC-Mk2 cells", "CELL_LINE", 252, 265], ["mRNAs", "RNA", 271, 276], ["A3C", "PROTEIN", 286, 289], ["HCoV", "PROTEIN", 294, 298], ["NL63", "PROTEIN", 299, 303], ["APOBEC3 proteins", "TEST", 103, 119], ["the HCoV", "TEST", 134, 142], ["A3C", "TEST", 192, 195], ["HCoV", "TEST", 201, 205], ["LLC", "TEST", 252, 255], ["mRNAs", "TEST", 271, 276], ["A3C", "TEST", 286, 289], ["HCoV", "TEST", 294, 298], ["immunofluorescence staining", "TEST", 319, 346], ["confocal microscopy", "TEST", 351, 370], ["LLC", "ANATOMY", 252, 255], ["Mk2 cells", "OBSERVATION", 256, 265]]], ["The analysis showed several clearly visible foci of co-localisation (Fig. 5b).", [["foci", "ANATOMY", 44, 48], ["The analysis", "TEST", 0, 12], ["several clearly visible foci of co-localisation", "PROBLEM", 20, 67], ["several", "OBSERVATION_MODIFIER", 20, 27], ["clearly", "OBSERVATION_MODIFIER", 28, 35], ["visible", "OBSERVATION_MODIFIER", 36, 43], ["foci", "OBSERVATION", 44, 48]]], ["Calculation of Manders\u2019 coefficient gave a value of 0.459, indicating the existence of an interaction between the two proteins.DiscussionAPOBEC3-mediated cytidine deamination has been described as an interim antiviral mechanism.", [["cytidine", "CHEMICAL", 154, 162], ["cytidine", "CHEMICAL", 154, 162], ["DiscussionAPOBEC3", "GENE_OR_GENE_PRODUCT", 127, 144], ["cytidine", "SIMPLE_CHEMICAL", 154, 162], ["DiscussionAPOBEC3", "PROTEIN", 127, 144], ["DiscussionAPOBEC3-mediated cytidine deamination", "TREATMENT", 127, 174], ["cytidine deamination", "OBSERVATION", 154, 174], ["antiviral mechanism", "OBSERVATION", 208, 227]]], ["Although APOBEC3 proteins were initially shown to primarily modify DNA templates, it has subsequently been demonstrated that they also use RNA as a substrate.", [["APOBEC3", "GENE_OR_GENE_PRODUCT", 9, 16], ["DNA", "CELLULAR_COMPONENT", 67, 70], ["APOBEC3 proteins", "PROTEIN", 9, 25], ["APOBEC3 proteins", "PROBLEM", 9, 25], ["DNA templates", "PROBLEM", 67, 80]]], ["The finding that APOBEC3 deaminases can mutate the HIV RNA genome first expanded their possible specificity16.", [["APOBEC3", "GENE_OR_GENE_PRODUCT", 17, 24], ["APOBEC3 deaminases", "PROTEIN", 17, 35], ["HIV RNA genome", "DNA", 51, 65], ["HIV", "SPECIES", 51, 54], ["HIV", "SPECIES", 51, 54], ["APOBEC3 deaminases", "PROBLEM", 17, 35], ["the HIV RNA genome", "PROBLEM", 47, 65], ["specificity", "TEST", 96, 107], ["APOBEC3 deaminases", "OBSERVATION", 17, 35]]], ["Thereafter, it was shown that A3G impairs the replication of mumps, measles and respiratory syncytial viruses.", [["mumps", "DISEASE", 61, 66], ["measles", "DISEASE", 68, 75], ["respiratory syncytial viruses", "DISEASE", 80, 109], ["A3G", "GENE_OR_GENE_PRODUCT", 30, 33], ["mumps", "ORGANISM", 61, 66], ["measles", "ORGANISM", 68, 75], ["respiratory syncytial viruses", "ORGANISM", 80, 109], ["A3G", "PROTEIN", 30, 33], ["respiratory syncytial viruses", "SPECIES", 80, 109], ["mumps", "PROBLEM", 61, 66], ["measles", "PROBLEM", 68, 75], ["respiratory syncytial viruses", "PROBLEM", 80, 109], ["A3G", "OBSERVATION", 30, 33], ["syncytial viruses", "OBSERVATION", 92, 109]]], ["This antiviral activity is not an effect of APOBEC3 enzymatic activity, but is thought to result from the interaction of A3G with viral transcripts18.", [["APOBEC3", "GENE_OR_GENE_PRODUCT", 44, 51], ["A3G", "GENE_OR_GENE_PRODUCT", 121, 124], ["APOBEC3", "PROTEIN", 44, 51], ["A3G", "PROTEIN", 121, 124], ["viral transcripts", "RNA", 130, 147], ["APOBEC3 enzymatic activity", "PROBLEM", 44, 70], ["viral transcripts", "TREATMENT", 130, 147], ["viral transcripts", "OBSERVATION", 130, 147]]], ["A3A has been shown to act as a mRNA-editing factor in human monocytes and monocyte-derived macrophages17.", [["monocytes", "ANATOMY", 60, 69], ["monocyte", "ANATOMY", 74, 82], ["macrophages", "ANATOMY", 91, 102], ["A3A", "CHEMICAL", 0, 3], ["A3A", "GENE_OR_GENE_PRODUCT", 0, 3], ["human", "ORGANISM", 54, 59], ["monocytes", "CELL", 60, 69], ["monocyte", "CELL", 74, 82], ["-derived macrophages17", "CELL", 82, 104], ["A3A", "PROTEIN", 0, 3], ["mRNA-editing factor", "PROTEIN", 31, 50], ["human monocytes", "CELL_TYPE", 54, 69], ["monocyte-derived macrophages17", "CELL_LINE", 74, 104], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59], ["a mRNA", "TEST", 29, 35], ["human monocytes", "TEST", 54, 69], ["monocyte", "TEST", 74, 82]]], ["However, APOBEC3-mediated deamination of viral RNA genomes has not previously been demonstrated for viruses that do not replicate through DNA intermediates.", [["APOBEC3", "GENE_OR_GENE_PRODUCT", 9, 16], ["DNA", "CELLULAR_COMPONENT", 138, 141], ["APOBEC3", "PROTEIN", 9, 16], ["viral RNA genomes", "DNA", 41, 58], ["APOBEC3", "PROBLEM", 9, 16], ["viral RNA genomes", "PROBLEM", 41, 58], ["viruses", "PROBLEM", 100, 107], ["APOBEC3", "OBSERVATION", 9, 16], ["viral RNA genomes", "OBSERVATION", 41, 58]]], ["Here, we investigated the antiviral effects of APOBEC3 proteins on human coronaviruses.", [["APOBEC3", "GENE_OR_GENE_PRODUCT", 47, 54], ["human", "ORGANISM", 67, 72], ["coronaviruses", "ORGANISM", 73, 86], ["APOBEC3 proteins", "PROTEIN", 47, 63], ["human", "SPECIES", 67, 72], ["human coronaviruses", "SPECIES", 67, 86], ["APOBEC3 proteins", "PROBLEM", 47, 63], ["human coronaviruses", "PROBLEM", 67, 86], ["antiviral effects", "OBSERVATION", 26, 43]]], ["HCoV-NL63 was selected as the model pathogen because of its prominent bias in nucleotide composition (low GC content), suggesting the possible shaping of the genome by cytidine deamination.DiscussionWe studied the interaction between HCoV and HAE cultures, as an in vitro model of the human airways, the primary entry site for human respiratory viruses. mRNA levels of genes encoding A3A, A3C and A3D were upregulated in HCoV-NL63-infected cultures.", [["HCoV", "ANATOMY", 234, 238], ["HAE cultures", "ANATOMY", 243, 255], ["airways", "ANATOMY", 291, 298], ["HCoV-NL63", "ANATOMY", 421, 430], ["cultures", "ANATOMY", 440, 448], ["nucleotide", "CHEMICAL", 78, 88], ["cytidine", "CHEMICAL", 168, 176], ["HAE", "DISEASE", 243, 246], ["respiratory viruses", "DISEASE", 333, 352], ["nucleotide", "CHEMICAL", 78, 88], ["cytidine", "CHEMICAL", 168, 176], ["HCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["genome", "CELLULAR_COMPONENT", 158, 164], ["cytidine", "SIMPLE_CHEMICAL", 168, 176], ["HCoV", "CELL", 234, 238], ["HAE cultures", "CELL", 243, 255], ["human", "ORGANISM", 285, 290], ["airways", "MULTI-TISSUE_STRUCTURE", 291, 298], ["human", "ORGANISM", 327, 332], ["A3A", "GENE_OR_GENE_PRODUCT", 384, 387], ["A3C", "GENE_OR_GENE_PRODUCT", 389, 392], ["A3D", "GENE_OR_GENE_PRODUCT", 397, 400], ["HCoV-NL63", "CELL", 421, 430], ["cultures", "CELL", 440, 448], ["HCoV", "PROTEIN", 0, 4], ["NL63", "DNA", 5, 9], ["HCoV and HAE cultures", "CELL_LINE", 234, 255], ["A3A", "PROTEIN", 384, 387], ["A3C", "PROTEIN", 389, 392], ["A3D", "PROTEIN", 397, 400], ["HCoV-NL63-infected cultures", "CELL_LINE", 421, 448], ["human", "SPECIES", 285, 290], ["human", "SPECIES", 327, 332], ["HCoV", "SPECIES", 0, 4], ["human", "SPECIES", 285, 290], ["human respiratory viruses", "SPECIES", 327, 352], ["HCoV", "SPECIES", 421, 425], ["HCoV", "TEST", 0, 4], ["its prominent bias in nucleotide composition (low GC content", "PROBLEM", 56, 116], ["cytidine deamination", "TREATMENT", 168, 188], ["HAE cultures", "TEST", 243, 255], ["human respiratory viruses", "PROBLEM", 327, 352], ["mRNA levels", "TEST", 354, 365], ["A3C", "TEST", 389, 392], ["A3D", "TEST", 397, 400], ["HCoV", "TEST", 421, 425], ["infected cultures", "PROBLEM", 431, 448], ["prominent", "OBSERVATION_MODIFIER", 60, 69], ["bias", "OBSERVATION", 70, 74], ["low GC", "OBSERVATION_MODIFIER", 102, 108], ["suggesting the possible", "UNCERTAINTY", 119, 142], ["cytidine deamination", "OBSERVATION", 168, 188], ["human airways", "ANATOMY", 285, 298], ["respiratory viruses", "OBSERVATION", 333, 352]]], ["Upregulation of APOBEC3 protein expression was previously shown to be dependent on interferon alpha, and it is associated with non-cytolytic clearance of human hepatitis B virus in primary hepatocytes32.", [["primary hepatocytes", "ANATOMY", 181, 200], ["hepatitis B", "DISEASE", 160, 171], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 16, 23], ["interferon alpha", "GENE_OR_GENE_PRODUCT", 83, 99], ["human", "ORGANISM", 154, 159], ["hepatitis B virus", "ORGANISM", 160, 177], ["hepatocytes", "CELL", 189, 200], ["APOBEC3 protein", "PROTEIN", 16, 31], ["interferon alpha", "PROTEIN", 83, 99], ["human", "SPECIES", 154, 159], ["hepatitis B virus", "SPECIES", 160, 177], ["human hepatitis B virus", "SPECIES", 154, 177], ["Upregulation of APOBEC3 protein expression", "PROBLEM", 0, 42], ["interferon alpha", "TREATMENT", 83, 99], ["non-cytolytic clearance", "PROBLEM", 127, 150], ["human hepatitis B virus", "PROBLEM", 154, 177], ["APOBEC3 protein expression", "OBSERVATION", 16, 42], ["dependent", "OBSERVATION_MODIFIER", 70, 79], ["interferon", "OBSERVATION", 83, 93], ["hepatitis", "OBSERVATION", 160, 169]]], ["Cytoplasmic DNA triggers production of type I interferon, leading to massive upregulation of APOBEC3A33,34.", [["Cytoplasmic", "ANATOMY", 0, 11], ["Cytoplasmic", "CELLULAR_COMPONENT", 0, 11], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["type I interferon", "GENE_OR_GENE_PRODUCT", 39, 56], ["APOBEC3A33,34", "GENE_OR_GENE_PRODUCT", 93, 106], ["type I interferon", "PROTEIN", 39, 56], ["APOBEC3A33,34", "PROTEIN", 93, 106], ["Cytoplasmic DNA", "PROBLEM", 0, 15], ["type I interferon", "PROBLEM", 39, 56], ["massive upregulation of APOBEC3A33,34", "PROBLEM", 69, 106], ["massive", "OBSERVATION_MODIFIER", 69, 76], ["upregulation", "OBSERVATION", 77, 89]]], ["Here, we investigated the effects of different APOBEC3 proteins, and found that expression of A3C, A3F or A3H limits coronavirus infection.", [["coronavirus infection", "DISEASE", 117, 138], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 47, 54], ["A3C", "GENE_OR_GENE_PRODUCT", 94, 97], ["A3F", "GENE_OR_GENE_PRODUCT", 99, 102], ["A3H", "GENE_OR_GENE_PRODUCT", 106, 109], ["coronavirus", "ORGANISM", 117, 128], ["APOBEC3 proteins", "PROTEIN", 47, 63], ["A3C", "PROTEIN", 94, 97], ["A3F", "PROTEIN", 99, 102], ["A3H", "PROTEIN", 106, 109], ["different APOBEC3 proteins", "TREATMENT", 37, 63], ["A3C", "TEST", 94, 97], ["A3H", "PROBLEM", 106, 109], ["coronavirus infection", "PROBLEM", 117, 138], ["APOBEC3 proteins", "OBSERVATION", 47, 63], ["coronavirus", "OBSERVATION_MODIFIER", 117, 128], ["infection", "OBSERVATION", 129, 138]]], ["Notably, some infectious progeny were produced in the presence of these proteins, and serial passaging of virus was possible.", [["some infectious progeny", "PROBLEM", 9, 32], ["these proteins", "PROBLEM", 66, 80], ["serial passaging of virus", "TREATMENT", 86, 111], ["some", "OBSERVATION_MODIFIER", 9, 13], ["infectious", "OBSERVATION", 14, 24]]], ["Surprisingly, if cells overexpressing A3C, A3F or A3H were infected with the progeny virions, no restriction of virus replication occurred.", [["cells", "ANATOMY", 17, 22], ["virions", "ANATOMY", 85, 92], ["cells", "CELL", 17, 22], ["A3C", "GENE_OR_GENE_PRODUCT", 38, 41], ["A3F", "GENE_OR_GENE_PRODUCT", 43, 46], ["A3H", "GENE_OR_GENE_PRODUCT", 50, 53], ["A3C", "PROTEIN", 38, 41], ["A3F", "PROTEIN", 43, 46], ["A3H", "PROTEIN", 50, 53], ["A3C", "TEST", 38, 41], ["A3H", "PROBLEM", 50, 53], ["the progeny virions", "TREATMENT", 73, 92], ["virus replication", "TREATMENT", 112, 129], ["virus", "OBSERVATION", 112, 117]]], ["Possible explanations for this effect are that the first viral passage results in selection of viral subspecies that are not affected by APOBEC3 activities, or that viral passage activates a viral factor or mechanism that can counteract APOBEC3 activities.DiscussionSerial passage of HCoV in APOBEC3-expressing cells did not result in hypermutation in progeny viruses.", [["cells", "ANATOMY", 311, 316], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 137, 144], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 237, 244], ["HCoV", "GENE_OR_GENE_PRODUCT", 284, 288], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 292, 299], ["cells", "CELL", 311, 316], ["APOBEC3", "PROTEIN", 137, 144], ["viral factor", "PROTEIN", 191, 203], ["APOBEC3", "PROTEIN", 237, 244], ["HCoV", "PROTEIN", 284, 288], ["APOBEC3-expressing cells", "CELL_LINE", 292, 316], ["the first viral passage", "PROBLEM", 47, 70], ["viral subspecies", "PROBLEM", 95, 111], ["viral passage", "PROBLEM", 165, 178], ["a viral factor", "PROBLEM", 189, 203], ["expressing cells", "PROBLEM", 300, 316], ["hypermutation in progeny viruses", "PROBLEM", 335, 367], ["viral subspecies", "OBSERVATION", 95, 111], ["hypermutation", "OBSERVATION", 335, 348], ["progeny viruses", "OBSERVATION", 352, 367]]], ["It is possible that HCoV-NL63 has reached a maximum level of AT content, so that new C \u2192 T or G \u2192 A changes in the genome result in a drastic drop in viral infectivity.", [["HCoV", "GENE_OR_GENE_PRODUCT", 20, 24], ["AT", "GENE_OR_GENE_PRODUCT", 61, 63], ["C \u2192 T", "GENE_OR_GENE_PRODUCT", 85, 90], ["G \u2192 A", "GENE_OR_GENE_PRODUCT", 94, 99], ["HCoV", "PROTEIN", 20, 24], ["NL63", "DNA", 25, 29], ["HCoV", "TEST", 20, 24], ["new C \u2192 T", "PROBLEM", 81, 90], ["a drastic drop", "PROBLEM", 132, 146], ["viral infectivity", "PROBLEM", 150, 167], ["drastic drop", "OBSERVATION", 134, 146], ["viral infectivity", "OBSERVATION", 150, 167]]], ["However, incubation of an RNA transcript containing potential deaminase hot-spots17 with A3C-enriched cell lysates did not result in hypermutation.DiscussionThe lack of hypermutation might have resulted from limited accessibility of the template or instability of A3C in the lysate.", [["cell lysates", "ANATOMY", 102, 114], ["lysate", "ANATOMY", 275, 281], ["A3C", "GENE_OR_GENE_PRODUCT", 89, 92], ["cell lysates", "CELL", 102, 114], ["A3C", "GENE_OR_GENE_PRODUCT", 264, 267], ["lysate", "ORGANISM_SUBSTANCE", 275, 281], ["RNA transcript", "RNA", 26, 40], ["A3C", "PROTEIN", 89, 92], ["A3C", "PROTEIN", 264, 267], ["an RNA transcript", "TREATMENT", 23, 40], ["potential deaminase hot-spots", "TEST", 52, 81], ["A3C", "TEST", 89, 92], ["enriched cell lysates", "TREATMENT", 93, 114], ["hypermutation", "PROBLEM", 133, 146], ["hypermutation", "PROBLEM", 169, 182], ["the template", "PROBLEM", 233, 245], ["A3C", "TREATMENT", 264, 267], ["the lysate", "TREATMENT", 271, 281], ["hypermutation", "OBSERVATION", 133, 146]]], ["We were not able to develop a HCoV-NL63 molecular clone containing GC-rich elements, most likely because of low stability of the reverse genetics system for this virus (data not shown).", [["clone", "CELL", 50, 55], ["HCoV-NL63 molecular clone", "DNA", 30, 55], ["GC-rich elements", "DNA", 67, 83], ["a HCoV", "TEST", 28, 34], ["NL63 molecular clone", "PROBLEM", 35, 55], ["this virus", "PROBLEM", 157, 167], ["most likely", "UNCERTAINTY", 85, 96], ["low stability", "OBSERVATION_MODIFIER", 108, 121]]], ["We therefore developed a HCoV-229E clone containing a GC-rich region35,36.", [["HCoV-229E clone", "DNA", 25, 40], ["GC-rich region35,36", "DNA", 54, 73], ["HCoV-229E", "SPECIES", 25, 34], ["a HCoV", "TEST", 23, 29]]], ["Replication of this virus was inhibited in cells expressing A3C, A3F or A3H, but no mutations were observed in the modified region.", [["cells", "ANATOMY", 43, 48], ["cells", "CELL", 43, 48], ["A3C", "GENE_OR_GENE_PRODUCT", 60, 63], ["A3F", "GENE_OR_GENE_PRODUCT", 65, 68], ["A3H", "GENE_OR_GENE_PRODUCT", 72, 75], ["A3C", "PROTEIN", 60, 63], ["A3F", "PROTEIN", 65, 68], ["A3H", "PROTEIN", 72, 75], ["this virus", "PROBLEM", 15, 25], ["mutations", "PROBLEM", 84, 93], ["no", "UNCERTAINTY", 81, 83], ["mutations", "OBSERVATION", 84, 93]]], ["The lack of observed hypermutation may result from proofreading and repair of the coronavirus RNA genome37, and suggests that inhibition of coronaviral replication by APOBEC3 proteins does not result from deamination of viral RNA.DiscussionIt was previously shown that, for some RNA viruses, APOBEC-mediated inhibition is deamination-independent.", [["APOBEC", "CHEMICAL", 292, 298], ["coronavirus", "ORGANISM", 82, 93], ["genome37", "GENE_OR_GENE_PRODUCT", 98, 106], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 167, 174], ["APOBEC", "GENE_OR_GENE_PRODUCT", 292, 298], ["coronavirus RNA genome37", "RNA", 82, 106], ["APOBEC3 proteins", "PROTEIN", 167, 183], ["viral RNA", "RNA", 220, 229], ["APOBEC", "PROTEIN", 292, 298], ["observed hypermutation", "PROBLEM", 12, 34], ["proofreading", "TREATMENT", 51, 63], ["repair", "TREATMENT", 68, 74], ["the coronavirus RNA genome37", "PROBLEM", 78, 106], ["coronaviral replication", "TREATMENT", 140, 163], ["APOBEC3 proteins", "PROBLEM", 167, 183], ["viral RNA", "PROBLEM", 220, 229], ["some RNA viruses", "PROBLEM", 274, 290], ["hypermutation", "OBSERVATION", 21, 34], ["viral RNA", "OBSERVATION", 220, 229]]], ["In our system, catalytically inactive A3C, A3F and A3H proteins only had marginal inhibitory effect on virus replication.", [["A3C", "GENE_OR_GENE_PRODUCT", 38, 41], ["A3F", "GENE_OR_GENE_PRODUCT", 43, 46], ["A3H", "GENE_OR_GENE_PRODUCT", 51, 54], ["A3C", "PROTEIN", 38, 41], ["A3F", "PROTEIN", 43, 46], ["A3H proteins", "PROTEIN", 51, 63], ["A3F", "TEST", 43, 46], ["A3H proteins", "PROBLEM", 51, 63], ["marginal inhibitory effect", "PROBLEM", 73, 99], ["virus replication", "TREATMENT", 103, 120], ["marginal inhibitory effect", "OBSERVATION", 73, 99]]], ["We suggest that APOBEC3 proteins may affect coronavirus replication by two mechanisms: first, by deamination of yet unidentified cellular targets or deamination of single sites in the coronaviral genome; and second, by direct, non-catalytic interaction with viral RNA and/or proteins.", [["cellular", "ANATOMY", 129, 137], ["coronaviral genome", "ANATOMY", 184, 202], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 16, 23], ["coronavirus", "ORGANISM", 44, 55], ["cellular", "CELL", 129, 137], ["APOBEC3 proteins", "PROTEIN", 16, 32], ["coronaviral genome", "DNA", 184, 202], ["viral RNA", "RNA", 258, 267], ["APOBEC3 proteins", "TREATMENT", 16, 32], ["coronavirus replication", "TREATMENT", 44, 67], ["cellular targets", "PROBLEM", 129, 145], ["deamination of single sites", "PROBLEM", 149, 176], ["viral RNA and/or proteins", "PROBLEM", 258, 283], ["cellular targets", "OBSERVATION", 129, 145], ["coronaviral genome", "ANATOMY", 184, 202]]], ["APOBEC proteins may interact with the coronaviral N protein, which is an essential structural protein for formation of the viral ribonucleocapsid, and which also has a role in virus replication38\u201342.", [["APOBEC", "GENE_OR_GENE_PRODUCT", 0, 6], ["ribonucleocapsid", "GENE_OR_GENE_PRODUCT", 129, 145], ["APOBEC proteins", "PROTEIN", 0, 15], ["coronaviral N protein", "PROTEIN", 38, 59], ["viral ribonucleocapsid", "PROTEIN", 123, 145], ["APOBEC proteins", "PROBLEM", 0, 15], ["the coronaviral N protein", "TEST", 34, 59], ["the viral ribonucleocapsid", "PROBLEM", 119, 145], ["structural protein", "OBSERVATION", 83, 101], ["viral ribonucleocapsid", "OBSERVATION", 123, 145]]], ["Our results demonstrated that all APOBEC3 proteins with inhibitory activity bound to the N protein.", [["APOBEC3", "GENE_OR_GENE_PRODUCT", 34, 41], ["APOBEC3 proteins", "PROTEIN", 34, 50], ["N protein", "PROTEIN", 89, 98], ["all APOBEC3 proteins", "PROBLEM", 30, 50], ["inhibitory activity bound", "PROBLEM", 56, 81]]], ["The direct, editing-independent mechanism by which APOBEC3 proteins inhibit HCoV-NL63 replication is still to be elucidated, but it is possible that interaction with the N protein interferes with virus replication and progeny production.DiscussionIn conclusion, our results show that three APOBEC3 proteins (A3C, A3F and A3H) inhibit coronaviral replication.", [["coronaviral", "ANATOMY", 334, 345], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 51, 58], ["HCoV", "GENE_OR_GENE_PRODUCT", 76, 80], ["NL63", "GENE_OR_GENE_PRODUCT", 81, 85], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 290, 297], ["A3C", "GENE_OR_GENE_PRODUCT", 308, 311], ["A3F", "GENE_OR_GENE_PRODUCT", 313, 316], ["A3H", "GENE_OR_GENE_PRODUCT", 321, 324], ["coronaviral", "CANCER", 334, 345], ["APOBEC3 proteins", "PROTEIN", 51, 67], ["N protein", "PROTEIN", 170, 179], ["APOBEC3 proteins", "PROTEIN", 290, 306], ["A3C", "PROTEIN", 308, 311], ["A3F", "PROTEIN", 313, 316], ["A3H", "PROTEIN", 321, 324], ["APOBEC3 proteins", "TEST", 51, 67], ["HCoV", "TEST", 76, 80], ["the N protein", "TREATMENT", 166, 179], ["virus replication", "TREATMENT", 196, 213], ["three APOBEC3 proteins", "TEST", 284, 306], ["A3C", "TEST", 308, 311], ["A3F", "TEST", 313, 316], ["coronaviral replication", "TREATMENT", 334, 357]]], ["The molecular mechanism of deaminase-dependent inhibition of coronavirus replication remains elusive and may depend on deamination of single sites in the coronaviral genome, or in a cellular target or targets.", [["coronaviral genome", "ANATOMY", 154, 172], ["cellular", "ANATOMY", 182, 190], ["deaminase", "SIMPLE_CHEMICAL", 27, 36], ["coronavirus", "ORGANISM", 61, 72], ["cellular", "CELL", 182, 190], ["deaminase", "PROTEIN", 27, 36], ["coronaviral genome", "DNA", 154, 172], ["deaminase-dependent inhibition", "TREATMENT", 27, 57], ["coronavirus replication", "PROBLEM", 61, 84], ["single sites", "PROBLEM", 134, 146], ["deaminase", "OBSERVATION", 27, 36], ["coronavirus replication", "OBSERVATION", 61, 84], ["coronaviral genome", "ANATOMY", 154, 172]]], ["Passage of HCoV-NL63 in cells expressing APOBEC3 proteins results in virus that is resistant to APOBEC-mediated inhibition, possibly indicating the presence of an unidentified factor that counteracts APOBEC3 activity.", [["cells", "ANATOMY", 24, 29], ["APOBEC", "CHEMICAL", 96, 102], ["HCoV", "GENE_OR_GENE_PRODUCT", 11, 15], ["cells", "CELL", 24, 29], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 41, 48], ["APOBEC", "GENE_OR_GENE_PRODUCT", 96, 102], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 200, 207], ["HCoV", "PROTEIN", 11, 15], ["NL63", "PROTEIN", 16, 20], ["APOBEC3 proteins", "PROTEIN", 41, 57], ["APOBEC", "PROTEIN", 96, 102], ["APOBEC3", "PROTEIN", 200, 207], ["HCoV", "TEST", 11, 15], ["APOBEC3 proteins", "TEST", 41, 57], ["virus", "PROBLEM", 69, 74], ["APOBEC3 proteins", "OBSERVATION", 41, 57], ["possibly indicating", "UNCERTAINTY", 124, 143], ["counteracts APOBEC3 activity", "OBSERVATION", 188, 216]]], ["The deaminase-independent component of viral inhibition may result from interaction between viral N protein and APOBEC3 proteins.Cell culture ::: MethodsLLC-Mk2 cells (Macaca mulatta epithelial kidney cells; ATCC: CCL-7) were cultured in H/E MEM (Hanks\u2019 MEM: Earle\u2019s MEM, 2:1 ratio; Thermo Fisher Scientific, Poland) with 3% fetal bovine serum (heat-inactivated; Thermo Fisher Scientific, Poland) and antibiotics: penicillin (100 U/ml), streptomycin (100 \u03bcg/ml), and ciprofloxacin (5 \u03bcg/ml).", [["Cell", "ANATOMY", 129, 133], ["MethodsLLC-Mk2 cells", "ANATOMY", 146, 166], ["epithelial kidney cells", "ANATOMY", 183, 206], ["ATCC", "ANATOMY", 208, 212], ["CCL-7", "ANATOMY", 214, 219], ["fetal", "ANATOMY", 325, 330], ["serum", "ANATOMY", 338, 343], ["penicillin", "CHEMICAL", 414, 424], ["streptomycin", "CHEMICAL", 437, 449], ["ciprofloxacin", "CHEMICAL", 467, 480], ["penicillin", "CHEMICAL", 414, 424], ["streptomycin", "CHEMICAL", 437, 449], ["ciprofloxacin", "CHEMICAL", 467, 480], ["viral N protein", "GENE_OR_GENE_PRODUCT", 92, 107], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 112, 119], ["Cell", "CELL", 129, 133], ["MethodsLLC-Mk2 cells", "CELL", 146, 166], ["Macaca", "ORGANISM", 168, 174], ["mulatta", "ORGANISM", 175, 182], ["epithelial kidney cells", "CELL", 183, 206], ["ATCC", "CELL", 208, 212], ["CCL-7", "CELL", 214, 219], ["bovine", "ORGANISM", 331, 337], ["serum", "ORGANISM_SUBSTANCE", 338, 343], ["penicillin", "SIMPLE_CHEMICAL", 414, 424], ["streptomycin", "SIMPLE_CHEMICAL", 437, 449], ["ciprofloxacin", "SIMPLE_CHEMICAL", 467, 480], ["deaminase", "PROTEIN", 4, 13], ["viral N protein", "PROTEIN", 92, 107], ["APOBEC3 proteins", "PROTEIN", 112, 128], ["MethodsLLC-Mk2 cells", "CELL_LINE", 146, 166], ["Macaca mulatta epithelial kidney cells", "CELL_TYPE", 168, 206], ["ATCC: CCL-7", "CELL_LINE", 208, 219], ["Macaca mulatta", "SPECIES", 168, 182], ["bovine", "SPECIES", 331, 337], ["Macaca mulatta", "SPECIES", 168, 182], ["bovine", "SPECIES", 331, 337], ["The deaminase", "TREATMENT", 0, 13], ["viral inhibition", "PROBLEM", 39, 55], ["viral N protein", "TEST", 92, 107], ["APOBEC3 proteins", "PROBLEM", 112, 128], ["Cell culture", "TEST", 129, 141], ["MethodsLLC", "TEST", 146, 156], ["Mk2 cells", "TEST", 157, 166], ["ATCC", "TEST", 208, 212], ["CCL", "TEST", 214, 217], ["3% fetal bovine serum (heat", "TREATMENT", 322, 349], ["antibiotics", "TREATMENT", 401, 412], ["penicillin", "TREATMENT", 414, 424], ["streptomycin", "TREATMENT", 437, 449], ["ciprofloxacin", "TREATMENT", 467, 480], ["viral inhibition", "OBSERVATION", 39, 55], ["Mk2 cells", "OBSERVATION", 157, 166], ["kidney", "ANATOMY", 194, 200]]], ["Human hepatocellular carcinoma Huh-7 (kindly provided by dr Lia van der Hoek, UvA, The Netherlands) and 293T (ATCC: CRL-3216; kidney epithelial) cell lines were cultured in Dulbecco\u2019s MEM (Thermo Fisher Scientific, Poland) with 10% fetal bovine serum (heat-inactivated; Thermo Fisher Scientific, Poland) and antibiotics: penicillin (100 U/ml), streptomycin (100 \u03bcg/ml), and ciprofloxacin (5 \u03bcg/ml).", [["hepatocellular carcinoma Huh-7", "ANATOMY", 6, 36], ["293T", "ANATOMY", 104, 108], ["CRL-3216", "ANATOMY", 116, 124], ["kidney epithelial) cell lines", "ANATOMY", 126, 155], ["fetal bovine serum", "ANATOMY", 232, 250], ["hepatocellular carcinoma", "DISEASE", 6, 30], ["penicillin", "CHEMICAL", 321, 331], ["streptomycin", "CHEMICAL", 344, 356], ["ciprofloxacin", "CHEMICAL", 374, 387], ["penicillin", "CHEMICAL", 321, 331], ["streptomycin", "CHEMICAL", 344, 356], ["ciprofloxacin", "CHEMICAL", 374, 387], ["Human", "ORGANISM", 0, 5], ["hepatocellular carcinoma Huh-7", "CELL", 6, 36], ["UvA", "CELL", 78, 81], ["293T", "CELL", 104, 108], ["CRL-3216", "CELL", 116, 124], ["kidney epithelial) cell lines", "CELL", 126, 155], ["bovine", "ORGANISM", 238, 244], ["serum", "ORGANISM_SUBSTANCE", 245, 250], ["penicillin", "SIMPLE_CHEMICAL", 321, 331], ["streptomycin", "SIMPLE_CHEMICAL", 344, 356], ["ciprofloxacin", "SIMPLE_CHEMICAL", 374, 387], ["ATCC: CRL-3216; kidney epithelial) cell lines", "CELL_LINE", 110, 155], ["Human", "SPECIES", 0, 5], ["bovine", "SPECIES", 238, 244], ["Human hepatocellular carcinoma Huh-7", "SPECIES", 0, 36], ["ATCC: CRL-3216", "SPECIES", 110, 124], ["bovine", "SPECIES", 238, 244], ["Human hepatocellular carcinoma", "PROBLEM", 0, 30], ["Huh", "TEST", 31, 34], ["CRL", "TEST", 116, 119], ["kidney epithelial) cell lines", "TREATMENT", 126, 155], ["10% fetal bovine serum (heat", "TREATMENT", 228, 256], ["antibiotics", "TREATMENT", 308, 319], ["penicillin", "TREATMENT", 321, 331], ["streptomycin", "TREATMENT", 344, 356], ["ciprofloxacin", "TREATMENT", 374, 387], ["hepatocellular", "ANATOMY", 6, 20], ["carcinoma", "OBSERVATION", 21, 30], ["kidney", "ANATOMY", 126, 132], ["epithelial", "ANATOMY_MODIFIER", 133, 143], ["cell lines", "OBSERVATION", 145, 155]]], ["Cells were maintained at 37 \u00b0C under 5% CO2.Human airway epithelium (HAE) cultures ::: MethodsHuman epithelial cells were isolated from conductive airways resected from transplant patients.", [["Cells", "ANATOMY", 0, 5], ["airway epithelium", "ANATOMY", 50, 67], ["HAE", "ANATOMY", 69, 72], ["MethodsHuman epithelial cells", "ANATOMY", 87, 116], ["airways", "ANATOMY", 147, 154], ["CO2", "CHEMICAL", 40, 43], ["HAE", "DISEASE", 69, 72], ["CO2", "CHEMICAL", 40, 43], ["Cells", "CELL", 0, 5], ["CO2", "SIMPLE_CHEMICAL", 40, 43], ["Human", "ORGANISM", 44, 49], ["airway epithelium", "TISSUE", 50, 67], ["MethodsHuman epithelial cells", "CELL", 87, 116], ["conductive airways", "MULTI-TISSUE_STRUCTURE", 136, 154], ["patients", "ORGANISM", 180, 188], ["Human airway epithelium (HAE) cultures", "CELL_LINE", 44, 82], ["MethodsHuman epithelial cells", "CELL_TYPE", 87, 116], ["Human", "SPECIES", 44, 49], ["patients", "SPECIES", 180, 188], ["Human", "SPECIES", 44, 49], ["Cells", "TEST", 0, 5], ["cultures", "TEST", 74, 82], ["MethodsHuman epithelial cells", "PROBLEM", 87, 116], ["conductive airways", "PROBLEM", 136, 154], ["transplant patients", "TREATMENT", 169, 188], ["airway", "ANATOMY", 50, 56], ["epithelial cells", "OBSERVATION", 100, 116], ["conductive", "OBSERVATION_MODIFIER", 136, 146], ["airways", "ANATOMY", 147, 154], ["resected", "OBSERVATION", 155, 163]]], ["The study was approved by the Bioethical Committee of the Medical University of Silesia in Katowice, Poland (approval no: KNW/0022/KB1/17/10 dated on 16.02.2010).", [["The study", "TEST", 0, 9]]], ["A written informed consent was obtained from all patients.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57]]], ["Tissues were procured at the Silesian Center for Heart Diseases, Zabrze, Poland.", [["Tissues", "ANATOMY", 0, 7], ["Heart", "ANATOMY", 49, 54], ["Heart Diseases", "DISEASE", 49, 63], ["Tissues", "CANCER", 0, 7], ["Heart Diseases", "PROBLEM", 49, 63], ["Zabrze", "TREATMENT", 65, 71], ["Heart", "ANATOMY", 49, 54], ["Diseases", "OBSERVATION", 55, 63]]], ["No organs/tissues were procured from prisoners.", [["organs", "ANATOMY", 3, 9], ["tissues", "ANATOMY", 10, 17], ["organs", "ORGAN", 3, 9], ["tissues", "TISSUE", 10, 17], ["organs/tissues", "PROBLEM", 3, 17], ["organs", "ANATOMY", 3, 9], ["tissues", "ANATOMY", 10, 17]]], ["Cells were dislodged by protease treatment, and later mechanically detached from the connective tissue.", [["Cells", "ANATOMY", 0, 5], ["connective tissue", "ANATOMY", 85, 102], ["Cells", "CELL", 0, 5], ["connective tissue", "TISSUE", 85, 102], ["protease", "PROTEIN", 24, 32], ["protease treatment", "TREATMENT", 24, 42], ["connective tissue", "OBSERVATION", 85, 102]]], ["Resulting primary cells were first cultured in selective media to proliferate.", [["primary cells", "ANATOMY", 10, 23], ["cells", "CELL", 18, 23], ["primary cells", "CELL_TYPE", 10, 23], ["Resulting primary cells", "PROBLEM", 0, 23], ["primary cells", "OBSERVATION", 10, 23]]], ["Further, cells were trypsinised and transferred onto permeable Transwell insert supports (\u03d5 = 6.5).", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14], ["permeable Transwell insert supports", "TREATMENT", 53, 88]]], ["Cell differentiation was stimulated by media additives and removal of media from the apical side.", [["Cell", "ANATOMY", 0, 4], ["apical", "ANATOMY", 85, 91], ["Cell", "CELL", 0, 4], ["media additives", "TREATMENT", 39, 54], ["removal of media from the apical side", "TREATMENT", 59, 96], ["apical", "ANATOMY_MODIFIER", 85, 91]]], ["In such a manner cells were cultured for 6\u20138 weeks to form well-differentiated, pseudostratified mucociliary epithelium43.", [["cells", "ANATOMY", 17, 22], ["mucociliary epithelium43", "ANATOMY", 97, 121], ["cells", "CELL", 17, 22], ["mucociliary epithelium43", "CELL", 97, 121], ["a manner cells", "TREATMENT", 8, 22], ["pseudostratified mucociliary epithelium43", "PROBLEM", 80, 121], ["mucociliary epithelium43", "OBSERVATION", 97, 121]]], ["All experiments were performed in accordance with relevant guidelines and regulations.Human airway epithelium (HAE) cultures ::: MethodsFor the virus infection, HAE cultures were washed thrice with 100 \u03bcl of 1 \u00d7 PBS, following inoculation with HCoV-NL63 (isolate Amsterdam 1) or influenza A virus (IVA, strain H3N2) or mock (cell lysate).", [["airway epithelium", "ANATOMY", 92, 109], ["HAE", "ANATOMY", 111, 114], ["HAE cultures", "ANATOMY", 161, 173], ["cell lysate", "ANATOMY", 325, 336], ["HAE", "DISEASE", 111, 114], ["infection", "DISEASE", 150, 159], ["HAE", "DISEASE", 161, 164], ["HCoV-NL63", "CHEMICAL", 244, 253], ["IVA", "CHEMICAL", 298, 301], ["Human", "ORGANISM", 86, 91], ["airway epithelium", "TISSUE", 92, 109], ["HAE cultures", "CELL", 161, 173], ["HCoV", "ORGANISM", 244, 248], ["Amsterdam 1", "ORGANISM", 263, 274], ["influenza A virus", "ORGANISM", 279, 296], ["H3N2", "ORGANISM", 310, 314], ["cell lysate", "CELL", 325, 336], ["Human airway epithelium (HAE) cultures", "CELL_LINE", 86, 124], ["HAE cultures", "CELL_LINE", 161, 173], ["Human", "SPECIES", 86, 91], ["influenza A virus", "SPECIES", 279, 296], ["Human", "SPECIES", 86, 91], ["HCoV", "SPECIES", 244, 248], ["Amsterdam 1", "SPECIES", 263, 274], ["influenza A virus", "SPECIES", 279, 296], ["cultures", "TEST", 116, 124], ["Methods", "TREATMENT", 129, 136], ["the virus infection", "PROBLEM", 140, 159], ["HAE cultures", "TEST", 161, 173], ["1 \u00d7 PBS", "TREATMENT", 208, 215], ["inoculation", "TEST", 227, 238], ["HCoV", "TEST", 244, 248], ["influenza A virus", "PROBLEM", 279, 296], ["H3N2", "PROBLEM", 310, 314], ["mock (cell lysate", "TREATMENT", 319, 336], ["airway", "ANATOMY", 92, 98]]], ["After 2 h incubation at 32\u00b0 (for HCoV-NL63) or 37 \u00b0C (for IVA) unbound virions were removed by washing with 100 \u03bcl of 1 \u00d7 PBS and HAE cultures were cultured at an air - liquid interphase until the end of the experiment.Virus preparation and titration ::: MethodsThe stock of HCoV-NL63 (isolate Amsterdam 1) was prepared using LLC-Mk2 cells.", [["virions", "ANATOMY", 71, 78], ["LLC-Mk2 cells", "ANATOMY", 326, 339], ["HAE", "DISEASE", 130, 133], ["HCoV-NL63", "CHEMICAL", 275, 284], ["HAE cultures", "CELL", 130, 142], ["Virus", "ORGANISM", 219, 224], ["HCoV", "GENE_OR_GENE_PRODUCT", 275, 279], ["LLC-Mk2 cells", "CELL", 326, 339], ["HAE cultures", "CELL_LINE", 130, 142], ["HCoV", "PROTEIN", 275, 279], ["LLC-Mk2 cells", "CELL_LINE", 326, 339], ["HCoV-NL63", "SPECIES", 275, 284], ["HCoV", "TEST", 33, 37], ["IVA) unbound virions", "TREATMENT", 58, 78], ["1 \u00d7 PBS", "TREATMENT", 118, 125], ["HAE cultures", "TEST", 130, 142], ["an air - liquid interphase", "TREATMENT", 160, 186], ["Virus preparation", "TREATMENT", 219, 236], ["Methods", "TREATMENT", 255, 262], ["HCoV", "TEST", 275, 279], ["LLC", "ANATOMY", 326, 329], ["Mk2 cells", "OBSERVATION", 330, 339]]], ["Six days post-infection (p.i.) infected cells were lysed by freeze-thawing and the resulting supernatant was stored at \u221280 \u00b0C. Mock sample was prepared in the same manner, from non-infected cells.", [["cells", "ANATOMY", 40, 45], ["supernatant", "ANATOMY", 93, 104], ["sample", "ANATOMY", 132, 138], ["cells", "ANATOMY", 190, 195], ["cells", "CELL", 40, 45], ["cells", "CELL", 190, 195], ["infected cells", "CELL_TYPE", 31, 45], ["non-infected cells", "CELL_TYPE", 177, 195], ["infected cells", "PROBLEM", 31, 45], ["Mock sample", "TEST", 127, 138], ["non-infected cells", "OBSERVATION", 177, 195]]], ["Virus yield was determined according to the method described by Reed and Muench44.", [["Virus", "ORGANISM", 0, 5], ["Virus yield", "PROBLEM", 0, 11]]], ["Briefly, cells infected with serially diluted virus were incubated at 32 \u00b0C for 6 days and the appearance of cytopathic effect (CPE) was monitored.Isolation of nucleic acids and reverse transcription (RT) ::: MethodsViral DNA/RNA Kit (A&A Biotechnology, Poland) was used for nucleic acid isolation from cell culture supernatants, according to the manufacturer\u2019s instructions.", [["cells", "ANATOMY", 9, 14], ["cell culture supernatants", "ANATOMY", 303, 328], ["nucleic acids", "CHEMICAL", 160, 173], ["nucleic acid", "CHEMICAL", 275, 287], ["cells", "CELL", 9, 14], ["DNA", "CELLULAR_COMPONENT", 222, 225], ["cell", "CELL", 303, 307], ["MethodsViral DNA", "DNA", 209, 225], ["cells infected", "PROBLEM", 9, 23], ["serially diluted virus", "PROBLEM", 29, 51], ["cytopathic effect", "PROBLEM", 109, 126], ["nucleic acids", "TREATMENT", 160, 173], ["reverse transcription", "TREATMENT", 178, 199], ["MethodsViral DNA/RNA Kit", "TREATMENT", 209, 233], ["nucleic acid isolation", "TREATMENT", 275, 297], ["cell culture supernatants", "TREATMENT", 303, 328], ["infected", "OBSERVATION_MODIFIER", 15, 23], ["cytopathic", "OBSERVATION_MODIFIER", 109, 119], ["nucleic acids", "OBSERVATION", 160, 173]]], ["Cellular RNA was isolated using Fenozol reagent (A&A Biotechnology, Poland), followed by DNase I treatment (Thermo Fisher Scientific, Poland). cDNA samples were prepared with a High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Poland), according to the manufacturer\u2019s instructions.Preparation of GC-rich infectious clone 299E virus mutant ::: MethodsRecombinant HCoV-229E containing a GC-rich region was generated using the vaccinia virus-based reverse genetic system as described previously36,45.", [["Cellular", "ANATOMY", 0, 8], ["samples", "ANATOMY", 148, 155], ["Fenozol", "CHEMICAL", 32, 39], ["HCoV-229E", "CHEMICAL", 384, 393], ["Fenozol", "CHEMICAL", 32, 39], ["Fenozol", "SIMPLE_CHEMICAL", 32, 39], ["DNase I", "GENE_OR_GENE_PRODUCT", 89, 96], ["GC-rich infectious clone 299E virus", "ORGANISM", 318, 353], ["vaccinia virus", "ORGANISM", 446, 460], ["Cellular RNA", "RNA", 0, 12], ["DNase I", "PROTEIN", 89, 96], ["MethodsRecombinant HCoV-229E", "DNA", 365, 393], ["GC-rich region", "DNA", 407, 421], ["HCoV-229E", "SPECIES", 384, 393], ["vaccinia virus", "SPECIES", 446, 460], ["Cellular RNA", "PROBLEM", 0, 12], ["Fenozol reagent", "TREATMENT", 32, 47], ["cDNA samples", "TEST", 143, 155], ["MethodsRecombinant HCoV", "TREATMENT", 365, 388], ["a GC-rich region", "TREATMENT", 405, 421], ["the vaccinia virus", "TREATMENT", 442, 460]]], ["In short, vaccinia virus containing the full-length HCoV-229E cDNA in which an Escherichia coli guanine phosphoribosyltransferase (GPT) was inserted between HCoV-229E 10098 and 10930 nucleotides was used to recombine with a plasmid containing HCoV-229E 9398\u201311580 nucleotides with a number of silent mutations (GC-rich region)46.", [["plasmid", "ANATOMY", 224, 231], ["guanine", "CHEMICAL", 96, 103], ["HCoV-229E 10098", "CHEMICAL", 157, 172], ["guanine", "CHEMICAL", 96, 103], ["nucleotides", "CHEMICAL", 183, 194], ["nucleotides", "CHEMICAL", 264, 275], ["vaccinia virus", "ORGANISM", 10, 24], ["HCoV", "GENE_OR_GENE_PRODUCT", 52, 56], ["Escherichia coli guanine phosphoribosyltransferase", "GENE_OR_GENE_PRODUCT", 79, 129], ["GPT", "GENE_OR_GENE_PRODUCT", 131, 134], ["full-length HCoV-229E cDNA", "DNA", 40, 66], ["Escherichia coli guanine phosphoribosyltransferase", "PROTEIN", 79, 129], ["GPT", "PROTEIN", 131, 134], ["HCoV-229E 10098", "DNA", 157, 172], ["plasmid", "DNA", 224, 231], ["HCoV-229E 9398", "DNA", 243, 257], ["GC-rich region)46", "DNA", 311, 328], ["Escherichia coli", "SPECIES", 79, 95], ["vaccinia virus", "SPECIES", 10, 24], ["Escherichia coli", "SPECIES", 79, 95], ["HCoV-229E 10098", "SPECIES", 157, 172], ["HCoV-229E 9398\u201311580", "SPECIES", 243, 263], ["vaccinia virus", "TREATMENT", 10, 24], ["an Escherichia coli guanine phosphoribosyltransferase (GPT)", "TEST", 76, 135], ["HCoV", "TEST", 157, 161], ["nucleotides", "TREATMENT", 183, 194], ["nucleotides", "TREATMENT", 264, 275], ["silent mutations", "PROBLEM", 293, 309], ["Escherichia coli", "OBSERVATION", 79, 95]]], ["The resulting vaccinia virus was used to rescue the mutant HCoV-229E, as described previously36,45.", [["vaccinia virus", "ORGANISM", 14, 28], ["HCoV-229E", "ORGANISM", 59, 68], ["mutant HCoV-229E", "DNA", 52, 68], ["vaccinia virus", "SPECIES", 14, 28], ["HCoV-229E", "SPECIES", 59, 68], ["The resulting vaccinia virus", "PROBLEM", 0, 28], ["vaccinia virus", "OBSERVATION", 14, 28]]], ["Plasmid DNA, recombinant vaccinia virus and recombinant HCoV-229E identities were confirmed by sequencing.quantitative PCR (qPCR) ::: MethodsRNA yields were assessed using real-time PCR (7500 Fast Real-Time PCR; Life Technologies, Poland).", [["Plasmid DNA", "CELLULAR_COMPONENT", 0, 11], ["recombinant vaccinia virus", "ORGANISM", 13, 39], ["recombinant HCoV-229E", "ORGANISM", 44, 65], ["Plasmid DNA", "DNA", 0, 11], ["recombinant HCoV-229E identities", "DNA", 44, 76], ["vaccinia virus", "SPECIES", 25, 39], ["HCoV-229E", "SPECIES", 56, 65], ["Plasmid DNA", "TREATMENT", 0, 11], ["recombinant vaccinia virus", "TREATMENT", 13, 39], ["recombinant HCoV", "TEST", 44, 60], ["quantitative PCR", "TEST", 106, 122], ["real-time PCR", "TEST", 172, 185], ["vaccinia virus", "OBSERVATION", 25, 39]]], ["HCoV-NL63 cDNA was amplified in a reaction mixture containing 1 \u00d7 TaqMan Universal PCR Master Mix (Thermo Fisher Scientific, Poland), in the presence of FAM/TAMRA (6-carboxyfluorescein/6-carboxytetramethylrhodamine) probe (100 nM specific) and primers (450 nM each)47.", [["FAM", "CHEMICAL", 153, 156], ["TAMRA", "CHEMICAL", 157, 162], ["6-carboxyfluorescein", "CHEMICAL", 164, 184], ["6-carboxytetramethylrhodamine", "CHEMICAL", 185, 214], ["FAM", "CHEMICAL", 153, 156], ["TAMRA", "CHEMICAL", 157, 162], ["6-carboxyfluorescein", "CHEMICAL", 164, 184], ["6-carboxytetramethylrhodamine", "CHEMICAL", 185, 214], ["HCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["FAM", "SIMPLE_CHEMICAL", 153, 156], ["TAMRA", "SIMPLE_CHEMICAL", 157, 162], ["6-carboxyfluorescein", "SIMPLE_CHEMICAL", 164, 184], ["6-carboxytetramethylrhodamine", "SIMPLE_CHEMICAL", 185, 214], ["HCoV-NL63 cDNA", "DNA", 0, 14], ["HCoV", "SPECIES", 0, 4], ["HCoV", "TEST", 0, 4], ["a reaction mixture", "TREATMENT", 32, 50], ["FAM/TAMRA", "TREATMENT", 153, 162], ["carboxyfluorescein", "TREATMENT", 166, 184], ["carboxytetramethylrhodamine) probe", "TREATMENT", 187, 221]]], ["Reaction was carried out according to the scheme: 2 min at 50 \u00b0C and 10 min at 92 \u00b0C, followed by 40 cycles of 15 sec at 92 \u00b0C and 1 min at 60 \u00b0C. Cellular cDNA was amplified in a reaction mixture containing 1 \u00d7 SYBRGreen Ready PCR Master Mix (Sigma-Aldrich, Poland) in the presence of primers (500 nM each).", [["Cellular", "ANATOMY", 147, 155], ["Cellular cDNA", "DNA", 147, 160], ["Cellular cDNA", "PROBLEM", 147, 160], ["a reaction mixture", "TREATMENT", 178, 196]]], ["TATA-box binding protein gene (TBP) was used as a household gene control and Rox was used as the reference dye.", [["TATA-box binding protein gene", "GENE_OR_GENE_PRODUCT", 0, 29], ["TBP", "GENE_OR_GENE_PRODUCT", 31, 34], ["Rox", "SIMPLE_CHEMICAL", 77, 80], ["TATA-box binding protein gene", "DNA", 0, 29], ["TBP", "DNA", 31, 34], ["Rox", "DNA", 77, 80], ["TATA-box binding protein gene (TBP)", "TREATMENT", 0, 35], ["a household gene control", "TREATMENT", 48, 72], ["Rox", "TREATMENT", 77, 80]]], ["Primer sequences are provided in Table 1.", [["Primer sequences", "DNA", 0, 16], ["Primer sequences", "TEST", 0, 16]]], ["Reaction was carried out according to the scheme: 10 min at 50 \u00b0C and 5 min at 95 \u00b0C, followed by 40 cycles of 30 sec at 95 \u00b0C, 30 sec at 56 \u00b0C and 45 sec at 75 \u00b0C. In order to assess the copy number for each gene, DNA standards were prepared, as described before47.Flow cytometry ::: MethodsLLC-Mk2 cells cultured in 6-well plate format (TPP) were washed with sterile 1 \u00d7 PBS, trypsinised, fixed with 4% formaldehyde, permeabilised with 0.1% Triton X-100 in 1 \u00d7 PBS and incubated for 1 h with blocking buffer (10% BSA in 1 \u00d7 PBS with 0.5% Tween 20).Flow cytometry ::: MethodsTo visualise HA-tagged APOBEC3 proteins after mRNA transfection, cells were incubated for 2 h at room temperature with mouse anti-HA-tag antibody (1 \u03bcg/ml, Antibodies-online, Germany) in 1 \u00d7 PBS with 3% BSA and 0.5% Tween 20, followed by 1 h incubation with Alexa Fluor 488-labeled goat anti-mouse antibody (2.5 \u03bcg/ml, Molecular Probes, Poland).Flow cytometry ::: MethodsTo evaluate HCoV-NL63 infection using flow cytometry, cells were incubated for 2 h at room temperature with mouse anti-HCoV-NL63-N antibody (1 \u03bcg/ml, Ingenansa, Spain) in 1 \u00d7 PBS with 3% BSA and 0.5% Tween 20, followed by 1 h incubation with Alexa Fluor 488-labeled goat anti-mouse antibody (2.5 \u03bcg/ml, Molecular Probes, Poland).", [["MethodsLLC-Mk2 cells", "ANATOMY", 285, 305], ["cells", "ANATOMY", 641, 646], ["cells", "ANATOMY", 1001, 1006], ["formaldehyde", "CHEMICAL", 405, 417], ["Triton X-100", "CHEMICAL", 443, 455], ["BSA", "CHEMICAL", 515, 518], ["BSA", "CHEMICAL", 779, 782], ["infection", "DISEASE", 969, 978], ["BSA", "CHEMICAL", 1134, 1137], ["formaldehyde", "CHEMICAL", 405, 417], ["Tween 20", "CHEMICAL", 540, 548], ["Tween 20", "CHEMICAL", 792, 800], ["Alexa Fluor 488", "CHEMICAL", 834, 849], ["Tween 20", "CHEMICAL", 1147, 1155], ["Alexa Fluor 488", "CHEMICAL", 1189, 1204], ["DNA", "CELLULAR_COMPONENT", 215, 218], ["MethodsLLC-Mk2 cells", "CELL", 285, 305], ["formaldehyde", "SIMPLE_CHEMICAL", 405, 417], ["Triton X-100", "SIMPLE_CHEMICAL", 443, 455], ["BSA", "SIMPLE_CHEMICAL", 515, 518], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 599, 606], ["cells", "CELL", 641, 646], ["mouse", "ORGANISM", 695, 700], ["BSA", "SIMPLE_CHEMICAL", 779, 782], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 834, 849], ["goat", "ORGANISM", 858, 862], ["HCoV", "GENE_OR_GENE_PRODUCT", 959, 963], ["cells", "CELL", 1001, 1006], ["mouse", "ORGANISM", 1055, 1060], ["BSA", "SIMPLE_CHEMICAL", 1134, 1137], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 1189, 1204], ["goat", "ORGANISM", 1213, 1217], ["MethodsLLC-Mk2 cells", "CELL_LINE", 285, 305], ["HA-tagged APOBEC3 proteins", "PROTEIN", 589, 615], ["mouse anti-HA-tag antibody", "PROTEIN", 695, 721], ["Antibodies", "PROTEIN", 732, 742], ["Alexa Fluor 488-labeled goat anti-mouse antibody", "PROTEIN", 834, 882], ["NL63", "PROTEIN", 1071, 1075], ["N antibody", "PROTEIN", 1076, 1086], ["Alexa Fluor 488-labeled goat anti-mouse antibody", "PROTEIN", 1189, 1237], ["mouse", "SPECIES", 695, 700], ["goat", "SPECIES", 858, 862], ["mouse", "SPECIES", 1055, 1060], ["goat", "SPECIES", 1213, 1217], ["mouse", "SPECIES", 695, 700], ["goat", "SPECIES", 858, 862], ["HCoV", "SPECIES", 959, 963], ["mouse", "SPECIES", 1055, 1060], ["goat", "SPECIES", 1213, 1217], ["MethodsLLC", "TEST", 285, 295], ["Mk2 cells", "TEST", 296, 305], ["sterile 1 \u00d7 PBS", "TREATMENT", 361, 376], ["4% formaldehyde", "TREATMENT", 402, 417], ["blocking buffer", "TREATMENT", 494, 509], ["MethodsTo visualise HA", "PROBLEM", 569, 591], ["tagged APOBEC3 proteins", "PROBLEM", 592, 615], ["mRNA transfection", "TREATMENT", 622, 639], ["mouse anti-HA", "TEST", 695, 708], ["tag antibody", "TEST", 709, 721], ["Antibodies", "TEST", 732, 742], ["PBS", "TEST", 767, 770], ["BSA", "TEST", 779, 782], ["Alexa Fluor", "TEST", 834, 845], ["labeled goat anti-mouse antibody", "TEST", 850, 882], ["MethodsTo evaluate", "TEST", 940, 958], ["HCoV", "TEST", 959, 963], ["NL63 infection", "PROBLEM", 964, 978], ["flow cytometry", "TEST", 985, 999], ["mouse anti-HCoV", "TEST", 1055, 1070], ["NL63", "TEST", 1071, 1075], ["antibody", "TEST", 1078, 1086], ["Ingenansa", "TEST", 1097, 1106], ["PBS", "TEST", 1122, 1125], ["BSA", "TEST", 1134, 1137], ["Alexa Fluor", "TEST", 1189, 1200], ["labeled goat anti-mouse antibody", "TEST", 1205, 1237], ["Mk2 cells", "OBSERVATION", 296, 305], ["infection", "OBSERVATION", 969, 978]]], ["Cells were then washed, re-suspended in 1 \u00d7 PBS and analysed with FACS Calibur (Becton Dickinson, USA) using Cell Quest software.APOBEC3 expression constructs and site-directed mutagenesis ::: MethodsSequence verified, C-terminal HA-tagged pTracer CMV2 plasmids (Thermo Fisher Scientific, Poland) encoding human A3A (GeneBank accession number (GB) NM_145699), A3C (GB: NM_014508), A3DE (GB: NM_152426), A3F (GB: NM_145298), APOBEC3G (GB: NM_021822) and A3H (GB: NM_181773) were prepared.", [["Cells", "ANATOMY", 0, 5], ["Cell", "ANATOMY", 109, 113], ["Cells", "CELL", 0, 5], ["Cell", "CELL", 109, 113], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 129, 136], ["human", "ORGANISM", 306, 311], ["A3A", "GENE_OR_GENE_PRODUCT", 312, 315], ["APOBEC3 expression constructs", "DNA", 129, 158], ["C-terminal HA-tagged pTracer CMV2 plasmids", "DNA", 219, 261], ["human A3A", "PROTEIN", 306, 315], ["APOBEC3G", "PROTEIN", 424, 432], ["human", "SPECIES", 306, 311], ["human", "SPECIES", 306, 311], ["1 \u00d7 PBS", "TREATMENT", 40, 47], ["APOBEC3 expression constructs", "TREATMENT", 129, 158], ["MethodsSequence", "TEST", 193, 208], ["C-terminal HA", "TEST", 219, 232], ["A3C", "TEST", 360, 363], ["A3F", "TEST", 403, 406], ["GB", "TEST", 408, 410], ["APOBEC3G", "TEST", 424, 432], ["GB", "TEST", 434, 436], ["NM", "TEST", 438, 440], ["A3H", "TEST", 453, 456], ["GB", "TEST", 458, 460], ["NM_", "TEST", 462, 465]]], ["Catalytic mutants of A3C (A3C_E68Q = mA3C), A3F (A3F_E251Q = mA3F) and A3H (A3H_E56Q = mA3H) were prepared using Quick Change mutagenesis with Phusion polymerase (Thermo Fisher Scientific, Poland)48.", [["mA3H", "CHEMICAL", 87, 91], ["A3C", "SIMPLE_CHEMICAL", 21, 24], ["A3C", "PROTEIN", 21, 24], ["A3C", "PROTEIN", 38, 41], ["A3F", "PROTEIN", 44, 47], ["A3F", "PROTEIN", 49, 52], ["A3F", "PROTEIN", 62, 65], ["A3H", "PROTEIN", 71, 74], ["A3H", "PROTEIN", 88, 91], ["Catalytic mutants", "TEST", 0, 17], ["A3C", "TEST", 21, 24], ["A3C_", "TEST", 26, 30], ["A3C", "TEST", 38, 41], ["A3F", "TEST", 44, 47], ["A3F", "TEST", 49, 52], ["A3H", "TEST", 71, 74], ["Phusion polymerase", "TREATMENT", 143, 161]]], ["Sequences of oligonucleotides used are listed in Table 2.Design of \u201chot-spot\u201d RNA ::: MethodsPlasmid construct containing several GC-rich domains was ordered at GeneArt Gene Synthesis (Thermo Fisher Scientific, Germany).", [["MethodsPlasmid construct", "DNA", 86, 110], ["GC-rich domains", "DNA", 130, 145], ["Sequences of oligonucleotides", "TREATMENT", 0, 29], ["MethodsPlasmid construct", "TREATMENT", 86, 110]]], ["The region was sequenced with primers 5\u2032-CTG TGG AAA ACC TTT GGC ATC-3\u2032 and 5\u2032-CTG TGG AAA ACC TTT GGC ATC-3\u2032.", [["primers 5\u2032-CTG TGG AAA ACC TTT GGC ATC-3\u2032 and 5\u2032-CTG TGG AAA ACC TTT GGC ATC-3\u2032", "DNA", 30, 109], ["primers", "TEST", 30, 37], ["CTG", "TEST", 41, 44], ["AAA", "TEST", 49, 52], ["TTT", "TEST", 57, 60], ["GGC", "TEST", 61, 64], ["ATC", "TEST", 65, 68], ["CTG", "TEST", 79, 82], ["ATC", "TEST", 103, 106]]], ["The plasmid was amplified in E. coli TOP10 strain and further used as a template in in vitro transcription reaction using T7 promoter, as described below.Preparation of mRNA molecules for transfection ::: MethodsAPOBEC3 plasmids described above were used as templates for amplification of APOBEC3 genes with forward primer containing the T7 promoter region (5\u2032-TCG GCC TCG TAG GCC TAA TAC GAC TCA CTA TAG GGA GAC TGA GAG AAC CCA CTG CTT AC-3\u2032) and specific reverse primer (listed in Table 2, 500 nM each).", [["plasmid", "ANATOMY", 4, 11], ["plasmids", "ANATOMY", 220, 228], ["E. coli", "ORGANISM", 29, 36], ["TOP10 strain", "CELL", 37, 49], ["T7", "GENE_OR_GENE_PRODUCT", 122, 124], ["MethodsAPOBEC3", "GENE_OR_GENE_PRODUCT", 205, 219], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 289, 296], ["plasmid", "DNA", 4, 11], ["T7 promoter", "DNA", 122, 133], ["mRNA molecules", "PROTEIN", 169, 183], ["MethodsAPOBEC3 plasmids", "DNA", 205, 228], ["APOBEC3 genes", "DNA", 289, 302], ["forward primer", "DNA", 308, 322], ["T7 promoter region", "DNA", 338, 356], ["reverse primer", "DNA", 457, 471], ["E. coli", "SPECIES", 29, 36], ["E. coli TOP10", "SPECIES", 29, 42], ["The plasmid", "TREATMENT", 0, 11], ["E. coli TOP10 strain", "TREATMENT", 29, 49], ["a template in in vitro transcription reaction", "TREATMENT", 70, 115], ["T7 promoter", "TREATMENT", 122, 133], ["MethodsAPOBEC3 plasmids", "TREATMENT", 205, 228], ["amplification of APOBEC3 genes", "TREATMENT", 272, 302], ["forward primer containing the T7 promoter region", "TREATMENT", 308, 356], ["TCG", "TEST", 361, 364], ["GCC", "TEST", 365, 368], ["TCG", "TEST", 369, 372], ["TAG", "TEST", 373, 376], ["GCC", "TEST", 377, 380], ["TAA", "TEST", 381, 384], ["TAC", "TEST", 385, 388], ["GAC", "TEST", 389, 392], ["TCA", "TEST", 393, 396], ["CTA", "TEST", 397, 400], ["TAG", "TEST", 401, 404], ["GGA", "TEST", 405, 408], ["GAC", "TEST", 409, 412], ["TGA", "TEST", 413, 416], ["GAG", "TEST", 417, 420], ["AAC", "TEST", 421, 424], ["CCA", "TEST", 425, 428], ["CTG", "TEST", 429, 432], ["CTT AC", "TEST", 433, 439], ["coli TOP10", "OBSERVATION", 32, 42], ["T7", "ANATOMY", 338, 340]]], ["DNA templates were purified using GeneJET PCR Purification Kit (Thermo Fisher Scientific, Poland) and further used for in vitro transcription with T7 RiboMAX Express Large Scale RNA Production System and Ribo m7G Cap Analog (Promega, Poland).", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA templates", "PROBLEM", 0, 13], ["GeneJET PCR", "TREATMENT", 34, 45], ["vitro transcription", "TREATMENT", 122, 141], ["T7 RiboMAX", "TREATMENT", 147, 157], ["Large Scale RNA Production System", "TREATMENT", 166, 199], ["Ribo m", "TREATMENT", 204, 210], ["Cap Analog", "TREATMENT", 213, 223]]], ["Resulting RNA was precipitated with LiCl, purified with 70% ethanol and polyadenylated using Poly(A) Tailing Kit (Thermo Fisher Scientific, Poland), according to the manufacturer\u2019s instructions.", [["LiCl", "CHEMICAL", 36, 40], ["ethanol", "CHEMICAL", 60, 67], ["Poly", "CHEMICAL", 93, 97], ["LiCl", "CHEMICAL", 36, 40], ["ethanol", "CHEMICAL", 60, 67], ["Poly(A)", "CHEMICAL", 93, 100], ["LiCl", "SIMPLE_CHEMICAL", 36, 40], ["ethanol", "SIMPLE_CHEMICAL", 60, 67], ["Resulting RNA", "PROBLEM", 0, 13], ["LiCl", "TREATMENT", 36, 40]]], ["RNA was then precipitated with lithium chloride (Thermo Fisher Scientific, Poland) and its concentration was assessed using a spectrophotometer.Transfection of plasmid DNA and mRNA ::: Methods293T cells were seeded on 10 cm2 dishes, cultured for 24 h at 37 \u00b0C with 5% CO2 and transfected with 8 \u00b5g of plasmid per dish using polyethylenimine (Sigma-Aldrich, Poland).", [["plasmid", "ANATOMY", 160, 167], ["293T cells", "ANATOMY", 192, 202], ["lithium chloride", "CHEMICAL", 31, 47], ["CO2", "CHEMICAL", 268, 271], ["polyethylenimine", "CHEMICAL", 324, 340], ["lithium chloride", "CHEMICAL", 31, 47], ["CO2", "CHEMICAL", 268, 271], ["polyethylenimine", "CHEMICAL", 324, 340], ["lithium chloride", "SIMPLE_CHEMICAL", 31, 47], ["DNA", "CELLULAR_COMPONENT", 168, 171], ["293T cells", "CELL", 192, 202], ["CO2", "SIMPLE_CHEMICAL", 268, 271], ["polyethylenimine", "SIMPLE_CHEMICAL", 324, 340], ["RNA", "RNA", 0, 3], ["plasmid DNA", "DNA", 160, 171], ["mRNA", "RNA", 176, 180], ["293T cells", "CELL_LINE", 192, 202], ["lithium chloride", "TREATMENT", 31, 47], ["a spectrophotometer", "TREATMENT", 124, 143], ["Transfection of plasmid DNA", "TREATMENT", 144, 171], ["Methods293T cells", "TREATMENT", 185, 202], ["5% CO2", "TEST", 265, 271], ["polyethylenimine", "TREATMENT", 324, 340]]], ["LLC-Mk2 and Huh-7 cells were seeded on 6-wells plates (TPP, Switzerland), cultured for 24 h at 37 \u00b0C with 5% CO2 and transfected with 3 \u00b5g mRNA per well (transcripts encoding APOBEC3 proteins or control GFP) using TransIT mRNA Transfection Reagent (Mirus, USA).", [["LLC-Mk2", "ANATOMY", 0, 7], ["Huh-7 cells", "ANATOMY", 12, 23], ["CO2", "CHEMICAL", 109, 112], ["CO2", "CHEMICAL", 109, 112], ["LLC-Mk2", "CELL", 0, 7], ["Huh-7 cells", "CELL", 12, 23], ["CO2", "SIMPLE_CHEMICAL", 109, 112], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 175, 182], ["GFP", "GENE_OR_GENE_PRODUCT", 203, 206], ["LLC-Mk2 and Huh-7 cells", "CELL_LINE", 0, 23], ["\u00b5g mRNA", "RNA", 136, 143], ["APOBEC3 proteins", "PROTEIN", 175, 191], ["GFP", "PROTEIN", 203, 206], ["LLC", "TEST", 0, 3], ["Mk2", "TEST", 4, 7], ["Huh", "TEST", 12, 15], ["TPP", "TEST", 55, 58], ["5% CO2", "TREATMENT", 106, 112], ["3 \u00b5g mRNA", "TREATMENT", 134, 143], ["APOBEC3 proteins", "TREATMENT", 175, 191], ["TransIT mRNA", "TEST", 214, 226], ["Mk2", "OBSERVATION", 4, 7], ["7 cells", "OBSERVATION_MODIFIER", 16, 23]]], ["Efficiency of transfection was assessed 24 h post-transfection in GFP-transfected cells using EVOS fluorescent microscope (Thermo Fisher Scientific, Poland).Western blot analysis ::: MethodsCells were trypsinised, centrifuged and resuspended in RIPA buffer (50 mM Tris, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, pH 7.5) followed by lysis in RIPA buffer for 30 min on ice.", [["cells", "ANATOMY", 82, 87], ["NaCl", "CHEMICAL", 277, 281], ["Nonidet P-40", "CHEMICAL", 286, 298], ["sodium deoxycholate", "CHEMICAL", 305, 324], ["Tris", "CHEMICAL", 264, 268], ["NaCl", "CHEMICAL", 277, 281], ["Nonidet P-40", "CHEMICAL", 286, 298], ["sodium deoxycholate", "CHEMICAL", 305, 324], ["GFP", "GENE_OR_GENE_PRODUCT", 66, 69], ["cells", "CELL", 82, 87], ["MethodsCells", "SIMPLE_CHEMICAL", 183, 195], ["Nonidet P-40", "SIMPLE_CHEMICAL", 286, 298], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 305, 324], ["GFP-transfected cells", "CELL_LINE", 66, 87], ["transfection in GFP", "TEST", 50, 69], ["fluorescent microscope", "TEST", 99, 121], ["MethodsCells", "TREATMENT", 183, 195], ["RIPA buffer", "TREATMENT", 245, 256], ["NaCl", "TREATMENT", 277, 281], ["1% Nonidet P", "TREATMENT", 283, 295], ["0.5% sodium deoxycholate", "TREATMENT", 300, 324], ["pH", "TEST", 336, 338], ["lysis in RIPA buffer", "TREATMENT", 356, 376], ["transfection", "OBSERVATION", 14, 26]]], ["Subsequently, samples were centrifuged (10 min at 12,000 \u00d7 g) and the pelleted cell debris was discarded.", [["samples", "ANATOMY", 14, 21], ["cell", "ANATOMY", 79, 83], ["cell", "CELL", 79, 83], ["samples", "TEST", 14, 21], ["the pelleted cell debris", "TREATMENT", 66, 90], ["pelleted cell debris", "OBSERVATION", 70, 90]]], ["Resulting supernatants were mixed with sample buffer (0.5 M Tris pH 6.8, 10% SDS, 50 mg/ml DTT), boiled for 5 min, cooled on ice, and separated on 10% polyacrylamide gels alongside dual color Page Ruler Pre-stained Protein size markers (Thermo Fisher Scientific, Poland).", [["supernatants", "ANATOMY", 10, 22], ["DTT", "CHEMICAL", 91, 94], ["polyacrylamide", "CHEMICAL", 151, 165], ["Protein size markers", "PROTEIN", 215, 235], ["sample buffer", "TEST", 39, 52], ["Tris pH", "TEST", 60, 67], ["10% SDS", "TREATMENT", 73, 80], ["ice", "TREATMENT", 125, 128], ["10% polyacrylamide gels", "TREATMENT", 147, 170], ["dual color", "TEST", 181, 191], ["size", "OBSERVATION_MODIFIER", 223, 227]]], ["The separated proteins were then transferred onto a Westran S PVDF membrane (GE Healthcare, Poland) by wet blotting (Bio-Rad, Poland) for 1 h, 100 Volts in transfer buffer: 25 mM Tris, 192 mM glycine, 20% methanol at 4 \u00b0C. The membranes were then blocked by overnight incubation at 4 \u00b0C in TBS-Tween (0.1%) buffer supplemented with 5% skimmed milk (BioShop, Canada).", [["membranes", "ANATOMY", 227, 236], ["milk", "ANATOMY", 343, 347], ["glycine", "CHEMICAL", 192, 199], ["methanol", "CHEMICAL", 205, 213], ["PVDF", "CHEMICAL", 62, 66], ["Tris", "CHEMICAL", 179, 183], ["glycine", "CHEMICAL", 192, 199], ["methanol", "CHEMICAL", 205, 213], ["Tween", "CHEMICAL", 294, 299], ["glycine", "SIMPLE_CHEMICAL", 192, 199], ["methanol", "SIMPLE_CHEMICAL", 205, 213], ["membranes", "CELLULAR_COMPONENT", 227, 236], ["milk", "ORGANISM_SUBSTANCE", 343, 347], ["a Westran S PVDF membrane", "TREATMENT", 50, 75], ["mM glycine", "TREATMENT", 189, 199], ["20% methanol", "TREATMENT", 201, 213], ["overnight incubation", "TREATMENT", 258, 278], ["5% skimmed milk", "TREATMENT", 332, 347]]], ["A rabbit anti-HA Taq antibody (1 \u03bcg/ml; Antibodies-online, USA) and horseradish peroxidase-labeled goat anti-rabbit IgG (0.35 \u03bcg/ml; Sigma-Aldrich, Poland) were used to detect the HA-tagged APOBEC3 proteins in cell lysates.", [["cell lysates", "ANATOMY", 210, 222], ["rabbit", "ORGANISM", 2, 8], ["anti-HA Taq antibody", "GENE_OR_GENE_PRODUCT", 9, 29], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 68, 90], ["goat", "ORGANISM", 99, 103], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 190, 197], ["cell lysates", "CELL", 210, 222], ["rabbit anti-HA Taq antibody", "PROTEIN", 2, 29], ["Antibodies", "PROTEIN", 40, 50], ["horseradish peroxidase", "PROTEIN", 68, 90], ["labeled goat anti-rabbit IgG", "PROTEIN", 91, 119], ["HA", "PROTEIN", 180, 182], ["APOBEC3 proteins", "PROTEIN", 190, 206], ["rabbit", "SPECIES", 2, 8], ["horseradish", "SPECIES", 68, 79], ["goat", "SPECIES", 99, 103], ["anti-rabbit", "SPECIES", 104, 115], ["rabbit", "SPECIES", 2, 8], ["goat", "SPECIES", 99, 103], ["A rabbit anti-HA Taq antibody", "TEST", 0, 29], ["Antibodies", "TEST", 40, 50], ["USA", "TEST", 59, 62], ["horseradish peroxidase", "TEST", 68, 90], ["labeled goat anti-rabbit IgG", "TREATMENT", 91, 119], ["the HA", "PROBLEM", 176, 182], ["tagged APOBEC3 proteins in cell lysates", "PROBLEM", 183, 222], ["APOBEC3 proteins", "OBSERVATION", 190, 206], ["cell lysates", "OBSERVATION", 210, 222]]], ["Mouse anti-HCoV-NL63-N protein antibody (500 ng/ml; Ingenansa, Spain) and horseradish peroxidase-labeled rabbit anti-mouse IgG (65 ng/ml; Dako, Denmark) were used to detect the HCoV-NL63 nucleocapsid protein.", [["Mouse", "ORGANISM", 0, 5], ["anti-HCoV", "GENE_OR_GENE_PRODUCT", 6, 15], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 74, 96], ["rabbit", "ORGANISM", 105, 111], ["HCoV", "GENE_OR_GENE_PRODUCT", 177, 181], ["Mouse anti-HCoV-NL63-N protein antibody", "PROTEIN", 0, 39], ["horseradish peroxidase", "PROTEIN", 74, 96], ["rabbit anti-mouse IgG", "PROTEIN", 105, 126], ["HCoV", "PROTEIN", 177, 181], ["NL63 nucleocapsid protein", "PROTEIN", 182, 207], ["Mouse", "SPECIES", 0, 5], ["horseradish", "SPECIES", 74, 85], ["rabbit", "SPECIES", 105, 111], ["anti-mouse", "SPECIES", 112, 122], ["Mouse", "SPECIES", 0, 5], ["rabbit", "SPECIES", 105, 111], ["HCoV", "SPECIES", 177, 181], ["Mouse anti-HCoV", "TEST", 0, 15], ["NL63", "TEST", 16, 20], ["protein antibody", "TEST", 23, 39], ["Ingenansa", "TEST", 52, 61], ["Spain", "TEST", 63, 68], ["horseradish peroxidase", "TEST", 74, 96], ["labeled rabbit anti-mouse IgG", "TEST", 97, 126], ["the HCoV", "TEST", 173, 181]]], ["A rabbit anti-GAPDH antibody (1:5000 dilution; Cell Signalling Technology, Poland) and horseradish peroxidase-labeled goat anti-rabbit IgG (0.35 \u03bcg/ml; Sigma-Aldrich, Poland) were used to detect the GAPDH in cell lysates.", [["Cell", "ANATOMY", 47, 51], ["cell lysates", "ANATOMY", 208, 220], ["rabbit", "ORGANISM", 2, 8], ["anti-GAPDH", "GENE_OR_GENE_PRODUCT", 9, 19], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 87, 109], ["goat", "ORGANISM", 118, 122], ["GAPDH", "GENE_OR_GENE_PRODUCT", 199, 204], ["cell lysates", "ORGANISM_SUBSTANCE", 208, 220], ["rabbit anti-GAPDH antibody", "PROTEIN", 2, 28], ["horseradish peroxidase", "PROTEIN", 87, 109], ["labeled goat anti-rabbit IgG", "PROTEIN", 110, 138], ["GAPDH", "PROTEIN", 199, 204], ["rabbit", "SPECIES", 2, 8], ["horseradish", "SPECIES", 87, 98], ["goat", "SPECIES", 118, 122], ["anti-rabbit", "SPECIES", 123, 134], ["rabbit", "SPECIES", 2, 8], ["goat", "SPECIES", 118, 122], ["A rabbit anti-GAPDH antibody", "TEST", 0, 28], ["dilution", "TEST", 37, 45], ["horseradish peroxidase", "TEST", 87, 109], ["labeled goat anti-rabbit IgG", "TREATMENT", 110, 138], ["the GAPDH in cell lysates", "PROBLEM", 195, 220], ["cell lysates", "OBSERVATION", 208, 220]]], ["All antibodies were diluted in 1% skimmed milk/TBS-Tween (0.1%).", [["Tween", "CHEMICAL", 51, 56], ["milk", "ORGANISM_SUBSTANCE", 42, 46], ["TBS-Tween", "SIMPLE_CHEMICAL", 47, 56], ["antibodies", "PROTEIN", 4, 14], ["All antibodies", "TREATMENT", 0, 14]]], ["The signal was developed using the Immobilon Western Chemiluminescent HRP Substrate (Millipore, USA) and visualised by exposing the membrane to an X-ray film (Kodak, Poland).Nucleocapsid protein binding analysis ::: MethodsAPOBEC3-expressing and control 293T cells were harvested 3 days post transfection in deaminase activity buffer, containing 0.2% Surfact-Amps NP-40 (Sigma-Aldrich, Poland), 30 mM 4-(2-hydroxyethyl)-1-piperazine-ethane-sulfonic acid (HEPES; pH 7.5), 100 mM KCl, 25 mM NaCl, 1.5 mM MgCl2, 1 mM DTT, 1 \u00d7 Halt protease and phosphatase inhibitor cocktail, and 10% glycerol17.", [["membrane", "ANATOMY", 132, 140], ["293T cells", "ANATOMY", 254, 264], ["Surfact-Amps NP-40", "CHEMICAL", 351, 369], ["4-(2-hydroxyethyl)-1-piperazine-ethane-sulfonic acid", "CHEMICAL", 401, 453], ["KCl", "CHEMICAL", 478, 481], ["NaCl", "CHEMICAL", 489, 493], ["MgCl2", "CHEMICAL", 502, 507], ["glycerol17", "CHEMICAL", 581, 591], ["4-(2-hydroxyethyl)-1-piperazine-ethane-sulfonic acid", "CHEMICAL", 401, 453], ["HEPES", "CHEMICAL", 455, 460], ["KCl", "CHEMICAL", 478, 481], ["NaCl", "CHEMICAL", 489, 493], ["MgCl2", "CHEMICAL", 502, 507], ["DTT", "CHEMICAL", 514, 517], ["glycerol17", "CHEMICAL", 581, 591], ["membrane", "CELLULAR_COMPONENT", 132, 140], ["MethodsAPOBEC3", "GENE_OR_GENE_PRODUCT", 216, 230], ["293T cells", "CELL", 254, 264], ["deaminase", "SIMPLE_CHEMICAL", 308, 317], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 371, 384], ["4-(2-hydroxyethyl)-1-piperazine-ethane-sulfonic acid", "SIMPLE_CHEMICAL", 401, 453], ["KCl", "SIMPLE_CHEMICAL", 478, 481], ["MgCl2", "SIMPLE_CHEMICAL", 502, 507], ["DTT", "SIMPLE_CHEMICAL", 514, 517], ["glycerol17", "SIMPLE_CHEMICAL", 581, 591], ["MethodsAPOBEC3", "PROTEIN", 216, 230], ["control 293T cells", "CELL_LINE", 246, 264], ["protease", "PROTEIN", 528, 536], ["phosphatase", "PROTEIN", 541, 552], ["the Immobilon Western", "TEST", 31, 52], ["an X-ray film", "TEST", 144, 157], ["Nucleocapsid protein binding analysis", "TEST", 174, 211], ["MethodsAPOBEC3", "TEST", 216, 230], ["transfection in deaminase activity buffer", "TREATMENT", 292, 333], ["Amps NP", "TREATMENT", 359, 366], ["piperazine", "TREATMENT", 422, 432], ["sulfonic acid (HEPES", "TREATMENT", 440, 460], ["pH", "TEST", 462, 464], ["25 mM NaCl", "TREATMENT", 483, 493], ["1.5 mM MgCl2", "TREATMENT", 495, 507], ["1 mM DTT", "TREATMENT", 509, 517], ["Halt protease", "TREATMENT", 523, 536], ["phosphatase inhibitor cocktail", "TREATMENT", 541, 571]]], ["Samples were centrifuged (10 min at 12,000 \u00d7 g), pelleted cell debris was discarded and resulting supernatants were stored at \u221280 \u00b0C. HCoV-NL63 N protein was prepared as described previously39.", [["Samples", "ANATOMY", 0, 7], ["cell", "ANATOMY", 58, 62], ["supernatants", "ANATOMY", 98, 110], ["cell", "CELL", 58, 62], ["HCoV-NL63 N", "GENE_OR_GENE_PRODUCT", 134, 145], ["HCoV", "PROTEIN", 134, 138], ["NL63 N protein", "PROTEIN", 139, 153], ["previously39", "PROTEIN", 180, 192], ["HCoV", "SPECIES", 134, 138], ["Samples", "TEST", 0, 7], ["pelleted cell debris", "TREATMENT", 49, 69], ["HCoV", "TEST", 134, 138], ["cell debris", "OBSERVATION", 58, 69]]], ["Cell lysates were incubated for 1 h at 37 \u00b0C with the purified N protein in 1 \u00d7 activity buffer, containing 100 mM KCl, 10 mM HEPES (pH 7.4), 100 \u00b5M ZnCl2, 1 mM DTT and 1 mM EDTA17.", [["Cell lysates", "ANATOMY", 0, 12], ["KCl", "CHEMICAL", 115, 118], ["ZnCl2", "CHEMICAL", 149, 154], ["EDTA17", "CHEMICAL", 174, 180], ["KCl", "CHEMICAL", 115, 118], ["HEPES", "CHEMICAL", 126, 131], ["ZnCl2", "CHEMICAL", 149, 154], ["DTT", "CHEMICAL", 161, 164], ["EDTA17", "CHEMICAL", 174, 180], ["Cell lysates", "CELL", 0, 12], ["ZnCl2", "SIMPLE_CHEMICAL", 149, 154], ["DTT", "SIMPLE_CHEMICAL", 161, 164], ["EDTA17", "SIMPLE_CHEMICAL", 174, 180], ["N protein", "PROTEIN", 63, 72], ["Cell lysates", "TEST", 0, 12], ["the purified N protein", "TREATMENT", 50, 72], ["100 mM KCl", "TREATMENT", 108, 118], ["10 mM HEPES", "TREATMENT", 120, 131], ["pH", "TEST", 133, 135], ["100 \u00b5M ZnCl2", "TREATMENT", 142, 154], ["DTT", "TEST", 161, 164], ["1 mM EDTA17", "TREATMENT", 169, 180]]], ["Subsequently, 15 \u00b5l of agarose spheres coated with anti-HA antibodies (Pierce, Poland) was added and samples were loaded onto co-immunoprecipitation columns.", [["samples", "ANATOMY", 101, 108], ["anti-HA antibodies", "PROTEIN", 51, 69], ["15 \u00b5l of agarose spheres", "TREATMENT", 14, 38], ["anti-HA antibodies (Pierce, Poland)", "TREATMENT", 51, 86], ["co-immunoprecipitation columns", "TREATMENT", 126, 156]]], ["After overnight incubation at 4 \u00b0C on a rotary shaker, proteins were eluted, according to the manufacturer\u2019s instructions.Analysis of HCoV-NL63 co-localisation with APOBEC3C ::: MethodsLLC-Mk2 cells were seeded on 6-wells plates and cultured for 24 h at 37 \u00b0C with 5% CO2.", [["MethodsLLC-Mk2 cells", "ANATOMY", 178, 198], ["CO2", "CHEMICAL", 268, 271], ["CO2", "CHEMICAL", 268, 271], ["HCoV", "GENE_OR_GENE_PRODUCT", 134, 138], ["MethodsLLC-Mk2 cells", "CELL", 178, 198], ["CO2", "SIMPLE_CHEMICAL", 268, 271], ["HCoV", "DNA", 134, 138], ["NL63", "DNA", 139, 143], ["APOBEC3C ::: MethodsLLC-Mk2 cells", "CELL_LINE", 165, 198], ["a rotary shaker", "TREATMENT", 38, 53], ["Analysis", "TEST", 122, 130], ["HCoV", "TEST", 134, 138], ["APOBEC3C", "TEST", 165, 173], ["MethodsLLC", "TEST", 178, 188], ["Mk2 cells", "PROBLEM", 189, 198], ["Mk2 cells", "OBSERVATION", 189, 198]]], ["1.5 \u03bcg of HCoV-NL63 N mRNA and 1.5 \u03bcg of A3C mRNA was co-transfected using the mRNA-In reagent (AMS Biotechnology, United Kingdom).", [["HCoV-NL63 N", "GENE_OR_GENE_PRODUCT", 10, 21], ["A3C", "GENE_OR_GENE_PRODUCT", 41, 44], ["1.5 \u03bcg of HCoV-NL63 N mRNA", "RNA", 0, 26], ["A3C mRNA", "RNA", 41, 49], ["mRNA", "RNA", 79, 83], ["HCoV", "TREATMENT", 10, 14], ["NL63 N mRNA", "TREATMENT", 15, 26], ["A3C mRNA", "TREATMENT", 41, 49], ["the mRNA", "TREATMENT", 75, 83]]], ["After 72 h incubation at 37 \u00b0C with 5% CO2, cells were fixed with 4% formaldehyde, permeabilised with 0.1% Triton X-100 in 1 \u00d7 PBS and incubated overnight at 4 \u00b0C with 10% BSA in 1 \u00d7 PBS with 0.5% Tween 20.", [["cells", "ANATOMY", 44, 49], ["CO2", "CHEMICAL", 39, 42], ["formaldehyde", "CHEMICAL", 69, 81], ["Triton X-100", "CHEMICAL", 107, 119], ["BSA", "CHEMICAL", 172, 175], ["CO2", "CHEMICAL", 39, 42], ["formaldehyde", "CHEMICAL", 69, 81], ["Tween 20", "CHEMICAL", 197, 205], ["CO2", "SIMPLE_CHEMICAL", 39, 42], ["cells", "CELL", 44, 49], ["formaldehyde", "SIMPLE_CHEMICAL", 69, 81], ["Triton X-100", "SIMPLE_CHEMICAL", 107, 119], ["BSA", "SIMPLE_CHEMICAL", 172, 175], ["5% CO2, cells", "TREATMENT", 36, 49]]], ["To visualise HCoV-NL63 N molecules, cells were incubated for 2 h at room temperature with rabbit anti-HCoV-NL63-N serum (1:100 dilution, kindly provided by dr Lia van der Hoek, UvA, The Netherlands) in 1 \u00d7 PBS with 3% BSA and 0.5% Tween 20, followed by 1 h incubation with Atto 488-labeled goat anti-rabbit IgG (5 \u03bcg/ml; Sigma-Aldrich, Poland).", [["cells", "ANATOMY", 36, 41], ["serum", "ANATOMY", 114, 119], ["anti-HCoV-NL63-N", "CHEMICAL", 97, 113], ["BSA", "CHEMICAL", 218, 221], ["Tween 20", "CHEMICAL", 231, 239], ["Atto 488", "CHEMICAL", 273, 281], ["cells", "CELL", 36, 41], ["rabbit", "ORGANISM", 90, 96], ["anti-HCoV", "SIMPLE_CHEMICAL", 97, 106], ["serum", "ORGANISM_SUBSTANCE", 114, 119], ["BSA", "SIMPLE_CHEMICAL", 218, 221], ["Atto 488", "SIMPLE_CHEMICAL", 273, 281], ["goat", "ORGANISM", 290, 294], ["HCoV", "PROTEIN", 13, 17], ["NL63 N molecules", "PROTEIN", 18, 34], ["Atto 488-labeled goat anti-rabbit IgG", "PROTEIN", 273, 310], ["rabbit", "SPECIES", 90, 96], ["goat", "SPECIES", 290, 294], ["anti-rabbit", "SPECIES", 295, 306], ["HCoV", "SPECIES", 13, 17], ["rabbit", "SPECIES", 90, 96], ["goat", "SPECIES", 290, 294], ["anti-rabbit", "SPECIES", 295, 306], ["HCoV", "TEST", 13, 17], ["room temperature", "TEST", 68, 84], ["rabbit anti-HCoV", "TEST", 90, 106], ["serum", "TEST", 114, 119], ["BSA", "TEST", 218, 221], ["Atto", "TEST", 273, 277], ["labeled goat anti-rabbit IgG", "TREATMENT", 282, 310]]], ["To detect HA-tagged A3C protein cells were incubated for 2 h at room temperature with mouse Alexa Fluor 647-labeled anti-HA-tag antibody (10 \u03bcg/ml; Thermo Fisher Scientific; Poland) in 1 \u00d7 PBS with 3% BSA and 0.5% Tween 20.", [["A3C protein cells", "ANATOMY", 20, 37], ["BSA", "CHEMICAL", 201, 204], ["Alexa Fluor 647", "CHEMICAL", 92, 107], ["Tween 20", "CHEMICAL", 214, 222], ["A3C", "GENE_OR_GENE_PRODUCT", 20, 23], ["cells", "CELL", 32, 37], ["mouse", "ORGANISM", 86, 91], ["Alexa Fluor 647", "SIMPLE_CHEMICAL", 92, 107], ["BSA", "SIMPLE_CHEMICAL", 201, 204], ["HA", "PROTEIN", 10, 12], ["A3C protein cells", "CELL_LINE", 20, 37], ["mouse Alexa Fluor 647-labeled anti-HA-tag antibody", "PROTEIN", 86, 136], ["mouse", "SPECIES", 86, 91], ["mouse", "SPECIES", 86, 91], ["HA", "PROBLEM", 10, 12], ["tagged A3C protein cells", "PROBLEM", 13, 37], ["mouse Alexa Fluor", "TEST", 86, 103], ["anti-HA-tag antibody", "TREATMENT", 116, 136], ["BSA", "TEST", 201, 204]]], ["Nuclear DNA was stained with DAPI (0.1 \u03bcg/ml; Sigma-Aldrich, Poland).", [["Nuclear", "ANATOMY", 0, 7], ["DAPI", "CHEMICAL", 29, 33], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["DNA", "CELLULAR_COMPONENT", 8, 11], ["DAPI", "SIMPLE_CHEMICAL", 29, 33], ["Nuclear DNA", "TEST", 0, 11], ["DAPI", "TEST", 29, 33]]], ["Immunostained cultures were mounted on glass slides with ProLong Gold antifade medium (Thermo Fisher Scientific; Poland).", [["cultures", "ANATOMY", 14, 22], ["Immunostained cultures", "TEST", 0, 22], ["glass slides", "TEST", 39, 51]]], ["Fluorescent images were acquired under a Zeiss LSM 710 confocal microscope (Carl Zeiss Microscopy GmbH).", [["Fluorescent images", "TEST", 0, 18]]], ["Images were acquired using ZEN 2012 SP1 software (Carl Zeiss Microscopy GmbH) and processed using ImageJ 1.47 v (National Institutes of Health, Bethesda, Maryland, USA).Statistical analysis ::: MethodsAll the experiments were performed in triplicate and the results are presented as mean \u00b1 SD.", [["SP1", "PROTEIN", 36, 39], ["Images", "TEST", 0, 6], ["ImageJ", "TEST", 98, 104], ["Methods", "TREATMENT", 194, 201]]], ["Student\u2019s t-test was used to determine significance of the obtained results.", [["Student\u2019s t-test", "TEST", 0, 16]]], ["P values < 0.05 were considered significant.", [["P values", "TEST", 0, 8]]]], "27aa830a786157f00a1f495cee7b01aa5f7dc00a": [["IntroductionSince early December 2019, several pneumonia cases of unknown origin were identified in Wuhan, Hubei province, China [1, 2] .", [["pneumonia", "DISEASE", 47, 56], ["several pneumonia cases", "PROBLEM", 39, 62], ["pneumonia", "OBSERVATION", 47, 56], ["unknown origin", "OBSERVATION_MODIFIER", 66, 80]]], ["The pathogen has been identified as a novel coronavirus and belongs to \u03b2-coronavirus genus that has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by International Committee on Taxonomy of Viruses [3] .", [["acute respiratory syndrome coronavirus", "DISEASE", 118, 156], ["coronavirus", "ORGANISM", 44, 55], ["\u03b2-coronavirus genus", "ORGANISM", 71, 90], ["coronavirus", "SPECIES", 44, 55], ["severe acute respiratory syndrome coronavirus", "SPECIES", 111, 156], ["SARS-CoV-2", "SPECIES", 160, 170], ["a novel coronavirus", "PROBLEM", 36, 55], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 111, 156], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["respiratory syndrome", "OBSERVATION", 124, 144]]], ["Additionally, the pneumonia caused by SARS-CoV-2 has been named as coronavirus disease 2019 (COVID-19) by World J o u r n a l P r e -p r o o f Health Organization (WHO) [4] .", [["pneumonia", "DISEASE", 18, 27], ["SARS", "DISEASE", 38, 42], ["coronavirus disease", "DISEASE", 67, 86], ["SARS-CoV-2", "ORGANISM", 38, 48], ["SARS-CoV", "SPECIES", 38, 46], ["the pneumonia", "PROBLEM", 14, 27], ["SARS", "PROBLEM", 38, 42], ["coronavirus disease", "PROBLEM", 67, 86], ["COVID", "TEST", 93, 98], ["pneumonia", "OBSERVATION", 18, 27], ["coronavirus disease", "OBSERVATION", 67, 86]]], ["COVID-19 has soon become a serious worldwide health problem and was declared as pandemic in March 2020 [5] [6] [7] [8] .", [["COVID-19", "CHEMICAL", 0, 8], ["5] [6] [7] [8]", "SIMPLE_CHEMICAL", 104, 118]]], ["By June 16, 2020, 7 .94 million cases were confirmed globally, including 84.82 thousand cases in China and 434.80 thousand patients have died from this viral infection worldwide, 4.65 thousand in China [7] .", [["viral infection", "DISEASE", 152, 167], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["this viral infection", "PROBLEM", 147, 167], ["viral", "OBSERVATION_MODIFIER", 152, 157], ["infection", "OBSERVATION", 158, 167]]], ["This novel virus shared 79.5% sequence identify to severe acute respiratory syndrome coronavirus (SARS-CoV), and spread from person to person [9] [10] [11] .IntroductionMany studies have reported the clinical characteristics of COVID-19 patients [1, 5, [12] [13] [14] , but the outbreak is still progressing, an updated analysis of cases in a relative large sample might help identify the defining the epidemiology and clinical features of COVID-19.IntroductionIn the present study, we aimed to describe the epidemiology and clinical characteristics of 1,663 hospitalized COVID-19 patients at single-center hospital, and to explore the associations between potential risk factors with COVID-19 severity.Data CollectionWe obtained the medical records for 1,663 hospitalized patients with laboratory-confirmed diagnosed COVID-19 from Tongji Hospital between January 14, 2020, and February 28, 2020.", [["acute respiratory syndrome coronavirus", "DISEASE", 58, 96], ["SARS-CoV)", "DISEASE", 98, 107], ["COVID-19", "CHEMICAL", 440, 448], ["patients", "ORGANISM", 237, 245], ["patients", "ORGANISM", 581, 589], ["patients", "ORGANISM", 773, 781], ["person", "SPECIES", 125, 131], ["person", "SPECIES", 135, 141], ["patients", "SPECIES", 237, 245], ["patients", "SPECIES", 581, 589], ["patients", "SPECIES", 773, 781], ["severe acute respiratory syndrome coronavirus", "SPECIES", 51, 96], ["SARS-CoV", "SPECIES", 98, 106], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 51, 96], ["COVID", "TEST", 228, 233], ["COVID", "TEST", 440, 445], ["the present study", "TEST", 464, 481], ["COVID", "TEST", 685, 690], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["respiratory syndrome coronavirus", "OBSERVATION", 64, 96]]], ["Admission criteria: the patient has clinical symptoms, a positive nucleic acid test, or CT suggests viral pneumonia.", [["nucleic acid", "CHEMICAL", 66, 78], ["pneumonia", "DISEASE", 106, 115], ["patient", "ORGANISM", 24, 31], ["patient", "SPECIES", 24, 31], ["clinical symptoms", "PROBLEM", 36, 53], ["a positive nucleic acid test", "PROBLEM", 55, 83], ["CT", "TEST", 88, 90], ["viral pneumonia", "PROBLEM", 100, 115], ["viral", "OBSERVATION_MODIFIER", 100, 105], ["pneumonia", "OBSERVATION", 106, 115]]], ["Demographic information, exposure history (Huanan seafood market exposure and family infection), medical history, comorbidities, signs and symptoms, chest computed tomography (CT) J o u r n a l P r e -p r o o f scanning, severity of COVID-19 and laboratory findings on admission were collected from electronic medical records.", [["infection", "DISEASE", 85, 94], ["comorbidities", "PROBLEM", 114, 127], ["signs and symptoms", "PROBLEM", 129, 147], ["chest computed tomography", "TEST", 149, 174], ["CT", "TEST", 176, 178], ["a l P r e -p r o o f scanning", "TEST", 190, 219], ["COVID", "TEST", 233, 238], ["chest", "ANATOMY", 149, 154]]], ["The study was approved by Tongji Hospital Ethics Committee.Data CollectionSeverity of COVID-19 was defined according to the diagnostic and treatment guideline (Version 5-6) published by the government [16, 17] .", [["The study", "TEST", 0, 9], ["COVID", "TEST", 86, 91]]], ["Severe COVID-19 was defined if they meet one of following criteria: (1) Respiratory distress with respiratory frequency \u2265 30 breaths per min with shortness of breath or difficulty breathing; (2) Oxygen saturation \u2264 93% at rest; (3) Artery partial pressure of oxygen (PaO2)/inspired oxygen fraction (FiO2) \u2264 300 mmHg (1mmHg = 0.133kPa).SARS-CoV-2 nucleic acid detectionThroat swab specimens were collected for the SARS-CoV-2 viral nucleic acid detection and stored in 5 mL virus preservation solution.", [["respiratory", "ANATOMY", 98, 109], ["Artery", "ANATOMY", 232, 238], ["Throat swab specimens", "ANATOMY", 368, 389], ["Respiratory distress", "DISEASE", 72, 92], ["shortness of breath", "DISEASE", 146, 165], ["oxygen", "CHEMICAL", 259, 265], ["oxygen", "CHEMICAL", 282, 288], ["SARS-CoV-2 nucleic acid", "CHEMICAL", 335, 358], ["nucleic acid", "CHEMICAL", 430, 442], ["Oxygen", "CHEMICAL", 195, 201], ["oxygen", "CHEMICAL", 259, 265], ["oxygen", "CHEMICAL", 282, 288], ["Oxygen", "SIMPLE_CHEMICAL", 195, 201], ["oxygen", "SIMPLE_CHEMICAL", 259, 265], ["PaO2", "SIMPLE_CHEMICAL", 267, 271], ["oxygen", "SIMPLE_CHEMICAL", 282, 288], ["Throat swab specimens", "CANCER", 368, 389], ["SARS-CoV", "SPECIES", 413, 421], ["Severe COVID", "PROBLEM", 0, 12], ["Respiratory distress", "PROBLEM", 72, 92], ["respiratory frequency", "PROBLEM", 98, 119], ["shortness of breath", "PROBLEM", 146, 165], ["difficulty breathing", "PROBLEM", 169, 189], ["Oxygen saturation", "TEST", 195, 212], ["Artery partial pressure of oxygen", "TREATMENT", 232, 265], ["PaO2", "TEST", 267, 271], ["inspired oxygen fraction", "TEST", 273, 297], ["FiO2", "TEST", 299, 303], ["SARS", "TEST", 335, 339], ["CoV", "TEST", 340, 343], ["nucleic acid detection", "TEST", 346, 368], ["Throat swab specimens", "TEST", 368, 389], ["the SARS", "TEST", 409, 417], ["CoV", "TEST", 418, 421], ["viral nucleic acid detection", "TEST", 424, 452], ["5 mL virus preservation solution", "TREATMENT", 467, 499], ["Respiratory", "ANATOMY", 72, 83], ["distress", "OBSERVATION", 84, 92], ["Artery", "ANATOMY", 232, 238], ["pressure", "OBSERVATION_MODIFIER", 247, 255]]], ["Virus RNA was extracted with 24 h on Tianlong PANA9600 automatic nucleic acid extraction system (Tianlong, ChinaEpidemiological characteristicsOn January 20, COVID-19 was included in the legal category B infectious diseases inSymptomatic and radiological characteristicsOf 1,663 patients, the main clinical symptoms were fever (85.8%), cough (36.0%), fatigue (23.6%) and chest tightness (11.9%), followed by diarrhea (4.6%), dyspnea Figure 3C ) and atelectasis (0.4%, Figure 3D ).Symptomatic and radiological characteristicsCompared with non-severe patients, the severe patients had a higher proportion of symptoms such as pleural effusion and bronchiectasis (all P<0.01).Laboratory findingsAs Table 3 shown, most of patients had normal white blood cell count (81.2%), with 9.2% increased and 9.6% decreased cases on admission.", [["chest", "ANATOMY", 371, 376], ["pleural", "ANATOMY", 623, 630], ["white blood cell", "ANATOMY", 737, 753], ["nucleic acid", "CHEMICAL", 65, 77], ["infectious diseases inSymptomatic", "DISEASE", 204, 237], ["fever", "DISEASE", 321, 326], ["cough", "DISEASE", 336, 341], ["fatigue", "DISEASE", 351, 358], ["chest tightness", "DISEASE", 371, 386], ["diarrhea", "DISEASE", 408, 416], ["dyspnea", "DISEASE", 425, 432], ["atelectasis", "DISEASE", 449, 460], ["pleural effusion", "DISEASE", 623, 639], ["bronchiectasis", "DISEASE", 644, 658], ["Virus", "ORGANISM", 0, 5], ["patients", "ORGANISM", 279, 287], ["chest", "ORGANISM_SUBDIVISION", 371, 376], ["patients", "ORGANISM", 549, 557], ["patients", "ORGANISM", 570, 578], ["pleural", "PATHOLOGICAL_FORMATION", 623, 630], ["patients", "ORGANISM", 717, 725], ["blood cell", "CELL", 743, 753], ["Virus RNA", "RNA", 0, 9], ["patients", "SPECIES", 279, 287], ["patients", "SPECIES", 549, 557], ["patients", "SPECIES", 570, 578], ["patients", "SPECIES", 717, 725], ["Virus RNA", "PROBLEM", 0, 9], ["COVID", "TEST", 158, 163], ["the main clinical symptoms", "PROBLEM", 289, 315], ["fever", "PROBLEM", 321, 326], ["cough", "PROBLEM", 336, 341], ["fatigue", "PROBLEM", 351, 358], ["chest tightness", "PROBLEM", 371, 386], ["diarrhea", "PROBLEM", 408, 416], ["dyspnea Figure 3C", "PROBLEM", 425, 442], ["atelectasis", "PROBLEM", 449, 460], ["Symptomatic and radiological characteristics", "PROBLEM", 480, 524], ["symptoms", "PROBLEM", 606, 614], ["pleural effusion", "PROBLEM", 623, 639], ["bronchiectasis", "PROBLEM", 644, 658], ["Laboratory findingsAs Table", "TEST", 672, 699], ["white blood cell count", "TEST", 737, 759], ["infectious", "OBSERVATION_MODIFIER", 204, 214], ["chest", "ANATOMY", 371, 376], ["atelectasis", "OBSERVATION", 449, 460], ["radiological characteristics", "OBSERVATION_MODIFIER", 496, 524], ["severe", "OBSERVATION_MODIFIER", 563, 569], ["pleural", "ANATOMY", 623, 630], ["effusion", "OBSERVATION", 631, 639], ["bronchiectasis", "OBSERVATION", 644, 658]]], ["Compared to non-severe patients, severe individuals tended to have higher levels of white blood cell count, neutrophil count/ percentage, platelet count, aspartate aminotransferase, urea, lactate dehydrogenase, and procalcitonin (all P<0.05, Table 3 ).Laboratory findingsIn addition, severe patients had lower levels of lymphocyte count/percentage, monocyte percentage, hemoglobin, and albulmin (all P<0.05, Table 3 ).", [["white blood cell", "ANATOMY", 84, 100], ["neutrophil", "ANATOMY", 108, 118], ["platelet", "ANATOMY", 138, 146], ["lymphocyte", "ANATOMY", 320, 330], ["monocyte", "ANATOMY", 349, 357], ["aspartate", "CHEMICAL", 154, 163], ["urea", "CHEMICAL", 182, 186], ["lactate", "CHEMICAL", 188, 195], ["aspartate", "CHEMICAL", 154, 163], ["urea", "CHEMICAL", 182, 186], ["lactate", "CHEMICAL", 188, 195], ["albulmin", "CHEMICAL", 386, 394], ["patients", "ORGANISM", 23, 31], ["individuals", "ORGANISM", 40, 51], ["white blood cell", "CELL", 84, 100], ["neutrophil", "CELL", 108, 118], ["platelet", "CELL", 138, 146], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 154, 180], ["urea", "SIMPLE_CHEMICAL", 182, 186], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 188, 209], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 215, 228], ["patients", "ORGANISM", 291, 299], ["lymphocyte", "CELL", 320, 330], ["monocyte", "CELL", 349, 357], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 370, 380], ["albulmin", "SIMPLE_CHEMICAL", 386, 394], ["aspartate aminotransferase", "PROTEIN", 154, 180], ["lactate dehydrogenase", "PROTEIN", 188, 209], ["procalcitonin", "PROTEIN", 215, 228], ["hemoglobin", "PROTEIN", 370, 380], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 291, 299], ["severe individuals", "PROBLEM", 33, 51], ["white blood cell count", "TEST", 84, 106], ["neutrophil count", "TEST", 108, 124], ["percentage", "TEST", 126, 136], ["platelet count", "TEST", 138, 152], ["aspartate aminotransferase", "TEST", 154, 180], ["urea", "TEST", 182, 186], ["lactate dehydrogenase", "TEST", 188, 209], ["procalcitonin", "TEST", 215, 228], ["Laboratory findings", "TEST", 252, 271], ["lymphocyte count", "TEST", 320, 336], ["percentage", "TEST", 337, 347], ["monocyte percentage", "TEST", 349, 368], ["hemoglobin", "TEST", 370, 380], ["albulmin", "TEST", 386, 394], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["neutrophil count", "OBSERVATION", 108, 124], ["severe", "OBSERVATION_MODIFIER", 284, 290], ["lymphocyte count", "OBSERVATION", 320, 336]]], ["Prothrombin time was longer in severe patients than in non-severe patients.", [["Prothrombin", "GENE_OR_GENE_PRODUCT", 0, 11], ["patients", "ORGANISM", 38, 46], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 66, 74], ["Prothrombin time", "TEST", 0, 16], ["severe", "OBSERVATION_MODIFIER", 31, 37]]], ["In the present study, we observed that non-severe and severe patients had higher levels of D-dimer.", [["patients", "ORGANISM", 61, 69], ["D-dimer", "GENE_OR_GENE_PRODUCT", 91, 98], ["D-dimer", "PROTEIN", 91, 98], ["patients", "SPECIES", 61, 69], ["the present study", "TEST", 3, 20], ["non-severe", "OBSERVATION_MODIFIER", 39, 49], ["severe", "OBSERVATION_MODIFIER", 54, 60]]], ["ComparedDiscussionIn the present study, the majority (79%) of 1,663 COVID-19 patients were aged over 50 years old.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["the present study", "TEST", 21, 38]]], ["A total of 2.8% were medical staff, and an exposure history of Huanan seafood market was document in 0.7%, and 7.4% were family infection.", [["infection", "DISEASE", 128, 137], ["Huanan seafood market", "TREATMENT", 63, 84], ["family infection", "PROBLEM", 121, 137], ["infection", "OBSERVATION", 128, 137]]], ["FeverJ o u r n a l P r e -p r o o fThe median age (64.0 y, IQR, 52.0-71.0) of all patients in the present study were older than other studies, which might be associated with the fact that more serious patients were admitted to Tongji hospital.", [["patients", "ORGANISM", 82, 90], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 201, 209], ["IQR", "TEST", 59, 62], ["other studies", "TEST", 128, 141]]], ["Moreover, severe patients tended to be elder, when compared to non-severe patients, which was consistent with the previous findings [12] .J o u r n a l P r e -p r o o fIn the present study, 2.8% of the patients were medical staff, and the percentage is lower than that reported by Wang et al., which might due to the size of the sample and policy of the hospital [14] .", [["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 202, 210], ["fIn the present study", "TEST", 167, 188], ["severe", "OBSERVATION_MODIFIER", 10, 16]]], ["In the present study, we found that severe and non-severe patients had a significant difference regarding the median days from symptom onset to hospital admission and from onset of symptoms to COVID-19 confirmation, which might indicate that timely medical treatment after the onset might be beneficial to control the condition.J o u r n a l P r e -p r o o fHypertension, diabetes mellitus and cardiovascular diseases were the most common underlying diseases, consistent with other previous studies [12] [13] [14] .", [["diabetes mellitus", "DISEASE", 372, 389], ["cardiovascular diseases", "DISEASE", 394, 417], ["patients", "ORGANISM", 58, 66], ["[12] [13] [14]", "SIMPLE_CHEMICAL", 499, 513], ["patients", "SPECIES", 58, 66], ["the present study", "TEST", 3, 20], ["symptoms", "PROBLEM", 181, 189], ["COVID", "TEST", 193, 198], ["timely medical treatment", "TREATMENT", 242, 266], ["fHypertension", "PROBLEM", 357, 370], ["diabetes mellitus", "PROBLEM", 372, 389], ["cardiovascular diseases", "PROBLEM", 394, 417], ["underlying diseases", "PROBLEM", 439, 458], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["non-severe", "OBSERVATION_MODIFIER", 47, 57], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["diabetes mellitus", "OBSERVATION", 372, 389], ["cardiovascular", "ANATOMY", 394, 408], ["diseases", "OBSERVATION", 409, 417], ["diseases", "OBSERVATION", 450, 458]]], ["In addition, we found severe patients had higher proportion of comorbidity such as hypertension, diabetes and coronary heart disease, which was consistent with Guan's report based on 1099 patients from 552 hospitals.", [["coronary", "ANATOMY", 110, 118], ["heart", "ANATOMY", 119, 124], ["hypertension", "DISEASE", 83, 95], ["diabetes", "DISEASE", 97, 105], ["coronary heart disease", "DISEASE", 110, 132], ["patients", "ORGANISM", 29, 37], ["heart", "ORGAN", 119, 124], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 188, 196], ["comorbidity", "PROBLEM", 63, 74], ["hypertension", "PROBLEM", 83, 95], ["diabetes", "PROBLEM", 97, 105], ["coronary heart disease", "PROBLEM", 110, 132], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["comorbidity", "OBSERVATION", 63, 74], ["hypertension", "OBSERVATION", 83, 95], ["diabetes", "OBSERVATION", 97, 105], ["coronary heart", "ANATOMY", 110, 124], ["disease", "OBSERVATION", 125, 132]]], ["However, Zhang et al. did not observed the similar findings, which might be associated with study sample size, different age and gender of the study subjects.J o u r n a l P r e -p r o o fIn line with previous study [12] [13] [14] 18] , of 1,663 patients in the present study, the main clinical symptoms were fever, cough, fatigue and chest tightness.", [["chest", "ANATOMY", 335, 340], ["fever", "DISEASE", 309, 314], ["cough", "DISEASE", 316, 321], ["fatigue", "DISEASE", 323, 330], ["chest tightness", "DISEASE", 335, 350], ["[12] [13] [14] 18", "SIMPLE_CHEMICAL", 216, 233], ["patients", "ORGANISM", 246, 254], ["chest", "ORGANISM_SUBDIVISION", 335, 340], ["patients", "SPECIES", 246, 254], ["the study", "TEST", 139, 148], ["a l P r e -p r o o fIn line", "TREATMENT", 168, 195], ["previous study", "TEST", 201, 215], ["the main clinical symptoms", "PROBLEM", 277, 303], ["fever", "PROBLEM", 309, 314], ["cough", "PROBLEM", 316, 321], ["fatigue", "PROBLEM", 323, 330], ["chest tightness", "PROBLEM", 335, 350], ["size", "OBSERVATION_MODIFIER", 105, 109], ["fIn", "ANATOMY", 187, 190], ["line", "OBSERVATION", 191, 195], ["chest", "ANATOMY", 335, 340]]], ["We found serious patients had a higher proportion of symptoms such as fever, cough, fatigue, chest tightness and loss of appetite, which was consistent with the study conducted by proportion of symptoms such as fever, cough, and chest tightness after further excluding the patients with underlying diseased.", [["chest", "ANATOMY", 93, 98], ["chest", "ANATOMY", 229, 234], ["fever", "DISEASE", 70, 75], ["cough", "DISEASE", 77, 82], ["fatigue", "DISEASE", 84, 91], ["chest tightness", "DISEASE", 93, 108], ["loss of appetite", "DISEASE", 113, 129], ["fever", "DISEASE", 211, 216], ["cough", "DISEASE", 218, 223], ["chest tightness", "DISEASE", 229, 244], ["patients", "ORGANISM", 17, 25], ["chest", "ORGANISM_SUBDIVISION", 93, 98], ["chest", "ORGANISM_SUBDIVISION", 229, 234], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 273, 281], ["symptoms", "PROBLEM", 53, 61], ["fever", "PROBLEM", 70, 75], ["cough", "PROBLEM", 77, 82], ["fatigue", "PROBLEM", 84, 91], ["chest tightness", "PROBLEM", 93, 108], ["loss of appetite", "PROBLEM", 113, 129], ["the study", "TEST", 157, 166], ["symptoms", "PROBLEM", 194, 202], ["fever", "PROBLEM", 211, 216], ["cough", "PROBLEM", 218, 223], ["chest tightness", "PROBLEM", 229, 244], ["underlying diseased", "PROBLEM", 287, 306], ["serious", "OBSERVATION_MODIFIER", 9, 16], ["chest", "ANATOMY", 93, 98], ["chest", "ANATOMY", 229, 234], ["diseased", "OBSERVATION", 298, 306]]], ["However, several previous researches [12] [13] [14] did not found the significant difference.", [["[12] [13] [14]", "SIMPLE_CHEMICAL", 37, 51], ["significant", "OBSERVATION_MODIFIER", 70, 81], ["difference", "OBSERVATION", 82, 92]]], ["The most common manifestations of chest CT were local patchy shadowing and ground-glass opacity, which were consistent with previous studies [12, 19] .", [["chest", "ANATOMY", 34, 39], ["chest CT", "TEST", 34, 42], ["local patchy shadowing", "PROBLEM", 48, 70], ["ground-glass opacity", "PROBLEM", 75, 95], ["previous studies", "TEST", 124, 140], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["chest", "ANATOMY", 34, 39], ["local", "OBSERVATION_MODIFIER", 48, 53], ["patchy", "OBSERVATION_MODIFIER", 54, 60], ["shadowing", "OBSERVATION_MODIFIER", 61, 70], ["ground-glass opacity", "OBSERVATION", 75, 95], ["consistent with", "UNCERTAINTY", 108, 123]]], ["Additionally, we observed that the severe patients had a higher proportion of symptoms such as pleural effusion and bronchiectasis, when compared with non-severe patients, which had not been reported yet.J o u r n a l P r e -p r o o fConsistent with previous studies [12] [13] [14] 18] , most of patients had normal white blood cell count, decreased levels of lymphocyte count/percentage, hemoglobin, and albulmin, increased levels of lactate dehydrogenase, C-reactive protein, increased D-dimer, procalcitonin, alanine aminotransferase, and aspartate aminotransferase.J o u r n a l P r e -p r o o fThese abnormal laboratory findings showed sustained inflammatory response, disturbed coagulation mechanism, liver and kidney damage after patients infected [12] .", [["pleural", "ANATOMY", 95, 102], ["white blood cell", "ANATOMY", 316, 332], ["lymphocyte", "ANATOMY", 360, 370], ["liver", "ANATOMY", 707, 712], ["kidney", "ANATOMY", 717, 723], ["pleural effusion", "DISEASE", 95, 111], ["bronchiectasis", "DISEASE", 116, 130], ["albulmin", "CHEMICAL", 405, 413], ["lactate", "CHEMICAL", 435, 442], ["alanine", "CHEMICAL", 512, 519], ["aspartate", "CHEMICAL", 542, 551], ["liver and kidney damage", "DISEASE", 707, 730], ["albulmin", "CHEMICAL", 405, 413], ["lactate", "CHEMICAL", 435, 442], ["alanine", "CHEMICAL", 512, 519], ["aspartate", "CHEMICAL", 542, 551], ["patients", "ORGANISM", 42, 50], ["pleural", "PATHOLOGICAL_FORMATION", 95, 102], ["patients", "ORGANISM", 162, 170], ["[12] [13] [14] 18", "SIMPLE_CHEMICAL", 267, 284], ["patients", "ORGANISM", 296, 304], ["white blood cell", "CELL", 316, 332], ["lymphocyte", "CELL", 360, 370], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 389, 399], ["albulmin", "SIMPLE_CHEMICAL", 405, 413], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 435, 456], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 458, 476], ["D-dimer", "GENE_OR_GENE_PRODUCT", 488, 495], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 497, 510], ["alanine", "AMINO_ACID", 512, 519], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 520, 536], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 542, 568], ["liver", "ORGAN", 707, 712], ["kidney", "ORGAN", 717, 723], ["patients", "ORGANISM", 737, 745], ["hemoglobin", "PROTEIN", 389, 399], ["lactate dehydrogenase", "PROTEIN", 435, 456], ["C-reactive protein", "PROTEIN", 458, 476], ["D-dimer", "PROTEIN", 488, 495], ["procalcitonin", "PROTEIN", 497, 510], ["alanine aminotransferase", "PROTEIN", 512, 536], ["aspartate aminotransferase", "PROTEIN", 542, 568], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 162, 170], ["patients", "SPECIES", 296, 304], ["patients", "SPECIES", 737, 745], ["symptoms", "PROBLEM", 78, 86], ["pleural effusion", "PROBLEM", 95, 111], ["bronchiectasis", "PROBLEM", 116, 130], ["fConsistent", "PROBLEM", 233, 244], ["previous studies", "TEST", 250, 266], ["white blood cell count", "TEST", 316, 338], ["lymphocyte count", "TEST", 360, 376], ["percentage", "TEST", 377, 387], ["hemoglobin", "TEST", 389, 399], ["albulmin", "TEST", 405, 413], ["increased levels of lactate dehydrogenase", "PROBLEM", 415, 456], ["C", "TEST", 458, 459], ["reactive protein", "TEST", 460, 476], ["procalcitonin", "TEST", 497, 510], ["alanine aminotransferase", "TEST", 512, 536], ["aspartate aminotransferase", "TEST", 542, 568], ["abnormal laboratory findings", "PROBLEM", 605, 633], ["sustained inflammatory response", "PROBLEM", 641, 672], ["disturbed coagulation mechanism", "PROBLEM", 674, 705], ["liver and kidney damage", "PROBLEM", 707, 730], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["pleural", "ANATOMY", 95, 102], ["effusion", "OBSERVATION", 103, 111], ["bronchiectasis", "OBSERVATION", 116, 130], ["lymphocyte count", "OBSERVATION", 360, 376], ["hemoglobin", "OBSERVATION_MODIFIER", 389, 399], ["reactive protein", "OBSERVATION", 460, 476], ["sustained", "OBSERVATION_MODIFIER", 641, 650], ["inflammatory response", "OBSERVATION", 651, 672], ["disturbed coagulation", "OBSERVATION", 674, 695], ["liver", "ANATOMY", 707, 712], ["kidney", "ANATOMY", 717, 723], ["damage", "OBSERVATION", 724, 730]]], ["Compared to non-severe patients, severe individuals tended to have higher levels of white blood cell count, neutrophil count/ percentage, platelet count, aspartate aminotransferase, urea, lactate dehydrogenase, D-dimer, and procalcitonin, which indicated severe patients might have more obvious inflammation, disturbed coagulation mechanism, liver and kidney damage.", [["white blood cell", "ANATOMY", 84, 100], ["neutrophil", "ANATOMY", 108, 118], ["platelet", "ANATOMY", 138, 146], ["liver", "ANATOMY", 342, 347], ["kidney", "ANATOMY", 352, 358], ["aspartate", "CHEMICAL", 154, 163], ["urea", "CHEMICAL", 182, 186], ["lactate", "CHEMICAL", 188, 195], ["inflammation", "DISEASE", 295, 307], ["liver and kidney damage", "DISEASE", 342, 365], ["aspartate", "CHEMICAL", 154, 163], ["urea", "CHEMICAL", 182, 186], ["lactate", "CHEMICAL", 188, 195], ["patients", "ORGANISM", 23, 31], ["individuals", "ORGANISM", 40, 51], ["white blood cell", "CELL", 84, 100], ["neutrophil", "CELL", 108, 118], ["platelet", "CELL", 138, 146], ["aspartate", "SIMPLE_CHEMICAL", 154, 163], ["aminotransferase", "SIMPLE_CHEMICAL", 164, 180], ["urea", "SIMPLE_CHEMICAL", 182, 186], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 188, 209], ["D-dimer", "SIMPLE_CHEMICAL", 211, 218], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 224, 237], ["patients", "ORGANISM", 262, 270], ["liver", "ORGAN", 342, 347], ["kidney", "ORGAN", 352, 358], ["aspartate aminotransferase", "PROTEIN", 154, 180], ["lactate dehydrogenase", "PROTEIN", 188, 209], ["D-dimer", "PROTEIN", 211, 218], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 262, 270], ["severe individuals", "PROBLEM", 33, 51], ["white blood cell count", "TEST", 84, 106], ["neutrophil count", "TEST", 108, 124], ["percentage", "TEST", 126, 136], ["platelet count", "TEST", 138, 152], ["aspartate aminotransferase", "TEST", 154, 180], ["urea", "TEST", 182, 186], ["lactate dehydrogenase", "TEST", 188, 209], ["D-dimer", "TEST", 211, 218], ["procalcitonin", "TEST", 224, 237], ["obvious inflammation", "PROBLEM", 287, 307], ["disturbed coagulation mechanism", "PROBLEM", 309, 340], ["liver and kidney damage", "PROBLEM", 342, 365], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["neutrophil count", "OBSERVATION", 108, 124], ["severe", "OBSERVATION_MODIFIER", 255, 261], ["obvious", "OBSERVATION_MODIFIER", 287, 294], ["inflammation", "OBSERVATION", 295, 307], ["coagulation", "OBSERVATION", 319, 330], ["liver", "ANATOMY", 342, 347], ["kidney", "ANATOMY", 352, 358], ["damage", "OBSERVATION", 359, 365]]], ["Previous study found that five COVID-19 patients younger than 50 years had a large-vessel stroke [20] , which indicated that COVID-19 might increase the risk of cardiovascular disease.", [["vessel", "ANATOMY", 83, 89], ["cardiovascular", "ANATOMY", 161, 175], ["vessel stroke", "DISEASE", 83, 96], ["COVID-19", "CHEMICAL", 125, 133], ["cardiovascular disease", "DISEASE", 161, 183], ["COVID-19", "CHEMICAL", 125, 133], ["patients", "ORGANISM", 40, 48], ["vessel", "MULTI-TISSUE_STRUCTURE", 83, 89], ["COVID-19", "GENE_OR_GENE_PRODUCT", 125, 133], ["cardiovascular", "ANATOMICAL_SYSTEM", 161, 175], ["patients", "SPECIES", 40, 48], ["Previous study", "TEST", 0, 14], ["a large-vessel stroke", "PROBLEM", 75, 96], ["COVID", "TEST", 125, 130], ["cardiovascular disease", "PROBLEM", 161, 183], ["large", "OBSERVATION_MODIFIER", 77, 82], ["vessel", "ANATOMY", 83, 89], ["stroke", "OBSERVATION", 90, 96], ["cardiovascular disease", "OBSERVATION", 161, 183]]], ["In the J o u r n a l P r e -p r o o f present study, we also found that non-severe and severe patients had higher levels of D-dimer.", [["D-dimer", "CHEMICAL", 124, 131], ["patients", "ORGANISM", 94, 102], ["D-dimer", "GENE_OR_GENE_PRODUCT", 124, 131], ["D-dimer", "PROTEIN", 124, 131], ["patients", "SPECIES", 94, 102], ["present study", "TEST", 38, 51], ["non-severe", "OBSERVATION_MODIFIER", 72, 82], ["severe", "OBSERVATION_MODIFIER", 87, 93]]], ["Additionally, we observed that leukocytosis and increased creatine kinase were positively associated with COVID-19 severity.J o u r n a l P r e -p r o o fThe strengths of present study included the relatively large sample size, and the ability to provide more information of epidemiological and clinical characteristics of patients infected with COVID-19.", [["leukocytosis", "DISEASE", 31, 43], ["creatine", "CHEMICAL", 58, 66], ["creatine", "CHEMICAL", 58, 66], ["COVID-19", "CHEMICAL", 346, 354], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 58, 73], ["patients", "ORGANISM", 323, 331], ["creatine kinase", "PROTEIN", 58, 73], ["COVID", "PROTEIN", 106, 111], ["patients", "SPECIES", 323, 331], ["leukocytosis", "PROBLEM", 31, 43], ["increased creatine kinase", "PROBLEM", 48, 73], ["COVID", "TEST", 106, 111], ["present study", "TEST", 171, 184], ["COVID", "TEST", 346, 351], ["leukocytosis", "OBSERVATION", 31, 43], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["creatine kinase", "OBSERVATION", 58, 73], ["large", "OBSERVATION_MODIFIER", 209, 214], ["size", "OBSERVATION_MODIFIER", 222, 226]]], ["It would enable us to investigate the associations between potential risk factors and COVID-19 severity with moderate statistical power.J o u r n a l P r e -p r o o fDifferent from previous studies [15, 21, 22] , the present study was the first comprehensive analysis of 1,663 hospitalized patients with laboratory-confirmed diagnosis of COVID-19 from January 14, 2020 to February 28, 2020 in Tongji Hospital.", [["patients", "ORGANISM", 290, 298], ["patients", "SPECIES", 290, 298], ["potential risk factors", "PROBLEM", 59, 81], ["COVID", "TEST", 86, 91], ["previous studies", "TEST", 181, 197], ["COVID", "TEST", 338, 343]]], ["Firstly, the present study was performed in single-center thus the findings may not be representative of general population.", [["the present study", "TEST", 9, 26], ["general population", "PROBLEM", 105, 123], ["may not be representative of", "UNCERTAINTY", 76, 104], ["population", "OBSERVATION", 113, 123]]], ["Secondly, we have not yet collected information on treatments in the present study.ConclusionsIn the present study, the majority of all COVID-19 patients were aged over 50 years old.", [["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["treatments", "TREATMENT", 51, 61], ["the present study", "TEST", 65, 82], ["the present study", "TEST", 97, 114]]], ["Fever, cough, fatigue and chest tightness were the most common symptoms in", [["chest", "ANATOMY", 26, 31], ["Fever", "DISEASE", 0, 5], ["cough", "DISEASE", 7, 12], ["fatigue", "DISEASE", 14, 21], ["chest tightness", "DISEASE", 26, 41], ["chest", "ORGANISM_SUBDIVISION", 26, 31], ["Fever", "PROBLEM", 0, 5], ["cough", "PROBLEM", 7, 12], ["fatigue", "PROBLEM", 14, 21], ["chest tightness", "PROBLEM", 26, 41], ["the most common symptoms", "PROBLEM", 47, 71], ["cough", "OBSERVATION", 7, 12], ["chest", "ANATOMY", 26, 31]]]], "PMC7342057": [["Ran and S. Zhao conceived the study and carried out the analysis.", [["Ran", "GENE_OR_GENE_PRODUCT", 0, 3], ["Ran", "PROTEIN", 0, 3], ["the study", "TEST", 26, 35], ["the analysis", "TEST", 52, 64]]], ["He received support from an Alibaba (China) - Hong Kong Polytechnic University Collaborative Research project.", [["support", "TREATMENT", 12, 19]]]]}